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Summary	  	  Positive-­‐sense	  single	  stranded	  RNA	  viruses,	  like	  those	  found	  within	  the	  Enterovirus	  genus,	  have	  error	  prone	  polymerases,	  short	  replication	  cycles	  and	  high	  yields	  that	  together	  generate	  genetic	  diversity.	  These	  advantageous	  evolutionary	  mechanisms	  enable	  the	  virus	  population	  to	  survive	  in	  changing	  environments.	  However,	  the	  majority	  of	  mutations	  that	  are	  introduced	  are	  lethal	  or	  deleterious.	  RNA	  recombination	  provides	  a	  mechanism	  that	  can	  remove	  a	  deleterious	  mutation	  and	  also	  provides	  an	  opportunity	  to	  break	  the	  link	  between	  mutations	  that	  are	  lethal	  and	  those	  that	  are	  beneficial	  in	  the	  same	  genome.	  	  
	  
The	  objectives	  of	  this	  investigation	  were	  to	  identify	  characteristics	  of	  the	  virus	  that	  were	  important	  in	  recombination.	  As	  genetic	  exchange	  in	  enteroviruses	  was	  postulated	  to	  be	  a	  replicative	  process,	  the	  role	  of	  the	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  was	  reasoned	  to	  be	  important.	  This	  study	  has	  benefited	  from	  utilising	  a	  novel	  reverse	  genetics	  in	  vitro	  cell	  based	  assay	  known	  as	  CRE-­‐REP.	  The	  assay	  allowed	  selection	  and	  isolation	  of	  viable	  recombinant	  virus	  as	  near	  to	  the	  recombination	  event	  as	  temporally	  possible.	  Results	  indicated	  that	  ‘copy	  choice’	  replicative	  recombination	  is	  a	  biphasic	  process	  with	  distinct	  template-­‐exchange	  and	  resolution	  events.	  Manipulating	  known	  RNA	  elements	  within	  the	  viral	  genome	  expanded	  the	  cell-­‐based	  assay	  further.	  Notably,	  this	  investigation	  suggested	  that	  fidelity	  of	  the	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  is	  a	  major	  determinant	  of	  recombination	  frequency.	  
	  
To	  further	  validate	  the	  cell-­‐based	  approach,	  a	  defined	  biochemical	  assay	  that	  allowed	  quantification	  of	  the	  template	  transfer	  event	  was	  developed	  in	  collaboration	  with	  Professor	  Craig	  Cameron.	  The	  results	  confirmed	  that	  the	  RdRp	  alone	  was	  sufficient	  for	  recombination	  and	  that	  fidelity	  was	  a	  major	  contributing	  factor	  to	  efficiency.	  The	  characterised	  high	  fidelity	  RdRp	  variants	  (e.g.	  K359R,	  G64S)	  reduced	  template	  transfer	  up	  to	  25-­‐fold.	  The	  biochemical	  assay	  was	  extended	  to	  investigate	  the	  sequence	  identity	  required	  for	  the	  template	  transfer	  event.	  These	  studies	  form	  the	  basis	  for	  the	  further	  biophysical	  dissection	  of	  a	  key	  evolutionary	  process	  present	  in	  many	  positive-­‐strand	  RNA	  viruses.	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  pair(s)	  	  CD	  	   cluster	  of	  differentiation	  	  cDNA	  	   complementary	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  CO2	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  dioxide	  	  CPE	  	   cytopathic	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  CRE	  	   cis-­‐acting	  replication	  element	  	  cVDPV	  	   circulating	  vaccine-­‐derived	  poliovirus	  	  D	  	   redundant	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  for	  adenine,	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  or	  thymine	  	  DAF	   Decay	  accelerating	  factor	  DAPI	  	   4’,6-­‐diamidino-­‐2-­‐phenylindole	  	  dH2O	  	   distilled	  water	  	  DI	  	   defective	  interfering	  	  DMEM	  	   Dulbecco’s	  modified	  Eagle’s	  medium	  	  DNA	  	   deoxyribonucleic	  acid	  	  DNase	  	   deoxyribonuclease	  	  ds	  	   double	  stranded	  	  DTT	  	   dithiothreitol	  	  dNTP	  	   deoxyribonucleotide	  triphosphate	  	  E.	  coli	  	   Escherichia	  coli	  	  EDTA	  	   ethylenediaminetetraacetic	  acid	  	  EMEM	  	   minimum	  essential	  medium	  with	  Earle’s	  salts	  	  ER	   Endoplasmic	  reticulum	  FISH	   Fluorescent	  in	  situ	  hybridisation	  FBS	  	   foetal	  bovine	  serum	  	  FLC	  	   full-­‐length	  clone	  	  g	  	   gram	  	  GFP	  	   green	  fluorescent	  protein	  	  GI	  	   gastrointestinal	  	  GMEM	  	   Glasgow	  minimum	  essential	  medium	  	  GuHCl	  	   guanidine	  hydrochloride	  	  HeLa	  	   human	  cervical	  cancer	  cell	  line	  	  HI	  	   heat	  inactivated	  	  hr	  	   hour	  	  ICAM-­‐1	  	   intracellular	  adhesion	  molecule	  type	  -­‐	  1	  	  IF	  	   immunofluorescence	  	  IMPDH	   Inosine	  monophosphate	  dehdrogenase	  IPV	  	   inactivated	  poliovirus	  vaccine	  	  IRES	  	   internal	  ribosome	  entry	  site	  	  K	  	   redundant	  nucleotide	  for	  guanine	  or	  thymine	  	  Kb	   kilobase	  pair	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LB	  	   Lysogeny	  broth	  	  M	  	   redundant	  nucleotide	  for	  adenine	  or	  cytosine	  	  mg	  	   milligram	  	  min	  	   minute	  	  miRNA	  	   microRNA	  	  ml	  	   millilitre	  	  mM	  	   millimolar	  	  MOI	  	   multiplicity	  of	  infection	  	  mRNA	  	   messenger	  RNA	  	  NCBI	  	   National	  Center	  for	  Biotechnology	  Information	  	  ng	  	   nanogram	  	  nm	  	   nanometre	  	  nt	  	   nucleotide	  	  NTR	   Non-­‐translated	  region	  OPV	  	   oral	  poliovirus	  vaccine	  	  ORF	  	   open	  reading	  frame	  	  PABPI	   poly(A)	  binding	  protein	  1	  PBS	  	   phosphate	  buffered	  saline	  	  PCBP2	  	   poly(rC)	  binding	  protein	  2	  	  PCR	  	   polymerase	  chain	  reaction	  	  PFU	  	   plaque	  forming	  unit	  	  pH	  	   power	  of	  hydrogen	  	  PS	  	   Penicillin	  and	  streptomycin	  	  PVR	  	   poliovirus	  type	  3	  receptor	  (CD155)	  	  R	  	   redundant	  nucleotide	  for	  adenine	  or	  guanine	  	  RC	   Replication	  complex	  RD	  	   rhabdomyosarcoma	  cells	  	  RdRp	  	   RNA-­‐dependent	  RNA	  polymerase	  	  RF	  	   replicative	  form	  	  RI	  	   replication	  intermediate	  	  RMP	   Ribavirin	  monophosphate	  RNA	  	   ribonucleic	  acid	  	  RNase	  	   ribonuclease	  	  rpm	  	   revolutions	  per	  minute	  	  RTP	   Ribavirin	  triphosphate	  RT-­‐PCR	  	   reverse	  transcription	  polymerase	  chain	  reaction	  	  SDS	  	   sodium	  dodecyl	  sulphate	  	  s	  	   second	  	  shRNA	  	   short	  hairpin	  RNA	  	  siRNA	  	   short	  interfering	  RNA	  	  TCID50	  	   50%	  tissue	  culture	  infective	  dose	  	  U	  	   unit	  	  μg	  	   microgram	  	  μl	  	   microlitre	  	  μM	  	   micromolar	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VAPP	   vaccine-­‐associated	  paralytic	  poliovirus	  	  VDPV	  	   vaccine-­‐derived	  poliovirus	  	  VPg	  	   virus	  protein	  genome	  linked	  	  v/v	  	   volume	  per	  volume	  total	  	  W	  	   redundant	  nucleotide	  for	  adenine	  or	  thymine	  	  w/v	  	   weight	  per	  volume	  total	  	  WHO	  	   World	  Health	  Organisation	  	  Y	  	   redundant	  nucleotide	  for	  cytosine	  or	  thymine	  	  °C	  	   degrees	  Celsius	  	  5-­‐FU	   5-­‐Fluorouracil	  or	  5-­‐Fluoro-­‐1H,3H-­‐pyrimidine-­‐2,4-­‐dione	  	  	  
Virus	  abbreviations	  	  
	  BA	   Baboon	  enterovirus	  (species	  A)	  CVA	  	   coxsackievirus	  A	  serotypes	  	  CVB	  	   coxsackievirus	  B	  serotypes	  	  EVB	   Enterovirus	  (species	  B)	  EVC	   Enterovirus	  (species	  C)	  EVD	   Enterovirus	  (species	  D)	  EVE	   Enterovirus	  (species	  E)	  EVF	   Enterovirus	  (species	  F)	  EVG	   Enterovirus	  (species	  G)	  EVH	   Enterovirus	  (species	  H)	  EVJ	   Enterovirus	  (species	  J)	  E30	  	   echovirus	  30	  (species	  B)	  	  E6	   echovirus	  6	  (species	  B)	  E7	  	   echovirus	  7	  (species	  B)	  	  EV68	   enterovirus	  68	  (species	  D)	  EV71	  	   enterovirus	  71	  (species	  A)	  	  FMDV	  	   foot-­‐and-­‐mouth	  disease	  virus	  	  HCV	  	   hepatitis	  C	  virus	  	  HEV	  	   human	  enterovirus	  	  RVA	   Rhinovirus	  species	  A	  RVB	   Rhinovirus	  species	  B	  RVC	   Rhinovirus	  species	  C	  PV	  	   poliovirus	  	  PV1	  	   poliovirus	  type	  1	  (species	  C)	  	  PV2	  	   poliovirus	  type	  2	  (species	  C)	  	  PV3	  	   poliovirus	  type	  3	  (species	  C)	  	  SV	   Simian	  enterovirus	  TBSV	  	   tomato	  bushy	  stunt	  virus	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Protein	  abbreviations	  
	   VP0	  	   precursor	  protein	  before	  cleavage	  to	  make	  VP2	  and	  VP4	  	  VP1	  	   capsid	  protein	  	  VP2	  	   capsid	  protein	  	  VP3	  	   capsid	  protein	  	  VP4	  	   capsid	  protein	  	  2A	   virus	  protease	  	  2BC	  	   precursor	  protein,	  interacts	  with	  cellular	  membranes	  	  2B	  	   interacts	  with	  cellular	  proteins,	  induces	  vesicles	  in	  cells	  	  2C	  	   interacts	  with	  cellular	  proteins,	  induces	  vesicles	  in	  cells	  	  3AB	  	   precursor	  protein,	  binds	  to	  one	  or	  more	  CRE's	  also	  has	  chaperone	  activity	  3A	  	   component	  of	  virus	  replication	  complex	  	  3B	  	   protein	  VPg	  	  3BC	   precursor	  protein	  with	  chaperone	  activity	  3CD	   precursor	  protein	  with	  protease	  activity,	  binds	  to	  one	  or	  more	  CREs	  	  3C	   virus	  protease	  	  3Dpol	  	   RNA-­‐dependent	  RNA	  polymerase	  (RdRp)	  	  VPg	  	   virion	  protein	  genome	  linked	  covalently	  to	  5’	  NCR	  of	  virus	  genome	  	  COPII	   Coat	  protein	  complex	  II	  p53	  	   tumour	  suppressor	  protein	  that	  regulates	  cell	  cycle	  	  PCBP2	  	   cellular	  protein,	  promotes	  PV	  replication	  by	  binding	  to	  RNA	  secondary	  structure	  elements	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CHAPTER	  ONE:	  Introduction	  	  Important	  positive-­‐sense	  single	  stranded	  RNA	  viruses	  like	  the	  human	  pathogens,	  poliovirus	  (PV)	  and	  rhinovirus,	  have	  a	  reputation	  of	  being	  one	  on	  nature’s	  swiftest	  evolvers	  due	  to	  their	  high	  mutation	  and	  replication	  rates.	  This	  provides	  the	  basis	  for	  genetic	  variation	  amongst	  this	  group	  of	  viruses	  and	  allows	  rapid	  selection	  of	  those	  variants	  that	  are	  most	  suitable	  to	  the	  environment	  at	  any	  one	  time.	  RNA	  viruses	  also	  have	  the	  ability	  to	  exchange	  vast	  regions	  of	  genetic	  material,	  in	  a	  process	  known	  as	  genetic	  recombination,	  which	  allows	  for	  far	  greater	  variation	  than	  is	  possible	  in	  a	  single	  round	  of	  replication.	  	  It	  has	  become	  apparent	  from	  the	  phylogenetic	  analysis	  of	  many	  positive	  sense	  RNA	  viruses	  that	  recombination	  has	  been	  a	  major	  driving	  force	  in	  their	  evolution.	  Many	  examples	  from	  nature	  and	  from	  cell	  based	  in	  vitro	  studies	  have	  attempted	  to	  highlight	  the	  potential	  mechanisms	  and	  triggers	  for	  the	  recombination	  event.	  However,	  except	  for	  an	  understanding	  of	  the	  underlying	  principles	  of	  recombination,	  very	  little	  is	  known	  about	  the	  viral	  and	  host	  factors	  that	  contribute	  to	  this	  process.	  	  This	  literature	  review	  primarily	  concentrates	  on	  a	  specific	  group	  of	  viruses	  that	  fall	  within	  the	  
Picornaviridae	  family,	  known	  as	  the	  genus	  enterovirus.	  The	  principles	  of	  classification,	  replication,	  evolution	  and	  recombination	  will	  be	  briefly	  considered.	  In	  the	  majority	  of	  cases	  the	  evidence	  provided	  is	  based	  upon	  the	  most	  widely	  studied	  picornavirus,	  poliovirus,	  which	  was	  also	  used	  primarily	  during	  the	  course	  of	  this	  investigation.	  	  
1.1 	  	  	  	  	  The	  Family	  Picornaviridae	  	  The	  picornaviruses	  are	  small,	  non-­‐enveloped	  RNA	  viruses	  that	  formally	  make	  up	  the	  family	  
Picornaviridae. They	  are	  amongst	  the	  simplest	  of	  vertebrate	  viruses	  comprising	  a	  single	  stranded	  positive	  sense	  RNA	  genome	  within	  a	  T	  =	  1	  (quasi	  T	  =	  3)	  icosahedral	  protein	  capsid	  of	  approximately	  30	  nm	  diameter	  (Tuthill	  et	  al.,	  2010,	  Rossmann	  et	  al.,	  1985).	  The	  group	  includes	  several	  closely	  related	  and	  medically	  important	  viruses	  such	  as	  poliovirus,	  rhinovirus,	  hepatitis	  A	  virus,	  coxsackievirus	  and	  echovirus.	  These	  viruses	  cause	  a	  wide	  range	  of	  acute	  diseases	  in	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humans,	  including	  poliomyelitis,	  the	  common	  cold,	  liver	  disease,	  heart	  disease,	  and	  aseptic	  meningitis.	  Poliovirus	  (genus	  enterovirus)	  is	  the	  best-­‐known	  and	  most	  studied	  member	  of	  the	  
Picornaviridae	  family	  and	  is	  generally	  considered	  the	  prototypical	  picornavirus	  (Contreras	  et	  al.,	  2002).	  After	  poliomyelitis,	  probably	  the	  most	  notable	  disease-­‐causing	  picornavirus	  is	  foot-­‐and-­‐mouth	  disease	  virus	  (FMDV;	  genus	  aphthovirus),	  which	  infects	  cloven-­‐hoofed	  animals	  such	  as	  cattle	  and	  swine	  (Bachrach,	  1968).	  	  
	  
Taxonomy	  
The	  International	  Committee	  on	  Taxonomy	  of	  Viruses	  (ICTV)	  groups	  viruses	  by	  order,	  family,	  genus	  and	  species.	  A	  group	  of	  species	  will	  form	  a	  genera	  and	  a	  group	  of	  genera	  will	  form	  a	  family.	  Historically,	  classification	  of	  a	  virus	  into	  a	  family	  was	  primarily	  based	  upon	  virion	  morphology,	  the	  nature	  of	  the	  genomic	  nucleic	  acid,	  replication	  strategy	  and	  host	  species	  (Hyypia	  et	  al.,	  1997).	  More	  recently,	  due	  to	  the	  advancement	  in	  molecular	  sequencing	  technology,	  classification	  has	  also	  taken	  into	  account	  genomic	  sequence	  similarities.	  For	  example,	  the	  classification	  of	  enteroviruses	  that	  infect	  humans	  has	  been	  primarily	  based	  upon	  the	  sequence	  of	  the	  structural	  protein	  VP1	  (Caro	  et	  al.,	  2001,	  Oberste	  et	  al.,	  2000,	  Oberste	  et	  al.,	  1999).	  Genetic	  variations	  within	  species	  allow	  them	  to	  be	  sub-­‐divided	  into	  serotypes	  and	  then	  further	  into	  strains.	  This	  concept	  is	  especially	  important	  when	  considering	  the	  high	  mutation	  rates	  of	  many	  picornaviruses	  that	  exist	  not	  as	  a	  single	  genotype	  but	  as	  a	  ‘quasi-­‐species’	  due	  to	  the	  high	  mutation	  rate	  of	  the	  virally	  encoded	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  (Eigen,	  1996).	  The	  classification	  of	  the	  family	  Picornaviridae	  is	  being	  continuously	  updated	  and	  most	  recently	  expanded	  to	  46	  species	  that	  are	  grouped	  into	  26	  genera	  (Knowles	  et	  al.,	  Europic	  2014).	  	  
	  
Genus	  enterovirus	  
The	  enteroviruses	  are	  a	  well-­‐characterised	  genus	  within	  the	  family	  Picornaviridae	  and	  as	  recently	  as	  2009	  were	  sub-­‐grouped	  into	  seven	  species	  which	  also	  included	  the	  Human	  
Rhinovirus	  (HRV)	  A-­‐C	  groups	  (McIntyre	  et	  al.,	  2013,	  Arden	  and	  Mackay,	  2009).	  In	  2012	  the	  ICTV	  re-­‐named	  and	  re-­‐classified	  many	  viruses	  into	  newly	  formed	  genera	  and	  simplified	  the	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nomenclature	  to	  remove	  many	  host	  species	  names.	  For	  example	  the	  previous	  Bovine	  enterovirus	  species	  group	  is	  now	  known	  as	  Enterovirus	  E.	  The	  genus	  enterovirus	  now	  currently	  consists	  of	  309	  serotypes	  that	  fall	  within	  12	  species	  groups	  (Knowles	  et	  al.,	  Europic	  2014)	  (summarised	  in	  table	  1.1).	  The	  enteroviruses	  that	  infect	  humans	  are	  particularly	  well	  studied	  as	  they	  contain	  important	  pathogens	  responsible	  for	  acute	  flaccid	  paralysis	  (including	  poliomyelitis),	  myocarditis,	  encephalitis	  and	  a	  variety	  of	  other	  ailments	  (Grist	  et	  al.,	  1978).	  They	  are	  currently	  divided	  into	  four	  phylogenetically	  distinct	  species	  known	  as	  Enterovirus	  A	  –	  D,	  with	  the	  prototype	  poliovirus	  serotypes	  belonging	  to	  group	  C	  (Knowles	  et	  al.,	  2012).	  	  
	  
Transmission	  and	  medically	  important	  enteroviruses	  
In	  biology	  and	  medicine	  the	  prefix	  term	  entero-­‐	  refers	  to	  the	  intestinal	  region.	  Enteroviruses	  primarily	  infect	  the	  cells	  of	  the	  intestine	  and	  are	  transmitted	  by	  the	  faecal-­‐oral	  and	  oral-­‐oral	  route	  by	  contact	  with	  water,	  food	  and	  ground	  contaminated	  with	  infected	  faeces.	  Additionally,	  transmission	  can	  occur	  through	  direct	  contact	  with	  secretions	  from	  ophthalmic	  and	  dermal	  lesions	  (Rajtar et al., 2008). Enteroviruses	  that	  are	  transmitted	  by	  the	  faecal-­‐oral	  route	  are	  very	  resilient	  to	  the	  extreme	  environmental	  conditions	  of	  the	  gastrointestinal	  tract	  (GI),	  virions	  remain	  stable	  at	  pH	  3–5	  for	  1–3	  hours,	  are	  not	  susceptible	  to	  proteolytic	  enzymes	  nor	  to	  bile	  salts	  and	  replicate	  efficiently	  at	  37	  °C	  (Rajtar	  et	  al.,	  2008).	  Rhinoviruses	  in	  contrast	  to	  the	  other	  members	  of	  the	  enterovirus	  genus	  are	  primarily	  transmitted	  from	  person	  to	  person	  via	  aerosol	  or	  contact	  (either	  direct	  or	  through	  fomites).	  Infection	  is	  efficiently	  initiated	  by	  intranasal	  inoculation	  where	  replication	  of	  the	  virus	  primarily	  occurs	  within	  the	  respiratory	  tract	  at	  temperatures	  of	  33	  °C	  (Jacobs	  et	  al.,	  2013).	  Enteroviruses	  that	  affect	  humans	  usually	  lead	  to	  infections	  that	  are	  asymptomatic	  or	  cause	  only	  mild	  illness.	  However,	  outbreaks	  of	  severe	  disease	  can	  be	  associated	  following	  enterovirus	  infection.	  For	  example,	  EV71,	  a	  member	  of	  the	  Enterovirus	  A	  species	  group	  can	  cause	  epidemics	  of	  hand,	  foot	  and	  mouth	  disease	  in	  young	  children	  that	  can	  also	  be	  associated	  with	  neurological	  symptoms	  (McMinn	  et	  al.,	  2001).	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Table	  1.1:	  Classification	  of	  the	  genus	  enterovirus	  
Species	  group	   Example	  Serotypes	  
Enterovirus	  A	   CVA2-­‐8,	  EV71,	  76,	  89-­‐92,	  SV19,	  43,	  BA13	  
Enterovirus	  B	   CVB1-­‐6,	  E1-­‐9,	  11-­‐21,	  24-­‐33,	  EVB73-­‐88	  
Enterovirus	  C	   PV1-­‐3,	  CVA1,	  11,	  13,	  17,	  19-­‐22,	  EVC95,	  96	  
Enterovirus	  D	   EVD68,	  70,	  94,	  111,	  120	  	  
Enterovirus	  E	   EVE1-­‐4	  
Enterovirus	  F	   EVF1-­‐6	  
Enterovirus	  G	   EVG1-­‐11	  
Enterovirus	  H	   EVH1	  
Enterovirus	  J	   SV6,	  EVJ103,	  108,	  112,	  115,	  121	  
Rhinovirus	  A	   RVA1,	  2,	  8-­‐13,	  18-­‐25,	  28-­‐34,	  38-­‐41,	  49-­‐68,	  100-­‐109	  
Rhinovirus	  B	   RVB3-­‐6,	  99-­‐106	  
Rhinovirus	  C	   RVC1-­‐54	  Abbreviations	  on	  pg	  14	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Respiratory	  illnesses	  like	  bronchiolitis	  and	  pneumonia	  have	  been	  associated	  following	  EV68	  infection,	  a	  member	  of	  the	  Enterovirus	  D	  species	  group	  (Oberste	  et	  al.,	  2004b).	  Echoviruses	  (species	  B),	  that	  were	  originally	  isolated	  from	  the	  faeces	  of	  asymptomatic	  patients	  have	  now	  been	  associated	  with	  aseptic	  meningitis,	  particularly	  in	  infants	  and	  young	  children	  (Rhoades	  et	  al.,	  2011,	  Leitch	  et	  al.,	  2009).	  	  
Poliovirus	  infection:	  Poliomyelitis	  and	  related	  illnesses	  	  The	  causative	  agent	  of	  poliomyelitis	  is	  the	  Enterovirus	  C	  member	  poliovirus	  (PV),	  which	  was	  first	  discovered	  in	  1908	  by	  Landsteiner	  and	  Popper	  who	  demonstrated	  bacterially	  sterile	  transmission	  of	  the	  disease	  from	  human	  to	  rhesus	  monkeys	  by	  injection	  of	  spinal	  fluid	  from	  a	  symptomatic	  child	  into	  the	  peritoneum	  of	  a	  monkey	  (Eggers,	  2002).	  The	  host	  receptor,	  CD155,	  is	  only	  expressed	  in	  primate	  cells,	  meaning	  PV	  has	  no	  other	  vectors	  of	  transmission	  (Mendelsohn	  et	  al.,	  1989).	  PV	  is	  spread	  through	  faecal-­‐oral	  transmission,	  the	  virus	  initially	  infects	  and	  replicates	  in	  the	  oropharynx	  and	  gut	  of	  the	  host,	  which	  commonly	  leads	  to	  the	  virus	  entering	  the	  bloodstream.	  In	  the	  majority	  of	  infections	  no	  clinical	  signs	  are	  shown	  (Nathanson	  and	  Kew,	  2010).	  The	  most	  severe	  outcome	  occurs	  if	  the	  virus	  crosses	  the	  blood-­‐brain	  barrier	  and	  invades	  the	  central	  nervous	  system	  (CNS)	  where	  it	  can	  destroy	  motor	  neurons	  in	  the	  grey	  matter	  of	  the	  spinal	  cord,	  causing	  muscular	  paralysis	  known	  as	  poliomyelitis,	  as	  the	  name	  suggests	  (polio	  =	  grey,	  myelitis/myelo	  =	  marrow).	  The	  incubation	  period	  for	  poliomyelitis	  is	  about	  10	  days	  and	  occurs	  in	  1	  out	  of	  150	  PV	  infections	  (Nathanson	  and	  Kew,	  2010).	  In	  around	  10%	  of	  PV	  infected	  individuals,	  a	  secondary	  illness	  called	  abortive	  poliomyelitis	  can	  occur.	  This	  form	  of	  infection	  can	  lead	  to	  a	  variety	  of	  clinical	  phenotypes,	  such	  as	  upper	  respiratory	  tract	  infection,	  gastrointestinal	  illness,	  and	  influenza	  like	  infections	  (Kroon	  et	  al.,	  1995).	  	  	  
Polio	  eradication	  strategy	  	  
In	  1988	  the	  World	  Health	  Organization	  (WHO)	  launched	  the	  first	  campaign	  for	  the	  eradication	  of	  poliovirus	  with	  the	  goal	  of	  eradicating	  polio	  by	  the	  year	  2000.	  Since	  that	  time	  the	  world	  has	  seen	  a	  99%	  decrease	  in	  polio	  cases.	  However,	  there	  are	  a	  few	  areas	  of	  the	  world	  where	  PV	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remains	  endemic	  in	  the	  human	  population,	  including	  Nigeria	  and	  the	  border	  between	  Afghanistan	  and	  Pakistan	  (www.polioeradication.org).	  The	  availability	  of	  a	  vaccine,	  a	  single	  host	  and	  good	  diagnostic	  tools	  were	  all	  key	  factors	  that	  suggested	  that	  poliovirus	  could	  be	  eradicated.	  	  
	  
Three	  antigenically	  distinct	  serotypes	  of	  poliovirus	  exist	  (1,	  2	  and	  3)	  and	  infection	  with	  one	  serotype	  does	  not	  convey	  protection	  against	  the	  others	  (Herremans	  et	  al.,	  2000).	  The	  oral	  poliovirus	  vaccine	  (OPV),	  licensed	  and	  introduced	  by	  Albert	  Sabin	  in	  1963,	  contains	  three	  attenuated	  strains	  of	  poliovirus	  that	  induce	  strong	  immunity	  against	  infection	  (Eggers,	  2002).	  The	  OPV	  was	  developed	  by	  continuously	  passaging	  each	  of	  the	  three	  parental	  strains	  at	  suboptimal	  temperatures	  in	  simian	  cells	  and	  tissues.	  Each	  of	  the	  three	  serotypes	  have	  been	  extensively	  studied	  with	  the	  critical	  point	  mutations	  characterised	  (Kew	  et	  al.,	  2005).	  The	  human	  immune	  response	  is	  generally	  able	  to	  recognise	  and	  destroy	  the	  attenuated	  virus	  before	  it	  causes	  significant	  disease.	  Unfortunately,	  the	  rapid	  evolution	  of	  the	  virus	  in	  the	  short	  time	  that	  it	  is	  replicating	  (~2	  weeks)	  in	  the	  vaccinated	  host,	  has	  led	  to	  some	  of	  the	  attenuated	  vaccine	  strains	  reverting	  back	  to	  wild-­‐type	  poliovirus	  which	  are	  subsequently	  shed	  as	  virulent	  virus	  (Dunn	  et	  al.,	  1990).	  If	  immunization	  coverage	  is	  low,	  the	  newly	  shed	  virulent	  virus	  may	  cause	  an	  outbreak	  of	  vaccine-­‐associated	  paralytic	  poliomyelitis	  (VAPP)	  among	  non-­‐immune	  individuals,	  thus	  remaining	  a	  significant	  threat	  in	  some	  areas	  of	  the	  world.	  The	  formalin	  inactivated	  virus	  vaccine	  (IPV),	  developed	  by	  Dr.	  Jonas	  Salk	  and	  licensed	  in	  1953,	  and	  used	  in	  the	  developed	  world	  circumvents	  this	  problem,	  but	  it	  is	  too	  expensive	  for	  the	  global	  eradication	  campaign	  (Salk,	  1954,	  Nathanson	  and	  Fine,	  2002).	  Vaccine-­‐derived	  polioviruses	  (VDPVs)	  also	  contribute	  to	  minor	  outbreaks	  of	  poliomyelitis.	  These	  outbreaks	  are	  linked	  to	  recombination	  events	  between	  circulating	  vaccine-­‐derived	  polioviruses	  (cVDPVs)	  and	  fellow	  members	  of	  the	  enterovirus	  C	  group,	  in	  particular	  coxsackie	  A	  viruses	  (Kew	  et	  al.,	  2002,	  Combelas	  et	  al.,	  2011).	  Taken	  together,	  the	  failure	  to	  eradicate	  polio	  completely	  may	  call	  for	  the	  development	  of	  antivirals	  and	  attenuated	  vaccine	  strains	  that	  are	  non-­‐recombinogenic.	  
	  




Figure	  1.1:	  Enterovirus	  capsid	  morphology	  Non-­‐enveloped,	  spherical,	  around	  30	  nm	  in	  diameter,	  icosahedral	  capsid	  surrounding	  the	  naked	  RNA	  genome.	  The	  capsid	  consists	  of	  a	  icosahedral	  arrangement	  of	  60	  protomers,	  each	  consisting	  of	  4	  polypeptides,	  VP1,	  VP2,	  VP3	  and	  VP4.	  VP4	  is	  located	  on	  the	  internal	  side	  of	  the	  capsid.	  Source:	  http://viralzone.expasy.org/all_by_species/97.html.	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Capsid	  morphology	  
	  All	  enteroviruses	  share	  a	  similar	  morphology	  with	  virus	  proteins	  1-­‐3	  (VP1-­‐3)	  together	  forming	  the	  icosahedral	  shell	  of	  the	  virion	  with	  VP4	  distributed	  on	  the	  inner	  surface	  of	  the	  virus	  particle.	  Prior	  to	  proteolytic	  processing	  the	  capsid	  proteins	  are	  considered	  the	  protomer	  (Hogle	  et	  al.,	  1985)	  (figure	  1.1).	  VP1–3	  each	  has	  a	  similar	  basic	  structure	  consisting	  of	  an	  eight-­‐stranded	  anti-­‐parallel	  β-­‐	  barrel.	  Proteolytically	  processed	  monomers	  assemble	  into	  pentameric	  subunits,	  12	  of	  which	  go	  on	  to	  form	  the	  complete	  icosahedral	  shell	  of	  the	  virus.	  Enteroviruses	  have	  a	  deep	  depression	  encircling	  the	  fivefold	  axis	  below	  VP1	  (Tuthill	  et	  al.,	  2010).	  This	  region	  is	  known	  as	  a	  ‘canyon’	  and	  in	  many	  cases	  is	  the	  site	  of	  interaction	  with	  cellular	  receptors	  (Colonno	  et	  al.,	  1988,	  Bernhardt	  et	  al.,	  1994).	  	  
	  
Cellular	  receptors	  and	  tropism	  
Receptors	  upon	  the	  surface	  of	  host	  cells	  play	  a	  fundamental	  role	  in	  the	  entry	  of	  most	  viruses.	  In	  the	  case	  of	  enteroviruses	  they	  are	  involved	  in	  cell	  attachment,	  signalling	  and	  endocytosis	  (Tuthill	  et	  al.,	  2010).	  Many	  of	  the	  important	  virus-­‐receptor	  interactions	  have	  been	  extensively	  characterised	  for	  the	  enterovirus	  genus	  with	  many	  of	  the	  host	  receptors	  falling	  within	  the	  immunoglobin	  superfamily	  of	  receptors	  (table	  1.2).	  Intercellular	  adhesion	  molecule-­‐1	  (ICAM-­‐1)	  is	  the	  receptor	  for	  many	  of	  the	  rhinoviruses	  and	  some	  coxsackie	  viruses	  (Greve	  et	  al.,	  1989,	  Evans	  and	  Almond,	  1998).	  The	  receptor	  for	  poliovirus	  is	  cluster	  of	  differentiation	  155	  (CD155),	  also	  known	  as	  PVR.	  This	  receptor	  is	  only	  found	  upon	  cells	  of	  primates,	  suggesting	  that	  this	  virus	  did	  not	  emerge	  from	  any	  animal	  reservoir	  (Mendelsohn	  et	  al.,	  1989).	  For	  the	  remaining	  coxsackie	  group	  of	  viruses,	  the	  primary	  receptor	  is	  the	  Coxsackie	  and	  adenovirus	  receptor	  (CAR)	  which	  is	  a	  component	  of	  the	  tight	  junction	  between	  cells	  in	  intact	  epithelium	  (Coyne	  and	  Bergelson,	  2005).	  The	  use	  of	  Decay	  accelerating	  factor	  (DAF)	  as	  a	  receptor	  by	  separate	  enterovirus	  species	  groups,	  for	  example	  group	  B	  echovirus	  members	  to	  group	  C	  coxsackie,	  implies	  that	  there	  is	  a	  distinct	  selective	  advantage	  in	  its	  use	  (Evans	  and	  Almond,	  1998).	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Table	  1.2:	  Example	  enteroviruses	  and	  their	  receptors	  
Serotype	   Receptor	  
Poliovirus	  1-­‐3	   CD155	  (PVR)	  
Rhinovirus	  (major	  group)	   ICAM-­‐1	  
Coxsackie	  A13,	  A18,	  A21	   ICAM-­‐1	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1.2 	  	  	  	  	  	  Poliovirus	  life-­‐cycle	  	  Poliovirus,	  as	  previously	  stated	  is	  the	  prototypical	  picornavirus,	  and	  has	  been	  the	  most	  widely	  studied.	  Therefore,	  the	  following	  section	  upon	  the	  virus	  life	  cycle	  of	  a	  member	  of	  the	  enterovirus	  genus	  is	  based	  solely	  upon	  poliovirus.	  
	  
Attachment	  and	  entry	  
The	  primary	  site	  of	  receptor	  interaction	  (CD155)	  upon	  the	  virus	  capsid	  is	  within	  a	  hydrophobic	  pocket	  that	  lies	  at	  the	  base	  of	  the	  ‘canyon’	  found	  around	  the	  five-­‐fold	  axis.	  The	  binding	  of	  the	  receptor	  to	  the	  virus	  acts	  as	  a	  trigger	  for	  the	  initiation	  of	  capsid	  structural	  transitions	  that	  lead	  to	  the	  ejection	  of	  all	  of	  the	  internal	  VP4	  protein	  and	  exposure	  of	  the	  N	  terminus	  of	  VP1	  (Fricks	  and	  Hogle,	  1990).	  Isolation	  of	  virus	  that	  has	  gone	  through	  this	  transition	  has	  showed	  that	  the	  particles	  are	  no	  longer	  infectious	  when	  external	  to	  the	  cellular	  environment.	  These	  intermediate	  particles	  sediment	  more	  slowly	  on	  sucrose	  gradients	  than	  mature	  particles	  and	  are	  know	  as	  ‘A’	  particles,	  or	  135S	  particles	  (Fricks	  and	  Hogle,	  1990).	  The	  binding	  and	  transition	  of	  the	  mature	  particle	  to	  the	  intermediate	  ‘A’	  particle	  leads	  to	  internalisation	  by	  endocytosis.	  Discovery	  of	  empty	  particles	  (80S)	  that	  have	  shed	  their	  genomic	  load	  has	  shown	  that	  there	  is	  a	  second	  transition	  that	  accounts	  for	  the	  delivery	  of	  genomic	  RNA	  into	  the	  host	  cell	  (Tuthill	  et	  al.,	  2010).	  The	  externalized	  VP4	  and	  N-­‐terminus	  of	  VP1	  are	  believed	  to	  form	  pores	  in	  the	  host	  membrane	  that	  leads	  to	  viral	  RNA	  being	  translocated	  through	  the	  vesicle	  membrane	  into	  the	  cytoplasm	  of	  the	  host	  cell	  (Levy	  et	  al.,	  2010).	  
	  
Genome	  and	  translation	  
	  Every	  member	  of	  the	  enterovirus	  genus,	  including	  poliovirus,	  has	  a	  non-­‐segmented	  single-­‐stranded	  positive-­‐sense	  RNA	  genome	  that	  is	  ~7.5	  kb	  in	  length	  which	  encodes	  a	  single	  polyprotein	  from	  a	  lengthy	  open	  reading	  frame	  (ORF)	  that	  makes	  up	  around	  90%	  of	  the	  genome.	  The	  genome	  is	  covalently	  linked	  to	  a	  22	  amino	  acid	  peptide	  found	  at	  its	  5’	  end,	  termed	  virion	  genome	  linked	  protein	  (VPg)	  (Pathak	  et	  al.,	  2007).	  The	  ORF	  itself	  is	  flanked	  at	  either	  end	  by	  a	  non-­‐translated	  region	  (NTR).	  The	  5’	  NTR	  is	  approximately	  750	  nt	  in	  length	  with	  the	  3’	  NTR	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  The	  polyprotein	  can	  be	  divided	  into	  three	  functional	  regions:	  P1,	  P2	  and	  P3,	  and	  are	  cleaved	  co-­‐	  and	  post-­‐translationally	  by	  viral	  2A	  and	  3C/3CD	  protease	  activities.	  The	  2A	  protease	  is	  involved	  in	  a	  single	  processing	  event	  where	  it	  catalyzes	  cleavage	  at	  the	  VP1/2A	  boundary	  in	  cis	  at	  a	  Tyr/Gly	  amino	  acid	  pair	  to	  release	  the	  P1	  region	  from	  the	  rest	  of	  the	  polyprotein	  (Krausslich	  et	  al.,	  1989).	  The	  3C-­‐dependent	  protease	  activity	  of	  3CD,	  and	  perhaps	  other	  3C-­‐	  containing	  precursors,	  is	  responsible	  for	  the	  remaining	  polyprotein	  cleavage	  events	  that	  occur	  in	  trans,	  with	  all	  3C	  protease	  mediated	  cleavage	  occurring	  at	  Gln/Gly	  amino	  acid	  pairs	  (Cameron	  et	  al.,	  2010,	  Semler	  et	  al.,	  1981a,	  Semler	  et	  al.,	  1981b).	  The	  processing	  of	  P3	  proteins	  is	  via	  two	  separate	  pathways.	  In	  the	  major	  pathway	  processing	  between	  3B	  and	  3C	  yields	  the	  precursor	  proteins	  3AB	  and	  3CD,	  with	  the	  minor	  pathway	  producing	  3A	  and	  3BCD	  proteins.	  The	  3BCD	  protein	  can	  be	  further	  cleaved	  to	  produce	  3BC	  and	  3Dpol;	  3BC	  can	  be	  cleaved	  further	  to	  produce	  3B	  and	  3C	  (figure	  1.2B)	  (Lawson	  and	  Semler,	  1992,	  Pathak	  et	  al.,	  2008).	  The	  temporal	  cascade	  of	  slow	  and	  fast	  proteolytic	  events	  that	  occurs	  throughout	  the	  polyprotein	  ensures	  the	  availability	  of	  the	  necessary	  proteins	  and	  precursors	  to	  disrupt	  host	  functioning	  and	  allow	  virus	  replication.	  P1	  proteins	  are	  the	  capsid	  proteins.	  Four	  capsid	  proteins	  exist:	  VP1–4.	  VP1	  and	  VP3	  are	  produced	  via	  3C	  mediated	  protease	  cleavage.	  VP2	  and	  VP4	  are	  produced	  in	  assembled	  virus	  particles	  that	  contain	  genomic	  RNA	  by	  autocatalytic	  cleavage	  of	  the	  precursor	  VP0	  protein	  (Cameron	  et	  al.,	  2010).	  The	  protease	  activities	  of	  2A	  and	  3C	  proteins	  are	  not	  exclusively	  






Figure	  1.2:	  Poliovirus	  genome	  layout	  
(A)	  The	  5’end	  is	  VPg	  linked.	  The	  5’	  NTR	  contains	  the	  cloverleaf	  and	  IRES.	  The	  polyprotein	  ORF	  consists	  of	  viral	  proteins	  P1,	  P2,	  and	  P3.	  P1	  proteins	  make	  up	  the	  structural	  capsid	  proteins.	  The	  P2	  and	  P3	  proteins	  include	  all	  non-­‐structural	  proteins	  involved	  in	  formation	  of	  replication	  complexes	  and	  RNA	  replication.	  After	  the	  polyprotein	  is	  the	  3’	  NTR	  containing	  stems	  X	  +	  Y	  followed	  by	  a	  poly(A)	  tail.	  The	  2C	  CRE	  is	  shown	  as	  a	  stem	  loop.	  Source:	  (Jiang	  et	  al.,	  2007)	  (B)	  Genome	  structure	  and	  cleavage	  products	  of	  poliovirus	  coding	  sequence.	  The	  arrow	  beneath	  2A	  indicates	  cleavage	  performed	  by	  2A	  in	  cis;	  the	  purple	  triangles	  indicate	  3C	  mediated	  cleavage	  sites	  that	  occur	  in	  trans;	  the	  white	  triangle	  indicates	  a	  postulated	  autocatalytic	  cleavage	  event.	  Source:	  http://viralzone.expasy.org/all_by_species/97.html.	  
 	  
	  
	   	  
naturally determined by a duplication event (15). The Picornaviri-
dae encode a pair of paralogous cysteine proteases, 3Cpro conserved
in the entire family, and 2Apro specific for a subset including
entero/rhinoviruses. Because of the highly restricted phyletic dis-
tribution of 2Apro, it is likely that this p otease originated by a
duplication of a common 3Cpro in an ncestor of entero/
rhinoviruses. Phylogenetic analysis of proteases of entero/
rhinoviruses confirmed that 3Cpro and 2Apro form separate
branches, which are similarly organized and rooted [supporting
information (SI) Fig. 4]. Both branches contain a cluster ofHEV-Cs
next to clusters of other entero/rhinoviruses, implying that PV and
C-CAV have originated from an immediate common ancestor.
The trees shown in Fig. 1B–Dwere rooted according to the 2Apro
! 3Cpro tree, using six sequences representing HEV-A (CAV4),
HEV-B (CBV2), HEV-D (HEVD), human rhinovirus A (HRV2),
human rhinovirus B (HRVB), and bovine enterovirus (BEV2)
species that were designated as outgroup. The tree for the P1
region, where recombination is not common (16, 17), revealed a
fully resolved clustered organization: nine groups were identified in
the HEV-C, starting with CAV1/19/22, followed by CAV21/24,
CAV11/15, CAV17, CAV20, CAV13/18, and finally PV3, PV2, and
PV1 serotypes (in sequential order from the root; Fig. 1B; SI Fig.
5A). The capsid controls receptor specificity, and C-CAV capsid
evolution has been accompanied by a diversification of ICAM use
(although CAV1/19/22 and CAV17 are yet to be characterized in
this respect) (6). As our rooted tree suggests, this continuous
evolutionmust have eventually led to the replacement of the ICAM
specificity to that of CD155 in the PV ancestor. The three PVs that
have evolved from the ancestral PV refined this specificity. Ac-
cording to amaximum-likelihood estimate, contemporary PVsmay
be separated from the most recent common ancestors of PVs and
HEV-C at, respectively, the 0.086 and 0.364 distances in the PI
region. Hence, only a small fraction of mutations accumulated in
the PV capsid since the HEV-C origin has been used to evolve the
CD155 specificity.
In contrast to the P1 region, PVs and some C-CAVs (except the
CAV1/19/22 subcluster) interleave in a poorly resolved cluster in
phylogenetic trees generated for the P2!P3 region and its individ-
ual proteins (Fig. 1C; SI Fig. 5 B, D–L), in agreement with the
results of others (16, 17). This topology was confirmed by using a
more complicated model (amino acid GTR, using autocorrelated
gamma rate variation) in a MrBayes-mediated analysis and a
maximum-likelihood tree inferred using the TREE-PUZZLE
package (18) under default parameters (data not shown). The
P2!P3 region compared with the P1 region has accepted fewer
substitutions (compare Fig. 1 B andC), indicating that its evolution
has been constrained much stronger. Two polar effects, linked to
intervirus distances and relative polyprotein positions, are evident
in this region. First, the closer theC-CAVs are toPVs in theP1 area,
the more readily these viruses intertwine in trees generated for
proteins downstream of P1. Second, the closer a protein is located
to the C terminus of the P2!P3 regions, the larger is the number
of C-CAVs that intertwine with PVs. As a result of these trends,
only the most distant CAV1/19/22 subcluster remains separated
A
B C D
Fig. 1. Phylogenetic analysis of HEV-C viruses based on polyprotein sequences. (A) Genome organization of PV, which is representative for all C-cluster HEVs.
The single-stranded genomic RNA is covalently linked to the viral-encoded protein VPg at the 5" end of the NTR (5"NTR). The 5"NTR consists of two cis-acting
domains, the cloverleaf, and the IRES. The coding region (open box) depicts the structural (P1) and nonstructural (P2 and P3) regions. Within the 2CATPase coding
region, the cis replication element (cre) and the locus of the Gdn!HCl-resistant marker (gr) are indicated. The 3"NTR contains a heteropolymeric region and is
polyadenylated. (B–D) Phylogenetic analyses of HEV-C. Six sequences of picornaviruses that are distant from the HEV-C were designated as outgroup. Branch
points in the trees have a posterior probability#0.50. The bar at the bottom left indicates the number of changes per site. See SI Fig. 5 formore detailed versions
of these trees. Sequence names are listed in SI Table 3. (B) Tree for the structural (P1) region of the polyprotein. The pseudoroot and six major nodes that were
affected in five trees, generated by reshuffling (SI Materials and Methods), are labeled in alphabetic order from the root (indicated by ‘‘x’’). The original and
derived trees were used to verify the PV origin from C-CAVs using likelihood tests that supported, besides the original tree, only one with the least perturbed
topology (SI Table 4). (C) Tree for the nonstructural (P2!P3) region of the polyprotein. (D) Tree for the complete polyprotein.
9458 ! www.pnas.org"cgi"doi"10.1073"pnas.0700451104 Jiang et al.
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directed	  to	  the	  viral	  polypeptide.	  For	  example,	  cleavage	  of	  eIF-­‐4G	  by	  the	  2A	  protease	  disrupts	  the	  host	  translation	  machinery,	  inhibiting	  cap-­‐dependent	  translation.	  Additionally,	  the	  cleavage	  products	  enhance	  IRES	  driven	  translation.	  This	  ensures	  that	  the	  host	  cannot	  translate	  cellular	  mRNA	  and	  allows	  viral	  protein	  production	  to	  increase	  significantly	  (Ventoso	  et	  al.,	  1998,	  Etchison	  et	  al.,	  1982).	  Similarly,	  the	  activity	  of	  the	  3C	  protease	  has	  been	  shown	  to	  disrupt	  host	  cellular	  processes.	  An	  important	  host	  cell-­‐cycle	  regulatory	  protein,	  p53,	  is	  cleaved	  by	  the	  3C	  protease	  with	  the	  aid	  of	  other	  host	  proteins	  (Weidman	  et	  al.,	  2001)	  	  
RNA	  replication	  -­‐	  replication	  complex	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RNA	  Replication	  -­‐	  negative	  sense	  intermediate	  
	  To	  produce	  a	  genome	  of	  positive	  polarity,	  replication	  of	  the	  viral	  RNA	  occurs	  via	  a	  negative	  sense	  intermediate,	  with	  cis-­‐acting	  RNA	  elements	  found	  in	  the	  5’	  and	  3’	  NTRs	  of	  the	  positive	  strand	  genome	  playing	  a	  key	  role.	  The	  first	  88	  nt	  of	  the	  poliovirus	  5′	  NTR	  forms	  a	  ‘cloverleaf’	  structure	  that	  binds	  viral	  polypeptides	  3C	  (or	  the	  3CD	  precursor	  protein),	  as	  well	  as	  a	  host	  protein	  PCBP2	  (poly[rC]-­‐binding	  protein)	  to	  form	  a	  ribonucleoprotein	  complex	  (Andino	  et	  al.,	  1990).	  The	  binding	  of	  3CD	  to	  the	  cloverleaf	  structure	  specifically	  inhibits	  binding	  of	  the	  host	  translational	  machinery	  and	  thus	  ensures	  a	  transition	  from	  translation	  to	  replication.	  This	  important	  regulatory	  step	  ensures	  that	  there	  is	  no	  ribosome	  -­‐	  RdRp	  collisions	  (Gamarnik	  and	  Andino,	  1998).	  The	  genome	  is	  then	  circularized	  by	  the	  interaction	  of	  the	  poly(A)	  binding	  protein	  (PABP1),	  which	  is	  bound	  to	  the	  poly(rA)	  tail,	  to	  the	  5’NTR	  ribonucleoprotein	  structure	  (Wang	  et	  al.,	  1999).	  Additionally,	  it	  has	  been	  shown	  that	  3AB	  and	  3CD	  also	  bind	  to	  cis-­‐acting	  elements	  in	  the	  3’NTR	  known	  as	  stems	  X	  +	  Y	  and	  this	  interaction	  aids	  genome	  circularisation	  (Mellits	  et	  al.,	  1998)	  (figure	  1.3A).	  Importantly,	  another	  cis-­‐acting	  replication	  element	  within	  the	  2C	  region	  of	  the	  poliovirus	  genome	  is	  also	  critical	  in	  RNA	  replication.	  The	  61-­‐nt	  stem	  loop	  structure	  with	  a	  terminal	  loop	  consisting	  of	  an	  AAACA	  motif	  is	  highly	  conserved	  in	  enteroviruses	  and	  is	  formally	  known	  as	  the	  CRE	  (Goodfellow	  et	  al.,	  2000).	  The	  CRE	  stem	  loop	  structure	  binds	  3D,	  3CD	  and	  3B	  (VPg)	  in	  which	  the	  latter	  protein	  acts	  as	  primer	  for	  elongation	  by	  the	  3Dpol	  (RdRp).	  The	  primer	  VPg,	  is	  firstly	  modified	  by	  the	  addition	  of	  two	  covalently	  linked	  uridine	  nt	  to	  a	  tyrosine	  residue	  found	  at	  the	  3rd	  position	  of	  the	  protein	  with	  the	  template	  for	  the	  uridylylation	  process	  believed	  to	  be	  the	  poly(rA)	  tail	  (Paul	  et	  al.,	  1998,	  Steil	  and	  Barton,	  2009).	  This	  protein-­‐protein	  bridge	  interaction,	  that	  is	  reliant	  upon	  the	  cis-­‐acting	  RNA	  elements	  described,	  brings	  3CD	  into	  the	  proximity	  to	  the	  3’	  end	  of	  the	  genome	  so	  that	  when	  3CD	  is	  proteolytically	  processed	  the	  3Dpol	  (RdRp)	  can	  interact	  with	  VPg-­‐pU-­‐pU	  stimulating	  synthesis	  of	  the	  negative	  sense	  RNA	  (figure	  1.3B)	  (Andino	  et	  al.,	  1990,	  Herold	  and	  Andino,	  2001).	  The	  enzymatic	  activity	  of	  the	  RdRp	  itself	  is	  reliant	  upon	  higher	  order	  structures	  formed	  between	  RdRp	  monomers.	  Substitutions	  of	  residues	  at	  the	  two	  known	  RdRp	  interfaces	  involved	  in	  the	  higher	  order	  lattice-­‐like	  structures	  can	  be	  lethal	  (Tellez	  et	  al.,	  2011,	  Hobson	  et	  al.,	  2001).	  
	  





Figure	  1.3:	  Replication	  complex	  formation	  and	  negative	  sense	  RNA	  initiation	  
(A)	  Formation	  of	  the	  replication	  complex.	  PV	  RNA	  replication	  occurs	  in	  large	  ER	  membrane	  associated	  complexes.	  Viral	  P2	  proteins,	  2C	  and	  2BC,	  sequester	  host	  cell	  membranes.	  Depicted	  is	  the	  genome	  circularization	  event	  mediated	  by	  3CD	  that	  stimulates	  negative	  sense	  RNA	  synthesis.	  Host	  proteins	  are	  not	  shown	  (B)	  Representation	  of	  negative-­‐strand	  synthesis	  by	  3Dpol.	  P3	  proteins	  (3A,	  3B	  [VPg],	  3CD	  and	  3Dpol)	  are	  responsible	  for	  RNA	  replication.	  The	  CRE	  within	  2C	  (cis-­‐acting	  replication	  element)	  aids	  the	  interaction	  of	  the	  elongation	  complex	  to	  the	  3’	  end	  of	  the	  genome.	  Adapted	  from	  (Murray	  and	  Barton,	  2003).	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The	  outcome	  of	  this	  stage	  of	  RNA	  replication	  is	  a	  double	  stranded	  replicative	  form	  (RF)	  where	  both	  positive	  and	  negative	  genomes	  are	  present.	  The	  peak	  of	  antisense	  RNA	  synthesis	  occurs	  at	  4	  hrs	  post	  infection,	  where	  antisense	  strands	  are	  found	  at	  a	  ratio	  of	  40:1	  to	  70:1	  when	  compared	  to	  the	  positive	  strand	  genome	  (Novak	  and	  Kirkegaard,	  1991).	  	  	  
RNA	  Replication	  -­‐	  Positive	  sense	  genome	  
	  The	  newly	  synthesized	  negative	  sense	  RNA	  is	  anchored	  to	  the	  replication	  complex	  via	  interaction	  with	  the	  2C	  protein.	  This	  interaction	  has	  been	  shown	  to	  occur	  because	  negative	  strand	  replication	  initiation	  can	  be	  inhibited	  by	  a	  chemical	  called	  guanidine	  hydrochloride	  and	  mutants	  that	  are	  resistant	  to	  this	  chemical	  can	  be	  mapped	  to	  the	  2C	  region	  (Barton	  and	  Flanegan,	  1997).	  The	  synthesis	  of	  positive	  strand	  genomic	  RNA	  is	  again	  initiated	  from	  a	  VPg-­‐pU-­‐pU	  modified	  primer.	  However,	  the	  modification	  of	  the	  VPg	  primer	  for	  positive	  sense	  RNA	  production	  is	  dependent	  upon	  the	  terminal	  AAACA	  of	  the	  2C	  CRE,	  with	  the	  first	  ‘A’	  nt	  serving	  as	  the	  templating	  base	  (Goodfellow	  et	  al.,	  2003a,	  Paul	  et	  al.,	  2000).	  Indeed,	  cell	  free	  in	  vitro	  translation	  and	  replication	  assays	  have	  shown	  that	  the	  synthesis	  of	  antisense	  RNA	  is	  not	  inhibited	  by	  mutation	  of	  the	  2C	  CRE	  sequence	  whereas	  positive	  strand	  synthesis	  is	  (Goodfellow	  et	  al.,	  2003b,	  Murray	  and	  Barton,	  2003).	  Upon	  initiation	  of	  positive	  strand	  RNA	  synthesis,	  the	  double	  stranded	  RF	  is	  melted	  and	  multiple	  copies	  of	  positive	  sense	  RNA	  are	  produced	  by	  elongation	  of	  the	  VPg-­‐pU-­‐pU	  primer	  from	  the	  3’	  end	  of	  the	  antisense	  template.	  At	  this	  stage	  the	  antisense	  RNA	  acts	  as	  replicative	  intermediate	  where	  multiple	  copies	  of	  positive	  sense	  RNA	  are	  produced	  from	  a	  single	  template	  (figure	  1.4)	  (Barton	  and	  Flanegan,	  1997).	  
	  
Packaging	  and	  release	  
	  Following	  multiple	  rounds	  of	  RNA	  replication.	  Positive	  strand	  genome	  is	  packaged	  into	  newly	  formed	  capsid	  structures	  in	  a	  process	  called	  encapsidation.	  Unlike	  the	  well-­‐characterised	  steps	  of	  RNA	  replication,	  this	  step	  is	  poorly	  understood.	  Early	  encapsidation	  studies	  suggested	  that	  the	  VPg	  protein	  acted	  as	  a	  signal	  (Nomoto	  et	  al.,	  1977).	  However,	  this	  cannot	  be	  the	  sole	  determinant	  as	  both	  positive	  and	  negative	  sense	  RNA	  has	  VPg	  covalently	  attached.	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Figure	  1.4:	  Negative	  strand	  and	  Positive	  strand	  synthesis	  	  (1)	  Initiation	  of	  negative-­‐strand	  RNA	  synthesis	  from	  the	  positive-­‐strand	  genome	  leads	  to	  the	  formation	  of	  the	  (2)	  double	  stranded	  replicative	  form	  (RF).	  (3)	  Positive-­‐strand	  initiation	  from	  the	  negative-­‐strand	  RNA	  template.	  (4)	  The	  negative	  strand	  replicative	  intermediate	  (RI)	  RNA,	  initiation	  of	  multiple	  positive-­‐strands	  from	  a	  single	  negative-­‐strand	  RNA.	  Black	  circle	  represents	  the	  RdRp.	  Adapted	  from	  (Barton	  and	  Flanegan,	  1997).	  	  	  	  	  	  	  	  	  	  
FIG 1.7 Asymmetrical RNA replication. (1) Initiation of negative-strand RNA 
synthesis from the positive-strand genom . (2) Form tion of replicative  form (RF)  
dsRNA. (3) Positive-strand initiation from the negative-strand RNA template. (4) 
Replicative form (RI) RNA, initiation of multiple positive-strands from a single 
negative-strand RNA. Time represents RNA replication in HeLa cytoplasmic 
extracts. Black circle represents RdRP, 3Dpol. Adapted from Barton and Flanegan. 
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A	  recent	  study	  has	  suggested	  that	  the	  3AB	  and	  3CD	  proteins	  aid	  movement	  of	  newly	  synthesized	  viral	  RNA	  to	  capsid	  particles	  (Oh	  et	  al.,	  2009).	  Another	  study	  has	  shown	  that	  a	  specific	  interaction	  between	  2C	  and	  VP3	  is	  required	  to	  thread	  viral	  RNA	  into	  the	  capsid	  particle	  (Liu	  et	  al.,	  2010).	  Release	  of	  poliovirus,	  like	  most	  picornaviruses,	  is	  primarily	  due	  to	  lysis	  of	  the	  host	  cell.	  There	  is	  some	  evidence	  however	  that	  release	  of	  virus	  can	  occur	  prior	  to	  lysis	  via	  components	  of	  the	  autophagy	  pathway	  (Bird	  et	  al.,	  2014).	  
	  
	  
1.3 	  	  	  	  Evolution	  	  Distinct	  characteristics	  of	  RNA	  virus	  replication	  aid	  their	  constant	  evolution	  and	  ensure	  their	  survival.	  These	  include:	  high	  mutation	  rates	  due	  to	  the	  error-­‐prone	  nature	  of	  the	  viral	  RdRp,	  high	  yields	  of	  virus,	  and	  short	  replication	  times.	  As	  a	  consequence,	  RNA	  viruses	  like	  poliovirus	  replicate	  as	  complex	  and	  dynamic	  mutant	  swarms,	  called	  viral	  quasi-­‐species	  (Domingo	  and	  Holland,	  1997).	  The	  quasi-­‐species	  theory	  provides	  a	  population-­‐based	  framework	  that	  allows	  analysis	  of	  RNA	  virus	  evolution.	  Quasi-­‐species	  exist	  as	  a	  cloud	  of	  diverse	  variants	  continuously	  generated	  from	  a	  related	  RNA	  sequence	  due	  to	  mutation	  and	  the	  ensuing	  population	  heterogeneity	  is	  the	  primary	  reason	  that	  new	  strains	  continuously	  emerge	  following	  selection	  pressures	  of	  the	  host,	  or	  from	  antiviral	  treatment	  (Lauring	  and	  Andino,	  2010).	  	  
	  
Error-­‐prone	  nature	  of	  the	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  
	  An	  interesting	  characteristic	  of	  many	  viral	  RdRp’s	  is	  that	  they	  generally	  have	  relatively	  low	  fidelity,	  meaning	  they	  have	  a	  greater	  frequency	  of	  misincorporated	  nucleotides	  compared	  to	  DNA	  polymerases.	  The	  fidelity	  difference	  can	  be	  largely	  attributed	  to	  the	  lack	  of	  ‘proof-­‐reading’	  capability	  of	  the	  RdRp.	  In	  contrast,	  DNA	  polymerases	  exhibit	  3’-­‐exonucleolytic	  activity	  that	  aids	  correct	  nucleotide	  incorporation	  (Arnold	  et	  al.,	  1999).	  The	  poliovirus	  RdRp has	  an	  estimated	  misinsertion	  error	  rate	  ranging	  from	  1.2	  x	  10-­‐4	  to	  1	  x	  10-­‐6	  nt	  for	  transition	  mutations	  and	  3.2	  x	  10-­‐5	  to	  4.3	  x	  10-­‐7 nt for	  transversion	  mutations	  (Freistadt	  et	  al.,	  2007).	  This	  rate	  of	  mutation	  is	  very	  high	  when	  compared	  to	  DNA	  polymerases	  with	  exonuclease	  activity	  (typically	  10-­‐9	  misincorporations	  per	  nucleotide	  copied)	  (Domingo	  et	  al.,	  2002).	  The	  low	  fidelity	  characteristic	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typically	  means	  that	  the	  poliovirus	  RdRp	  inserts	  around	  two	  wrong	  bases	  per	  genome	  copied.	  This	  enables	  the	  virus	  to	  form	  sub-­‐populations,	  or	  quasi-­‐species,	  that	  differ	  from	  the	  parental	  virus	  by	  only	  one	  or	  more	  nucleotides	  (Vignuzzi	  et	  al.,	  2006).	  When	  fidelity	  and	  high	  population	  yields	  are	  taken	  together,	  the	  potential	  to	  select	  variants	  in	  the	  population	  that	  escape	  host	  or	  antiviral	  pressures	  becomes	  apparent.	  The	  selection	  of	  the	  three	  attenuated	  poliovirus	  serotypes	  that	  make	  up	  the	  oral	  polio	  vaccine	  (OPV)	  is	  a	  good	  example.	  All	  three	  were	  serially	  passaged	  in	  monkey	  cells,	  which	  eventually	  selected	  variants	  with	  multiple	  point	  mutations	  that	  were	  no	  longer	  able	  to	  replicate	  efficiently	  in	  human	  motor	  neuron	  cells	  and	  cause	  poliomyelitis.	  The	  attenuated	  viruses	  were	  still	  able	  to	  infect	  the	  gut	  cells,	  the	  site	  of	  natural	  infection,	  eliciting	  the	  desired	  immune	  response	  (Kew	  et	  al.,	  2005).	  Reversion	  of	  the	  attenuating	  phenotype	  by	  a	  point	  mutation	  (uracil-­‐to-­‐cytosine)	  at	  position	  472	  of	  PV3	  Sabin	  OPV	  within	  the	  5′	  NTR	  and	  its	  IRES	  has	  been	  associated	  with	  vaccine-­‐associated	  paralytic	  poliomyelitis	  (VAPP)	  (Gnanashanmugam	  et	  al.,	  2007).	  There	  is	  also	  a	  fine	  line	  between	  low	  fidelity	  and	  the	  ability	  of	  the	  virus	  to	  propagate	  successfully,	  and	  this	  can	  be	  used	  as	  a	  mechanism	  to	  attenuate	  a	  virus	  population.	  Many	  RNA	  viruses	  like	  poliovirus	  have	  an	  RdRp	  that	  exists	  on	  the	  edge	  of	  ‘error	  catastrophe’	  (Crotty	  and	  Andino,	  2002)	  with	  the	  majority	  of	  mutations	  encoded	  being	  lethal	  or	  deleterious	  (Stern	  et	  al.,	  2014,	  Acevedo	  et	  al.,	  2014).	  Any	  further	  decrease	  in	  polymerase	  fidelity	  may	  be	  lethal	  to	  the	  virus	  population.	  For	  example,	  as	  previously	  stated,	  the	  average	  misincorporation	  of	  nucleotide	  per	  genome	  copied	  in	  poliovirus	  is	  two.	  If	  this	  were	  to	  increase	  to	  four	  or	  above	  then	  the	  virus	  may	  be	  unable	  to	  propagate	  (Crotty	  and	  Andino,	  2002).	  Current	  antiviral	  efforts	  have	  focused	  on	  modifying	  the	  fidelity	  of	  the	  viral	  polymerase.	  Firstly,	  decreasing	  fidelity	  by	  use	  of	  nucleotide	  analogous	  like	  ribavirin	  that	  induces	  lethal	  mutagenesis	  of	  a	  viral	  population	  (Crotty	  et	  al.,	  2000,	  Crotty	  et	  al.,	  2001,	  Crotty	  and	  Andino,	  2002,	  Vignuzzi	  et	  al.,	  2005).	  Indeed,	  the	  antiviral	  ribavirin	  alongside	  pegylated	  interferon	  alpha	  is	  used	  in	  the	  treatment	  of	  those	  suffering	  chronic	  Hepatitis	  C	  infection	  (Deterding	  et	  al.,	  2013).	  Or	  secondly,	  by	  introduction	  of	  specific,	  well-­‐characterised	  point	  mutations	  that	  increase	  polymerase	  fidelity	  to	  reduce	  the	  adaptability	  of	  the	  virus	  population	  to	  the	  selection	  pressures	  of	  the	  host	  (Vignuzzi	  et	  al.,	  2006,	  Weeks	  et	  al.,	  2012).	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By	  understanding	  polymerase	  fidelity	  and	  the	  quasi-­‐species	  theory	  in	  positive	  strand	  RNA	  viruses	  allows	  a	  certain	  amount	  of	  prediction	  in	  virus	  evolution.	  For	  example	  extensive	  sequence	  analysis	  has	  highlighted	  that	  selection	  pressure	  differs	  depending	  upon	  the	  area	  of	  the	  genome	  you	  look	  at,	  with	  the	  capsid	  region	  being	  the	  most	  variable	  (Hyypia	  et	  al.,	  1997).	  However,	  the	  fidelity	  of	  the	  RdRp	  cannot	  solely	  account	  for	  variability	  and	  evolutionary	  rates	  in	  viruses	  like	  polio	  (Freistadt	  et	  al.,	  2007).	  Another	  key	  mechanism,	  genetic	  recombination,	  plays	  a	  vital	  role	  in	  the	  evolution	  of	  RNA	  viruses.	  
	  
Genetic	  Recombination	  
The	  process	  of	  recombination	  that	  takes	  place	  in	  RNA	  viruses	  results	  in	  the	  formation	  of	  hybrid	  RNA	  molecules	  from	  parental	  genomes	  of	  mixed	  origin.	  This	  process	  can	  occur	  within	  a	  single	  genomic	  segment,	  termed	  RNA	  recombination.	  For	  those	  viruses	  that	  possess	  segmented	  genomes,	  an	  exchange	  of	  entire	  genomic	  segments	  between	  viruses	  can	  occur	  and	  this	  exchange	  is	  usually	  termed	  reassortment.	  Although	  RNA	  recombination	  and	  reassortment	  are	  mechanistically	  very	  different,	  both	  require	  that	  two	  or	  more	  viruses	  infect	  the	  same	  host	  cell	  (Simon-­‐Loriere	  and	  Holmes,	  2011).	  Unlike	  ‘genetic	  drift’	  that	  is	  associated	  with	  the	  gradual	  accumulation	  of	  mutations,	  genetic	  recombination	  can	  lead	  to	  dramatic	  changes	  to	  significant	  parts	  of	  the	  genome.	  The	  ability	  to	  exchange	  vast	  regions	  of	  genetic	  information,	  in	  a	  process	  akin	  to	  sexual	  reproduction,	  not	  only	  aids	  rapid	  evolution	  it	  also	  frees	  advantageous	  mutations	  from	  deleterious	  genomic	  baggage	  (Simon-­‐Loriere	  and	  Holmes,	  2011).	  Recombination	  therefore	  provides	  a	  mechanism	  that	  ensures	  the	  mutational	  robustness	  of	  a	  viral	  population.	  The	  mechanisms	  of	  recombination	  in	  single	  stranded	  RNA	  viruses	  will	  now	  be	  considered.	  
	  
	  
Replicative	  ‘RdRp’	  dependent	  recombination	  -­‐	  ‘copy-­‐choice’	  
	  The	  most	  widely	  accepted	  model	  of	  RNA	  recombination	  is	  ‘copy	  choice’.	  In	  this	  process,	  the	  RdRp	  switches	  from	  one	  RNA	  molecule	  (the	  donor	  template)	  to	  another	  (the	  acceptor	  template)	  during	  synthesis	  of	  the	  negative	  sense	  RNA	  strand	  while	  remaining	  bound	  to	  the	  nascent	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nucleic	  acid	  chain.	  The	  product	  of	  this	  switch	  is	  a	  negative	  sense	  RNA	  molecule	  carrying	  sequence	  derived	  from	  both	  parental	  templates	  (figure	  1.5A)	  (Lai,	  1992a,	  Lai,	  1992b).	  The	  newly	  formed	  chimeric	  negative	  sense	  strand	  is	  then	  subsequently	  used	  as	  a	  template	  to	  produce	  positive	  sense	  RNA.	  Early	  experimental	  evidence	  strongly	  supports	  the	  notion	  that	  template	  exchange,	  or	  ‘copy-­‐choice’	  recombination	  occurs	  during	  negative	  strand	  synthesis	  (Kirkegaard	  and	  Baltimore,	  1986b).	  The	  Kirkegaard	  and	  Baltimore	  study	  used	  an	  approach	  involving	  a	  pair	  of	  poliovirus	  mutants	  whose	  RNA	  replication	  could	  be	  suppressed	  by	  incubations	  at	  either	  a	  restrictive	  temperature	  or	  in	  the	  presence	  of	  guanidine	  hydrochloride	  (a	  potent	  inhibitor	  on	  antisense	  RNA	  synthesis).	  The	  conditions	  restrictive	  for	  one	  or	  the	  other	  of	  the	  partners	  could	  be	  predicted	  to	  differently	  affect	  the	  frequency	  of	  recombination.	  The	  experimental	  findings	  were	  strongly	  in	  favour	  of	  the	  ‘copy-­‐choice’	  model	  (Kirkegaard	  and	  Baltimore,	  1986b).	  Two	  additional	  factors	  may	  also	  account	  for	  the	  preferred	  occurrence	  of	  recombination	  during	  negative	  strand	  synthesis.	  Firstly,	  the	  availability	  of	  acceptor	  template	  is	  presumed	  to	  have	  a	  direct	  impact	  upon	  recombination	  frequency	  (Jarvis	  and	  Kirkegaard,	  1992).	  During	  an	  infection,	  positive	  sense	  strands	  are	  far	  more	  abundant	  than	  negative	  sense	  templates.	  Secondly,	  the	  synthesis	  of	  the	  negative	  sense	  strand	  leads	  to	  the	  formation	  of	  a	  double	  stranded	  replicative	  form	  (RF).	  The	  availability	  of	  the	  negative	  strand	  template	  for	  any	  recombination	  event	  will	  therefore	  be	  limited	  (Agol,	  1997).	  	  	  
It	  is	  logical	  to	  assume	  that	  for	  replicative	  recombination	  to	  occur	  parental	  RNA	  will	  need	  to	  be	  in	  close	  proximity,	  i.e.	  inside	  the	  same	  replication	  complex.	  Recombination	  has	  been	  shown	  to	  occur	  in	  vitro	  between	  two	  different	  poliovirus	  serotypes	  as	  early	  as	  2.5	  hrs	  post	  infection	  (Egger	  and	  Bienz,	  2002).	  A	  fluorescent	  in	  situ	  hybridisation	  (FISH)	  technique	  that	  used	  type	  specific	  riboprobes	  showed	  that	  replication	  of	  the	  two	  serotypes	  initiated	  at	  distinct	  sites	  that	  later	  overlapped	  at	  specific	  peri-­‐nuclear	  locations,	  providing	  a	  clear	  opportunity	  for	  recombination	  to	  occur.	  Subsequent	  RT-­‐PCR	  analysis	  confirmed	  recombination	  between	  the	  PV1	  (Mahoney)	  and	  PV2	  (Sabin)	  serotypes	  (Egger	  and	  Bienz,	  2002).	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Template	  switching	  that	  occurs	  at	  regions	  of	  sequence	  similarity	  between	  the	  nascent	  and	  the	  acceptor	  nucleic	  acid	  molecules,	  is	  deemed	  ‘precise’	  or	  ‘homologous’	  because	  no	  additional	  sequences	  are	  generally	  present	  (Lai,	  1992b).	  ‘Imprecise	  recombination’	  may	  also	  occur.	  Sequence	  similarity	  between	  the	  two	  parental	  sequences	  may	  be	  close	  to,	  although	  not	  necessarily	  at,	  the	  crossover	  site.	  This	  can	  produce	  a	  genome	  where	  additional	  sequence,	  deletions	  or	  nucleotide	  mismatches	  may	  be	  present	  (Nagy	  and	  Simon,	  1997,	  Agol,	  1997).	  Under	  these	  circumstances	  the	  genome	  may	  still	  be	  functional	  providing	  a	  full	  complement	  of	  viral	  protein	  encoding	  genes	  are	  present.	  The	  role	  of	  deletion	  via	  ‘imprecise	  recombination’	  can	  account	  for	  the	  formation	  of	  defective	  interfering	  particles	  (DI).	  Following	  extensive	  passaging,	  poliovirus	  species	  lacking	  >10%	  of	  their	  genome	  have	  been	  isolated	  (Cole	  et	  al.,	  1971).	  In	  these	  examples	  deletions	  were	  in	  frame	  and	  found	  within	  the	  capsid-­‐coding	  region	  of	  the	  genome.	  The	  encapsidation	  of	  the	  defective	  genomes	  was	  only	  possible	  due	  to	  the	  presence	  of	  a	  helper	  virus	  that	  could	  produce	  the	  required	  intact	  capsid	  proteins	  (Agol,	  1997).	  Analysis	  of	  other	  serotypes	  of	  PV	  that	  produced	  (DI)	  particles	  showed	  no	  specificity	  to	  location	  of	  deletion,	  and	  ruled	  out	  the	  potential	  for	  cryptic	  ribozyme	  or	  host	  endonuclease	  activity.	  This	  indicated	  a	  random	  template	  switch	  during	  replication	  rather	  than	  any	  other	  non-­‐replicative	  mechanism	  (Kuge	  et	  al.,	  1986).	  Genetic	  exchange	  between	  different,	  and	  genetically	  dissimilar,	  genomic	  regions	  or	  between	  non-­‐related	  RNA	  molecules,	  can	  lead	  to	  ‘non-­‐homologous’	  recombination.	  As	  non-­‐homologous	  RNA	  recombination	  involves	  regions	  with	  little	  sequence	  similarity,	  it	  will	  often	  produce	  non-­‐functional	  genotypes	  (figure	  1.5B)	  (Simon-­‐Loriere	  and	  Holmes,	  2011).	  
	  
‘Forced	  copy-­‐choice’	  and	  non-­‐replicative	  recombination	  
Unlike	  ‘copy-­‐choice’	  where	  the	  donor	  template	  is	  intact	  a	  process	  termed	  ‘forced	  copy-­‐choice’	  can	  account	  for	  genetic	  recombination.	  Early	  work	  with	  retroviruses	  has	  shown	  that	  the	  template-­‐switching	  event	  occurs	  when	  there	  is	  a	  break	  in	  the	  donor	  template	  that	  forces	  the	  reverse	  transcriptase	  (RT)	  to	  seek	  an	  alternate	  functional	  template.	  In	  this	  process	  sequence	  homology	  of	  the	  nascent	  strand	  may	  dictate	  where	  the	  polymerase	  anneals	  upon	  the	  acceptor	  template	  (Coffin,	  1979).	  Additionally,	  chimeric	  RNA	  molecules	  can	  be	  formed	  in	  a	  non-­‐replicative	  way	  that	  does	  not	  involve	  any	  polymerase	  activity.	  Studies	  involving	  non-­‐replicative	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truncated	  PV	  partners	  and	  bacteriophage	  Qβ	  suggested	  that	  a	  trans-­‐esterification	  reaction	  involving	  both	  templates	  occurred	  that	  produced	  a	  fully	  functional	  genome	  (Gmyl	  et	  al.,	  1999,	  Gmyl	  et	  al.,	  2003,	  Chetverin	  et	  al.,	  1997).	  Alternatively,	  studies	  involving	  pestiviruses	  and	  Hepatitis	  C	  virus	  have	  postulated	  the	  involvement	  of	  cellular	  exonucleases	  and	  RNA	  ligases	  in	  the	  process	  of	  recombination	  (Scheel	  et	  al.,	  2013,	  Galli	  and	  Bukh,	  2014,	  Gallei	  et	  al.,	  2004).	  
	  
Examples	  of	  recombination	  in	  enteroviruses	  
Genetic	  evidence	  for	  recombination	  between	  viral	  RNAs	  was	  first	  reported	  in	  the	  early	  1960s.	  Mixed	  infections	  of	  two	  strains	  of	  poliovirus	  where	  each	  exhibited	  a	  characteristic	  phenotype	  (e.g.	  resistance	  to	  guanidine	  hydrochloride	  or	  resistance	  to	  inhibitors	  found	  in	  bovine	  sera)	  resulted	  in	  the	  appearance	  of	  variants	  expressing	  the	  two	  markers	  simultaneously	  (Hirst,	  1962,	  Ledinko,	  1963).	  In	  recipients	  of	  the	  live	  attenuated	  poliovirus	  vaccine	  recombinants	  are	  excreted	  within	  7	  days	  (Cammack	  et	  al.,	  1988,	  Guillot	  et	  al.,	  2000,	  Cuervo	  et	  al.,	  2001).	  Indeed,	  recombination	  between	  the	  Sabin	  vaccine	  strains	  and	  co-­‐circulating	  enteroviruses	  contribute	  to	  minor	  outbreaks	  of	  poliomyelitis	  in	  areas	  of	  low	  vaccination	  coverage	  (Kew	  et	  al.,	  2002).	  Three	  groups	  of	  rhinoviruses	  (A-­‐C)	  currently	  fall	  within	  the	  enterovirus	  genus	  and	  there	  is	  evidence	  for	  frequent	  recombination	  between	  group	  A	  and	  group	  C	  that	  involves	  the	  adjacent	  5’NTR	  and	  VP2/VP4	  genome	  regions	  (Lukashev,	  2010).	  Genetic	  drift	  is	  reliant	  upon	  random	  mutation.	  Sequence	  analysis	  of	  six	  coxsackie	  B	  viruses	  (CVB	  -­‐	  species	  B)	  serotypes	  over	  a	  26-­‐year	  period	  showed	  that	  all	  clinical	  isolates	  over	  this	  period	  were	  recombinant	  relative	  to	  the	  prototype	  strain	  of	  the	  same	  serotype	  (Oberste	  et	  al.,	  2004a).	  Furthermore,	  studies	  have	  indicated	  that	  recombinant	  forms	  of	  particular	  human	  enterovirus	  serotypes	  appear	  in	  a	  population,	  are	  successful	  in	  certain	  geographical	  regions	  and	  then	  are	  rapidly	  replaced	  in	  a	  predictable	  manner	  with	  characteristic	  half-­‐lives	  (Leitch	  et	  al.,	  2009,	  McWilliam	  Leitch	  et	  al.,	  2012).	  The	  advancement	  in	  phylogenetic	  analysis	  clearly	  shows	  that	  recombination	  that	  leads	  to	  ‘genetic	  shift’	  in	  areas	  outside	  of	  the	  capsid-­‐coding	  region	  is	  a	  major	  mechanism	  used	  by	  this	  group	  of	  viruses	  to	  continuously	  evolve.	  
	  





Figure	  1.5:	  Replicative	  ‘copy-­‐choice’	  models	  of	  RNA	  recombination	  




Figure 1.5 Current replication-dependent template switching models for RNA 
recombination. (A) Tem late switching during replication. The RdRp exchanges 
one template (donor) for another (acceptor) at corresponding positions in the 
genome. There are several possibilities as to why the RdRp is removed from the 
donor template (see text). (B) Diagrams depicting precise and imprecise 
rec mbination events during replication. Non-homologous recombination is also 
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Factors	  influencing	  recombination	  
The	  result	  of	  many	  separate	  recombination	  events	  have	  been	  observed	  and	  characterized	  in	  nature,	  with	  attempts	  made	  to	  relate	  recombination	  junctions	  to	  particular	  sequences	  and	  secondary	  structures	  within	  the	  virus	  genome.	  At	  present,	  it	  is	  suggested	  that	  the	  RdRp	  pauses	  or	  terminates	  at	  certain	  RNA	  sequence	  motifs	  (Nagy	  and	  Bujarski,	  1997).	  Sequence	  signals	  include:	  A/U	  –	  rich	  and	  U	  –	  rich	  sequences,	  which	  may	  promote	  polymerase	  slippage	  (King,	  1988a).	  Other	  factors	  that	  are	  thought	  to	  play	  a	  role	  in	  recombination	  junctions	  are	  the	  ability	  of	  the	  parental	  RNA	  strands	  to	  form	  stable	  heteroduplexes	  near	  or	  at	  the	  recombination	  junctions	  (Romanova	  et	  al.,	  1986).	  Additionally,	  long	  hairpin	  structures	  within	  one/both	  parental	  strand	  at	  the	  recombination	  junction	  are	  linked	  to	  an	  advanced	  opportunity	  to	  recombine	  (Tolskaya	  et	  al.,	  1987,	  Dedepsidis	  et	  al.,	  2010).	  Indeed,	  a	  recent	  study	  on	  intratypic	  recombination	  involving	  PV1	  tagged	  with	  synonymous	  mutations	  showed	  that	  sequence	  composition	  and	  RNA	  structure	  correlated	  with,	  in	  a	  predictable	  and	  modifiable	  manner,	  recombination	  hotspots	  (Runckel	  et	  al.,	  2013).	  Alongside	  this,	  nucleotide	  mismatches	  have	  also	  been	  linked	  to	  replicase	  stalling	  and	  template	  exchange	  during	  RNA	  replication	  (Agol,	  1997).	  	  
	  
It	  could	  be	  fair	  to	  say	  that	  our	  understanding	  of	  the	  mechanisms	  and	  factors	  that	  contribute	  to	  replicative	  recombination	  in	  enteroviruses	  have	  not	  advanced	  that	  much	  from	  the	  initial	  findings	  of	  the	  mid	  1980’s.	  Only	  indirect	  discussion	  can	  be	  formed	  due	  to	  the	  methodology	  previously	  employed.	  There	  is	  potential	  to	  suggest	  that	  the	  historical	  isolates	  that	  have	  been	  characterised	  may	  not	  accurately	  represent	  the	  initial	  product	  of	  recombination.	  The	  majority	  of	  recombinant	  sequences	  analysed	  thus	  far	  in	  previous	  studies	  have	  been	  gained	  either	  from	  highly	  selected	  field	  isolates,	  or	  from	  in	  vitro	  studies	  that	  have	  used	  permissive	  and	  susceptible	  cell	  lines	  like	  HeLa.	  There	  is	  a	  risk	  that	  selection	  pressure	  in	  this	  highly	  dynamic	  environment	  has	  allowed	  the	  characterisation	  of	  only	  those	  recombinants	  that	  are	  ‘fit’	  enough	  to	  compete.	  Additionally,	  experimental	  data	  is	  limited	  as	  there	  is	  currently	  no	  efficient	  cell-­‐free	  system	  that	  recapitulates	  the	  recombination	  event.	  	  
	   41	  
1.4 	  	  	  	  	  Aims	  	  Recombination	  clearly	  plays	  a	  significant	  role	  in	  the	  evolution	  of	  RNA	  viruses	  including	  enteroviruses.	  The	  triggers	  and	  the	  specific	  mechanisms	  of	  recombination	  in	  enteroviruses	  remains	  poorly	  understood	  with	  no	  consensus	  on	  sequence	  motifs	  or	  location.	  The	  aim	  of	  this	  study	  was	  to	  build	  on	  an	  in	  vitro	  experimental	  system	  developed	  by	  a	  previous	  student,	  Kym	  Lowry.	  The	  elegant	  cell	  based	  assay	  allows	  the	  isolation	  and	  subsequent	  characterisation	  of	  intertypic	  and	  intratypic	  poliovirus	  recombinants	  in	  the	  absence	  of	  parental	  genomes.	  Importantly,	  competition	  and	  selection	  pressures	  are	  minimised	  as	  much	  as	  possible.	  	  
Specific	  aims	  
• To	  quantify	  relative	  recombination	  frequency	  between	  intratypic	  and	  intertypic	  poliovirus	  partners	  
• To	  identify	  differences	  in	  early	  recombinants	  to	  those	  following	  serial	  passage	  /	  selection	  
• To	  determine	  if	  recombination	  is	  primarily	  a	  replicative	  or	  non-­‐replicative	  process	  
• To	  determine	  the	  characteristics	  of	  the	  RNA	  dependent	  RNA	  polymerase	  that	  are	  important	  in	  template	  switching	  
• To	  expand	  the	  original	  Lowry	  in	  vitro	  cell	  based	  recombination	  assay	  
• To	  develop	  a	  cell-­‐free	  biochemical	  assay	  to	  characterise	  the	  template	  switching	  event	  
• To	  investigate	  if	  RNA	  sequence	  or	  structure	  influences	  recombination	  frequency	  and,	  or	  location	  
• To	  develop	  a	  reproducible	  fluorescent	  in	  situ	  hybridisation	  (FISH)	  approach	  that	  would	  allow	  observation	  of	  RNA	  location	  during	  a	  co-­‐infection	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CHAPTER	  2:	  Materials	  and	  Methods	  	  
2.1 Cell	  Culture	  and	  Virological	  Methods	  
 
2.1.1 Cell	  maintenance	  	  Human	  cervical	  (HeLa),	  human	  embryonic	  rhabdomyosarcoma	  (RD),	  human	  embryonic	  kidney	  (HEK293T),	  and	  murine	  fibroblast	  (L929)	  cells	  were	  grown	  as	  monolayers	  in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	  supplemented	  with	  100	  μg/ml	  of	  streptomycin,	  100	  U/ml	  of	  penicillin,	  2	  mM	  L-­‐glutamine,	  and	  10%	  heat	  inactivated	  (HI)-­‐foetal	  bovine	  serum	  (FBS).	  Baby	  hamster	  kidney	  cells	  stably	  transfected	  with	  a	  T7	  RNA	  polymerase	  expression	  plasmid	  (BsrT7)	  were	  maintained	  in	  Glasgow	  Minimum	  Essential	  Medium	  (GMEM)	  supplemented	  with	  100	  μg/ml	  of	  streptomycin,	  100	  U/ml	  of	  penicillin,	  2	  mM	  L-­‐glutamine,	  and	  10%	  HI-­‐FBS.	  Antibiotic	  G418	  was	  also	  added	  to	  BsrT7	  cell	  medium	  to	  select	  cells	  containing	  the	  T7	  RNA	  polymerase	  gene	  under	  control	  of	  the	  cytomegalovirus	  (CMV)	  promoter	  and	  the	  neomycin	  resistance	  gene	  (Buchholz	  et	  al.,	  1999).	  All	  cells	  were	  passaged	  using	  trypsin-­‐	  ethylenediaminetetracetic	  acid	  (EDTA).	  
2.1.2 RNA	  transfection	  of	  mammalian	  cell	  lines	  	  Purified	  RNA	  (amounts	  as	  specified	  elsewhere)	  in	  H2O	  was	  made	  up	  to	  100	  μl	  in	  serum	  and	  antibiotic	  free	  medium	  and	  mixed	  with	  an	  equal	  volume	  solution	  of	  Lipofectamine	  2000	  (3:1	  Lipofectamine	  2000	  to	  μg	  RNA),	  (Invitrogen)	  in	  similar	  medium.	  The	  mixture	  was	  incubated	  according	  to	  the	  manufacturer’s	  instructions	  and	  added	  to	  cell	  monolayers	  in	  either	  6	  or	  12-­‐well	  tissue	  culture	  plates.	  
2.1.3 Luciferase	  assay	  	  Supernatant	  was	  removed	  from	  transfected	  cell	  monolayers,	  cells	  were	  briefly	  washed	  with	  PBS	  and	  lysed	  using	  200	  μl	  1	  x	  Glo	  Lysis	  Buffer	  (Promega®)	  per	  well	  in	  a	  12-­‐	  well	  plate.	  The	  oxidation	  reaction	  was catalysed	  by	  the	  addition	  of	  50	  μl	  cell	  lysate	  (luciferase	  enzyme)	  to	  50	  μl	  room	  temperature	  Bright-­‐GloTM	  Luciferase	  Assay	  System	  (Promega®)	  substrate	  and	  shielded	  from	  the	  light	  for	  5	  mins.	  Luciferase	  activity	  was	  measured	  using	  a	  luminometer	  (Turner	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Biosystems)	  with	  values	  normalised	  to	  mock	  transfection	  controls.	  
2.1.4 Isolation	  of	  media	  from	  transfected	  cells	  	  Media	  from	  individually	  or	  co-­‐transfected	  cells	  was	  isolated	  at	  48-­‐72	  hrs	  post	  transfection.	  Any	  cellular	  debris	  was	  pelleted	  by	  centrifugation,	  with	  media	  being	  placed	  into	  new	  1.5	  ml	  microfuge	  tubes.	  Plaque	  assays	  were	  then	  carried	  out	  to	  detect	  virus.	  
2.1.5 Tissue	  culture	  infectious	  dose50	  (TCID50)	  	  Recombinant	  virus	  from	  co-­‐transfections	  was	  titred	  by	  TCID50	  which	  measures	  the	  quantity	  of	  virus	  required	  to	  infect	  50%	  of	  inoculated	  microplate	  wells	  per	  sample	  (Minor,	  1985).	  Each	  well	  of	  96-­‐well	  plates	  was	  seeded	  with	  2.5	  x	  104	  HeLa	  cells,	  allowing	  for	  four	  replicates	  of	  titration	  per	  sample.	  In	  a	  separate	  96-­‐well	  round-­‐bottomed	  plate,	  a	  serial	  10-­‐fold	  dilution	  of	  sample	  with	  DMEM/10%	  FBS/penicillin-­‐	  streptomycin	  (PS)	  from	  10-­‐1	  to	  10-­‐12	  was	  performed.	  Media	  was	  removed	  from	  confluent	  cells,	  100	  μl	  of	  the	  appropriate	  virus	  dilution	  was	  added	  to	  each	  well,	  (including	  100	  μl	  DMEM/10%	  FBS/PS	  to	  control	  wells)	  and	  incubated	  for	  1	  hour	  at	  37°C/5%	  CO2.	  An	  extra	  100	  μl	  DMEM/10%	  FBS/PS	  was	  added	  per	  well	  and	  plates	  were	  incubated	  for	  four	  days.	  Plates	  were	  stained	  with	  crystal	  violet	  for	  one	  hour	  and	  rinsed	  with	  tap	  water	  before	  drying	  upside	  down	  on	  paper	  towel. Virus	  titre	  was	  expressed	  as	  log10	  TCID50/ml	  (Reed	  &	  Muench,	  1938).	  
2.1.6 Plaque	  assay	  	  RD	  or	  HeLa	  cells	  were	  seeded	  in	  6	  or	  12-­‐well	  plates	  and	  grown	  to	  95%	  confluency.	  Where	  appropriate	  ten-­‐fold	  dilutions	  of	  virus	  stock	  were	  made	  in	  DMEM.	  Once	  medium	  was	  removed	  from	  seeded	  wells,	  cells	  were	  washed	  with	  sterile	  PBS	  then	  inoculated	  with	  500	  μl	  of	  prepared	  virus	  and	  incubated	  for	  30	  mins	  at	  37°C	  in	  the	  presence	  of	  5%	  CO2/air	  to	  allow	  absorption	  to	  occur.	  Plaque	  overlay	  media	  (refer	  to	  section	  2.6	  for	  contents)	  was	  added	  to	  each	  well	  and	  plates	  were	  incubated	  inverted	  for	  two	  to	  three	  days	  at	  37°C	  in	  the	  presence	  of	  5%	  CO2/air.	  Cells	  were	  stained	  with	  crystal	  violet	  solution	  and	  re-­‐stained	  post-­‐removal	  of	  the	  plaque	  overlay	  media.	  Plaques	  were	  counted	  and	  the	  virus	  titre	  expressed	  as	  plaque	  forming	  units	  per	  millilitre	  (PFU/ml).	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2.1.7 Plaque	  purification	  by	  limiting	  dilution	  	  Recombinant	  virus	  from	  RNA	  transfections	  was	  biologically	  cloned	  by	  limiting	  dilution	  in	  96-­‐well	  microtitre	  plates.	  Virus	  dilutions	  were	  performed	  using	  a	  multichannel	  pipette	  in	  a	  round	  bottomed	  96-­‐well	  microtitre	  plate	  (Sterilin)	  prior	  to	  transfer	  onto	  fresh	  cell	  monolayers.	  Fifty-­‐five	  microlitres	  of	  serum-­‐free	  media	  was	  added	  to	  each	  well	  prior	  to	  addition	  of	  diluted	  virus.	  Approximately	  55	  μl	  diluted	  virus	  supernatant	  was	  added	  to	  each	  well	  in	  the	  top	  row.	  After	  mixing	  by	  pipetting,	  55	  μl	  of	  solution	  was	  transferred	  to	  the	  next	  row	  (already	  containing	  55	  μl	  serum-­‐	  free	  media).	  Pipette	  tips	  were	  discarded	  after	  the	  mixture	  was	  mixed	  in	  each	  row	  and	  these	  two-­‐fold	  dilutions	  continued	  down	  the	  plate.	  Fifty	  microlitres	  was	  transferred	  from	  each	  well	  onto	  a	  fresh	  cell	  monolayer	  in	  flat	  bottomed	  96-­‐well	  plates	  seeded	  with	  2.6	  x	  104	  HeLa	  cells/well.	  The	  plates	  were	  left	  to	  allow	  for	  virus	  absorption	  for	  30	  mins	  at	  37°C	  in	  the	  presence	  of	  5%	  CO2/air.	  An	  extra	  200	  μl	  serum-­‐free	  media	  was	  added	  to	  each	  well	  and	  plates	  were	  incubated	  at	  37°C/5%	  CO2/air.	  After	  4	  days,	  the	  supernatant	  was	  transferred	  to	  a	  new	  microtitre	  plate	  and	  cell	  monolayers	  were	  stained	  by	  crystal	  violet	  for	  the	  presence	  of	  complete	  CPE.	  RNA	  was	  extracted	  from	  the	  highest	  dilution	  of	  virus	  supernatant	  per	  column	  and	  RT-­‐PCR	  was	  carried	  out	  to	  amplify	  the	  crossover	  region	  of	  the	  recombinant	  virus.	  
2.1.8 Virus	  infections	  	  Cell	  monolayers	  (RD	  or	  HeLa)	  were	  inoculated	  with	  virus	  at	  the	  stated	  MOI.	  Virus	  was	  absorbed	  onto	  monolayers	  for	  30	  mins	  at	  37°C/5%	  CO2/air.	  Virus	  supernatant	  was	  removed	  and	  replaced	  with	  medium	  supplemented	  with	  or	  without	  10%	  HI-­‐FBS.	  For	  passaging,	  virus	  supernatant	  was	  removed	  24	  hours	  post-­‐infection,	  upon	  completion	  of	  full	  cytopathic	  effect	  (CPE;	  appearance	  of	  cell	  rounding	  or	  detached	  cells).	  
2.1.9 Disruption	  of	  cellular	  microtubules	  and	  nocodazole	  treatment	  	  Following	  the	  protocol	  taken	  from	  Egger	  &	  Bienz,	  2005.	  To	  disrupt	  microtubules,	  cells	  were	  kept	  for	  10	  min	  at	  0°C.	  Nocodazole	  at	  concentrations	  of	  5	  mM	  (Sigma)	  was	  added	  to	  prevent	  re-­‐polymerization	  of	  microtubules	  upon	  rewarming	  to	  37°C.	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2.2 Molecular	  Genetic	  Techniques	  	  
2.2.1 Plasmid	  DNA	  extractions	  from	  Escherichia	  coli	  using	  commercial	  kits	  	  	  Overnight	  cultures	  (5	  ml	  and	  100	  ml)	  of	  transformed	  E.	  coli	  in	  Lysogeny	  broth	  (LB)	  broth	  with	  the	  appropriate	  antibiotic	  for	  selection	  were	  pelleted	  in	  preparation	  for	  mini-­‐preps	  and	  midi-­‐preps	  respectively.	  Small-­‐scale	  isolations	  were	  carried	  out	  using	  GeneJETTM	  Plasmid	  Mini-­‐prep	  Kit	  (Fermentas)	  according	  to	  the	  protocol	  provided.	  Plasmid	  DNA	  was	  eluted	  in	  50	  μl	  distilled	  H2O.	  Medium	  scale	  isolations	  were	  performed	  according	  to	  the	  instructions	  supplied	  with	  the	  QIAfilterTM	  Plasmid	  Midi	  Kit	  (Qiagen)	  and	  DNA	  was	  re-­‐suspended	  in	  200	  μl	  dH2O.	  A	  list	  of	  plasmids/replicons	  used	  during	  this	  project	  is	  outlined	  in	  table	  2.1	  at	  the	  end	  of	  this	  chapter.	  
2.2.2 Virus	  RNA	  extractions	  from	  cell	  culture	  supernatant	  	  RNeasy	  Mini	  Kit	  (Qiagen)	  was	  used	  for	  RNA	  extraction	  from	  supernatant	  recovered	  from	  virus	  infections	  or	  transfections	  according	  to	  the	  manufacturer’s	  instructions.	  RNA	  was	  stored	  at	  	  	  	  	  	  	  	  	  -­‐80°C	  and	  was	  thawed	  in	  an	  ice	  bath	  when	  required.	  
2.2.3 PCR	  product	  column	  clean	  up	  	  	  QIAquickPCR®	  Purification	  Kit	  (Qiagen)	  was	  used	  for	  purification	  of	  DNA	  from	  PCR	  reactions	  according	  to	  the	  manufacturer’s	  instructions.	  DNA	  was	  stored	  at	  -­‐20°C	  until	  required.	  
2.2.4 Extraction	  of	  DNA	  from	  agarose	  gel	  	  Deoxyribonucleic	  acid	  fragments	  were	  extracted	  from	  agarose	  gel	  using	  the	  DNA	  Extraction	  Kit	  (Qiagen)	  according	  to	  the	  manufacturer’s	  instructions.	  The	  DNA	  was	  eluted	  in	  20	  -­‐	  40	  μl	  dH2O	  and	  quantitated	  by	  spectrophotometry	  and	  then	  used	  for	  all	  down-­‐stream	  activities.	  
2.2.5 Transformation	  of	  E.	  coli	  with	  plasmid	  DNA	  	  Around	  3	  μl	  ligation	  mixture	  (or	  1	  μl	  plasmid	  DNA	  where	  appropriate)	  was	  added	  to	  50	  μl	  ice-­‐thawed	  α-­‐Select	  Chemically	  Competent	  Escherichia	  coli	  (Bioline)	  and	  stored	  in	  an	  ice	  bath	  for	  20	  mins.	  The	  mix	  was	  placed	  in	  a	  42°C	  waterbath	  for	  35	  seconds	  before	  being	  returned	  to	  ice	  for	  2	  mins.	  Five	  hundred	  microlitres	  of	  SOC	  medium	  (Sambrook	  and	  Russell,	  2001)	  was	  added	  before	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incubating	  the	  tube	  in	  a	  37°C	  shaker	  (225	  rpm)	  for	  1	  hour.	  One	  hundred	  and	  seventy-­‐five	  microlitres	  of	  cells	  were	  plated	  onto	  LB	  agar	  plates	  supplemented	  with	  appropriate	  antibiotic	  selection	  and	  incubated	  overnight	  at	  37°C.	  
2.2.6 Ligation	  of	  DNA	  fragments	  	  Digested	  DNA	  fragments	  or	  PCR	  products	  were	  ligated	  into	  vectors	  at	  a	  molar	  ratio	  of	  3:1	  (insert:vector)	  in	  a	  20	  μl	  reaction	  containing	  1	  x	  Ligation	  Buffer	  (400	  mM	  Tris-­‐	  HCl,	  100	  mM	  MgCl2,	  100	  mM	  dithiothreitol	  (DTT),	  5	  mM	  adenosine	  trisphosphate	  (ATP)	  (pH	  7.8	  at	  25°C))	  and	  5	  U	  T4	  DNA	  Ligase	  (Fermentas).	  Reactions	  were	  incubated	  at	  room	  temperature	  for	  2	  hrs	  and	  used	  directly	  without	  further	  purification	  for	  bacterial	  transformations.	  
2.2.7 DNA	  sequencing	  	  All	  sequencing	  reactions	  were	  set	  up	  in	  a	  10	  μl	  total	  volume	  mix	  using	  25	  pmol	  of	  appropriate	  primer.	  Plasmid	  sequencing	  required	  400-­‐500	  ng,	  whereas	  PCR	  fragment	  sequencing	  required	  100-­‐400	  ng.	  GATC	  Biotech	  sequenced	  all	  DNA	  samples.	  
2.2.8 Restriction	  enzyme	  digestion	  	  Digestion	  of	  DNA	  was	  carried	  out	  using	  the	  manufacturer’s	  recommended	  amount	  of	  restriction	  enzyme	  in	  a	  solution	  containing	  1	  x	  the	  specific	  supplied	  reaction	  buffer,	  and	  if	  required,	  with	  100	  μg/ml	  bovine	  serum	  albumin	  (BSA).	  Incubation	  temperature	  and	  subsequent	  thermal	  inactivation	  were	  carried	  out	  according	  to	  the	  manufacturer’s	  instructions.	  The	  digestion	  reaction	  was	  incubated	  from	  1	  to	  4	  hrs	  before	  being	  run	  on a 1%	  weight	  per	  volume	  total	  (w/v)	  agarose	  gel	  for	  size/banding	  pattern	  analysis.	  The	  restriction	  sites	  used	  to	  linearise	  plasmids	  during	  this	  project	  are	  outlined	  in	  table	  2.2	  at	  the	  end	  of	  this	  chapter.	  
2.2.9 In	  vitro	  reverse	  transcription	  (cDNA	  synthesis)	  	  Reverse	  transcription	  reactions	  were	  carried	  out	  using	  Superscript	  II	  Reverse	  Transcriptase	  (Invitrogen).	  Ten	  microlitres	  of	  purified	  RNA	  (at	  unknown	  concentration)	  was	  incubated	  in	  a	  mixture	  containing	  100	  pmol	  oligo	  dT	  (Invitrogen),	  10	  mM	  dNTP	  mix	  and	  1.5	  μl	  H2O	  for	  5	  min	  at	  65°C.	  Following	  a	  2	  min	  cool	  on	  an	  ice	  bath,	  0.2	  μmoles	  DTT,	  1	  x	  Superscript	  Buffer	  (250	  mM	  Tris-­‐HCl,	  pH	  8.3	  at	  RT,	  375	  mM	  KCl,	  15	  mM	  MgCl2),	  and	  20	  U	  RiboLock	  RNase	  Inhibitor	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(Fermentas)	  was	  added	  and	  incubated	  for	  2	  mins	  at	  42°C.	  Two	  hundred	  units	  of	  Superscript	  II	  were	  added	  to	  the	  reaction	  before	  a	  final	  50	  min	  incubation	  at	  42°C	  and	  reaction	  termination	  at	  70°C	  for	  15	  mins.	  The	  cDNA	  mixture	  was	  stored	  at	  -­‐20°C	  while	  not	  in	  use.	  
2.2.10 	  	  Amplification	  of	  DNA	  fragments	  (up	  to	  3kb)	  -­‐	  PCR	  	  	  A	  master	  mix	  was	  prepared	  containing	  1	  x	  Taq	  Buffer	  with	  (NH4)2SO4	  (750	  mM	  Tris-­‐HCl	  (pH	  8.8	  at	  25.5°C),	  200	  mM	  (NH4)2SO4,	  0.1%	  Tween-­‐20),	  2.5	  mM	  each	  deoxyribonucelotide	  triphosphate	  (dNTP),	  30	  pmoles	  of	  the	  relevant	  forward	  and	  reverse	  oligonucleotide,	  and	  2.5	  U	  Taq	  DNA	  Polymerase	  (Fermentas)	  in	  a	  50	  μl	  reaction	  volume.	  
Thermal	  cycling	  comprised	  30	  -­‐	  40	  cycles	  as	  follows:	  one	  cycle	  of	  denaturation	  for	  2	  mins	  at	  95°C,	  29-­‐34	  cycles	  of	  denaturation	  for	  1	  min	  at	  95°C,	  annealing	  for	  30	  sec	  at	  55°C	  (or	  different	  according	  to	  oligonucleotide	  conditions)	  and	  elongation	  for	  1	  min/kilo	  base	  pairs	  (kps)	  at	  72°C,	  and	  a	  last	  cycle	  of	  5	  min	  at	  72°C.	  A	  list	  of	  oligonucleotides	  is	  recorded	  in	  section	  2.9	  at	  the	  end	  of	  this	  chapter.	  
2.2.11 	  	  	  	  Site-­‐directed	  mutagenesis	  	  Point	  mutations	  were	  introduced	  into	  cDNAs	  using	  QuikChange®	  II	  XL	  Site-­‐directed	  Mutagenesis	  Kit	  (Stratagene).	  Briefly,	  20	  to	  40-­‐mer	  oligonucleotides	  were	  designed	  for	  opposite	  strands	  of	  the	  plasmid	  and	  incorporated	  nucleotide	  mutations	  necessary	  for	  the	  project.	  The	  plasmids	  were	  amplified	  by	  PCR	  using	  the	  mutagenic	  oligonucleotides	  in	  table	  2.3	  according	  to	  the	  provided	  protocol.	  Competent	  E.	  coli	  cells	  provided	  with	  the	  kit	  were	  transformed	  with	  amplified	  plasmid	  and	  individual	  clones	  sequenced	  to	  confirm	  the	  presence	  of	  specifically	  introduced	  mutations.	  The	  mutated	  regions	  were	  subsequently	  sub-­‐cloned	  into	  a	  reliable,	  characterised	  construct	  to	  ensure	  no	  additional	  off	  target	  changes	  were	  incorporated	  and	  sequenced	  to	  confirm.	  
2.2.12 	  	  	  	  	  Overlap	  extension	  PCR	  	  This	  method	  was	  used	  when	  multiple	  changes	  to	  virus	  cDNA	  was	  required.	  Polymerase	  chain	  reaction	  oligonucleotides	  that	  were	  complementary	  to	  the	  virus	  cDNA	  and	  carrying	  the	  desired	  mutation(s)	  were	  designed	  to	  ensure	  that	  mismatches	  were	  at	  least	  10	  base	  pairs	  (bps)	  from	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either	  the	  5’	  or	  3’	  end	  of	  the	  oligonucleotide.	  Two	  DNA	  fragments	  that	  overlapped	  in	  the	  region	  based	  upon	  the	  mutagenic	  oligonucleotides	  were	  produced	  using	  appropriate	  external	  oligonucleotides.	  Oligonucleotides	  used	  to	  construct	  pRLucΔCRE_3’CRE	  and	  pPV3-­‐LIKE	  are	  shown	  in	  tables	  2.4	  and	  2.5	  respectively.	  Following	  column	  purification,	  the	  two	  DNA	  fragments	  were	  then	  used	  in	  a	  linear	  polymerase	  chain	  reaction	  that	  lacked	  the	  external	  oligonucleotides.	  Briefly,	  9	  cycles	  of	  PCR	  consisted	  of:	  
95°C	  -­‐	  2	  minutes	  95°C	  -­‐	  30	  seconds	  56°C	  -­‐	  30	  seconds	  72°C	  -­‐	  Variable	  depending	  on	  length	  of	  product	  (typically	  1	  min	  per	  Kb)	  Followed	  by	  a	  final	  extension:	  72°C	  -­‐	  5	  minutes	  	  	  4°C	  -­‐	  Hold	  The	  two	  external	  oligonucleotides	  were	  then	  added	  at	  standard	  concentrations	  as	  recommended	  by	  the	  manufacturers	  protocol.	  Twenty-­‐nine	  cycles	  of	  PCR	  were	  then	  used	  at	  standard	  conditions,	  using	  annealing	  temperatures	  best	  suited	  for	  the	  two	  external	  oligonucleotides	  being	  used.	  Extension	  time	  was	  also	  based	  upon	  the	  size	  of	  the	  desired	  product.	  
2.2.13 	  Construction	  of	  pSL3Δ,	  ΔpT7Rep3-­‐L	  and	  ΔpRLucWT	  	  pT7Rep3-­‐L	  and	  pRLucWT	  were	  digested	  with	  PmlI	  and	  PacI	  and	  re-­‐ligated	  following	  Klenow	  fragment	  treatment	  to	  produce	  suitable	  blunt	  ends.	  This	  effectively	  removed	  the	  entire	  IRES	  and	  the	  majority	  of	  the	  luciferase	  coding	  region.	  Similarly,	  pT7FLC/SL3	  was	  digested	  with	  XhoI	  and	  SalI	  and	  re-­‐ligated,	  removing	  the	  polymerase-­‐coding	  region.	  No	  Klenow	  fragment	  treatment	  was	  required	  given	  the	  complementarity	  in	  sticky-­‐ends.	  
2.2.14 In	  vitro	  transcription	  	  Linearised	  plasmid	  for	  RNA	  transcription	  was	  first	  prepared	  by	  column	  purification	  using	  the	  QIAquickPCR®	  Purification	  Kit	  (Qiagen)	  and	  re-­‐suspended	  in	  RNase-­‐free	  water.	  T7	  MEGAscript	  Kit®	  (Ambion)	  was	  used	  for	  in	  vitro	  transcription	  following	  the	  manufacturers	  protocol.	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Between	  1.5	  and	  2	  μL	  of	  RNA	  was	  confirmed	  on	  a	  1%	  agarose	  gel	  before	  column	  purification	  using	  RNeasy	  Mini	  Kit	  (Qiagen)	  and	  quantification	  on	  a	  spectrophotometer.	  
	  
2.3 Biochemical	  assay	  Sym-­‐subU	  and	  denaturing	  PAGE	  analysis	  	  
2.3.1 Symmetrical	  -­‐	  Substrate	  ‘U’	  biochemical	  assay	  	  Following	  the	  protocol	  taken	  from	  Arnold	  &	  Cameron,	  1999.	  An	  initial	  assay	  mix	  comprising	  of	  50	  mM	  HEPES	  pH	  7.5,	  5	  mM	  MgCl2,	  10	  mM	  Beta-­‐mercaptoethanol	  (BME),	  60	  µM	  ZnCl2,	  1	  µM	  symmetrical	  substrate	  ‘U’	  (annealed	  labelled	  primer-­‐template	  described	  fully	  in	  chapter	  six)	  and	  	  500	  µM	  ATP	  were	  warmed	  in	  a	  water	  bath	  at	  30°C.	  	  Following	  5	  min	  incubation,	  purified	  poliovirus	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  and	  variants	  (see	  text	  for	  description)	  was	  added	  at	  a	  concentration	  of	  5	  μM	  (see	  Gohara	  et	  al.,	  1999	  for	  purification	  of	  polio	  RdRp	  protocol).	  An	  additional	  5	  mins	  incubation	  period	  followed	  that	  allowed	  stable	  elongation	  complexes	  to	  form	  and	  the	  incorporation	  of	  the	  first	  nucleotide.	  A	  second	  assay	  mix	  was	  then	  rapidly	  added	  that	  comprised	  500	  µM	  CTP,	  GTP	  and	  UTP,	  60	  µM	  RNA	  acceptor	  template	  (variations	  described	  in	  text)	  and	  1	  mM	  MgCl2.	  	  Samples	  were	  quenched	  (EDTA)	  for	  polymerase	  activity	  at	  timed	  intervals	  (described	  in	  text)	  with	  products	  analysed	  by	  7M	  urea	  denaturing	  polyacrylamide	  gel	  electrophoresis	  (PAGE).	  	  
2.3.2 Denaturing	  PAGE	  and	  phosphorimaging	  	  An	  equal	  volume	  of	  loading	  buffer,	  10	  μl	  (90%	  formamide,	  0.025%	  bromophenol	  blue,	  and	  0.025%	  xylene	  cyanol),	  was	  added	  to	  10	  μl	  of	  the	  quenched	  reaction	  mixtures	  and	  heated	  to	  70°C	  for	  2–5	  min	  prior	  to	  loading	  5	  μl	  on	  a	  20%	  denaturing	  polyacrylamide	  containing	  1x	  TBE	  and	  7M	  urea.	  Electrophoresis	  was	  performed	  in	  1x	  TBE	  at	  75	  watts.	  Gels	  were	  visualized	  by	  using	  a	  PhosphorImager	  and	  quantitated	  by	  using	  the	  ImageQuant	  software	  (Molecular	  Dynamics).	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2.3.3 Quantification	  of	  total	  RNA	  product	  and	  %	  of	  template	  transfer	  	  ImageQuant	  software	  (Molecular	  Dynamics)	  was	  used	  to	  quantify	  total	  RNA.	  Four	  regions	  were	  selected:	  -­‐	  10mer	  (Sym-­‐subU),	  11mer	  (Sym-­‐subU	  +	  ATP),	  n>1	  (Extended	  Sym-­‐subU)	  and	  the	  product	  of	  template	  switching.	  Addition	  of	  these	  gave	  total	  RNA	  values.	  Percentage	  of	  transfer	  product	  was	  calculated	  as	  follows:	  -­‐	  Transfer	  product	  reads	  /	  Total	  reads	  x	  100.	  	  	  
2.4 Fluorescent	  in	  situ	  hybridisation	  (FISH)	  (Appendix	  only)	  	  
2.4.1 Stellaris	  probe	  storage	  	  Sets	  of	  Stellaris	  probes	  were	  manufactured	  and	  shipped	  by	  Biosearch	  Technologies™.	  The	  dry	  mixes	  of	  probes	  were	  dissolved	  in	  200	  μL	  of	  nuclease-­‐free	  TE	  (10	  mM	  Tris-­‐HCl,	  1	  mM	  sodium	  EDTA,	  pH	  8.0)	  to	  give	  a	  stock	  solution	  of	  25	  μM	  mixed	  oligonucleotides.	  Aliquots	  of	  probe	  (10	  μl)	  were	  stored	  at	  -­‐20°C	  and	  thawed	  in	  an	  ice	  bucket	  when	  required.	  Each	  aliquot	  was	  used	  a	  maximum	  of	  three	  times.	  
2.4.2 Cell	  seeding	  and	  virus	  infection	  	  HeLa	  cells	  were	  seeded	  upon	  sterile	  1	  mm	  coverslips	  in	  12-­‐well	  plates.	  Required	  density	  at	  time	  of	  infection	  was	  80%.	  Cell	  monolayers	  were	  gently	  washed	  twice	  in	  1x	  PBS	  prior	  to	  virus	  inoculation.	  All	  cells	  were	  singularly	  or	  dual	  infected	  at	  an	  M.O.I	  of	  10.	  Virus	  was	  absorbed	  onto	  monolayers	  for	  30	  mins	  at	  37°C/5%	  CO2/air.	  Virus	  supernatant	  was	  then	  removed	  and	  cell	  monolayers	  were	  then	  gently	  washed	  twice	  in	  1x	  PBS	  before	  addition	  of	  new	  media	  to	  each	  well.	  
2.4.3 Cell	  fixation	  	  HeLa	  cell	  monolayers	  were	  fixed	  at	  4	  hrs	  post	  infection.	  Media	  supernatant	  was	  removed	  from	  each	  well	  and	  each	  monolayer	  was	  gently	  washed	  twice	  in	  1x	  PBS.	  Cell	  monolayers	  were	  then	  covered	  in	  ice	  cold	  100%	  ethanol	  and	  fixed	  for	  20	  minutes	  at	  -­‐20°C.	  Cell	  monolayers	  were	  then	  gently	  washed	  twice	  in	  1x	  PBS.	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2.4.4 Sample	  denaturing	  	  Cell	  monolayers	  were	  thermally	  denatured	  in	  order	  to	  probe	  for	  the	  anti-­‐sense	  viral	  RNA.	  Briefly,	  following	  fixation	  cell	  monolayers	  were	  incubated	  in	  95%	  formamide,	  0.1%	  SSC	  (saline	  sodium	  citrate)	  at	  65°C	  for	  10	  minutes.	  Cells	  were	  then	  washed	  twice	  in	  0.1%	  SSC	  in	  preparation	  for	  probe	  hybridisation.	  
2.4.5 Stellaris	  probe	  hybridisation	  	  One	  microliter	  of	  the	  re-­‐suspended	  Stellaris	  probe	  were	  added	  to	  the	  hybridisation	  buffer	  (section	  2.6)	  to	  give	  a	  final	  volume	  of	  20	  μl.	  The	  washed	  coverslip	  was	  then	  placed	  on	  top	  of	  the	  probe	  mix	  face	  down	  (cell	  monolayer	  in	  contact	  with	  probe).	  Samples	  were	  then	  stored	  in	  a	  humidified	  chamber	  at	  37°C	  overnight.	  
2.4.6 Slide	  preparation	  	  Following	  overnight	  probe	  hybridisation	  coverslips	  were	  washed	  in	  the	  recommended	  wash	  solution	  (section	  2.6)	  twice	  for	  30	  minutes	  at	  37°C.	  Wash	  solution	  was	  removed	  and	  coverslips	  were	  then	  washed	  twice	  in	  2x	  SSC.	  Coverslips	  were	  then	  mounted	  face	  down	  in	  Vectashield	  mounting	  medium	  containing	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  on	  to	  glass	  slides	  (Menzel-­‐Glaser)	  and	  stored	  in	  the	  dark	  at	  4°C	  for	  future	  fluorescence	  microscopy.	  
2.5 Poliovirus	  recombinant	  nomenclature	  	  The	  reference	  sequences	  of	  poliovirus	  type	  3	  Leon	  (Genbank	  #X00925),	  type	  1	  Mahoney	  (Genbank	  #V01149)	  or	  the	  type	  1	  Mahoney-­‐derived	  luciferase-­‐encoding	  sub-­‐genomic	  replicon	  (pRLucWT)	  was	  used	  to	  number	  the	  recombinant	  genomes	  in	  this	  study.	  To	  facilitate	  definition	  of	  junctions	  defined	  in	  clonal	  groups	  of	  recombinant	  virus	  genomes	  a	  standardised	  naming	  scheme	  was	  used;	  the	  5’	  components	  were	  numbered	  from	  the	  first	  to	  last	  nucleotide	  derived	  from	  the	  acceptor	  (pT7FLC/SL3).	  The	  remaining	  3’	  nomenclature	  indicates	  the	  first	  to	  last	  nucleotide	  derived	  from	  the	  donor	  template	  (poliovirus	  type	  3	  or	  the	  type	  1	  derived	  sub-­‐genomic	  replicon).	  For	  example	  #105B	  =	  [PV3	  (1-­‐	  3491)	  Luc	  (137)	  -­‐	  PV1	  -­‐	  A	  Tail],	  1-­‐3491	  relates	  to	  sequence	  from	  acceptor	  template	  (pT7FLC/SL3),	  Luc	  (137)	  -­‐	  PV1	  -­‐	  A	  Tail	  indicates	  the	  final	  137-­‐nt	  from	  the	  luciferase	  coding	  gene	  followed	  by	  the	  remaining	  P2	  and	  P3	  regions	  from	  the	  PV1	  sub-­‐genomic	  replicon.	  Where	  recombination	  has	  occurred	  downstream	  of	  the	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luciferase	  coding	  region	  defined	  numbering	  based	  upon	  the	  PV1	  or	  PV3	  reference	  sequences	  are	  provided.	  All	  recombinant	  viral	  sequences	  were	  aligned	  to	  the	  parental	  PV3	  =	  Leon	  strain	  and	  PV1	  =	  Mahoney	  strain	  reference	  sequences	  (if	  applicable).	  All	  sequence	  differences	  to	  the	  acceptor	  (pT7FLC/SL3)	  template	  are	  indicated.	  	  
2.6 Stock	  Solutions	  and	  Buffers	  	  
Crystal	  violet	  
0.5	  g	  crystal	  violet	  powder	  in	  20	  ml	  100%	  ethanol,	  880	  ml	  dH2O	  containing	  0.9	  g	  NaCl	  and	  100	  ml	  40%	  formaldehyde.	  
6	  x	  DNA	  agarose	  gel	  loading	  buffer	  
25	  mg	  bromophenol	  blue	  to	  3	  ml	  100%	  glycerol.	  Make	  up	  to	  10	  ml	  with	  dH2O.	  Store	  at	  RT.	  	  
Guanidine	  hydrochloride	  
Guanidine	  hydrochloride	  powder	  dissolved	  in	  H2O	  at	  200mM.	  
Plaque	  overlay	  medium	  
10%	  v/v	  Minimum	  Essential	  Medium	  (EMEM)	  with	  Earle’s	  salts	  (10x),	  1%	  v/v	  L-­‐	  glutamine,	  3%	  v/v	  7.5%	  sodium	  bicarbonate,	  2%	  v/v	  FCS,	  1%	  v/v	  PS,	  and	  30%	  v/v	  2%	  agar.	  
Agar	  for	  plaque	  overlay	  medium	  
2%	  w/v	  bacto-­‐agar	  (Dibco)	  in	  distilled	  water.	  Microwaved	  to	  dissolve	  powder,	  autoclaved	  and	  stored	  at	  RT.	  	  
Penicillin/streptomycin	  
Filter	  sterilised	  10000	  U/ml	  of	  penicillin	  and	  10000	  μg/ml	  streptomycin	  in	  distilled	  water.	  	  
DMEM,	  GMEM/G418,	  10	  x	  EMEM,	  trypsin/EDTA,	  and	  sterile	  PBS	  
Supplied	  by	  the	  Media	  Preparation	  facility	  in	  School	  of	  Life	  Sciences,	  University	  of	  Warwick.	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Stellaris	  probe	  hybridisation	  buffer	  
1	  g	  dextran	  sulfate,	  1	  ml	  20x	  SSC,	  1	  ml	  deionized	  formamide.	  Nuclease	  free	  water	  to	  10	  ml	  final	  volume	  (all	  supplied	  by	  Sigma)	  
Stellaris	  probe	  wash	  solution	  
5	  ml	  20x	  SSC,	  5	  ml	  deionized	  formamide.	  Nuclease	  free	  water	  to	  50	  ml	  final	  volume.	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2.7 List	  of	  DNA	  plasmids	  	  
Table	  2.1:	  List	  of	  sub-­‐genomic	  replicons	  and	  full-­‐length	  clones	  used	  in	  this	  study	  
Plasmid	  name	   Description	   Reference	  pE7Luc	   E7	  Replicon	  with	  capsid	  replaced	  by	  luciferase,	  derived	  from	  pT7E7	   Chris	  Bull	  and	  Minghui	  Ao	  (in	  house)	  pT7E7ΔCRE	   pT7E7	  with	  mutated	  CRE,	  unable	  to	  synthesise	  positive-­‐sense	  RNA	   Kym	  Lowry	  (in	  house)	  pRLucWT	   PV1	  replicon	  with	  capsid	  replaced	  with	  luciferase	   Andino	  et	  al.,	  1993	  pRLuc-­‐G64S	   pRLucWT	  with	  G64S	  substitution	  within	  the	  3Dpol	  region	   Vignuzzi	  et	  al.,	  2006	  pRLuc-­‐D79H	   pRLucWT	  with	  D79H	  substitution	  within	  the	  3Dpol	  region	   This	  project	  pRLuc-­‐Y275H	   pRLucWT	  with	  Y275H	  substitution	  within	  the	  3Dpol	  region	   This	  project	  pRLuc-­‐D79H-­‐Y275H	   pRLucWT	  with	  D79H	  and	  Y275H	  substitutions	  within	  the	  3Dpol	  region	   This	  project	  pRLuc-­‐K359R	   pRLucWT	  with	  K359R	  substitution	  within	  the	  3Dpol	  region	   Weeks	  et	  al.,	  2012	  pRLucΔCRE	   pRLucWT	  with	  mutated	  CRE,	  unable	  to	  synthesise	  positive-­‐	  sense	  RNA	   This	  project	  pRLucΔCRE_3'CRE	   pRLucWT	  with	  mutated	  native	  CRE,	  carrying	  a	  synthetic	  CRE	  in	  its	  3'NTR	   This	  project	  pRLucΔCRE_3'CRE-­‐K359R	   pRLucΔCRE_3'CRE	  with	  a	  K359R	  substitution	  within	  the	  3Dpol	  region	   This	  project	  pT7Rep3-­‐L	   PV3	  replicon	  with	  capsid	  replaced	  by	  luciferase	  derived	  from	  pT7FLC	   Barclay	  et	  al.,	  1998	  pT7Rep3-­‐L-­‐G64S	   pT7rep3-­‐L	  with	  a	  G64S	  substitution	  within	  the	  3Dpol	  region	   This	  project	  pT7rep3-­‐L-­‐Y275H	   pT7rep3-­‐L	  with	  a	  Y275H	  substitution	  within	  the	  3Dpol	  region	   This	  project	  pT7FLC	   Full-­‐length	  PV3	  Leon	  P3/Leon/37	  infectious	  clone	   Goodfellow	  et	  al.,	  2000	  pT7FLC/SL3	   pT7FLC	  with	  mutated	  CRE,	  unable	  to	  synthesise	  positive-­‐sense	  RNA	   Goodfellow	  et	  al.,	  2000	  pT7FLC/SL3-­‐G64S	   pT7FLC/SL3	  with	  a	  G64S	  substitution	  in	  the	  3Dpol	  region	   This	  project	  pT7FLC/SL3-­‐K359R	   pT7FLC/SL3	  with	  a	  K359R	  substitution	  in	  the	  3Dpol	  region	   This	  project	  pT7FLC/SL3-­‐Y275H	   pT7FLC/SL3	  with	  a	  Y275H	  substitution	  in	  the	  3Dpol	  region	   This	  project	  pT7FLC/SL3-­‐D79H-­‐Y275H	   pT7FLC/SL3	  with	  a	  D79H	  and	  Y275H	  substitution	  in	  the	  3Dpol	  region	   This	  project	  pPV1FLC	   Full-­‐length	  PV1	  Mahoney	  infectious	  clone	   This	  project	  pPV1FLCΔCRE	   PV1FLC	  with	  mutated	  CRE	  unable	  to	  synthesise	  positive-­‐sense	  RNA	   This	  project	  
	  
	   55	  
pFLCΔCRE_3'CRE	   PV1FLC	  with	  mutated	  native	  CRE,	  carrying	  a	  synthetic	  CRE	  in	  its	  3'NTR	   This	  project	  pSL3Δ	   pT7FLC/SL3	  with	  the	  3Dpol	  coding	  region	  removed	   This	  project	  ΔpT7Rep3-­‐L	   pT7Rep3-­‐L	  with	  the	  5'NTR	  removed	   This	  project	  ΔpT7Rep3-­‐L-­‐G64S	   pT7Rep3-­‐L	  with	  5’NTR	  removed	  carrying	  a	  G64S	  substitution	  in	  the	  3Dpol	  region	   This	  Project	  ΔpRLucWT	   pRLucWT	  with	  the	  5'NTR	  removed	   This	  project	  pJC105B	   Molecular	  clone	  of	  an	  imprecise	  PV3/1	  recombinant	   This	  project	  	  	  
2.8 Restriction	  enzymes	  to	  linearise	  plasmids	  	  
Table	  2.2:	  Restriction	  enzymes	  used	  to	  linearise	  plasmids	  for	  RNA	  transcription	  
Plasmid	  name	   Restricton	  enzyme	   Linearised	  size	  (bp)	  pE7Luc	   XhoI	   9726	  pT7E7ΔCRE	   NotI	   10328	  pRLucWT	   ApaI	   ~10500	  pRLuc-­‐G64S	   ApaI	   ~10500	  pRLuc-­‐D79H	   ApaI	   ~10500	  pRLuc-­‐Y275H	   ApaI	   ~10500	  pRLuc-­‐D79H-­‐Y275H	   ApaI	   ~10500	  pRLuc-­‐K359R	   ApaI	   ~10500	  pRLucΔCRE	   ApaI	   ~10500	  pRLucΔCRE_3'CRE	   ApaI	   ~10500	  pRLucΔCRE_3'CRE-­‐K359R	   ApaI	   ~10500	  pT7Rep3-­‐L	   SalI	   10231	  pT7Rep3-­‐L-­‐G64S	   SalI	   10231	  pT7rep3-­‐L-­‐Y275H	   SalI	   10231	  pT7FLC	   SalI	   11128	  pT7FLC/SL3	   SalI	   11128	  pT7FLC/SL3-­‐G64S	   SalI	   11128	  pT7FLC/SL3-­‐K359R	   SalI	   11128	  pT7FLC/SL3-­‐Y275H	   SalI	   11128	  pT7FLC/SL3-­‐D79H-­‐Y275H	   SalI	   11128	  pPV1FLC	   ApaI	   ~11400	  pPV1FLCΔCRE	   ApaI	   ~11400	  pFLCΔCRE_3'CRE	   ApaI	   ~11400	  pSL3Δ	   NruI	   9716	  ΔpT7Rep3-­‐L	   SalI	   8201	  ΔpT7Rep3-­‐L-­‐G64S	   SalI	   8201	  ΔpRLucWT	   ApaI	   ~8500	  pJC105B	   ApaI	   11267	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2.9 List	  of	  oligonucleotides	  	  
Table	  2.3:	  Mutagenic	  oligonucleotides	  used	  throughout	  the	  study	  
Mutagenic	  
primer	   Sequence	  
PV1-­‐G64S-­‐F	   CTCCAAGTACGTGTCTAACAAAATTACTGAAGTGGATGAG	  
PV1-­‐G64S-­‐R	   CTCATCCACTTCAGTAATTTTGTTAGACACGTACTTGGAG	  
PV1-­‐K359R-­‐F	   CTAACTATGACTCCAGCTGACCGATCAGCTACATTTG	  
PV1-­‐K359R-­‐R	   CAAATGTAGCTGATCGGTCAGCTGGAGTCATAGTTA	  
PV1-­‐D79H-­‐F	   GTACATGAAAGAGGCAGTACATCACTATGCTGGCCAGC	  
PV1-­‐D79H-­‐R	   GACATGAGCTGGCCAGCATAGTGATGTACTGCCTCTTTCATGTAC	  
PV1-­‐Y275H-­‐F	   CTAAACCACTCACACCACCTGCATAAGAATAAAACATACTGTGTCAAGG	  
PV1-­‐Y275H-­‐R	   CCTTGACACAGTATGTTTTATTCTTATGCAGGTGGTGTGAGTGGTTTAG	  
PV3-­‐G64S-­‐F	   CAATCTTCTCTAAGTATGTATCGAACAAGATCACTGAGGTGG	  
PV3-­‐G64S-­‐R	   CCACCTCAGTGATCTTGTTCGATACATACTTAGAGAAGATTG	  
PV3-­‐K359R-­‐F	   CATGACTCCGGCAGATAGGTCTGCCACTTTTGAGAC	  
PV3-­‐K359R-­‐R	   GTCTCAAAAGTGGCAGACCTATCTGCCGGAGTCATG	  
PV3-­‐D79H-­‐F	   GATGAGTACATGAAAGAGGCAGTGCATCATTATGCTGGACAACTTATG	  
PV3-­‐D79H-­‐R	   CATAAGTTGTCCAGCATAATGATGCACTGCCTCTTTCATGTACTCATC	  
PV3-­‐Y275H-­‐F	   CTTAACCATTCACACCACTTGCATAAAAACAAGATATATTGTGTT	  
PV3-­‐Y275H-­‐R	   AACACAATATATCTTGTTTTTATGCAAGTGGTGTGAATGGTTAAG	  	  
	  
Table	  2.4:	  Oligonucleotides	  used	  to	  construct	  pRLuc_ΔCRE_3’CRE	  
Name	   Sequence	  CRE_MUT-­‐F	   CAACTATATCCAATTTAAATCCAAACACCGTATCGAACCAG	  CRE_MUT-­‐R	   CTGGTTCGATACGGTGTTTGGATTTAAATTGGATATAGTTG	  BSSHII-­‐F	   CATTTTAGGCGCGCTAACCCTACCTCAGTCGAATTGG	  BSSHII-­‐R	   GGTTAGCGCGCCTAAAATGAGTCAAGCCAACGGCGGTAC	  SYNTH_CRE-­‐F	   CGCGCCCGGGTAAGAGCAAACACCGTATTACCCGGG	  SYNTH_CRE-­‐R	   CGCGCCCGGGTAATACGGTGTTTGCTCTTACCCGGG	  
	  
Table	  2.5:	  Oligonucleotides	  used	  to	  construct	  pPV3-­‐LIKE	  
Name	   Sequence	  PV3-­‐LIKE-­‐F	   GGAAATACTACCCAGTATCCTTTGTGGGACCCACCTTC	  PV3-­‐LIKE-­‐R	   CTAAGCCACTGCCATGGTGAAGCATCACACCCAAGAAGAA	  pRLuc_5'-­‐F	   GACATAGCTTACTGGGACG	  pRLuc_5'-­‐R	   GATACTGGGTAGTATTTCCT	  pRLuc_3'-­‐F	   CACCATGGCAGTGGCTTAG	  pRLuc_3'-­‐R	   CCACTGTTGATACCATCT	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Table	  2.6:	  Additional	  oligonucleotides	  used	  throughout	  this	  study	  
Name	   Sequence	  
GEN-­‐4615R	   RTADCCRTCRAAGTGWKMYGG	  
PV1/3-­‐3280F	   AACACRTMMGWGTCTGGTGC	  
PV1-­‐3004F	   GCAAACCTCATCAAATCCATCA	  
PV1-­‐3679R	   GAGCATATGGGACTGGTA	  
PV1-­‐5594F	   GAAGTGGAGATCTTGGATGCC	  
PV1-­‐5440R	   TCCTTGTACCTTTGCTGTCCG	  
PV3-­‐2995F	   GCAAACATCTTCCAACCCGTCC	  
PV3-­‐3249F	   CGCATTTACATGAAACCC	  
PV3-­‐5191-­‐R	   GGAGTCAACTGCTTGAAGCAGA	  
PV3-­‐5587F	   GAGGTTGAAATCCTAGACGCT	  
PV3-­‐7390R	   CCGAATTAAAGAAAAATTTACCCCTAC	  
EV7-­‐6F	   CAGATCATGTACATACC	  
EV7-­‐5247R	   GACACGAATGTGGTTAGTGC	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CHAPTER	  THREE:	  The	  Biphasic	  Nature	  of	  Enterovirus	  
Recombination	  	  	  
3.1 Introduction	  	  Many	  recombinant	  enteroviruses	  have	  been	  isolated	  and	  characterised	  from	  field	  samples	  following	  outbreaks	  of	  infection	  (Kew	  et	  al.,	  2002,	  Zhang	  et	  al.,	  2010,	  Oberste	  et	  al.,	  2004a).	  Early	  studies	  have	  highlighted	  potential	  triggers	  found	  in	  the	  RNA	  sequence	  and	  RNA	  secondary	  structure	  that	  provides	  preferential	  sites	  for	  recombination	  (section	  1.3).	  However,	  the	  mechanisms	  of	  recombination	  still	  remain	  poorly	  understood.	  The	  field	  isolates	  studied	  in	  all	  examples	  have	  been	  exposed	  to	  a	  highly	  selective	  and	  dynamic	  environment,	  and	  may	  not	  necessarily	  represent	  the	  initial	  recombinant	  molecules	  produced.	  Characterising	  the	  mechanisms	  that	  drive	  recombination	  will	  help	  us	  understand	  a	  basic	  evolutionary	  mechanism.	  Additionally,	  potential	  strategies	  to	  limit	  the	  occurrences	  of	  such	  events	  can	  be	  developed.	  This	  would	  be	  helpful	  in	  the	  fight	  to	  eradicate	  poliovirus	  for	  example;	  production	  of	  a	  live	  attenuated	  vaccine	  strain	  that	  doesn’t	  recombine	  would	  be	  very	  beneficial	  to	  this	  process.	  	  Recombination	  is	  a	  rare	  event,	  with	  intertypic	  recombinants	  estimated	  to	  have	  frequencies	  of	  1x	  10-­‐6	  (Kirkegaard	  and	  Baltimore,	  1986b,	  Jiang	  et	  al.,	  2007).	  Identification	  of	  recombinant	  genomes	  in	  a	  population	  that	  is	  predominately	  made	  up	  of	  parental	  viruses	  has	  therefore	  been	  an	  issue	  in	  all	  cell	  based	  studies.	  Early	  in	  vitro	  approaches	  have	  largely	  relied	  upon	  crossing	  parental	  genomes	  carrying	  different	  selectable	  markers.	  Those	  that	  ‘escape’	  the	  selection	  process	  will	  have	  inherited	  the	  mutations	  from	  the	  two	  parental	  strains	  and	  would	  be	  recombinant	  viruses	  (Kirkegaard	  and	  Baltimore,	  1986a).	  There	  is	  no	  doubt	  that	  such	  studies	  have	  provided	  some	  interesting	  observations,	  most	  notably	  the	  ‘copy-­‐choice’	  model	  of	  recombination	  (section	  1.3).	  Although,	  identification	  of	  the	  recombinant	  viruses	  isolated	  under	  such	  selective	  pressures	  was	  limited	  to	  only	  a	  small	  region	  of	  the	  genome	  as	  defined	  by	  the	  selectable	  markers	  and	  may	  again	  not	  have	  represented	  the	  initial	  recombination	  event.	  An	  additional	  risk	  of	  reversion	  is	  also	  a	  possibility	  in	  such	  approaches,	  with	  a	  point	  mutation	  reverting	  a	  genome	  back	  to	  wild	  type	  around	  10-­‐100	  fold	  more	  likely	  that	  an	  intertypic	  recombination	  event	  (Crotty	  et	  al.,	  2001).	  To	  overcome	  such	  issues,	  a	  novel	  in	  vitro	  assay	  has	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been	  developed	  by	  a	  previous	  student	  (Kym	  Lowry)	  that	  uses	  two	  defective	  parental	  genomes	  that	  are	  each	  unable	  to	  generate	  infectious	  virus.	  Only	  a	  recombination	  event	  can	  produce	  a	  genome	  that	  can	  be	  potentially	  infectious.	  	  
Methodology	  	  The	  first	  parental	  RNA	  is	  a	  sub-­‐genomic	  replicon	  that	  has	  a	  large	  deletion	  of	  the	  virus	  genome.	  The	  capsid	  region	  (P1)	  was	  replaced	  with	  a	  reporter	  gene;	  in	  this	  study	  it	  is	  a	  firefly	  luciferase	  gene.	  This	  type	  of	  genome	  can	  translate	  and	  replicate	  successfully	  as	  it	  contains	  the	  key	  cis-­‐acting	  elements	  and	  is	  a	  well	  established	  approach	  used	  to	  study	  polioviruses	  (Barclay	  et	  al.,	  1998,	  Percy	  et	  al.,	  1992).	  The	  lack	  of	  a	  capsid	  region	  ensures	  no	  virus	  particles	  are	  produced	  when	  transfected	  into	  permissive	  cells	  alone.	  In	  any	  recombination	  assay	  this	  genome	  would	  provide	  the	  non-­‐structural	  P2	  and	  P3	  regions,	  and	  is	  therefore	  considered	  the	  ‘donor’.	  The	  second	  genome	  (the	  acceptor	  in	  a	  recombination	  event)	  would	  be	  required	  to	  produce	  the	  capsid-­‐coding	  region,	  but	  carry	  a	  defect	  in	  the	  non-­‐structural	  region	  preventing	  production	  of	  a	  viable	  virus	  upon	  transfection.	  A	  suitable	  candidate	  is	  the	  well	  characterised	  genome	  that	  carries	  eight	  synonymous	  mutations	  in	  the	  highly	  conserved	  2C	  CRE	  that	  disrupts	  positive	  strand	  RNA	  synthesis	  (Goodfellow	  et	  al.,	  2003a).	  This	  genome	  can	  produce	  negative	  strand	  RNA	  so	  is	  considered	  suitable	  for	  a	  replicative	  recombination	  assay,	  as	  it	  is	  believed	  recombination	  occurs	  during	  negative	  strand	  synthesis	  (Kirkegaard	  and	  Baltimore,	  1986b).	  This	  approach	  relies	  upon	  delivering	  both	  RNA	  templates	  into	  cells,	  via	  transfection,	  where	  subsequent	  recombination	  and	  genomic	  re-­‐arrangements	  can	  occur.	  Donation	  of	  a	  capsid	  from	  one	  parental	  genome	  and	  a	  functional	  CRE	  from	  the	  other	  parental	  genome	  would	  in	  principle	  produce	  a	  viable	  virus,	  and	  is	  termed	  the	  CRE-­‐REP	  assay	  (figure	  3.1).	  In	  principle,	  this	  provides	  a	  region	  of	  1.058	  Kb,	  between	  the	  end	  of	  VP1	  and	  the	  2C	  CRE,	  where	  recombination	  can	  occur.	  Importantly,	  the	  use	  of	  rodent	  cell	  lines	  like	  the	  murine	  L929	  or	  baby	  hamster	  BsrT7	  cells	  allows	  minimal	  selection	  of	  recombinant	  virus	  as	  is	  possible.	  Both	  cell	  types	  lack	  the	  poliovirus	  receptor	  CD155,	  but	  can	  support	  RNA	  replication.	  They	  are	  therefore	  deemed	  permissive	  but	  not	  susceptible	  to	  infection.	  Any	  recombinant	  virus	  produced	  and	  released	  from	  the	  cell	  into	  the	  media	  supernatant	  cannot	  re-­‐infect	  neighbouring	  cells.	  This	  ensures	  that	  the	  recombinant	  virus	  is	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isolated	  and	  characterised	  as	  near	  to	  the	  recombination	  event	  as	  possible.	  Additionally,	  by	  minimising	  selection,	  this	  approach	  allows	  isolation	  of	  a	  range	  of	  recombinant	  regardless	  of	  growth	  advantages.	  This	  is	  in	  contrast	  to	  previous	  in	  vitro	  cell	  based	  approaches	  that	  have	  largely	  used	  HeLa	  cells	  that	  are	  susceptible	  to	  re-­‐infection	  due	  to	  the	  availability	  of	  receptor.	  This	  may	  have	  biased	  the	  identification	  of	  recombinant	  viruses	  to	  the	  ones	  that	  had	  a	  growth	  advantage	  over	  others.	  Quantification	  of	  any	  recombinant	  virus	  is	  by	  plaque	  assay,	  media	  supernatant	  is	  isolated	  from	  transfected	  rodent	  cells	  following	  an	  incubation	  period	  and	  subsequently	  used	  with	  permissive	  and	  susceptible	  cell	  lines	  like	  HeLa	  (section	  2.1	  for	  full	  description).	  	  The	  CRE-­‐REP	  has	  allowed	  various	  combinations	  of	  enterovirus	  partners	  to	  be	  used	  previously	  (Lowry	  et	  al.,	  2014).	  The	  primary	  enterovirus	  serotypes	  studied	  in	  this	  investigation	  were	  poliovirus	  type	  1	  (Mahoney)	  and	  type	  3	  (Leon).	  This	  was	  due	  to	  the	  availability	  of	  cDNA,	  the	  subsequent	  re-­‐producibility	  of	  the	  CRE-­‐REP	  assay	  when	  using	  these	  partners	  (outlined	  in	  text	  later),	  and	  the	  vast	  amount	  of	  past	  research	  into	  the	  life	  cycle	  of	  this	  virus.	  	  	  
Aims	  The	  aim	  was	  to	  build	  upon	  the	  findings	  of	  a	  previous	  student,	  Kym	  Lowry.	  These	  included:	  comparing	  intratypic	  and	  intertypic	  poliovirus	  recombination	  frequencies,	  characterisation	  of	  early	  intratypic	  and	  intertypic	  recombinant	  isolates,	  cell	  specificity	  and	  characterisation	  of	  early	  intertypic	  recombinants	  to	  those	  following	  serial	  passage.	  In	  addition,	  it	  was	  felt	  important	  to	  develop	  a	  non-­‐replicative	  recombination	  assay	  that	  would	  contrast	  the	  CRE-­‐REP	  assay,	  which	  was	  presumed	  to	  be	  replicative	  i.e.	  recombinant	  virus	  genome	  produced	  during	  replication	  of	  the	  parental	  RNA.	  This	  would	  determine	  if	  the	  recombinant	  progeny	  was	  produced	  via	  a	  replicative	  mechanism	  like	  ‘copy-­‐choice’,	  whilst	  also	  highlighting	  the	  relative	  contribution	  of	  non-­‐replicative	  recombination	  to	  the	  overall	  yield	  of	  virus.	  The	  results	  in	  this	  chapter	  have	  contributed	  to	  the	  manuscript	  Lowry	  et	  al.,	  2014.	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Figure	  3.1:	  Overview	  of	  the	  CRE-­‐REP	  assay	  Two	  genomes,	  upper	  [dark	  shading]	  bears	  a	  defective	  CRE	  indicated	  as	  a	  broken	  line	  with	  a	  superimposed	  X	  in	  the	  2C-­‐coding	  region.	  Lower	  genome	  is	  a	  luciferase-­‐encoding	  sub-­‐genomic	  replicon	  (light	  shading).	  	  Following	  co-­‐transfection	  into	  permissive	  cells	  (indicated	  by	  an	  arrow),	  a	  recombinant	  replication	  competent	  genome	  may	  be	  recovered	  of	  the	  generic	  structure	  shown,	  consisting	  of	  the	  5’	  part	  of	  the	  genome	  derived	  from	  the	  CRE-­‐defective	  parent	  (the	  recipient)	  and	  the	  3’	  part	  of	  the	  genome	  from	  the	  luciferase-­‐encoding	  replicon	  (the	  donor).	  	  The	  graduated	  shading	  between	  the	  3’	  end	  of	  the	  VP1-­‐coding	  region	  and	  the	  2C	  CRE	  indicates	  the	  area	  within	  which	  recombination	  must	  occur	  to	  produce	  a	  functional	  genome.	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3.2 Intraserotypic	  and	  interserotypic	  recombination	  ratio	  	  Sequence	  similarity	  between	  parental	  genomes	  may	  provide	  a	  limitation	  to	  recombination	  frequency.	  It	  has	  been	  postulated	  that	  intertypic	  recombination	  frequency	  may	  be	  as	  much	  as	  100-­‐fold	  lower	  than	  intratypic	  recombination	  (King,	  1988b,	  Tolskaya	  et	  al.,	  1983).	  This	  has	  been	  further	  supported	  by	  the	  work	  of	  Kirkegaard	  &	  Baltimore	  who	  found	  a	  similar	  phenomenon	  when	  using	  two	  parental	  genomes	  that	  carried	  resistance	  markers	  (Kirkegaard	  and	  Baltimore,	  1986a).	  The	  CRE-­‐REP	  assay	  has	  been	  previously	  used	  successfully	  to	  isolate	  intratypic	  and	  intertypic	  recombinant	  polioviruses	  (Lowry	  et	  al.,	  2014).	  By	  combining	  parental	  partners	  known	  to	  recombine	  these	  studies	  were	  extended	  to	  allow	  the	  relative	  frequencies	  to	  be	  ascertained.	  Both	  the	  PV3	  sub-­‐genomic	  replicon	  pT7Rep-­‐3L	  and	  the	  PV3	  CRE	  mutant	  pT7FLC/SL3	  were	  linearised	  with	  SalI.	  The	  PV1	  replicon	  pRLucWT	  was	  linearised	  with	  ApaI.	  All	  three	  templates	  were	  used	  to	  transcribe	  RNA	  in	  vitro	  using	  T7	  polymerase.	  Intratypic	  recombination	  frequency	  was	  measured	  using	  the	  PV3/3	  partners	  (SL3	  and	  Rep3-­‐L).	  Comparative	  intertypic	  recombination	  frequency	  was	  measured	  using	  the	  PV3/1	  partners	  (SL3	  and	  RLucWT).	  In	  a	  standardised	  protocol,	  two	  micrograms	  of	  RNA	  were	  co-­‐transfected	  into	  L929	  cell	  monolayers	  in	  6-­‐well	  plates	  using	  Lipofectamine	  2000	  at	  a	  ratio	  of	  1:1	  (replicon:	  CRE	  mutant	  genome)	  in	  three	  separate	  experiments.	  Additional	  single	  transfection	  controls	  were	  also	  carried	  out.	  Cells	  were	  incubated	  for	  48	  hrs	  to	  allow	  a	  suitable	  time	  for	  recombination	  to	  occur.	  At	  this	  point	  media	  supernatant	  (containing	  potential	  recombinants)	  was	  harvested	  and	  500	  μl	  was	  used	  diluted	  or	  undiluted	  (as	  indicated)	  to	  inoculate	  monolayers	  of	  HeLa	  cells	  in	  6-­‐well	  plates	  for	  plaque	  assays.	  Plates	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet,	  and	  photographed	  (figure	  3.2).	  The	  null	  hypothesis	  would	  be	  that	  the	  observed	  frequency	  of	  recombinants	  in	  the	  PV3/PV3	  experiments	  is	  equal	  to	  the	  observed	  frequency	  of	  recombinants	  in	  the	  PV3/PV1	  experiments.	  
	  
When	  RLucWT	  or	  SL3	  were	  transfected	  into	  L929	  cells	  alone	  no	  virus	  was	  detected.	  Viable	  intertypic	  recombinant	  virus	  was	  detected	  in	  all	  three	  co-­‐transfections	  as	  observed	  by	  plaque	  formation.	  Yields	  of	  PV3/1	  recombinant	  virus	  averaged	  at	  115	  pfu/ml.	  Similarly,	  viable	  PV3/3	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Figure	  3.2:	  Virus	  recovered	  from	  L929	  murine	  cells	  co-­‐transfected	  with	  intertypic	  and	  
intratypic	  poliovirus	  partners.	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recombinants	  were	  produced	  from	  the	  co-­‐transfected	  cells.	  Individual	  transfections	  produced	  no	  virus	  (data	  not	  shown).	  In	  contrast	  to	  PV3/1	  recombination,	  yields	  of	  PV3/3	  virus	  was	  significantly	  higher	  (as	  determined	  by	  chi-­‐square	  test)	  and	  averaged	  at	  1.1	  x	  103	  pfu/ml.	  	  
3.3 Precise	  and	  imprecise	  recombination	  
The	  type	  of	  recombinant	  produced	  from	  intratypic	  and	  intertypic	  partners	  may	  provide	  insight	  into	  the	  mechanism	  of	  template	  switching.	  The	  CRE-­‐REP	  assay	  has	  previously	  been	  used	  to	  characterise	  the	  recombination	  junctions	  of	  over	  100	  intertypic	  PV3/1	  recombinant	  isolates	  (Lowry	  et	  al.,	  2014).	  The	  in-­‐depth	  study	  on	  recombinants	  isolated	  from	  a	  co-­‐transfection	  using	  RNA	  generated	  from	  pRLucWT	  and	  pT7FLC/SL3	  cDNA	  showed	  that	  additional	  sequence	  is	  typically	  found	  at	  the	  recombination	  junction	  (hereafter	  termed	  ‘imprecise’	  recombinants).	  Indeed,	  the	  largest	  insert	  identified	  was	  321	  nt.	  All	  isolates	  were	  in-­‐frame,	  maintaining	  the	  open	  reading	  frame	  (ORF)	  and	  further	  extensive	  analysis	  could	  find	  no	  obvious	  link	  between	  RNA	  sequence	  to	  sites	  of	  recombination	  (figure	  3.3).	  Of	  the	  136	  genomes	  in	  which	  the	  sequence	  could	  be	  unambiguously	  identified,	  95	  (70%)	  contained	  additional	  sequences,	  forming	  17/20	  (85%)	  distinct	  sequence	  junctions	  analysed.	  A	  striking	  feature	  of	  the	  imprecise	  recombinants	  recovered	  was	  their	  clustering	  in	  regions	  encoding	  the	  amino	  and	  carboxyl	  termini	  of	  2A,	  termed	  cluster	  1	  and	  cluster	  2	  respectively.	  The	  consequences	  of	  this	  clustering	  were	  that	  the	  majority	  (94/95	  individual	  sequences	  in	  16/17	  groups)	  of	  imprecise	  recombinants	  retained	  the	  ability	  to	  encode	  non-­‐chimeric	  versions	  of	  the	  2A	  and	  2B	  proteins.	  The	  only	  isolate	  that	  encoded	  a	  chimeric	  protein	  had	  a	  recombination	  junction	  adjacent	  to	  the	  2A	  /	  2B	  boundary.	  This	  isolate	  only	  had	  one	  amino	  acid	  within	  the	  2B	  gene	  that	  was	  not	  coded	  from	  the	  donor	  template,	  and	  this	  amino	  acid	  was	  the	  same	  between	  each	  parent.	  This	  means	  that	  the	  2B	  protein	  translated	  was	  the	  same	  amino	  acid	  sequence	  as	  the	  PV1	  replicon.	  
	  
In	  contrast,	  a	  small	  amount	  of	  characterised	  isolates	  obtained	  using	  the	  intratypic	  partners,	  Rep3-­‐L	  and	  SL3,	  have	  generally	  been	  shown	  to	  have	  no	  additional	  sequence	  at	  the	  recombination	  junction	  (hereafter	  termed	  ‘precise’	  recombinants).	  Unlike	  their	  intertypic	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counterparts	  the	  junctions	  of	  the	  ‘precise’	  intratypic	  recombinants	  could	  not	  be	  identified	  due	  to	  the	  sequence	  identity	  between	  the	  two	  parental	  genomes.	  In	  this	  current	  study	  twenty	  PV3/3	  recombinant	  isolates	  were	  biologically	  cloned	  using	  a	  limiting	  dilution	  approach	  (section	  2.1.7).	  RNA	  was	  extracted	  from	  biologically	  cloned	  virus	  and	  reverse	  transcribed	  to	  produce	  cDNA	  (section	  2.2.9).	  The	  specific	  region	  of	  recombination	  between	  the	  end	  of	  VP1	  and	  the	  2C	  CRE	  was	  amplified	  using	  the	  primers	  PV3-­‐2995F	  and	  PV3-­‐5191R.	  Additionally,	  a	  number	  of	  PV3/1	  recombinant	  isolates	  were	  also	  amplified	  using	  a	  similar	  approach	  for	  comparison	  (RT-­‐PCR).	  The	  zone	  of	  recombination	  for	  these	  biologically	  cloned	  isolates	  was	  amplified	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  The	  majority	  of	  the	  PV3/1	  recombinants	  amplified	  by	  RT-­‐PCR	  looked	  to	  contain	  additional	  sequence	  within	  the	  amplified	  region	  when	  compared	  to	  a	  PCR	  product	  from	  a	  wild-­‐type	  genome	  length	  control	  (figure	  3.4A),	  a	  result	  that	  supports	  previous	  observations	  (Lowry	  et	  al.,	  2014).	  These	  were	  not	  sequenced.	  In	  contrast,	  only	  three	  of	  the	  twenty	  PV3/3	  isolates	  looked	  to	  have	  additional	  sequence,	  as	  shown	  by	  a	  larger	  PCR	  product	  when	  compared	  to	  a	  wild-­‐type	  length	  genome	  control	  (figure	  3.4B).	  All	  twenty	  PCR	  products	  were	  sequenced	  using	  the	  same	  primers	  that	  were	  used	  to	  amplify	  from	  the	  cDNA	  (Figure	  3.4C).	  The	  first	  ‘imprecise’	  clone	  PV3	  (1-­‐3451/3)	  PV3	  (3356/8	  -­‐	  A	  tail)	  has	  an	  additional	  96	  nt	  in	  viral	  sequence	  2A	  (section	  2.5	  for	  recombinant	  nomenclature	  scheme).	  The	  second	  clone,	  PV3	  (1-­‐3393/4)	  PV3	  (3355/6	  -­‐	  A	  tail)	  has	  an	  additional	  39	  nt	  also	  inserted	  in	  the	  2A	  sequence.	  Finally,	  the	  third	  clone	  PV3	  (1-­‐3453)	  Luc	  (63)	  PV3	  (3292	  -­‐	  A	  tail)	  has	  the	  largest	  insert	  of	  222	  nt.	  In	  this	  example	  the	  recombinant	  genome	  also	  includes	  63	  nt	  of	  the	  C-­‐terminus	  of	  the	  firefly	  luciferase	  gene.	  In	  all	  three	  isolates	  the	  ORF	  is	  maintained	  and	  the	  full	  complement	  of	  viral	  proteins	  are	  present.	  They	  have	  all	  inherited	  the	  capsid-­‐coding	  region	  from	  the	  SL3	  template	  and	  inherited	  the	  majority	  of	  the	  non-­‐structural	  P2	  and	  P3	  regions	  from	  the	  Rep3-­‐L.	  Crossover	  positions	  were	  determined	  from	  full-­‐length	  PV3	  sequence	  strain	  Leon	  (GenBank	  accession	  number	  X00925).	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Figure	  3.3:	  Twenty	  distinct	  recombination	  junctions	  identified	  from	  136	  cloned	  PV3/1	  
recombinants	  Schematic	  diagram	  showing	  the	  location	  of	  recombinant	  junctions	  characterised	  following	  co-­‐transfection	  of	  murine	  L929	  cells	  with	  CRE-­‐defective	  type	  3	  poliovirus	  genome	  (SL3;	  dark	  shading)	  and	  poliovirus	  type	  1	  sub-­‐genomic	  replicon	  RNA	  (RLucWT;	  light	  shading).	  The	  graduated	  shading	  in	  the	  upper	  genome	  indicates	  the	  region	  within	  which	  recombination	  must	  have	  occurred	  to	  generate	  viable	  progeny	  virus.	  The	  expanded	  portion	  of	  the	  genomes	  (below)	  indicates	  the	  position	  of	  the	  junctions	  in	  the	  donor	  (RLucWT)	  and	  recipient	  (SL3)	  genomes.	  Solid	  lines	  indicate	  the	  groups	  of	  imprecise	  junctions	  –	  defined	  by	  sequence	  –	  which	  are	  grouped	  into	  two	  clusters	  spanning	  the	  P1/P2	  and	  2A/2B	  boundaries.	  The	  thickened	  line	  in	  one	  of	  the	  cluster	  1	  imprecise	  recombinants	  indicates	  the	  genome	  bearing	  additional	  sequence	  derived	  from	  the	  5’	  NTR.	  Precise	  recombinants	  are	  indicated	  with	  vertical	  dotted	  lines	  within	  the	  2A	  and	  2C	  coding	  regions.	  Ref:	  (Lowry	  et	  al.,	  2014)	  	  	  
and seventh (P7) passage were compared with the parental
poliovirus type 1 and type 3 (Figure 3ab). The initial small plaque
phen type (P2) increased by P7 to ne close to that of either
poliovirus types 1 or 3. In a single step growth analysis the P7 virus
was indistinguishable from poliovirus type 1 or type 3, whereas the
P2 virus had a lower yield at all time points tested, with a titre at
24 hours ,1 log10 reduced. This suggested that serial passage of
#51G resulted in changes that favoured the selection of viruses
with faster replication kinetics and a large plaque phenotype. RNA
therefore was purified at P2, P3, P7 and P12, reverse transcribed
and the region spanning the recombination junction amplified by
PCR using oligonucleotides PV3-2995F and GEN-4615R. In early
passages (P2, P3) a single product was amplified of ,1.7 kb but
was largely replaced by P7 (and totally by P12) with a PCR
product of a reduced size (Figure 3c). The P7 product was cloned
and eight resulting cDNAs selected at random were sequenced.
Four distinct junction sequences between poliovirus types 1 and
3 were identified (Figure 3d; #51G-a to –d in Figure S2). In each
case the product contained a precise junction in which there were
no additional duplicated sequences from either parental genome.
Figure 2. Recombination generates imprecise junctions with genome duplications. A) Imprecise recombinants recovered following co-
transfection of murine L929 cells with RNA generated in vitro from pT7Rep3-L (upper genome) and pT7/SL3 (lower genome). The junction sequence
of two imprecise recombinants, indicated with dashed lines, are shown. Upper and lower case characters are used to distinguish between those
derived from the CRE-defective genome (pT7/SL3) and sub-genomic replicon (pT7Rep3-L) respectively, with the extent of the sequence numbered
according to the reference genomes (see Materials and Methods). For each imprecise recombinant the number prefixed with a plus sign indicates the
additional nucleotides incorporated at the junction. B) Schematic diagram showing the location of recombinant junctions characterised following co-
transfection of murine L929 cells with CRE-defective type 3 poliovirus genome (pT7/SL3; dark shading) and poliovirus type 1 sub-genomic replicon
RNA (pRLucWT; light shading). The graduated shading in the upper genome indicates the region within which recombination must have occurred to
generate viable progeny virus. The expanded portion of the genomes (below) indicate the position of the junctions in the polymerase donor
(pRLucWT) and recipient (pT7/SL3) genomes. Solid lines indicate the groups of imprecise ju ctions – defined by sequence – which are grouped into
two clusters spanning the P1/P2 and 2A/2B boundaries. The thickened line in one of the cluster 1 imprecise recombinants indicates the genome
bearing additional sequence derived from the 59 NCR (#25A see Figure 3). Precise recombinants are indicated with vertical dotted lines within the 2A
and 2C codin regions.
doi:10.1371/journal.ppat.1004191.g002
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Figure	  3.4:	  Comparison	  of	  intratypic	  and	  intertypic	  Poliovirus	  recombinants.	  
(A)	  Representative	  gel	  electrophoresis	  of	  RT-­‐PCR	  product	  of	  the	  PV3/1	  recombination	  region.	  Ethidium	  bromide	  stained	  1%	  agarose	  gels	  showing	  a	  heterogeneous	  mixture	  of	  amplified	  virus	  sequences	  from	  biologically	  cloned	  PV3/1	  recombinants,	  N	  and	  P	  =	  negative	  and	  positive	  controls	  respectively	  (B)	  Representative	  gel	  electrophoresis	  of	  RT-­‐PCR	  product	  of	  the	  PV3/3	  recombination	  region.	  Ethidium	  bromide	  stained	  1%	  agarose	  gels	  showing	  a	  general	  homogeneous	  mixture	  of	  amplified	  virus	  sequences	  from	  biologically	  cloned	  PV3/3	  recombinants,	  P	  =	  positive	  control	  (C)	  Sites	  of	  imprecise	  crossover	  junctions	  in	  recovered	  PV3/PV3	  recombinants.	  PV3	  =	  Leon	  strain,	  GenBank	  accession	  numbers	  X00925.	  REC	  =	  indicates	  recombinant	  sequence,	  red	  boxes	  shows	  indicate	  sequence	  identity	  in	  the	  region	  of	  template	  switching.	  Dashes	  indicate	  nt	  identity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated.	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3.4 Enterovirus	  species	  B	  intratypic	  recombination	  	  	  During	  the	  initial	  stages	  of	  this	  investigation	  attempts	  to	  expand	  the	  CRE-­‐REP	  assay	  into	  a	  different	  enterovirus	  species	  group	  was	  considered.	  The	  availability	  of	  suitable	  cDNA	  meant	  that	  echovirus	  6	  and	  7	  were	  chosen.	  These	  two	  viruses	  share	  similar	  genome	  length	  and	  layouts	  to	  poliovirus,	  and	  their	  CRE	  is	  located	  in	  the	  2C	  region.	  This	  ensured	  a	  similar	  region	  of	  recombination	  was	  available.	  Additionally,	  sequence	  divergence	  within	  the	  potential	  recombination	  region	  is	  20%,	  very	  similar	  to	  the	  PV3/1	  divergence	  of	  22%.	  An	  echovirus	  sub-­‐genomic	  replicon	  (E7Luc)	  and	  a	  CRE	  defective	  full-­‐length	  clone	  (E7ΔCRE)	  (Kym	  Lowry	  thesis)	  were	  used	  in	  a	  similar	  fashion	  to	  the	  species	  C	  poliovirus	  intratypic	  partners	  previously	  outlined.	  	  A	  total	  of	  2	  μg	  of	  RNA	  was	  co-­‐transfected	  at	  a	  1:1	  ratio	  using	  Lipofectamine	  2000	  (replicon:	  CRE	  mutant	  genome)	  into	  BsrT7	  baby	  hamster	  kidney	  cells	  in	  a	  6-­‐well	  plate.	  Media	  supernatant	  was	  isolated	  at	  48	  hrs	  post	  transfection	  and	  500	  μl	  undiluted	  supernatant	  was	  used	  to	  inoculate	  human	  embryonic	  rhabdomyosarcoma	  cells	  (RD)	  monolayers	  for	  plaque	  assays.	  Plates	  were	  incubated	  for	  48	  hrs,	  stained	  with	  crystal	  violet,	  and	  photographed.	  Individual	  transfection	  controls	  produced	  no	  virus,	  as	  expected.	  The	  co-­‐transfected	  cells	  did	  produce	  recombinant	  virus	  as	  indicated	  by	  plaque	  formation	  (figure	  3.5).	  The	  yield	  was	  calculated	  to	  be	  26	  pfu/ml.	  The	  recombinant	  virus	  population	  was	  subsequently	  biologically	  cloned	  in	  RD	  cells	  and	  the	  region	  of	  recombination	  amplified	  by	  RT-­‐PCR	  using	  the	  primers	  EV7-­‐6F	  and	  EV7-­‐5247R.	  The	  homogenous	  population	  of	  PCR	  products	  all	  migrated	  in	  a	  similar	  fashion	  to	  the	  control.	  Subsequent	  sequence	  analysis	  indicated	  that	  all	  the	  PCR	  products	  were	  2382	  base	  pairs	  (bp)	  in	  length	  and	  wild-­‐type	  E7,	  with	  no	  additional	  sequence	  present.	  	  	  Importantly,	  the	  ability	  to	  isolate	  recombinant	  virus	  from	  a	  different	  species	  group	  provides	  further	  validity	  to	  the	  overall	  experimental	  approach.	  During	  the	  course	  of	  this	  study	  an	  E6	  d’Amori	  strain	  sub-­‐genomic	  replicon	  carrying	  a	  firefly	  luciferase	  gene	  in	  place	  of	  the	  P1	  region	  was	  produced	  that	  would	  allow	  E7/E6	  intertypic	  recombination	  to	  be	  investigated	  via	  a	  CRE-­‐REP	  style	  experiment.	  Sequence	  analysis	  confirmed	  the	  replicons	  identity	  and	  luciferase	  assays	  indicated	  that	  the	  replicon	  replicated	  well	  (data	  not	  shown).	  However	  no	  intertypic	  E7/E6	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Figure	  3.5:	  Identification	  and	  biological	  cloning	  of	  E7/E7	  recombinant	  viruses.	  	  
(A)	  Individual	  transfection	  and	  co-­‐transfection	  supernatant	  was	  inoculated	  undiluted	  onto	  a	  fresh	  RD	  cell	  monolayer	  and	  overlaid	  with	  plaque	  overlay	  medium.	  Cells	  were	  stained	  48	  hrs	  post-­‐infection	  with	  crystal	  violet.	  Viable	  virus	  is	  evident	  by	  the	  presence	  of	  plaques.	  (B)	  Gel	  electrophoresis	  of	  RT-­‐PCR	  product	  of	  recombination	  region	  following	  biological	  cloning	  of	  recombinant	  virus.	  Ethidium	  bromide	  stained	  1%	  agarose	  gels	  showing	  a	  homogeneous	  mixture	  of	  amplified	  virus	  sequences	  from	  cloned	  recombinants.	  N	  =	  negative	  control,	  P	  =	  positive	  control.	  
	  	  	  	  	  	  	  	  	  	  	  	  E7luc	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  E7ΔCRE 
E7luc	  +	  E7ΔCRE 
	  	  	  	  	  	  	  	  	  	  	  	  	  E7/7	  isolates 
	  	  N	  	  	  	  	  	  	  	  	  	  P 
2.5	  Kb 
	   72	  
recombinants	  were	  isolated.	  Many	  separate	  experiments	  were	  carried	  out	  that	  used	  altered	  donor:	  acceptor	  template	  ratios	  as	  well	  as	  different	  rodent	  cell	  lines	  (L929	  and	  BsrT7).	  Due	  to	  the	  good	  reproducibility	  of	  the	  species	  C	  poliovirus	  CRE-­‐REP	  assay	  a	  decision	  was	  made	  to	  concentrate	  the	  majority	  of	  future	  work	  on	  these	  partners.	  	  
	  
3.5 Intertypic	  poliovirus	  recombinants	  isolated	  from	  HeLa	  cells	  	  Previous	  studies	  and	  indeed	  the	  majority	  of	  the	  work	  presented	  in	  this	  thesis	  are	  based	  upon	  a	  system	  that	  uses	  rodent	  cell	  lines	  from	  which	  recombinant	  virus	  is	  recovered	  (L929	  and	  BsrT7	  respectively).	  The	  imprecise	  nature	  of	  many	  of	  the	  intertypic	  recombinants	  isolated	  could	  have	  been	  due	  to	  the	  host	  environment	  that	  is	  specific	  to	  rodent	  cell	  lines.	  The	  influence	  of	  host	  cell	  type	  and	  the	  type	  of	  recombinant	  produced	  was	  therefore	  considered.	  A	  co-­‐transfection	  of	  HeLa	  cells	  with	  the	  intertypic	  partners	  RLucWT	  and	  SL3	  was	  carried	  out	  using	  a	  total	  of	  2	  μg	  of	  RNA	  at	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant	  genome)	  in	  a	  6-­‐well	  plate.	  Individual	  transfection	  controls	  were	  also	  done.	  HeLa	  cells	  are	  human	  cells	  that	  have	  the	  poliovirus	  receptor	  CD155,	  so	  are	  susceptible	  to	  re-­‐infection	  unlike	  the	  rodent	  cell	  lines	  that	  are	  typically	  used.	  Additionally,	  HeLa	  cells	  have	  been	  widely	  used	  in	  the	  majority	  of	  studies	  with	  poliovirus	  so	  were	  considered	  the	  most	  appropriate.	  It	  was	  decided	  that	  harvesting	  of	  the	  media	  supernatant	  at	  24	  hrs	  post	  transfection	  instead	  of	  the	  normal	  48	  hr	  incubation	  would	  minimise	  any	  selection	  and	  allow	  characterisation	  of	  the	  early	  products	  of	  recombination.	  Following	  the	  incubation	  period,	  500	  μl	  of	  the	  media	  supernatant	  was	  used	  to	  inoculate	  fresh	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs	  and	  stained	  with	  crystal	  violet.	  Individual	  transfections	  of	  either	  parental	  genome	  produced	  no	  virus,	  as	  expected.	  Co-­‐transfected	  cells	  produced	  viable	  recombinant	  virus	  as	  indicated	  by	  plaque	  formation	  and	  yield	  of	  PV3/1	  recombinant	  virus	  was	  calculated	  to	  be	  32	  pfu/ml.	  Recombinant	  virus	  was	  biologically	  cloned	  using	  a	  limiting	  dilution	  method	  and	  the	  recombination	  region	  was	  amplified	  by	  RT-­‐PCR	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  The	  products	  of	  the	  PCR	  reaction	  indicated	  additional	  sequence	  when	  	  compared	  to	  the	  control,	  which	  was	  1335	  bp	  in	  length	  (figure	  3.6).	  The	  migration	  of	  the	  PCR	  products	  amplified	  from	  recombinant	  cDNA	  indicated	  that	  all	  are	  imprecise	  in	  nature,	  similar	  to	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  PV3	  (1-­‐3475/76)	  Luc	  (32/33)	  	  -­‐	  PV1	  -­‐	  A	  tail	  	  
PV3: ATACTGTAAGCATCATGTGGAATAGA 
LUC: GAGAGA-CCT---A-A-GCC--G-AG 
REC: ---------------A-GCC--G-AG 	  	  
Figure	  3.6:	  Biologically	  cloned	  PV3/PV1	  recombinants	  from	  a	  HeLa	  cell	  co-­‐transfection.	  
(A)	  Ethidium	  bromide	  stained	  1%	  agarose	  gel	  showing	  the	  non-­‐uniform	  virus	  fragments	  from	  biologically	  cloned	  recombinants	  isolated	  from	  a	  HeLa	  cell	  co-­‐transfection.	  N	  =	  negative	  control,	  P	  =	  positive	  control	  (B)	  Imprecise	  recombinant	  example.	  PV3	  =	  Leon	  strain	  (GenBank	  accession	  numbers	  X00925),	  LUC	  =	  Luciferase	  sequence	  carried	  by	  the	  PV1	  replicon	  and	  REC	  =	  recombinant	  sequence.	  Red	  boxes	  show	  nt	  identity	  at	  cross-­‐over	  junctions.	  Dashes	  indicate	  nt	  identity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated.	  	  
Isolated	  recombinants	  1-­‐10 
N	  	  	  	  	  	  P 
1.5	  Kb 
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the	  phenomenon	  seen	  in	  rodent	  cells.	  This	  indicates	  that	  the	  initial	  recombination	  event	  incorporating	  additional	  sequences	  at	  the	  site	  of	  recombination	  is	  not	  a	  cell	  specific	  trait.	  Three	  of	  the	  PCR	  products	  were	  sequenced,	  with	  all	  returning	  the	  same	  sequence	  PV3	  (1-­‐3475/76)	  Luc	  (32/33)	  	  -­‐	  PV1	  -­‐	  A	  tail.	  These	  ‘imprecise’	  isolates	  have	  an	  additional	  150	  nt	  when	  compared	  to	  wild-­‐type	  genome	  length.	  	  	  	  
3.6 Resolution	  of	  imprecise	  intertypic	  recombinants	  	  The	  identification	  of	  intertypic	  recombinants	  (PV3/1)	  carrying	  additional	  sequence	  at	  the	  recombination	  junctions	  in	  this	  study	  and	  the	  Lowry	  study	  was	  somewhat	  unexpected.	  Recombinant	  polioviruses	  characterised	  from	  field	  isolates	  following	  outbreaks	  of	  infection	  never	  carry	  any	  additional	  sequences	  (Kew	  et	  al.,	  2002,	  Zhang	  et	  al.,	  2010,	  King,	  1988b).	  Perhaps	  the	  methodology	  employed	  in	  the	  CRE-­‐REP	  assay	  had	  isolated	  the	  very	  early	  recombinant	  genomes	  that	  had	  not	  been	  exposed	  to	  any	  selection	  pressure?	  Indeed,	  passaging	  of	  imprecise	  intertypic	  recombinants	  has	  provided	  evidence	  to	  suggest	  that	  the	  primary	  products	  of	  recombination	  go	  through	  a	  secondary	  event	  that	  selects	  virus	  where	  all	  additional	  sequences	  have	  been	  lost	  and	  the	  genome	  returns	  to	  wild-­‐type	  length	  (Lowry	  et	  al.,	  2014).	  This	  provides	  the	  hypothesis	  that	  recombination	  in	  enteroviruses	  is	  a	  biphasic	  event.	  An	  initial	  promiscuous	  recombination	  event	  that	  incorporates	  additional	  sequence	  is	  then	  followed	  by	  loss	  of	  the	  additional	  sequence	  after	  serial	  passage	  in	  permissive	  and	  susceptible	  cells	  (HeLa	  for	  example)	  in	  a	  process	  hereafter	  termed	  ‘resolution’.	  	  
Serial	  passaging	  of	  three	  ‘imprecise’	  PV3/1	  recombinant	  viruses	  Three	  ‘imprecise’	  recombinant	  viruses	  that	  had	  been	  identified	  were	  chosen	  for	  serial	  passaging	  in	  HeLa	  cells.	  The	  first	  two	  had	  imprecise	  junctions	  that	  spanned	  the	  VP1/2A	  cleavage	  boundary	  (cluster	  1	  isolates)	  and	  had	  been	  isolated	  and	  characterised	  in	  the	  Lowry	  study.	  These	  were	  designated	  as	  #53A	  [PV3	  (1-­‐3505)	  Luc	  (168)	  -­‐	  PV1	  -­‐	  A	  Tail],	  and	  #105B	  [PV3	  (1-­‐	  3491)	  Luc	  (137)	  -­‐	  PV1	  -­‐	  A	  Tail],	  which	  carry	  an	  additional	  294	  and	  249	  nt	  respectively.	  An	  isolate	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characterised	  in	  this	  study	  known	  as	  #E1	  [PV3	  (1-­‐3858/59)	  PV1	  3774/75	  -­‐	  A	  Tail]	  had	  an	  imprecise	  junction	  at	  the	  C-­‐terminus	  of	  2A	  carrying	  an	  additional	  75	  nt	  (cluster	  2	  isolate).	  All	  were	  serially	  passaged	  individually	  in	  HeLa	  cells	  in	  T20	  flasks	  12	  times.	  Virus	  samples	  were	  taken	  at	  various	  passages	  and	  subjected	  to	  RT-­‐PCR	  analysis.	  The	  region	  of	  recombination	  from	  the	  end	  of	  VP1	  to	  the	  2C	  CRE	  was	  amplified	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  The	  PCR	  band	  size	  of	  #53A	  (with	  all	  additional	  sequence)	  is	  1629bp.	  By	  passage	  5	  three	  bands	  can	  be	  seen,	  one	  representing	  junction	  with	  insert,	  one	  intermediate	  and	  one	  smaller	  band.	  By	  passage	  7	  all	  additional	  sequence	  looks	  to	  have	  been	  lost	  and	  the	  PCR	  product	  has	  migrated	  as	  far	  as	  the	  wild	  type	  control	  (figure	  3.7).	  The	  passaging	  of	  #105B	  and	  #E1	  also	  show	  a	  similar	  phenomenon	  (figures	  3.8	  and	  3.9	  respectively).	  The	  recombinant	  #105B	  looks	  to	  have	  a	  band	  primarily	  migrating	  to	  the	  same	  position	  as	  the	  wild	  type	  control	  at	  passage	  11.	  Only	  #E1	  looks	  to	  have	  retained	  any	  additional	  sequence	  but	  there	  is	  a	  clear	  change	  in	  PCR	  product	  size	  following	  passage.	  In	  all	  three	  examples	  the	  serial	  passaging	  of	  	  ‘imprecise’	  recombinant	  genomes	  has	  led	  to	  a	  secondary	  stage	  where	  additional	  sequence	  was	  lost.	  Indeed,	  the	  biologically	  cloned	  isolates	  from	  each	  group	  that	  were	  isolated	  and	  characterised	  by	  RT-­‐PCR	  at	  passage	  12	  all	  migrated	  in	  a	  similar	  fashion	  to	  a	  wild	  type	  genome	  length	  PCR	  product.	  All	  amplified	  regions	  from	  the	  biologically	  cloned	  isolates	  at	  passage	  12	  were	  sequenced	  to	  characterise	  their	  altered	  recombination	  junctions.	  The	  eight	  ‘resolved’	  #53A	  isolates	  all	  returned	  the	  same	  sequence.	  The	  #105B	  isolates	  returned	  two	  unique	  sequences	  and	  the	  #E1	  isolates	  returned	  one	  unique	  sequence.	  In	  the	  three	  groups,	  all	  had	  lost	  the	  additional	  sequence	  and	  the	  genomes	  were	  wild	  type	  in	  length,	  or	  ‘precise’	  recombinants	  (figure	  3.10ABC).	  The	  majority	  of	  the	  ‘imprecise’	  PV3/1	  isolates	  characterised	  in	  the	  Lowry	  study	  provided	  recombination	  junctions	  that	  could	  be	  identified	  down	  to	  a	  single	  nucleotide.	  As	  previously	  stated	  no	  obvious	  link	  to	  RNA	  sequence	  could	  be	  identified	  at	  this	  stage,	  with	  recombination	  seemingly	  ‘promiscuous’.	  It	  is	  interesting	  to	  note	  that	  in	  all	  the	  examples	  of	  ‘resolved’	  recombination	  in	  this	  study,	  all	  the	  junctions	  are	  ambiguous	  i.e.	  we	  were	  unable	  to	  identify	  the	  exact	  position	  of	  recombination	  due	  to	  sequence	  identity	  between	  the	  parental	  genomes.	  Importantly,	  all	  of	  the	  passaged	  isolates	  had	  new	  recombination	  junctions	  that	  could	  have	  arisen	  from	  the	  initial	  ‘imprecise’	  parental	  genome	  following	  resolution	  (figure	  3.10D).	  	  
	   76	  
A	  








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3.7:	  Serial	  passaging	  of	  PV3/1	  recombinant	  #53A	  
(A)	  Ethidium	  bromide	  stained	  1%	  agarose	  gel.	  (N)	  Indicates	  negative	  control.	  The	  positive	  control	  (P)	  represents	  a	  wild	  type	  genome	  length	  product	  from	  a	  PCR	  reaction	  using	  primers	  that	  amplified	  the	  specific	  recombination	  region.	  Products	  from	  RT-­‐PCR	  can	  be	  seen	  from	  passages	  3,	  5,	  and	  7	  respectively.	  Arrows	  show	  1.5	  Kb	  size	  marker	  (B)	  Limiting	  dilution	  approach	  to	  biologically	  clone	  recombinant	  virus	  from	  passage	  12.	  (C)	  RT-­‐PCR	  derived	  product	  from	  8	  biologically	  cloned	  recombinant	  viruses	  from	  passage	  12,	  (P)	  represents	  the	  wild	  type	  genome	  length	  PCR	  product.	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Figure	  3.8:	  Serial	  passaging	  of	  PV3/1	  recombinant	  #105B	  
(A)	  Ethidium	  bromide	  stained	  1%	  agarose	  gel.	  Products	  from	  RT-­‐PCR	  can	  be	  seen	  from	  passages	  3,	  5,	  7,	  9	  and	  11	  respectively.	  Arrows	  show	  1.5	  Kb	  size	  marker	  (B)	  RT-­‐PCR	  derived	  product	  from	  8	  biologically	  cloned	  recombinant	  viruses	  from	  passage	  12,	  (P)	  represents	  control	  PCR	  from	  wild	  type	  length	  genome.	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Figure	  3.9:	  Serial	  passaging	  of	  PV3/1	  recombinant	  virus	  #E1	  
(A)	  Ethidium	  bromide	  stained	  1%	  agarose	  gel.	  (N)	  Indicates	  negative	  control.	  The	  positive	  control	  (P)	  represents	  a	  wild	  type	  genome	  length	  product	  from	  a	  PCR	  reaction	  using	  primers	  that	  amplified	  the	  specific	  recombination	  region.	  Products	  from	  RT-­‐PCR	  can	  be	  seen	  from	  passages	  3,	  5,	  7,	  9	  and	  11	  respectively.	  Arrows	  show	  1.5	  Kb	  size	  marker	  (B)	  RT-­‐PCR	  derived	  product	  from	  7	  biologically	  cloned	  recombinant	  viruses	  from	  passage	  12,	  (P)	  represents	  control	  PCR	  from	  wild	  type	  length	  genome.	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Figure	  3.10:	  Sites	  of	  the	  recombination	  junctions	  in	  the	  passaged	  recombinants	  #53A,	  
#105B	  and	  #E1.	  	  	  PV3	  =	  Leon	  strain,	  PV1	  =	  Mahoney	  strain	  (GenBank	  accession	  numbers	  X00925	  and	  V01149	  respectively),	  REC	  =	  recombinant	  sequence.	  Red	  boxes	  indicate	  sequence	  identity	  at	  positions	  of	  template	  switching.	  Dashes	  indicate	  nt	  similarity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated	  (A)	  One	  unique	  crossover	  site	  from	  clones	  after	  recombinant	  #53A	  was	  serially	  passaged	  through	  HeLa	  cells	  (B)	  Two	  unique	  crossover	  sites	  after	  recombinant	  #105B	  were	  serially	  passaged	  through	  HeLa	  cells	  (C)	  One	  unique	  crossover	  site	  after	  recombinant	  #E1	  was	  serially	  passaged	  through	  HeLa	  cells	  (D)	  Recombinants	  are	  colour	  coded	  as	  follows,	  PURPLE	  =	  #53A	  [PV3	  (1-­‐3505)	  Luc	  (168)	  -­‐	  PV1	  -­‐	  A	  Tail],	  GREEN	  =	  #105B	  [PV3	  (1-­‐	  3491)	  Luc	  (137)	  -­‐	  PV1	  -­‐	  A	  Tail]	  and	  BLUE	  =	  #E1	  [PV3	  (1-­‐3858/59)	  PV1	  3774/75	  -­‐	  A	  Tail].	  Dashed	  arrows	  represent	  the	  initial	  recombinants	  with	  insert	  sequence.	  Arrows	  represent	  biologically	  cloned	  precise	  recombinants	  derived	  from	  serial	  passage	  of	  the	  initial	  recombinant.
A
VP4 VPg
VP1VP3VP2 2A 2B 2C 3A 3C 3D
2A 2B 2C 3A 3C 3Dluc
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3.7 Construction	  of	  the	  molecular	  clone	  JC105B	  	  The	  isolation	  of	  resolved	  recombinant	  viruses	  utilised	  a	  limiting	  dilution	  approach.	  One	  limitation	  of	  such	  an	  approach	  is	  the	  possibility	  that	  the	  population	  of	  virus	  may	  not	  be	  clonal,	  and	  could	  potentially	  contain	  additional	  recombinant	  virus.	  This	  seems	  to	  be	  evident	  with	  a	  result	  shown	  in	  the	  Lowry	  PhD	  thesis,	  where	  a	  serially	  passaged	  imprecise	  recombinant	  virus	  produced	  precise	  recombinant	  genome	  sequences	  that	  could	  not	  have	  arisen	  from	  the	  original	  biologically	  cloned	  virus.	  This	  was	  not	  observed	  in	  section	  3.6	  where	  all	  of	  the	  resolved	  recombinant	  genomes	  could	  have	  arisen	  from	  the	  initial	  ‘imprecise’	  recombinants.	  However,	  the	  resolution	  step	  where	  additional	  sequence	  was	  lost	  could	  still	  have	  been	  due	  to	  the	  presence	  of	  a	  low	  level	  of	  a	  precise	  recombinant	  virus	  that	  out-­‐competes	  the	  imprecise	  recombinant	  population	  following	  a	  suitable	  passage	  length.	  The	  resolution	  event	  needed	  to	  be	  unambiguously	  characterised.	  	  
To	  overcome	  this,	  a	  molecular	  clone	  of	  an	  imprecise	  recombinant	  that	  was	  identical	  in	  sequence	  to	  an	  isolate	  known	  as	  #105B	  was	  constructed	  by	  a	  two-­‐step	  cloning	  strategy	  by	  Dr.	  Jonathon	  Cook	  (the	  construct	  hereafter	  known	  as	  JC105B	  is	  described	  in	  figure	  3.11A).	  The	  decision	  to	  produce	  this	  ‘imprecise’	  recombinant	  cDNA	  was	  based	  upon	  the	  availability	  of	  suitable	  restriction	  enzyme	  sites	  for	  cloning.	  The	  PCR	  product	  used	  in	  the	  first	  step	  of	  cloning	  was	  synthesised	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  The	  entire	  region	  of	  cloned	  cDNA	  was	  sequenced	  to	  confirm	  its	  identity	  and	  RNA	  was	  transcribed	  using	  T7	  polymerase.	  One	  microgram	  of	  the	  RNA	  produced	  was	  then	  used	  to	  transfect	  L929	  cells	  in	  a	  12-­‐well	  plate.	  Transfection	  supernatant	  was	  isolated	  at	  24	  hrs	  post	  transfection	  and	  a	  serial	  dilution	  was	  used	  to	  inoculate	  RD	  cell	  monolayers	  for	  a	  plaque	  assay.	  Cells	  were	  incubated	  for	  48	  hrs,	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  3.11B).	  As	  indicated	  by	  the	  plaque	  formation,	  the	  RNA	  was	  infectious	  and	  virus	  yield	  was	  calculated	  to	  be	  8	  x	  104	  pfu/ml.	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Figure	  3.11:	  Construction	  of	  the	  molecular	  recombinant	  clone	  JC105B	  	  
(A)	  The	  construction	  of	  the	  intertypic	  recombinant	  JC105B	  occurred	  in	  a	  two-­‐step	  process.	  Firstly,	  the	  amplified	  recombination	  region	  from	  the	  original	  #105B	  isolate	  was	  sub-­‐cloned	  into	  the	  pT7FLC/SL3	  plasmid	  using	  the	  unique	  restriction	  sites	  BssHII	  and	  XhoI.	  Secondly,	  the	  non-­‐structural	  region	  of	  the	  PV1	  replicon	  (pRLucWT)	  was	  sub-­‐cloned	  into	  the	  intermediate	  plasmid	  (pJC3830)	  using	  the	  XhoI	  site	  along	  with	  the	  two	  unique	  blunt	  cutting	  sites	  (NruI	  and	  SspI)	  to	  produce	  the	  complete	  construct	  (pJC3849)	  (B)	  Crystal	  violet	  stained	  RD	  cells	  infected	  with	  a	  dilution	  series	  of	  transfection	  supernatant	  and	  overlaid	  with	  plaque	  overlay	  medium.	  The	  supernatant	  was	  obtained	  from	  a	  transfection	  of	  L929	  cells	  with	  RNA	  produced	  from	  pJC3849.	  	  	  	  	  
	  	  	  	  	  	  	  	  	  Negative	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  undiluted	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐4 
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3.8 Serial	  passage	  of	  the	  molecular	  clone	  JC105B	  	  To	  validate	  the	  experimental	  evidence	  provided	  from	  the	  serial	  passage	  of	  three	  biological	  ‘imprecise’	  recombinants,	  virus	  derived	  from	  JC105B	  was	  also	  passaged	  in	  HeLa	  cells.	  Unlike	  the	  original	  12-­‐passage	  regime,	  this	  virus	  was	  passaged	  only	  7	  times.	  It	  was	  reasoned	  that	  this	  would	  provide	  the	  best	  opportunity	  to	  isolate	  possible	  intermediate	  sized	  recombinant	  viruses	  that	  neither	  resembled	  the	  original	  nor	  the	  completely	  resolved	  genome.	  RNA	  was	  extracted	  from	  various	  passages	  and	  subjected	  to	  RT-­‐PCR	  analysis.	  The	  primers	  used	  to	  amplify	  the	  specific	  region	  of	  recombination	  were	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  Like	  its	  biological	  counterpart,	  JC105B	  went	  through	  a	  ‘resolution’	  stage	  following	  passage	  (figure	  3.12).	  At	  passage	  4	  two	  PCR	  products	  can	  be	  visualised	  that	  are	  smaller	  than	  the	  expected	  1584	  bp	  size	  of	  JC105B	  with	  complete	  insert.	  One	  of	  these	  bands	  migrated	  as	  far	  as	  the	  wild	  type	  control,	  suggesting	  a	  fully	  resolved	  product.	  The	  second	  PCR	  product	  looked	  intermediate	  in	  size,	  smaller	  than	  the	  105B	  with	  insert	  yet	  larger	  than	  the	  wild	  type	  band.	  Subsequent	  isolation	  of	  individual	  clones	  from	  passage	  7	  material,	  using	  a	  limiting	  dilution	  approach,	  produced	  a	  heterogeneous	  population	  of	  PCR	  products.	  Six	  clones	  were	  sequenced,	  with	  one	  providing	  an	  identical	  sequence	  to	  a	  previously	  isolated	  precise	  #105B	  biological	  clone	  shown	  in	  figure	  3.10B	  [PV3	  (1-­‐3367/3379)	  -­‐	  PV1	  -­‐	  A	  tail].	  A	  second	  precise	  junction	  was	  also	  identified	  [PV3	  (1-­‐3401/3411)	  -­‐	  PV1	  -­‐	  A	  tail].	  In	  both	  examples	  the	  exact	  location	  of	  the	  new	  junction	  cannot	  be	  determined	  due	  to	  sequence	  identity	  of	  the	  parental	  genomes	  from	  which	  the	  clone	  was	  produced	  (figure	  3.13).	  The	  remaining	  four	  clones	  exhibited	  the	  same	  ‘imprecise’	  junction,	  but	  this	  was	  different	  to	  the	  original	  JC105B	  construct.	  The	  latter	  retained	  a	  57	  nt	  insert	  derived	  from	  the	  C-­‐terminal	  part	  of	  the	  firefly	  luciferase	  reporter	  gene,	  but	  had	  lost	  the	  remainder	  of	  the	  insert	  that	  was	  present	  in	  the	  JC105B	  construct.	  This	  was	  an	  intermediate	  recombinant,	  a	  phenomenon	  not	  characterised	  before.	  	  	  Taken	  together,	  two	  conclusions	  can	  be	  drawn	  from	  this	  experiment.	  Firstly,	  the	  imprecise	  recombinants	  isolated	  from	  L929	  are	  the	  likely	  progenitors	  of	  the	  precise	  recombinants	  subsequently	  selected	  by	  serial	  passage	  in	  HeLa	  cells.	  Secondly,	  the	  identification	  of	  precise	  and	  imprecise	  recombinant	  with	  a	  duplicate	  sequence	  reduced	  in	  length	  from	  the	  input	  suggests	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that	  process	  of	  resolution	  may	  progress	  using	  a	  step-­‐wise	  mechanism	  via	  intermediate	  imprecise	  recombinants.	  In	  principle,	  this	  event	  could	  have	  occurred	  in	  cis	  where	  the	  additional	  sequences	  are	  ‘looped’	  out	  upon	  the	  same	  template	  during	  RNA	  replication.	  Alternatively,	  the	  resolution	  event	  could	  have	  occurred	  in	  trans,	  involving	  another	  acceptor	  template	  via	  a	  copy-­‐choice	  like	  recombination	  event.	   	  









Figure	  3.12:	  Changes	  in	  the	  crossover	  region	  of	  passaged	  molecular	  clone	  JC105B	  
recombinant.	  	  Following	  seven	  passages	  through	  HeLa	  cells.	  RT-­‐PCR	  product	  of	  amplified	  region	  in	  the	  recombinant	  virus	  was	  run	  on	  1%	  agarose	  gel	  and	  stained	  with	  ethidium	  bromide	  (A)	  New	  construct	  JC105B	  recombinant	  crossover	  region	  gradually	  reduced	  in	  size	  from	  1584	  bp	  (with	  insert)	  (N)	  indicates	  negative	  control;	  (P)	  indicates	  the	  positive	  control	  representing	  a	  wild	  type	  genome	  length	  product.	  Two	  bands	  can	  be	  seen	  from	  p4	  onward,	  the	  smaller	  being	  1335	  bp	  (length	  of	  precise	  crossover)	  the	  larger	  band	  represented	  an	  intermediate	  recombinant	  (B)	  Ethidium	  bromide	  stained	  1%	  agarose	  gel	  showing	  the	  non-­‐uniform	  PCR	  products	  from	  biologically	  cloned	  recombinants	  isolated	  from	  p7.	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Figure	  3.13:	  Sites	  of	  the	  recombination	  junctions	  in	  the	  passaged	  JC105B	  	  
(A)	  Precise	  recombinants.	  PV3	  =	  Leon	  strain,	  PV1	  =	  Mahoney	  strain	  (GenBank	  accession	  numbers	  X00925	  and	  V01149	  respectively),	  REC	  =	  recombinant	  sequence.	  Red	  boxes	  show	  nt	  similarity	  at	  cross-­‐over	  junctions.	  Dashes	  indicate	  nt	  similarity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated	  (B)	  Imprecise	  intermediate	  recombinant.	  LUC	  =	  Luciferase	  sequence	  carried	  by	  the	  PV1	  replicon,	  the	  remaining	  nomenclature	  is	  the	  same	  as	  (A).	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3.9 Contribution	  of	  non-­‐replicative	  recombination	  	  The	  development	  of	  the	  CRE-­‐REP	  assay	  was	  based	  upon	  the	  assumption	  that	  recombination	  occurs	  via	  the	  ‘copy-­‐choice’	  mechanism.	  The	  identification	  of	  additional	  sequences	  at	  the	  recombination	  junctions	  is	  something	  that	  has	  been	  seen	  in	  other	  in	  vitro	  cell	  based	  assays	  involving	  other	  positive	  sense	  strand	  RNA	  viruses	  like	  Bovine	  viral	  diarrhea	  virus	  (BVDV),	  Hepatitis	  C	  and	  Brome	  mosaic	  virus	  (Scheel	  et	  al.,	  2013,	  Nagy	  and	  Bujarski,	  1997,	  Gallei	  et	  al.,	  2004).	  The	  BVDV	  study	  utilised	  partners	  that	  were	  unable	  to	  replicate,	  indicating	  that	  the	  recombination	  process	  was	  likely	  via	  another	  mechanism.	  Additionally,	  as	  outlined	  in	  section	  1.3,	  poliovirus	  recombinants	  have	  also	  been	  isolated	  via	  a	  non-­‐replicative	  approach	  (Gmyl	  et	  al.,	  1999,	  Gmyl	  et	  al.,	  2003).	  Previous	  interpretations	  of	  the	  results	  obtained	  in	  the	  CRE-­‐REP	  assay	  suggested	  that	  the	  recombination	  event	  is	  replicative.	  It	  was	  shown	  that	  production	  of	  recombinant	  progeny	  could	  be	  inhibited	  by	  the	  use	  of	  a	  potent	  inhibitor	  (guanidine	  hydrochloride)	  of	  negative	  RNA	  strand	  synthesis	  (Lowry	  PhD	  thesis).	  However,	  if	  recombination	  in	  the	  CRE-­‐REP	  assay	  were	  from	  a	  non-­‐replicative	  mechanism	  then	  the	  use	  of	  an	  inhibitor	  of	  replication	  would	  produce	  the	  same	  result.	  All	  replication	  of	  the	  recombinant	  genome	  would	  be	  inhibited	  whether	  it	  via	  a	  replicative	  process	  or	  non-­‐replicative.	  In	  principle,	  the	  recombination	  we	  observed	  could	  have	  been	  entirely	  replication	  independent.	  If	  the	  process	  of	  recombination	  in	  the	  CRE-­‐REP	  assay	  were	  primarily	  replicative	  we	  would	  expect	  far	  more	  recombinant	  progeny	  than	  via	  a	  non-­‐replicative	  assay,	  which	  is	  presumably	  far	  more	  inefficient.	  	  In	  order	  to	  investigate	  the	  contribution	  of	  non-­‐replicative	  recombination	  in	  our	  overall	  assay	  constructs	  were	  developed	  that	  completely	  ablated	  their	  ability	  to	  replicate	  within	  the	  host	  cell.	  Firstly,	  the	  region	  encoding	  the	  RdRp	  (3D)	  was	  removed	  from	  the	  pT7FLC/SL3	  template	  producing	  a	  construct	  known	  as	  pSL3Δ.	  Secondly,	  a	  region	  from	  the	  5’	  end	  extending	  into	  the	  luciferase	  reporter	  gene	  was	  removed	  from	  both	  replicons	  pRLucWT	  and	  pT7rep3-­‐L	  (section	  2.2.13	  for	  full	  description)	  producing	  ΔpRLucWT	  and	  ΔpT7Rep3-­‐L	  respectively	  (figure	  3.14).	  This	  would	  ensure	  that	  the	  translated	  product	  of	  the	  SL3Δ	  RNA	  template	  would	  be	  unable	  to	  replicate	  due	  to	  the	  lack	  of	  RdRp	  activity.	  Additionally,	  the	  sub-­‐genomic	  replicons	  would	  not	  be	  translated	  due	  to	  the	  removal	  of	  the	  5’	  NTR.	  These	  constructs	  mimicked	  the	  ones	  used	  by	  Gmyl	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and	  colleagues	  when	  investigating	  non-­‐replicative	  recombination	  in	  polioviruses.	  For	  any	  viable	  recombinant	  to	  be	  produced	  a	  non-­‐replicative	  process,	  involving	  unknown	  step(s),	  would	  be	  required	  to	  modify	  the	  genomes	  and	  produce	  a	  recombinant	  virus	  capable	  of	  replication.	  Importantly,	  the	  region	  within	  which	  recombination	  must	  occur	  between	  the	  end	  on	  VP1	  upon	  SL3Δ	  and	  the	  intact	  2C	  CRE	  on	  the	  sub-­‐genomic	  replicon	  remained	  the	  same.	  This	  ensured	  that	  comparison	  of	  recombinant	  yield	  to	  the	  replicative	  CRE-­‐REP	  assay	  could	  be	  carried	  out.	  	  	  A	  comparison	  of	  recombinant	  virus	  yield	  from	  replicative	  and	  non-­‐replicative	  intertypic	  and	  intratypic	  partners	  was	  carried	  out.	  The	  SL3Δ	  cDNA	  was	  linearised	  with	  NruI	  and	  the	  ΔpRLucWT	  and	  ΔpT7Rep3-­‐L	  constructs	  were	  linearised	  with	  ApaI	  and	  SalI	  respectively.	  All	  were	  used	  as	  templates	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  As	  a	  positive	  control,	  a	  CRE-­‐REP	  assay	  was	  carried	  out	  alongside	  the	  non-­‐replicative	  assay	  (hereafter	  termed	  NON-­‐REP).	  This	  ensured	  that	  a	  representative	  comparison	  of	  both	  processes	  of	  recombination	  was	  done.	  L929	  cells	  were	  seeded	  in	  a	  12-­‐well	  plate	  and	  were	  co-­‐transfected	  with	  0.5	  μg	  total	  RNA	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant)	  in	  triplicate.	  The	  NON-­‐REP	  assay	  used	  a	  similar	  approach,	  using	  an	  equimolar	  ratio	  of	  RNA	  to	  the	  CRE-­‐REP	  assay	  in	  all	  co-­‐transfections	  (190	  ng	  ΔRLucWT	  or	  ΔRep3-­‐L	  /	  205	  ng	  SL3Δ).	  Individual	  control	  transfections	  were	  also	  done.	  Incubations	  were	  extended	  post	  transfection	  to	  60	  hrs.	  It	  was	  reasoned	  that	  any	  non-­‐replicative	  process	  might	  take	  longer	  than	  its	  replicative	  counterpart,	  so	  an	  extension	  in	  incubation	  would	  provide	  the	  best	  opportunity	  for	  recombination	  to	  occur.	  Transfection	  supernatant	  was	  harvested	  after	  the	  incubation	  period	  and	  used	  to	  inoculate	  HeLa	  cell	  monolayers.	  Following	  60	  hrs	  of	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  photographed.	  Comparison	  of	  intertypic	  progeny	  virus	  yield	  by	  plaque	  assay	  indicated	  that	  recombination	  via	  a	  non-­‐replicative	  pathway	  is	  far	  more	  inefficient	  than	  the	  replicative	  pathway	  (figure	  3.15).	  Recombinant	  virus	  was	  produced	  using	  the	  PV3/1	  partners	  in	  the	  NON-­‐REP	  assay,	  but	  the	  yield	  was	  only	  3.8%	  of	  the	  yield	  produced	  in	  the	  CRE-­‐REP	  assay.	  Similarly,	  intratypic	  non-­‐replicative	  partners	  also	  produced	  recombinant	  progeny	  (figure	  3.16).	  The	  yield	  represented	  ~	  1%	  of	  the	  yield	  from	  the	  replicative	  intratypic	  partners.	  The	  use	  of	  L929	  cells,	  that	  lack	  the	  poliovirus	  receptor,	  ensured	  that	  the	  amount	  of	  recombinant	  virus	  that	  was	  isolated	  from	  both	  assays	  was	  representative	  of	  the	  recombination








	  	  	  	  
Figure	  3.14:	  Non-­‐replicative	  recombination	  partners	  
(A)	  SL3	  construct	  with	  the	  3Dpol	  region	  removed	  (SL3Δ),	  as	  indicated	  by	  the	  dashed	  red	  lines,	  for	  description	  see	  section	  2.2.13	  (B)	  PV1	  and	  PV3	  sub-­‐genomic	  replicons	  with	  the	  majority	  of	  the	  IRES	  and	  luciferase	  coding	  gene	  removed	  (ΔpRLucWT	  &	  ΔpT7rep3-­‐L	  respectively),	  as	  indicated	  by	  dashed	  black	  line.	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Figure	  3.15:	  Intertypic	  non-­‐replicative	  recombination	  frequency	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Figure	  3.16:	  Intratypic	  non-­‐replicative	  recombination	  frequency	  





















	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Rep3-­‐L	  /	  SL3 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  100	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐1	   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ΔRep3-­‐L	  /	  SL3Δ 	  	  	  	  	  	  	  	  	  	  	  	  	  100	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10-­‐1 
	   93	  
process	  in	  both	  systems.	  These	  results	  strongly	  suggest	  that	  recombination	  in	  the	  CRE-­‐REP	  assay,	  regardless	  of	  parental	  genome,	  is	  primarily	  replicative.	  	  
3.10 	  	  Discussion	  	  Recombination	  is	  a	  well-­‐defined	  phenomenon	  in	  enteroviruses,	  as	  well	  as	  other	  important	  positive-­‐strand	  RNA	  virus	  pathogens.	  However,	  the	  underlying	  mechanism(s)	  by	  which	  recombinants	  arise	  is	  relatively	  poorly	  understood.	  Studies	  on	  replicative	  recombination	  have	  suggested	  that	  the	  copy-­‐choice	  template-­‐switching	  model	  is	  additionally	  influenced	  by	  sequence	  homology	  between	  parental	  genomes,	  or	  by	  the	  RNA	  secondary	  structure	  of	  donor	  or	  recipient	  templates	  (section	  1.3).	  	  
	  
The	  analysis	  of	  historical	  isolates	  has	  generally	  implied	  that	  the	  selected	  recombinant	  genome	  contains	  a	  junction	  that	  reflects	  the	  point	  at	  which	  the	  polymerase	  switched	  from	  donor	  to	  recipient	  template.	  The	  development	  of	  a	  novel	  in	  vitro	  assay	  that	  generates	  recombinant	  enteroviruses	  in	  the	  absence	  of	  parental	  virus	  background	  allows	  the	  isolation	  of	  recombinants	  soon	  after	  they	  have	  arisen.	  This	  minimises	  additional	  selection	  and	  competition	  that	  may	  occur	  following	  serial	  passage.	  The	  experimental	  evidence	  gained	  has	  provided	  some	  interesting	  results	  to	  debate.	  	  
	  
A	  previous	  study	  using	  this	  approach	  (Lowry	  et	  al.,	  2014)	  has	  shown	  that	  the	  primary	  progeny	  from	  intertypic	  recombination	  are	  largely	  ‘imprecise’	  in	  nature,	  with	  clustering	  of	  junctions	  primarily	  found	  within	  two	  main	  gene	  boundaries:	  VP1/2A	  and	  2A/2B.	  The	  consequences	  of	  this	  clustering	  are	  that	  the	  majority	  of	  imprecise	  recombinants	  retained	  the	  ability	  to	  encode	  non-­‐chimeric	  versions	  of	  the	  2A	  and	  2B	  proteins.	  This	  clustering	  maybe	  a	  consequence	  of	  the	  overriding	  requirement	  for	  functional	  2A	  and	  2B	  proteins	  in	  the	  initial	  recombinant	  and	  this	  may	  not	  occur	  in	  a	  single	  step.	  Indeed,	  functionality	  at	  this	  early	  stage	  seems	  paramount,	  as	  an	  in-­‐depth	  analysis	  of	  over	  100	  intertypic	  recombinant	  isolates	  could	  find	  no	  obvious	  or	  clear	  link	  between	  RNA	  sequence	  and	  only	  a	  limited	  link	  between	  RNA	  secondary	  structure	  and	  the	  site	  of	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recombination	  (Lowry	  et	  al.,	  2014).	  	  
	  
The	  characterisation	  of	  an	  imprecise	  intertypic	  recombinant	  virus	  from	  a	  co-­‐transfection	  of	  HeLa	  cells	  indicated	  that	  the	  promiscuous	  nature	  of	  recombination	  was	  not	  as	  a	  result	  of	  a	  rodent	  cell	  specific	  factor.	  Only	  a	  minimal	  amount	  of	  progeny	  were	  sequenced	  and	  they	  could	  all	  have	  arisen	  from	  the	  same	  recombination	  event,	  but	  the	  principle	  of	  imprecise	  recombination	  was	  shown.	  The	  recombinant	  sequence	  itself,	  shown	  in	  figure	  3.6,	  suggested	  a	  switch	  from	  the	  PV1	  replicon	  template	  to	  the	  acceptor	  template	  at	  an	  ‘A’	  triplet	  motif.	  Intertypic	  poliovirus	  recombination	  junctions	  have	  been	  linked	  to	  similar	  sequences	  in	  a	  previous	  study	  (King,	  1988b).	  	  
	  
It	  has	  been	  suggested	  that	  the	  reason	  why	  fewer	  intertypic	  and	  interspecies	  recombinants	  are	  observed	  in	  nature	  is	  due	  to	  the	  sequence	  divergence	  between	  RNA	  partners	  (Kirkegaard	  and	  Baltimore,	  1986b).	  Using	  standardised	  conditions,	  the	  CRE-­‐REP	  assay	  showed	  that	  intratypic	  recombination	  frequency	  is	  significantly	  higher	  than	  intertypic	  recombination	  (Chi	  square	  test).	  Indeed,	  approximately	  10-­‐fold	  more	  frequent,	  which	  is	  a	  figure	  slightly	  less	  than	  the	  100-­‐fold	  difference	  previously	  postulated	  (Kirkegaard	  and	  Baltimore,	  1986b,	  King,	  1988b,	  Tolskaya	  et	  al.,	  1983).	  Although,	  the	  amount	  of	  recombinant	  progeny	  isolated	  may	  be	  inherently	  linked	  to	  its	  type.	  Perhaps,	  intratypic	  recombinants	  replicate	  better	  than	  intertypic	  recombinants	  following	  the	  initial	  recombination	  event	  due	  to	  correct	  protein-­‐to-­‐protein	  interactions.	  This	  would	  affect	  the	  overall	  yield	  of	  virus	  and	  not	  necessarily	  represent	  the	  actual	  number	  of	  recombination	  events.	  The	  qualitative	  data	  suggested	  that	  the	  type	  of	  recombinant,	  precise	  or	  imprecise,	  could	  be	  directly	  linked	  to	  the	  sequence	  identity	  of	  the	  parental	  genomes.	  In	  section	  3.3,	  isolation	  and	  characterisation	  of	  intratypic	  recombinant	  virus	  indicated	  that	  only	  a	  minor	  amount	  were	  imprecise	  with	  additional	  sequence	  at	  the	  recombination	  junction	  (3/20).	  This	  contrasts	  to	  the	  generally	  imprecise	  intertypic	  recombinants	  isolated	  to	  date.	  These	  findings	  suggest	  that	  sequence	  identity	  may	  indeed	  influence	  location	  of	  recombination.	  Although,	  section	  3.6	  described	  the	  secondary	  stage	  of	  recombination	  in	  enteroviruses,	  a	  stage	  we	  term	  ‘resolution’.	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All	  three	  imprecise	  intertypic	  recombinants	  lost	  all	  the	  additional	  sequence	  following	  serial	  passage	  in	  HeLa	  cells	  and	  returned	  to	  wild	  type	  length.	  Sequence	  analysis	  of	  the	  ‘resolved’	  isolates	  indicated	  new	  recombination	  junctions,	  where	  the	  precise	  location	  of	  recombination	  could	  not	  be	  identified	  due	  to	  sequence	  identity	  of	  the	  parental	  genomes.	  This	  finding	  was	  further	  supported	  by	  the	  construction	  of	  a	  molecular	  clone	  that	  represented	  one	  of	  the	  passaged	  imprecise	  recombinants.	  Similarly,	  this	  construct	  went	  through	  the	  resolution	  process	  and	  produced	  a	  genome	  indistinguishable	  from	  wild	  type	  in	  length.	  Sequence	  analysis	  also	  highlighted	  sequence	  identity	  at	  the	  new	  recombination	  junctions	  and	  provided	  a	  junction	  that	  was	  exactly	  the	  same	  as	  the	  biological	  clone	  that	  carried	  the	  same	  imprecise	  sequence.	  This	  strongly	  suggests	  that	  the	  characterisation	  of	  intertypic	  field	  isolates	  that	  has	  proposed	  sequence	  identity	  at	  the	  recombination	  junction	  (King,	  1988b)	  have	  missed	  the	  early	  events	  of	  recombination	  and	  only	  characterised	  the	  end	  product.	  The	  sequence	  identity	  found	  within	  the	  resolved	  recombination	  junctions	  may	  indicate	  that	  sequence	  does	  play	  a	  role,	  but	  perhaps	  not	  during	  the	  initial	  stage	  which	  seems	  a	  more	  promiscuous	  process	  that	  may	  be	  subjected	  to	  other	  primary	  limitations	  e.g.	  packaging	  restraints	  and	  protein-­‐protein	  functionality.	  It	  also	  remains	  to	  be	  determined	  if	  the	  resolution	  stage	  of	  recombination	  is	  a	  cis	  or	  trans	  event	  that	  involves	  the	  viral	  RdRp.	  In	  principle,	  it	  could	  be	  either	  or	  even	  both.	  The	  fewer	  imprecise	  intratypic	  recombinants	  isolated	  may	  actually	  be	  a	  reflection	  of	  their	  ability	  to	  resolve	  at	  a	  faster	  rate	  than	  an	  imprecise	  intertypic	  recombinant.	  Potentially,	  the	  characterised	  intratypic	  recombinants	  in	  section	  3.3	  had	  already	  gone	  through	  the	  secondary	  resolution	  stage	  where	  any	  additional	  sequence	  is	  lost.	  Indeed,	  a	  single	  poliovirus	  genome	  is	  replicated	  an	  average	  of	  six	  times	  in	  a	  single	  cell	  (Schulte	  et	  al.,	  2015).	  Perhaps	  sequence	  identity	  is	  a	  key	  factor	  during	  subsequent	  rounds	  of	  replication	  within	  the	  same	  cell	  following	  the	  initial	  promiscuous	  recombination	  event?	  To	  answer	  this	  an	  imprecise	  intratypic	  recombinant,	  similar	  to	  JC105B	  could	  be	  produced.	  Serial	  passaging	  of	  such	  a	  recombinant,	  when	  compared	  to	  an	  intertypic	  version	  (JC105B)	  might	  highlight	  any	  differences	  in	  the	  resolution	  process.	  
	  
The	  ability	  to	  extend	  the	  CRE-­‐REP	  assay	  into	  a	  species	  B	  enterovirus	  group	  indicates	  that	  the	  approach	  may	  be	  universal	  to	  these	  genera	  of	  viruses.	  The	  inability	  to	  isolate	  intertypic	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recombinant	  (E7/E6)	  was	  disappointing.	  They	  share	  similar	  divergent	  genomes	  as	  that	  of	  PV3/PV1	  at	  ~	  20%,	  indicating	  their	  suitability	  to	  the	  assay.	  As	  stated,	  this	  study	  has	  shown	  that	  intratypic	  recombination	  frequency	  is	  10	  fold	  higher	  than	  intertypic,	  a	  finding	  broadly	  in	  line	  with	  previous	  studies	  (Kirkegaard	  and	  Baltimore,	  1986b).	  The	  inability	  to	  recover	  E7/E6	  recombinant	  virus	  is	  therefore	  not	  surprising	  given	  the	  relatively	  low	  frequency	  of	  E7/7	  recombinants	  isolated	  from	  BsrT7	  cells.	  Potentially	  the	  permissive	  cells	  that	  were	  being	  used	  were	  sub-­‐optimal	  for	  this	  species	  of	  virus.	  Unfortunately,	  due	  to	  time	  restrictions	  an	  extended	  study	  of	  this	  group	  was	  not	  carried	  out	  and	  it	  was	  determined	  that	  all	  future	  experiments	  would	  concentrate	  upon	  the	  enterovirus	  C	  poliovirus.	  
	  
The	  CRE-­‐REP	  assay,	  in	  principle,	  could	  have	  produced	  the	  initial	  recombinant	  virus	  by	  either	  a	  non-­‐replicative	  or	  replicative	  pathway.	  The	  development	  of	  the	  NON-­‐REP	  assay	  that	  was	  based	  on	  previous	  non-­‐replicative	  approaches	  (Gmyl	  et	  al.,	  1999,	  Gmyl	  et	  al.,	  2003)	  allowed	  quantification	  of	  viable	  recombinants	  within	  the	  same	  1058	  nt	  region	  between	  the	  2C	  CRE	  and	  P1	  coding	  region.	  This	  allowed	  the	  relative	  contribution	  of	  non-­‐replicative	  recombination	  to	  the	  CRE-­‐REP	  assay	  to	  be	  calculated.	  The	  very	  low	  yield	  of	  recombinant	  progeny	  in	  the	  NON-­‐REP	  assay	  when	  compared	  to	  the	  postulated	  replicative	  approach	  strongly	  suggested	  that	  recombination	  in	  the	  CRE-­‐REP	  assay	  was	  primarily	  replicative.	  	  
	  
The	  suggestion	  that	  an	  imprecise	  replicative	  recombination	  process	  results	  in	  partial	  duplication	  of	  the	  virus	  genome	  also	  has	  implications	  for	  the	  wider	  understanding	  in	  the	  evolution	  of	  positive	  strand	  RNA	  viruses.	  There	  are	  several	  well-­‐characterised	  evolutionary	  duplication	  events	  that	  have	  shaped	  the	  picornavirus	  genome.	  For	  example,	  the	  capsid	  proteins	  (VP1-­‐3)	  share	  a	  common	  ‘jelly	  roll’	  structure	  (Hogle	  et	  al.,	  1985)	  that	  have	  arisen	  from	  duplication.	  Another	  example	  is	  the	  tandem	  repeat	  regions	  that	  encode	  the	  three	  contiguous	  VPg	  proteins	  of	  foot	  and	  mouth	  disease	  virus	  (Forss	  and	  Schaller,	  1982)	  and	  even	  the	  non-­‐contiguous	  2A	  and	  3C	  proteases	  (Palmenberg	  at	  al.,	  2010).	  In	  addition,	  other	  positive	  strand	  RNA	  viruses	  exhibit	  genome	  duplications	  (Simon-­‐Loriere	  and	  Holmes,	  2013)	  such	  as	  the	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multiple	  VPg	  proteins	  of	  some	  dicistroviruses,	  which	  can	  encode	  as	  many	  as	  six	  from	  one	  genome.	  It	  was	  postulated	  that	  the	  redundancy	  in	  VPg	  coding	  provided	  an	  advantage	  in	  overall	  replication	  rates	  (Nakashima	  and	  Shibuya,	  2006).	  Additionally,	  the	  functionally	  distinct	  adjacent	  leader	  proteinases	  of	  the	  Closteroviridae,	  that	  have	  arisen	  from	  duplication	  events,	  provide	  common	  protease	  activities	  but	  also	  possess	  specialised	  functions	  in	  virus	  RNA	  replication,	  virus	  invasion	  and	  cell-­‐to-­‐cell	  movement	  (Peng	  et	  al.,	  2001).	  The	  type	  of	  imprecise	  recombination	  event	  described	  in	  section	  3.3,	  potentially	  coupled	  with	  partial	  resolution,	  could	  account	  for	  this	  ‘evolution	  by	  duplication’.	  Likewise,	  duplication	  and	  subsequent	  resolution	  events	  could	  explain	  the	  unique	  C-­‐A-­‐B	  motif	  arrangement	  in	  the	  palm	  domain	  of	  the	  polymerase	  reported	  in	  some	  Alphavirus-­‐like	  insect	  tetraviruses	  (Gorbalenya	  et	  al.,	  2002).	  Other	  than	  the	  ancestral	  evolution	  of	  the	  capsid	  proteins	  the	  majority	  of	  these	  involve	  duplication	  of	  relatively	  short	  sequences,	  and	  this	  is	  presumed	  to	  reflect	  intrinsic	  constraints	  on	  genome	  length	  that	  may	  prevent	  their	  fixation	  (Simon-­‐Loriere	  and	  Holmes,	  2013).	  
	  
In	  summary,	  recombination	  in	  enteroviruses	  is	  a	  biphasic	  process	  that	  provides	  an	  insight	  into	  the	  potential	  mechanisms	  of	  genome	  evolution.	  The	  observations	  in	  section	  3.9	  strongly	  suggested	  that	  the	  process	  of	  recombination	  in	  the	  CRE-­‐REP	  assay	  was	  primarily	  replicative.	  The	  characteristics	  of	  the	  viral	  RdRp	  (a	  key	  factor	  in	  the	  copy-­‐choice	  model	  of	  recombination)	  that	  determine	  recombination	  frequency	  were	  therefore	  considered	  an	  area	  of	  interest.	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CHAPTER	  FOUR:	  Fidelity	  of	  the	  RNA	  Dependent	  RNA	  
Polymerase	  (RdRp)	  Influences	  Replicative	  Recombination	  
Frequency	  	  
4.1 	  	  	  	  	  Introduction	  
The	  results	  presented	  in	  chapter	  three	  highlighted	  the	  biphasic	  nature	  of	  recombination	  in	  enteroviruses.	  The	  use	  of	  an	  in	  vitro	  assay	  known	  as	  CRE-­‐REP	  has	  shown	  that	  intertypic	  recombination	  is	  initially	  a	  promiscuous	  event	  where	  additional	  sequence	  can	  be	  incorporated	  at	  the	  recombination	  junction	  (Lowry	  et	  al.,	  2014).	  The	  overriding	  criteria	  for	  viable	  virus	  at	  this	  early	  stage	  are	  the	  ability	  to	  produce	  a	  genome	  that	  is	  functional.	  Clustering	  of	  recombination	  junctions	  to	  cleavage	  boundaries	  ensures	  progeny	  inherit	  complete	  protein	  coding	  regions	  from	  one	  or	  the	  other	  parent.	  This	  suggests	  that	  protein-­‐protein	  interactions	  during	  the	  course	  of	  replication	  are	  vital,	  and	  play	  a	  role	  in	  the	  yield	  and	  type	  of	  recombinant	  isolated.	  	  	  The	  development	  of	  a	  non-­‐replicative	  assay	  (NON-­‐REP)	  that	  had	  the	  same	  potential	  region	  of	  recombination	  showed	  that	  recombinants	  isolated	  from	  the	  CRE-­‐REP	  assay	  was	  primarily	  due	  to	  a	  replicative	  mechanism.	  The	  next	  step	  in	  this	  investigation	  was	  to	  look	  at	  the	  role	  of	  the	  viral	  RNA	  dependent	  RNA	  polymerase	  (RdRp)	  in	  recombination.	  If	  the	  output	  of	  the	  CRE-­‐REP	  assay	  were	  due	  to	  replicative	  recombination	  then	  it	  would	  be	  reasonable	  to	  postulate	  that	  characteristics	  of	  the	  RdRp	  are	  important.	  Positive	  sense	  strand	  RNA	  viruses	  have	  low	  fidelity	  RdRps	  (section	  1.3).	  A	  nucleotide	  misincorporation	  event	  has	  been	  proposed	  as	  a	  trigger	  for	  template	  switching,	  and	  this	  can	  be	  directly	  linked	  to	  the	  inherent	  low	  fidelity	  of	  the	  RdRp	  (Agol,	  1997).	  Known	  mutagens	  and	  well-­‐characterised	  RdRp	  mutations	  have	  been	  shown	  to	  decrease	  and	  increase	  RdRp	  fidelity	  respectively	  (Crotty	  et	  al.,	  2000,	  Crotty	  et	  al.,	  2001,	  Crotty	  and	  Andino,	  2002,	  Pfeiffer	  and	  Kirkegaard,	  2003,	  Arnold	  et	  al.,	  2005,	  Weeks	  et	  al.,	  2012,	  Korboukh	  et	  al.,	  2014).	  By	  incorporating	  known	  mutagens	  and	  a	  high	  fidelity	  RdRp	  variant	  into	  both	  NON-­‐REP	  and	  CRE-­‐REP	  assays	  a	  correlation	  between	  fidelity	  and	  recombination	  may	  be	  identified.
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Aims	  The	  aim	  was	  to	  analyse	  the	  influence	  of	  known	  mutagens	  that	  decrease	  wild	  type	  RdRp	  fidelity	  and	  then	  contrast	  this	  to	  a	  known	  RdRp	  variant	  that	  has	  a	  higher	  fidelity	  phenotype.	  The	  role	  of	  fidelity	  in	  recombination	  frequency	  was	  investigated	  by	  performing	  NON-­‐REP	  and	  CRE-­‐REP	  assays	  with	  mutagen	  and	  then	  with	  a	  high	  fidelity	  RdRp	  variant.	  By	  using	  both	  experimental	  systems	  it	  was	  believed	  a	  clear	  distinction	  could	  be	  identified.	  Additional	  aims	  were	  to	  incorporate	  a	  drug	  known	  as	  nocodazole,	  a	  known	  inhibitor	  of	  replication	  complex	  coalescence	  (Egger	  and	  Bienz,	  2005).	  It	  was	  reasoned	  that	  for	  replicative	  recombination	  to	  occur	  a	  key	  prerequisite	  would	  be	  co-­‐localisation	  of	  parental	  RNA	  within	  the	  same	  replication	  complex.	  The	  influence	  of	  RNA	  co-­‐localisation	  on	  both	  NON-­‐REP	  and	  CRE-­‐REP	  approaches	  was	  therefore	  examined.	  The	  results	  in	  this	  chapter	  have	  also	  contributed	  to	  the	  manuscript	  by	  Lowry	  et	  al.,	  2014.	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4.2 	  	  	  	  	  Influence	  of	  RdRp	  fidelity	  on	  non-­‐replicative	  recombination	  
Positive	  strand	  RNA	  virus	  populations	  are	  a	  collection	  of	  similar	  but	  genetically	  different	  viruses.	  They	  exist	  as	  a	  quasi	  species	  due	  to	  the	  high	  mutation	  rates	  of	  the	  low	  fidelity	  replicase	  (Vignuzzi	  et	  al.,	  2005).	  This	  is	  an	  advantageous	  adaptation	  that	  allows	  for	  rapid	  evolution	  in	  changing	  environments.	  However,	  any	  increase	  in	  mutation	  rate	  could	  push	  the	  viral	  population	  into	  ‘error	  catastrophe’,	  a	  phenomenon	  where	  the	  accumulation	  of	  errors	  becomes	  lethal,	  leading	  to	  viral	  extinction	  (Crotty	  and	  Andino,	  2002).	  The	  use	  of	  mutagens	  that	  increase	  the	  error	  rate	  would,	  in	  principle,	  tip	  the	  virus	  population	  into	  ‘error	  catastrophe’.	  	  	  One	  such	  mutagen	  is	  ribavirin,	  a	  nucleoside	  analogue	  that	  can	  be	  incorporated	  by	  viral	  polymerases,	  causing	  mutations	  by	  allowing	  base	  mismatches	  (Pfeiffer	  and	  Kirkegaard,	  2003,	  Crotty	  et	  al.,	  2000,	  Crotty	  et	  al.,	  2001,	  Crotty	  and	  Andino,	  2002).	  An	  in	  vitro	  system	  capable	  of	  measuring	  the	  kinetics	  and	  biochemical	  properties	  of	  the	  RdRp	  has	  showed	  that	  ribavirin	  triphosphate	  (RTP)	  is	  directly	  incorporated	  into	  the	  poliovirus	  genome	  (Crotty	  et	  al.,	  2000).	  Ribavirin	  is	  templated	  by	  cytidine	  or	  uridine	  and	  incorporated	  in	  the	  place	  of	  GMP	  or	  AMP,	  leading	  to	  transition	  mutations	  (Cameron	  and	  Castro,	  2001).	  Indeed,	  the	  rate	  of	  incorporation	  and	  binding	  affinity	  of	  the	  RdRp	  for	  RTP	  is	  similar	  to	  the	  incorporation	  kinetics	  of	  incorrect	  nucleotides	  (Cameron	  and	  Castro,	  2001).	  It	  was	  reasoned	  that	  the	  incorporation	  (or	  attempted	  incorporation)	  of	  RTP	  by	  the	  viral	  RdRp	  would	  lead	  to	  an	  un-­‐favourable	  thermodynamic	  event.	  This	  would	  mimic	  incorrect	  nucleotide	  incorporation	  that	  may	  lead	  to	  an	  increase	  in	  recombination.	  	  	  	  In	  principle,	  the	  progeny	  produced	  from	  the	  NON-­‐REP	  assay	  (section	  3.9)	  is	  mediated	  by	  a	  currently	  unknown	  mechanism	  that	  is	  independent	  of	  the	  viral	  RdRp.	  It	  was	  therefore	  important	  to	  see	  if	  recombination	  frequency	  in	  this	  approach	  was	  influenced	  by	  a	  mutagen	  that	  is	  known	  to	  directly	  interact	  with	  the	  viral	  RdRp.	  A	  NON-­‐REP	  assay	  was	  carried	  out	  using	  intratypic	  partners	  SL3Δ	  and	  ΔRep3-­‐L,	  using	  similar	  experimental	  conditions	  described	  in	  section	  3.9.	  One	  difference	  was	  the	  incorporation	  of	  100	  μM	  of	  ribavirin.	  This	  level	  of	  the	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mutagen	  was	  determined	  to	  be	  the	  correct	  amount	  due	  to	  historical	  studies	  showing	  that	  this	  level	  is	  sub-­‐lethal,	  but	  can	  lead	  to	  a	  decrease	  in	  RdRp	  fidelity	  (Vignuzzi	  et	  al.,	  2005).	  L929	  murine	  cells	  were	  incubated	  with	  ribavirin	  two	  hours	  pre-­‐transfection	  and	  the	  mutagen	  was	  added	  to	  the	  media	  post	  transfection.	  Transfection	  supernatant	  was	  harvested	  at	  60	  hrs	  and	  used	  undiluted	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays	  (figure	  4.1).	  Quantification	  of	  recombinant	  progeny	  showed	  that	  the	  presence	  of	  ribavirin	  had	  no	  significant	  effect	  on	  the	  overall	  yield	  of	  intratypic	  recombinant	  virus	  in	  the	  NON-­‐REP	  assay.	  	  	  The	  passage	  of	  polio	  in	  the	  presence	  of	  100	  μM	  ribavirin	  selects	  for	  a	  glycine	  to	  serine	  change	  at	  position	  64	  of	  the	  3D	  RdRp	  coding	  region	  (G64S)	  (Vignuzzi	  et	  al.,	  2005,	  Pfeiffer	  and	  Kirkegaard,	  2003).	  This	  region	  of	  the	  RdRp	  lies	  within	  a	  small	  region	  spanning	  the	  fingers	  and	  thumb	  domain,	  an	  area	  outside	  the	  known	  functional	  domains	  of	  the	  viral	  RdRp	  (Arnold	  et	  al.,	  2005).	  The	  replacement	  of	  glycine	  for	  the	  bulkier	  serine	  affects	  a	  key	  conformational	  change	  step	  that	  precedes	  phosphoryl	  transfer	  during	  nucleotide	  incorporation,	  increasing	  fidelity	  four-­‐fold	  (Arnold	  et	  al.,	  2005).	  To	  contrast	  the	  ribavirin	  experiment,	  this	  well-­‐characterised	  mutation	  was	  introduced	  into	  the	  RdRp	  (3D)	  coding	  region	  of	  the	  ΔpT7rep3-­‐L	  template	  (the	  only	  RdRp	  coding	  region	  present	  in	  the	  NON-­‐REP	  assay	  due	  to	  the	  removal	  of	  3D	  in	  SL3Δ).	  	  An	  experiment,	  which	  replaced	  the	  ΔRep3-­‐L	  with	  the	  ΔRep3-­‐L-­‐G64S,	  was	  carried	  out	  which	  had	  similar	  experimental	  conditions	  to	  the	  NON-­‐REP	  assay	  outlined	  in	  section	  3.9.	  Quantification	  of	  recombinant	  progeny	  indicated	  no	  significant	  difference	  between	  the	  two	  conditions	  (figure	  4.2).	  Conclusions	  from	  this	  area	  of	  the	  investigation	  are	  that	  polymerase	  fidelity	  does	  not	  influence	  the	  yield	  of	  recombinant	  progeny	  produced	  from	  the	  NON-­‐REP	  recombination	  assay.	  	  	  









Figure	  4.1:	  Intratypic	  NON-­‐REP	  assay	  +/-­‐	  100	  μM	  ribavirin	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Figure	  4.2:	  Influence	  of	  the	  high	  fidelity	  polymerase	  (G64S)	  upon	  intratypic	  non-­‐
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4.3 	  	  	  	  	  Influence	  of	  RdRp	  fidelity	  on	  the	  CRE-­‐REP	  assay	  	  
The	  influence	  of	  RdRp	  fidelity	  was	  investigated	  in	  the	  CRE-­‐REP	  assay.	  The	  high	  fidelity	  mutation	  (G64S)	  was	  introduced	  into	  the	  RdRp	  coding	  region	  (3D)	  of	  the	  replicons,	  pRLucWT	  and	  pT7rep3-­‐L	  and	  the	  potential	  acceptor	  template	  pT7FLC/SL3,	  by	  overlap	  extension	  PCR	  (section	  2.2.12).	  It	  was	  important	  to	  know	  how	  the	  mutation	  affected	  the	  overall	  replication	  kinetics	  of	  the	  virus.	  If	  there	  was	  a	  difference	  in	  replication	  then	  this	  may	  have	  had	  an	  effect	  on	  overall	  recombinant	  progeny	  yield	  that	  would	  have	  nothing	  to	  do	  with	  fidelity.	  	  	  	  It	  has	  been	  reported	  that	  this	  mutation	  has	  no	  impact	  upon	  replication	  when	  compared	  to	  wild-­‐type	  (Vignuzzi	  et	  al.,	  2006).	  A	  similar	  approach	  used	  by	  Vignuzzi	  and	  colleagues	  was	  employed.	  Briefly,	  250	  ng	  of	  the	  PV1	  replicon	  (RLucWT)	  or	  the	  mutant	  RLuc-­‐G64S	  were	  transfected	  into	  L929	  cells	  in	  duplicate	  with	  samples	  taken	  at	  various	  time-­‐points	  and	  measured	  for	  luciferase	  activity	  (section	  2.1.3)	  (figure	  4.3A).	  In	  general,	  the	  replication	  kinetics,	  as	  measured	  by	  luciferase	  activity,	  was	  similar	  between	  the	  two	  replicons	  in	  agreement	  with	  previous	  findings	  (Vignuzzi	  et	  al.,	  2006).	  As	  replication	  kinetics	  between	  the	  two	  was	  similar	  it	  was	  decided	  to	  proceed	  with	  an	  intertypic	  CRE-­‐REP	  assay	  that	  incorporated	  the	  high	  fidelity	  polymerase	  variant.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  co-­‐transfected	  in	  triplicate	  with	  RLucWT	  and	  SL3	  or	  RLuc-­‐G64S	  and	  SL3-­‐G64S.	  Total	  RNA	  was	  0.5	  μg	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant	  genome).	  Cells	  were	  incubated	  for	  48	  hrs	  post	  transfection	  and	  media	  supernatant	  was	  then	  harvested	  and	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  sixty	  hours	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  plaques	  quantified	  (figure	  4.3BC).	  Results	  indicated	  that	  the	  introduction	  of	  the	  high	  fidelity	  G64S	  mutation	  into	  the	  donor	  and	  acceptor	  templates	  had	  significantly	  reduced	  intertypic	  recombination	  frequency	  to	  5%	  of	  partners	  bearing	  a	  wild	  type	  RdRp	  (as	  analysed	  by	  student	  T-­‐test).	  A	  small	  quantity	  of	  the	  G64S	  recombinant	  progeny	  was	  biologically	  cloned	  and	  the	  presence	  of	  the	  G64S	  mutation	  confirmed	  by	  sequencing	  (data	  not	  shown).
























































Figure	  4.3:	  Influence	  of	  a	  high	  fidelity	  polymerase	  (G64S)	  upon	  replication	  and	  Intertypic	  
recombination	  	  
(A)	  Replication	  kinetics	  of	  a	  PV1	  sub-­‐genomic	  replicon	  (RLucWT)	  bearing	  a	  G64S	  high	  fidelity	  polymerase	  mutation.	  250	  ng	  of	  RNA	  generated	  in	  vitro	  was	  transfected	  into	  L929	  cells.	  Samples	  were	  taken	  at	  the	  times	  indicated	  and	  luciferase	  activity	  was	  measured	  in	  light	  units	  and	  normalised	  using	  a	  mock	  transfected	  control.	  Error	  bars	  indicate	  standard	  deviation	  of	  two	  independent	  samples	  (B)	  Influence	  of	  a	  high	  fidelity	  polymerase	  upon	  the	  frequency	  of	  intertypic	  recombination.	  RNA	  partners	  as	  indicated.	  The	  data	  represents	  the	  mean	  from	  three	  independent	  samples.	  Error	  bars	  indicate	  standard	  deviation.	  Asterisk;	  P	  <	  0.01	  by	  Student’s	  T-­‐test	  test	  (C)	  Representative	  crystal	  violet	  stained	  HeLa	  cell	  monolayers	  inoculated	  with	  undiluted	  transfection	  supernatant	  and	  overlayed	  with	  plaque	  assay	  over	  lay	  medium.	  RNA	  partners	  as	  indicated.	  Control	  wells	  containing	  only	  one	  RNA	  partner	  were	  free	  of	  plaques	  (not	  shown)	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To	  further	  verify	  these	  findings	  a	  similar	  experimental	  approach	  was	  used	  with	  the	  CRE-­‐REP	  intratypic	  partners,	  Rep3-­‐L	  and	  SL3.	  A	  luciferase	  assay	  showed	  that	  the	  G64S	  mutation	  had	  little	  effect	  upon	  the	  replication	  kinetics	  of	  the	  sub-­‐genomic	  replicon	  when	  compared	  to	  wild	  type,	  a	  similar	  finding	  to	  the	  PV1	  replicon.	  A	  subsequent	  CRE-­‐REP	  assay	  showed	  that	  intratypic	  recombination	  frequency	  fell	  to	  10%	  of	  wild	  type	  when	  the	  high	  fidelity	  G64S	  mutation	  was	  present	  (figure	  4.4).	  The	  results	  from	  the	  two	  experiments	  indicated	  that	  intertypic	  and	  intratypic	  recombination	  is	  adversely	  affected	  by	  higher	  than	  normal	  RdRp	  fidelity.	  	  	  
It	  remained	  to	  be	  determined	  if	  an	  increase	  in	  fidelity	  affected	  the	  type	  of	  recombinant	  isolated.	  To	  answer	  this,	  a	  number	  of	  intertypic	  recombinants	  were	  isolated	  from	  the	  high	  fidelity	  intertypic	  CRE-­‐REP	  assay	  supernatant	  that	  was	  used	  previously	  (figure	  4.3).	  Biological	  cloning	  was	  done	  by	  a	  limiting	  dilution	  approach,	  and	  the	  1.058	  Kb	  zone	  of	  recombination	  amplified	  by	  RT-­‐PCR	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  Six	  unique	  PV3/1	  junctions	  were	  characterised,	  five	  had	  additional	  sequences	  with	  one	  being	  precise	  with	  no	  additional	  sequences	  present	  when	  compared	  to	  wild	  type	  poliovirus.	  A	  similar	  clustering	  to	  gene	  boundaries,	  as	  seen	  previously,	  was	  observed.	  Four	  junctions	  were	  at,	  or	  spanned	  the	  VP1/2A	  boundary	  (cluster	  one	  isolates,	  figure	  4.5AB).	  The	  remaining	  two	  junctions	  were	  at	  or	  spanned	  the	  2A/2B	  boundary	  (cluster	  two	  isolates,	  figure	  4.5CD).	  The	  location	  of	  template	  switching	  with	  the	  precise	  recombinant	  junction	  in	  cluster	  two	  could	  not	  be	  completely	  identified	  due	  to	  limited	  sequence	  identity	  between	  parental	  genomes.	  One	  interesting	  observation	  in	  75%	  of	  the	  imprecise	  cluster	  one	  junctions	  is	  that	  template	  switching	  seems	  to	  have	  occurred	  at	  an	  ‘A/U’	  dinucleotide	  upon	  the	  donor	  template,	  a	  similar	  finding	  to	  that	  seen	  in	  a	  previous	  study	  (King,	  1988b).	  Although,	  the	  King	  et	  al.,	  study	  looked	  at	  precise	  recombinants	  only.	  The	  remaining	  isolate	  in	  this	  group	  has	  left	  the	  donor	  template	  just	  before	  an	  A-­‐rich	  motif.	  The	  imprecise	  cluster	  two	  isolate	  has	  a	  sequence	  that	  also	  suggests	  that	  template	  switching	  has	  occurred	  at	  a	  ‘U’	  dinucleotide.	  	  	  	  	  




















































Figure	  4.4:	  Influence	  of	  a	  high	  fidelity	  polymerase	  (G64S)	  upon	  replication	  and	  Intratypic	  
recombination	  
(A)	  Replication	  kinetics	  of	  a	  PV3	  replicon	  (Rep3-­‐L)	  bearing	  a	  G64S	  high	  fidelity	  polymerase	  mutation.	  250ng	  of	  RNA	  generated	  in	  vitro	  was	  transfected	  into	  L929	  cells.	  Samples	  were	  taken	  at	  the	  times	  indicated	  and	  luciferase	  activity	  was	  measured	  in	  light	  units	  and	  normalised	  using	  a	  mock	  transfected	  control.	  Error	  bars	  indicate	  standard	  deviation	  of	  two	  independent	  samples	  
(B)	  Influence	  of	  a	  high	  fidelity	  polymerase	  upon	  the	  frequency	  of	  Intratypic	  recombination.	  The	  data	  represents	  the	  mean	  from	  three	  independent	  samples.	  RNA	  partners	  as	  indicated.	  Error	  bars	  indicate	  standard	  deviation.	  Asterisk;	  P	  <	  0.01	  by	  Student’s	  T-­‐test	  test	  (C)	  Representative	  crystal	  violet	  stained	  HeLa	  cell	  monolayers	  inoculated	  with	  diluted	  transfection	  supernatant	  and	  overlayed	  in	  plaque	  assay	  overlay	  medium.	  Dilutions	  as	  indicated.	  RNA	  partners	  as	  indicated.	  Control	  wells	  containing	  only	  one	  RNA	  partner	  were	  free	  of	  plaques	  (data	  not	  shown)	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  Tail)	  	  
PV3: AGATCTGCAACTACCATCTCGCCACTA 
PV1: T--C-ACAT-TGGATTCGGACA-CAA- 
REC: ---------------TCGGACA-CAA- 	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Figure	  4.5:	  Biologically	  cloned	  PV3/1	  recombinants	  obtained	  from	  co-­‐transfection	  of	  RNA	  
partners	  bearing	  the	  high	  fidelity	  G64S	  mutation	  
(A)	  Genome	  sequences	  of	  four	  biologically	  cloned	  intertypic	  recombinant	  viruses	  with	  junctions	  that	  fall	  within	  cluster	  one	  	  (B)	  Dashed	  arrows	  indicates	  points	  of	  crossover	  from	  donor	  (replicon)	  to	  acceptor	  template	  (CRE	  mutant)	  in	  the	  cluster	  one	  isolates.	  Colour	  codes	  match	  nomenclature	  in	  (A)	  (C)	  Genome	  sequences	  of	  two	  biologically	  cloned	  intertypic	  recombinant	  virus	  that	  fall	  within	  cluster	  two	  (D)	  Dashed	  arrows	  indicate	  points	  of	  crossover	  from	  donor	  (replicon)	  to	  acceptor	  template	  (CRE	  mutant)	  in	  the	  cluster	  two	  isolates.	  Colour	  codes	  match	  nomenclature	  in	  (C)	  PV3	  =	  Leon	  strain,	  PV1	  =	  Mahoney	  strain	  (GenBank	  accession	  numbers	  X00925	  and	  V01149	  respectively),	  LUC	  =	  Luciferase	  sequence	  carried	  by	  the	  PV1	  replicon.	  REC	  =	  recombinant	  sequence.	  Red	  boxes	  indicate	  sequence	  identity	  in	  the	  region	  of	  template	  switching.	  Dashes	  indicate	  nt	  identity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated.	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4.4 	  	  	  	  	  Influence	  of	  ribavirin	  on	  poliovirus	  yield	  	  	  
The	  increase	  in	  RdRp	  fidelity	  had	  a	  striking	  impact	  upon	  recombination	  frequency.	  It	  was	  therefore	  decided	  to	  contrast	  these	  observations	  by	  testing	  the	  influence	  of	  a	  known	  mutagen	  that	  decreases	  RdRp	  fidelity.	  The	  incorporation	  into	  nascent	  viral	  RNA	  and	  subsequent	  mutagenesis	  caused	  by	  the	  nucleoside	  analogue	  ribavirin	  has	  been	  outlined	  in	  section	  4.2.	  In	  the	  context	  of	  this	  study,	  an	  initial	  experiment	  was	  set	  up	  to	  measure	  the	  overall	  reduction	  in	  virus	  yield	  following	  mutagen	  treatment.	  This	  was	  deemed	  important,	  as	  it	  would	  aid	  interpretations	  of	  any	  CRE-­‐REP	  assay	  that	  included	  the	  mutagen.	  HeLa	  cells	  in	  a	  6-­‐well	  plate	  were	  treated	  with	  ribavirin	  two	  hours	  prior	  to	  infection	  and	  throughout	  subsequent	  incubation.	  Cells	  were	  infected	  with	  a	  full	  length	  PV3	  at	  an	  M.O.I	  of	  0.01	  and	  incubated	  for	  48	  hrs.	  Media	  supernatant	  was	  then	  isolated	  and	  dilutions	  were	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  virus	  plaques	  counted	  with	  the	  titre	  converted	  to	  pfu/ml	  (figure	  4.6).	  All	  titres	  were	  normalised	  as	  a	  percentage	  of	  an	  untreated	  control.	  The	  use	  of	  the	  mutagen	  led	  to	  a	  dramatic	  fall	  in	  viable	  virus.	  Ribavirin	  treatment	  levels	  of	  100	  μM	  and	  400	  μM	  led	  to	  a	  75%	  and	  2-­‐log10	  reduction	  in	  virus	  yield	  respectively,	  in	  line	  with	  previous	  studies	  (Pfeiffer	  and	  Kirkegaard,	  2003,	  Vignuzzi	  et	  al.,	  2005).	  It	  was	  also	  considered	  important	  to	  see	  if	  ribavirin	  treatment	  had	  any	  effect	  on	  transfection	  efficiency	  of	  L929	  cells.	  This	  was	  an	  important	  control	  that	  would	  aid	  interpretation	  of	  any	  CRE-­‐REP	  assay	  that	  included	  the	  mutagen.	  In	  order	  to	  measure	  transfection	  efficiency	  the	  replicon	  pT7Rep3-­‐L	  was	  linearised	  with	  the	  restriction	  enzyme	  XhoI.	  The	  unique	  site	  is	  located	  at	  position	  6050	  of	  the	  PV3	  sequence,	  very	  near	  to	  the	  3C/3D	  cleavage	  boundary	  (figure	  4.7A).	  The	  cDNA	  was	  used	  as	  a	  template	  to	  transcribe	  RNA	  using	  a	  T7	  polymerase.	  All	  RNA	  transcripts	  that	  were	  produced	  lacked	  the	  RdRp	  coding	  region,	  ensuring	  a	  translation	  only	  readout.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  treated	  with	  ribavirin	  2	  hours	  prior	  to	  transfection.	  Cells	  were	  transfected	  with	  250	  ng	  of	  the	  truncated	  replicon	  RNA,	  in	  triplicate,	  and	  luciferase	  activity	  was	  measured	  at	  4	  hours	  post	  transfection	  and	  normalised	  to	  a	  mock-­‐transfected	  control	  (figure	  4.7B).	  The	  luciferase	  signal	  measured	  was	  from	  translation	  only,	  as	  RNA	  replication	  was	  inhibited	  by	  the	  lack	  of	  RdRp	  coding	  sequence.	  Results	  showed	  that	  transfection	  efficiency	  is	  not	  affected	  by	  ribavirin	  treatment.	  





	  	  	  





























Figure	  4.7:	  The	  effect	  of	  ribavirin	  on	  transfection	  efficiency	  in	  L929	  cells	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4.5 	  	  	  	  	  The	  influence	  of	  ribavirin	  treatment	  on	  the	  CRE-­‐REP	  assay	  
As	  ribavirin	  treatment	  seemed	  to	  be	  non-­‐toxic	  and	  have	  little	  effect	  upon	  transfection	  efficiency	  it	  was	  decided	  to	  continue	  with	  a	  CRE-­‐REP	  assay	  that	  incorporated	  the	  mutagen.	  L929	  cells	  in	  12-­‐well	  plates	  were	  treated	  with	  various	  concentrations	  of	  ribavirin	  (as	  indicated)	  2	  hrs	  prior	  to	  transfection	  and	  then	  maintained	  post-­‐transfection.	  Five	  hundred	  nanograms	  of	  RNA	  in	  a	  1:1	  ratio	  (RLucWT	  /	  SL3)	  was	  transfected	  in	  triplicate	  wells.	  Cells	  were	  then	  incubated	  for	  48	  hrs.	  Transfection	  supernatant	  was	  harvested	  and	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays	  and	  incubated	  for	  sixty	  hours.	  Cells	  were	  then	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  4.8).	  Following	  quantification	  of	  recombinant	  progeny	  it	  was	  obvious	  to	  note	  that	  treatment	  of	  L929	  cells	  with	  100	  μM	  or	  200	  μM	  of	  ribavirin	  led	  to	  a	  significant	  increase	  in	  intertypic	  recombinant	  yield	  (as	  measured	  by	  Students	  T-­‐test).	  At	  these	  same	  levels	  PV3	  virus	  replication	  is	  inhibited	  by	  75	  %	  and	  81	  %	  respectively	  (see	  figure	  4.6).	  No	  recombinant	  was	  isolated	  from	  ribavirin	  treatment	  at	  400	  μM.	  This	  is	  not	  surprising	  given	  that	  this	  level	  of	  mutagen	  reduced	  PV3	  virus-­‐yield	  by	  over	  2-­‐log10.	  In	  a	  similar	  approach,	  intratypic	  recombination	  in	  the	  presence	  of	  varying	  ribavirin	  level	  was	  also	  investigated.	  A	  similar	  phenomenon	  was	  observed	  (figure	  4.9).	  Treatment	  of	  L929	  cells	  with	  ribavirin	  led	  to	  a	  significant	  increase	  in	  recombination	  frequency	  (measured	  by	  Students	  T-­‐test).	  However,	  the	  significant	  increase	  was	  limited	  to	  50	  μM	  levels	  of	  the	  mutagen,	  less	  than	  that	  observed	  in	  the	  intertypic	  experiment.	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4.6 	  	  	  	  	  The	  influence	  of	  5-­‐fluorouracil	  treatment	  on	  the	  CRE-­‐REP	  assay	  	  Another	  nucleoside	  analogue	  with	  a	  similar	  mode	  of	  action	  to	  ribavirin	  is	  the	  mutagen	  5-­‐fluorouracil	  (5-­‐FU).	  This	  chemical	  is	  a	  pyrimidine	  analogue	  that	  is	  extensively	  used	  in	  cancer	  chemotherapy.	  5-­‐FU,	  like	  ribavirin,	  can	  also	  be	  metabolised	  into	  its	  triphosphate	  form	  and	  be	  used	  as	  a	  substrate	  by	  viral	  RNA	  dependent	  RNA	  polymerases	  leading	  to	  lethal	  mutagenesis	  (Agudo	  et	  al.,	  2009,	  Perales	  et	  al.,	  2009),	  and	  the	  reduction	  in	  virus	  yield	  following	  mutagen	  treatment	  has	  been	  well	  characterised	  (Crotty	  and	  Andino,	  2002,	  Vignuzzi	  et	  al.,	  2005).	  The	  increase	  in	  recombination	  frequency	  observed	  in	  the	  presence	  of	  ribavirin	  therefore	  warranted	  the	  use	  of	  5-­‐FU.	  	  	  A	  similar	  approach	  to	  that	  described	  in	  section	  4.4	  was	  undertaken	  to	  measure	  the	  overall	  reduction	  in	  PV3	  yield	  following	  mutagen	  treatment	  (figure	  4.10A).	  This	  was	  an	  important	  control	  that	  would	  aid	  in	  the	  subsequent	  interpretation	  of	  any	  CRE-­‐REP	  assay	  carried	  out	  in	  the	  presence	  of	  the	  mutagen.	  The	  detrimental	  effect	  of	  5-­‐FU	  was	  apparent	  during	  the	  course	  of	  the	  experiment,	  concentrations	  above	  100	  μM	  led	  to	  toxicity	  and	  cell	  death	  prior	  to	  infection	  (not	  observed	  with	  ribavirin).	  This	  observation	  would	  have	  had	  an	  obvious	  impact	  on	  overall	  virus	  yield,	  something	  that	  would	  need	  to	  be	  considered	  in	  any	  CRE-­‐REP	  assay.	  5-­‐FU	  levels	  of	  100	  μM,	  the	  highest	  non-­‐toxic	  level	  observed,	  led	  to	  a	  2-­‐log10	  fall	  in	  virus	  yield.	  A	  second	  infectivity	  assay	  involving	  PV3	  was	  carried	  out	  using	  lower	  concentrations	  of	  5-­‐FU.	  This	  was	  deemed	  appropriate	  given	  the	  toxicity	  issues	  seen	  in	  the	  first	  assay.	  Three	  concentrations	  were	  used	  (20-­‐40	  μM)	  in	  triplicate,	  with	  HeLa	  cells	  being	  treated	  2	  hours	  prior	  to	  infection	  and	  then	  post	  infection	  with	  mutagen.	  Cells	  in	  a	  6-­‐well	  plate	  were	  infected	  at	  an	  M.O.I	  of	  0.01	  and	  incubated	  for	  48	  hrs.	  Dilutions	  of	  harvested	  media	  supernatant	  were	  then	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  virus	  plaques	  counted	  with	  titre	  converted	  to	  pfu/ml	  and	  normalised	  as	  a	  percentage	  of	  an	  untreated	  control	  (figure	  4.10B).	  Results	  indicated	  that	  treatments	  of	  between	  20-­‐40	  μM	  led	  to	  a	  maximum	  fall	  of	  80%	  in	  PV3	  yield,	  similar	  to	  the	  results	  obtained	  when	  virus	  yield	  was	  measured	  following	  ribavirin	  treatment	  at	  a	  concentration	  of	  200	  μM.	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An	  intratypic	  CRE-­‐REP	  assay	  was	  carried	  out	  using	  four	  concentrations	  of	  5-­‐FU	  that	  varied	  from	  20	  μM	  to	  160	  μM.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  treated	  with	  mutagen	  2	  hrs	  prior	  and	  then	  post	  transfection.	  A	  total	  of	  0.5	  μg	  RNA	  was	  co-­‐transfected	  in	  triplicate	  wells	  in	  a	  1:1	  ratio	  (Rep3-­‐L	  /	  SL3).	  Cells	  were	  incubated	  for	  48	  hrs.	  Dilutions	  of	  harvested	  media	  supernatant	  were	  then	  used	  to	  inoculate	  RD	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  4.10CD).	  Yield	  of	  recombinant	  progeny	  indicated	  that	  treatments	  of	  20	  μM	  and	  40	  μM	  of	  5-­‐FU	  led	  to	  a	  significant	  increase	  in	  recombination	  frequency.	  This	  result	  correlates	  well	  with	  the	  results	  obtained	  in	  the	  presence	  of	  ribavirin.	  Under	  conditions	  where	  virus	  viability	  is	  reduced	  by	  around	  80%,	  recombination	  frequency,	  as	  measured	  by	  yield	  from	  the	  CRE-­‐REP	  assay,	  increases.	  Treatments	  of	  80	  μM	  and	  above	  led	  to	  a	  fall	  in	  recombination	  frequency,	  which	  can	  be	  associated	  to	  the	  high	  loss	  of	  virus	  viability	  at	  these	  levels.	  	  	  	  A	  similar	  approach	  was	  used	  to	  look	  at	  the	  impact	  of	  5-­‐FU	  upon	  intertypic	  recombination	  frequency.	  All	  conditions	  were	  the	  same	  as	  the	  intratypic	  CRE-­‐REP	  assay,	  with	  only	  the	  PV3	  replicon	  (Rep3-­‐L)	  being	  replaced	  with	  the	  PV1	  replicon	  (RLucWT).	  Unlike	  the	  intratypic	  assay,	  only	  a	  concentration	  of	  40	  μM	  led	  to	  a	  significant	  increase	  in	  recombination	  frequency	  (figure	  4.11).	  	  Treatments	  above	  this	  amount	  led	  to	  a	  fall	  or	  loss	  of	  recombinant	  virus,	  which	  was	  expected	  given	  that	  these	  doses	  led	  to	  a	  fall	  in	  infectivity	  of	  around	  2	  log10.	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Figure	  4.10:	  Intratypic	  recombination	  in	  the	  presence	  of	  varying	  levels	  of	  5-­‐FU	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4.7 The	  influence	  of	  higher	  ribavirin	  concentrations	  on	  the	  high	  fidelity	  
variant	  (G64S)	  in	  the	  CRE-­‐REP	  assay	  	  The	  high	  fidelity	  variant	  (G64S),	  as	  previously	  mentioned,	  was	  selected	  via	  serial	  passage	  of	  virus	  in	  the	  presence	  of	  the	  mutagen	  ribavirin.	  However,	  the	  ribavirin	  resistance	  phenotype	  that	  the	  G64S	  mutation	  provides	  is	  not	  complete.	  Ribavirin	  doses	  in	  the	  range	  of	  400	  μM	  to	  800	  μM	  increase	  mutation	  rates	  in	  a	  population	  of	  viruses	  carrying	  this	  high	  fidelity	  variant,	  in	  a	  similar	  fashion	  previously	  outlined	  (Pfeiffer	  and	  Kirkegaard,	  2003).	  	  	  It	  was	  therefore	  decided	  to	  test	  the	  G64S	  high	  fidelity	  RdRp	  with	  a	  higher	  dose	  of	  ribavirin.	  Perhaps	  the	  reduction	  in	  recombination	  frequency	  due	  to	  increased	  fidelity	  could	  be	  reversed	  if	  a	  higher	  dose	  was	  used?	  An	  intertypic	  CRE-­‐REP	  assay	  was	  set	  up	  that	  used	  the	  high	  fidelity	  PV1	  replicon	  RLuc-­‐G64S	  along	  with	  the	  PV3	  CRE	  mutant	  (SL3).	  A	  dose	  of	  600	  μM	  ribavirin	  was	  deemed	  appropriate	  as	  it	  was	  at	  the	  mid-­‐point	  of	  doses	  used	  in	  a	  previous	  study	  that	  were	  shown	  to	  have	  a	  mutagenic	  effect	  (Pfeiffer	  and	  Kirkegaard,	  2003).	  At	  these	  levels	  the	  mutagen	  does	  not	  affect	  translation	  and	  replication	  of	  a	  sub-­‐genomic	  replicon	  bearing	  a	  G64S	  mutation,	  but	  does	  reduce	  RdRp	  fidelity	  (Vignuzzi	  et	  al.,	  2006).	  This	  was	  an	  important	  fact	  to	  consider,	  as	  any	  alteration	  in	  recombination	  frequency	  would	  therefore	  be	  directly	  related	  to	  fidelity	  only.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  incubated	  with	  the	  mutagen	  2	  hrs	  prior	  to	  transfection	  and	  following,	  with	  no	  obvious	  toxic	  affect	  to	  the	  cells	  observed.	  Five	  hundred	  nanograms	  of	  RNA	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant)	  was	  transfected	  in	  triplicate	  wells	  and	  incubated	  for	  48	  hrs.	  Dilutions	  of	  harvested	  media	  supernatant	  were	  then	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  4.12).	  Quantification	  of	  recombinant	  progeny	  indicated	  that	  treatment	  with	  a	  higher	  dose	  of	  ribavirin	  led	  to	  a	  significant	  increase	  in	  recombination	  frequency	  of	  around	  3-­‐fold	  when	  compared	  to	  mock	  treated	  controls	  (determined	  by	  student	  T-­‐Test).	  Although,	  ribavirin	  treatment	  led	  to	  a	  smaller	  plaque	  phenotype	  -­‐	  this	  was	  presumably	  due	  to	  additional	  mutations	  that	  were	  present	  in	  the	  recombinant	  genome.	  This	  result	  further	  supports	  a	  direct	  role	  for	  the	  RdRp	  in	  recombination.	  It	  also	  strongly	  suggests	  that	  fidelity	  is	  a	  key	  characteristic	  that	  determines	  recombination	  frequency.	  	  









Figure	  4.12:	  Influence	  of	  a	  high	  fidelity	  polymerase	  (G64S)	  upon	  intertypic	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  +	  600μM	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4.8 Characterisation	  of	  PV3/1	  recombinant	  clones	  produced	  in	  the	  
presence	  of	  ribavirin	  	  The	  direct	  interaction	  of	  ribavirin	  with	  viral	  RdRp’s	  has	  already	  been	  outlined	  in	  section	  4.2.	  The	  increase	  in	  recombination	  frequency	  observed	  when	  CRE-­‐REP	  partners	  were	  co-­‐transfected	  in	  the	  presence	  of	  ribavirin	  suggested	  that	  its	  incorporation,	  or	  attempted	  incorporation,	  might	  have	  been	  sufficient	  to	  induce	  an	  increase	  in	  template	  switching.	  It	  would	  be	  reasonable	  to	  suggest	  that	  if	  ribavirin	  were	  incorporated	  into	  the	  RNA	  that	  a	  transition	  mutation	  may	  be	  observable.	  It	  was	  decided	  to	  isolate	  and	  sequence	  a	  number	  of	  intertypic	  recombinant	  biological	  clones,	  which	  had	  arisen	  from	  a	  co-­‐transfection	  in	  the	  presence	  of	  ribavirin.	  If	  ribavirin	  were	  having	  a	  direct	  influence	  upon	  template	  switching	  then	  perhaps	  sequence	  analysis	  of	  a	  number	  of	  junctions	  would	  highlight	  a	  potential	  sequence	  motif,	  or	  indeed	  mutation	  that	  could	  be	  linked	  to	  the	  nucleoside	  analogue.	  Intertypic	  isolates	  were	  obtained	  by	  a	  limiting	  dilution	  approach.	  It	  was	  deemed	  most	  suitable	  to	  use	  one	  of	  the	  100	  -­‐	  200	  μM	  ribavirin	  transfection	  supernatants,	  which	  were	  isolated	  from	  the	  intertypic	  CRE-­‐REP	  assay	  (figure	  4.8).	  These	  samples	  had	  shown	  a	  2-­‐3-­‐fold	  increase	  in	  recombination	  compared	  to	  untreated	  controls.	  	  	  	  Biological	  cloning	  was	  done	  by	  a	  limiting	  dilution	  approach,	  and	  the	  1.058	  Kb	  zone	  of	  recombination	  amplified	  by	  RT-­‐PCR	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R.	  A	  total	  of	  nine	  unique	  PV3/1	  recombinant	  junctions	  were	  characterised	  (figure	  4.13A).	  Four	  of	  the	  characterised	  recombinant	  junctions	  fell	  within	  cluster	  one	  (VP1/2A	  boundary),	  and	  all	  of	  the	  isolates	  in	  this	  region	  were	  imprecise	  and	  carried	  additional	  sequence	  when	  compared	  to	  wild	  type	  poliovirus	  genome	  length	  (figure	  4.13B).	  Two	  of	  the	  recombinants	  had	  junctions	  that	  suggested	  template	  switching	  had	  occurred	  at	  or	  just	  before	  an	  ‘A’	  dinucleotide	  upon	  the	  donor	  template.	  One	  isolate	  had	  a	  junction	  that	  spanned	  a	  ‘U’	  dinucleotide	  with	  the	  final	  imprecise	  junction	  at	  a	  ‘UA’	  sequence	  upon	  the	  donor	  template.	  Two	  of	  the	  characterised	  recombinant	  junctions	  fell	  within	  cluster	  two,	  a	  region	  that	  spans	  the	  2A/2B	  boundary	  (figure	  4.13C).	  One	  was	  imprecise,	  and	  carried	  additional	  sequence.	  This	  isolate	  had	  a	  junction	  that	  suggested	  template	  switching	  had	  occurred	  at	  a	  ‘UU’	  dinucleotide	  upon	  the	  donor	  template.	  The	  final	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Figure	  4.13:	  Biologically	  cloned	  PV3/1	  recombinants	  obtained	  from	  co-­‐transfection	  of	  
RNA	  partners	  in	  the	  presence	  of	  100	  -­‐	  200	  μM	  ribavirin	  
(A)	  Dashed	  arrows	  indicate	  points	  of	  crossover	  from	  donor	  (replicon)	  to	  acceptor	  template	  (CRE	  mutant)	  in	  all	  of	  the	  isolates.	  Colour	  codes	  same	  as	  nomenclature	  of	  recombinants.	  PV3	  =	  Leon	  strain,	  PV1	  =	  Mahoney	  strain	  (GenBank	  accession	  numbers	  X00925	  and	  V01149	  respectively),	  LUC	  =	  Luciferase	  sequence	  carried	  by	  the	  PV1	  replicon.	  REC	  =	  recombinant	  sequence.	  Red	  boxes	  indicate	  sequence	  homology	  in	  the	  region	  of	  template	  switching.	  (B)	  Genome	  sequences	  of	  four	  biologically	  cloned	  intertypic	  recombinant	  viruses	  with	  junctions	  that	  fall	  within	  cluster	  one	  (C)	  Genome	  sequences	  of	  two	  biologically	  cloned	  intertypic	  recombinant	  virus	  that	  fall	  within	  cluster	  two	  (D)	  Genome	  sequences	  of	  two	  biologically	  cloned	  intertypic	  recombinants	  that	  fall	  outside	  of	  the	  cluster	  one	  and	  cluster	  two	  regions.	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recombinant	  in	  this	  area	  was	  precise	  with	  no	  additional	  sequence	  when	  compared	  to	  wild	  type	  poliovirus	  length.	  Similarly,	  its	  junction	  mapped	  to	  a	  ‘UU’	  dinucleotide	  upon	  the	  donor	  template.	  	  Two	  final	  isolates	  were	  characterised	  that	  had	  recombinant	  junctions	  that	  were	  precise	  with	  no	  additional	  sequence	  present	  (figure	  4.13D).	  In	  both	  examples	  the	  exact	  location	  of	  recombination	  could	  not	  be	  found	  due	  to	  sequence	  identity	  between	  parental	  genomes.	  The	  two	  isolates	  fell	  outside	  of	  the	  characterised	  cluster	  one	  and	  cluster	  two	  regions	  that	  span	  protein	  cleavage	  boundaries.	  Both	  had	  sequences	  that	  encoded	  chimeric	  protein,	  something	  rarely	  observed	  in	  the	  genomes	  of	  imprecise	  intertypic	  recombinants	  isolated	  from	  the	  CRE-­‐REP	  assay.	  Although,	  precise	  recombination	  within	  the	  2C	  region	  is	  something	  that	  has	  been	  seen	  before	  and	  seems	  to	  be	  tolerated	  (Lowry	  et	  al.,	  2014).	  The	  isolation	  of	  a	  recombinant	  genome	  with	  a	  junction	  within	  this	  region	  was	  therefore	  not	  surprising.	  It	  was	  surprising	  to	  see	  an	  isolate	  that	  had	  a	  recombination	  junction	  midway	  through	  the	  2A	  coding	  region.	  However,	  this	  recombinant	  genome	  may	  not	  necessarily	  represent	  the	  product	  of	  the	  initial	  crossover	  event.	  The	  Lowry	  study	  found	  imprecise	  isolates	  where	  the	  recombination	  site	  upon	  the	  acceptor	  template	  was	  in	  a	  similar	  position.	  Potentially,	  this	  isolate	  had	  already	  gone	  through	  the	  secondary	  resolution	  events	  characterised	  in	  section	  3.6.	  This	  would	  explain	  why	  it	  is	  precise	  with	  no	  additional	  sequence.	  	  A	  final	  intertypic	  recombinant	  junction	  was	  characterised	  that	  had	  sequence	  that	  suggested	  two	  recombination	  events	  had	  occurred	  (figure	  4.14AB).	  An	  initial	  template	  switch	  from	  the	  luciferase-­‐coding	  region	  on	  the	  donor	  template	  (RLucWT)	  to	  a	  region	  within	  the	  capsid	  coding	  area	  of	  the	  acceptor	  template	  (SL3)	  was	  identified.	  This	  would	  be	  considered	  a	  trans	  event.	  Sequence	  analysis	  suggested	  that	  a	  second	  recombination	  event	  occurred	  where	  the	  RdRp	  left	  at	  a	  point	  in	  the	  capsid	  coding	  region	  and	  replication	  begins	  adjacent	  to	  the	  VP1/2A	  boundary	  upon	  the	  SL3	  template.	  In	  principle,	  this	  could	  have	  occurred	  in	  cis	  upon	  the	  same	  acceptor	  template	  or,	  by	  a	  template	  switch	  to	  another	  acceptor	  template.	  A	  double	  recombination	  event	  like	  this	  has	  been	  observed	  before	  in	  an	  isolate	  known	  as	  25A	  (Lowry	  et	  al.,	  2014).	  No	  obvious	  dinucleotide	  or	  sequence	  motif	  was	  identified	  with	  the	  double	  recombinant	  isolate.
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Figure	  4.14:	  Intertypic	  recombinant	  isolate	  with	  a	  double	  template	  switch	  
(A)	  Genome	  sequence	  of	  a	  biologically	  cloned	  intertypic	  recombinant	  that	  has	  two-­‐recombination	  junctions.	  PV3	  =	  Leon	  strain,	  LUC	  =	  Luciferase	  sequence	  carried	  by	  the	  PV1	  replicon	  (GenBank	  accession	  numbers	  X00925	  and	  V01149	  respectively).	  CAP	  =	  Capsid	  sequence	  of	  PV3,	  REC	  =	  recombinant	  sequence.	  Red-­‐boxed	  dinucleotide	  indicates	  sequence	  identity	  in	  the	  region	  of	  the	  first	  template	  switch.	  Yellow	  box	  indicates	  capsid-­‐coding	  sequence	  followed	  by	  a	  secondary	  recombination	  event.	  Dashes	  indicate	  nt	  identity	  with	  PV3,	  any	  differences	  in	  sequence	  are	  indicated	  (B)	  Dashed	  arrow	  (Black)	  indicates	  the	  first	  point	  of	  crossover	  from	  donor	  (replicon)	  to	  acceptor	  template	  (CRE	  mutant).	  Dashed	  arrow	  (Red)	  indicates	  second	  positional	  switch	  upon	  the	  acceptor	  template	  only.	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4.9 	  	  	  	  	  Impact	  of	  fidelity	  on	  the	  resolution	  process	  
The	  biphasic	  nature	  of	  recombination	  in	  enteroviruses	  has	  been	  discussed	  in	  section	  3.10,	  where	  a	  molecular	  clone	  known	  as	  JC105B	  was	  shown	  to	  go	  through	  the	  same	  ‘resolution’	  stages	  as	  a	  biological	  clone	  of	  the	  same	  sequence	  (#105B,	  section	  3.6).	  Potentially,	  the	  loss	  of	  additional	  sequence	  could	  have	  been	  due	  to	  secondary	  recombination	  events.	  If	  this	  were	  replicative,	  like	  ‘copy-­‐choice’,	  then	  RdRp	  fidelity	  may	  impact	  the	  resolution	  process	  in	  a	  similar	  fashion	  to	  the	  recombination	  events	  observed	  in	  the	  CRE-­‐REP	  assay.	  To	  answer	  this	  question,	  the	  high	  fidelity	  G64S	  mutation	  was	  sub-­‐cloned	  into	  the	  JC105B	  cDNA	  from	  the	  pRLuc-­‐G64S	  cDNA	  using	  the	  unique	  restriction	  enzymes	  BglII	  and	  ApaI.	  The	  construct	  was	  then	  linearised	  with	  ApaI	  and	  used	  as	  a	  template	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  A	  similar	  experimental	  approach	  to	  that	  outlined	  in	  section	  3.8	  was	  used,	  where	  250	  ng	  of	  JC105B	  and	  JC105B-­‐G64S	  RNA	  were	  transfected	  individually	  into	  L929	  cells	  and	  allowed	  to	  incubate	  for	  48	  hrs.	  The	  transfection	  supernatant	  was	  then	  isolated	  and	  then	  subjected	  to	  a	  further	  ten	  serial	  passages	  in	  HeLa	  cells.	  Viral	  RNA	  was	  isolated	  from	  each	  passage	  and	  subjected	  to	  RT-­‐PCR	  analysis.	  The	  JC105B	  material	  was	  amplified	  using	  the	  primers	  PV1/3-­‐3280F	  and	  GEN-­‐4615R	  and	  the	  G64S	  variant	  was	  amplified	  using	  the	  primers	  PV3-­‐3249F	  and	  PV1-­‐3679R.	  The	  JC105B	  molecular	  clone	  that	  carried	  a	  wild-­‐type	  sequence	  RdRp	  went	  through	  a	  similar	  ‘resolution	  event’	  observed	  in	  chapter	  three	  (figure	  4.15A).	  This	  was	  included	  as	  a	  control	  to	  compare	  to	  the	  G64S	  variant.	  The	  appearance	  of	  a	  smaller	  PCR	  product	  can	  be	  seen	  by	  passage	  4,	  which	  seems	  to	  migrating	  as	  far	  as	  the	  SL3	  control	  (wild	  type	  length).	  The	  pattern	  of	  resolution	  in	  the	  JC105B-­‐G64S	  variant	  differed	  dramatically	  to	  the	  JC105B	  molecular	  clone	  (figure	  4.15B).	  The	  appearance	  of	  a	  smaller	  PCR	  product	  does	  not	  appear	  until	  passage	  8,	  and	  a	  mixed	  population	  can	  still	  be	  seen	  at	  passage	  10.	  This	  observation	  strongly	  suggests	  that	  the	  resolution	  event	  may	  indeed	  be	  due	  to	  replicative	  recombination	  and	  is	  affected	  by	  RdRp	  fidelity.	  To	  further	  support	  this	  interpretation,	  it	  was	  decided	  to	  passage	  the	  JC105B-­‐G64S	  variant	  in	  the	  presence	  of	  ribavirin.	  As	  shown	  previously,	  recombination	  frequency	  in	  the	  CRE-­‐REP	  assay	  with	  the	  G64S	  variant	  increased	  when	  ribavirin	  was	  present.	  In	  this	  experiment	  400	  μM	  was	  added	  to	  HeLa	  cells	  at	  each	  passage.	  Products	  of	  RT-­‐PCR	  indicated	  that	  the	  presence	  of	  ribavirin	  has	  led	  to	  the	  










Figure	  4.15:	  Resolution	  of	  a	  molecular	  clone	  with	  a	  high	  fidelity	  polymerase	  +/-­‐	  ribavirin	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loss	  of	  additional	  sequence	  by	  passage	  4,	  four	  passages	  earlier	  than	  without	  the	  mutagen	  (figure	  4.15C).	  	  	  
4.10 Influence	  of	  nocodazole	  treatment	  on	  the	  CRE-­‐REP	  assay	  
For	  genetic	  re-­‐arrangements	  to	  occur,	  like	  recombination,	  genomes	  must	  be	  closely	  juxtaposed,	  presumably	  in	  the	  same	  membrane	  associated	  replication	  complex.	  As	  described	  in	  chapter	  one,	  replication	  of	  the	  viral	  RNA	  occurs	  in	  replication	  complexes	  (RCs),	  which	  are	  rosette	  like	  vesicles	  derived	  from	  the	  host	  endoplasmic	  reticulum.	  A	  technique	  known	  as	  fluorescent	  in	  situ	  hybridisation	  (FISH)	  showed	  that	  individual	  replication	  complexes	  initially	  form	  on	  the	  endoplasmic	  reticulum	  where	  synthesis	  of	  negative	  strand	  RNA	  begins.	  The	  individual	  complexes	  then	  move	  in	  a	  microtubule	  (MT)	  dependent	  fashion	  to	  a	  peri-­‐nuclear	  location	  where	  positive	  strand	  RNA	  synthesis	  follows	  (Egger	  and	  Bienz,	  2005).	  The	  movement	  of	  RCs	  to	  a	  similar	  location	  within	  the	  cell	  leads	  to	  a	  coalescence,	  so	  mixing	  their	  RNA	  contents.	  Indeed,	  by	  use	  of	  strain	  specific	  riboprobes	  mixing	  of	  replication	  complexes	  occurs	  following	  RC	  migration	  which	  may	  contribute	  to	  the	  recombination	  process	  (Egger	  and	  Bienz,	  2002).	  	  
	  
Nocodazole	  is	  an	  anti-­‐neoplastic	  agent	  that	  exerts	  its	  effect	  in	  cells	  by	  interfering	  with	  the	  polymerisation	  of	  microtubules.	  The	  treatment	  of	  cells	  with	  nanomolar	  concentrations	  of	  the	  drug	  has	  been	  shown	  to	  lead	  to	  microtubule	  instability	  (Vasquez	  et	  al.,	  1997).	  The	  migration	  pattern	  of	  poliovirus	  replication	  complexes	  can	  also	  be	  affected	  by	  nocodazole	  treatment.	  Transient	  chilling	  of	  host	  cells	  disrupts	  the	  MTs;	  re-­‐polymerization	  is	  then	  blocked	  by	  addition	  of	  the	  drug.	  This	  has	  profound	  effects	  on	  the	  localisation	  pattern	  of	  poliovirus	  replication	  complexes,	  with	  a	  more	  diffuse	  localisation	  pattern	  following	  treatment	  (Egger	  and	  Bienz,	  2005).	  Indeed,	  the	  altered	  pattern	  of	  RC	  movement	  reduces	  co-­‐localisation	  of	  different	  PV	  serotypes	  by	  up	  50%	  when	  compared	  to	  untreated	  cells,	  whilst	  having	  no	  impact	  on	  replication	  
per	  se	  (Egger	  and	  Bienz,	  2005).	  The	  results	  in	  this	  chapter	  so	  far	  have	  indicated	  that	  recombination	  frequency	  can	  be	  affected	  when	  fidelity	  of	  the	  RdRp	  is	  manipulated.	  This	  implies	  that	  the	  templates	  involved	  in	  the	  genetic	  re-­‐arrangements	  are	  in	  close	  proximity,	  presumably	  within	  the	  same	  replication	  complex.	  The	  flexibility	  of	  the	  CRE-­‐REP	  and	  NON-­‐REP	  assays	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allowed	  the	  introduction	  of	  nocodazole	  into	  the	  experiment.	  If	  co-­‐localisation	  of	  viral	  RNA	  could	  be	  affected	  then	  perhaps	  recombination	  frequency	  would	  be	  reduced?	  	  
As	  a	  control,	  it	  was	  deemed	  prudent	  to	  analyse	  the	  effect	  of	  the	  drug	  on	  replication	  of	  a	  PV3	  full-­‐length	  clone	  to	  assess	  whether	  the	  drug	  treatment	  would	  affect	  replication	  levels	  and	  therefore	  bias	  any	  interpretation	  of	  recombination	  frequency.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  transiently	  chilled	  to	  disrupt	  the	  MTs	  then	  treated	  with	  5mM	  nocodazole.	  Control	  cells	  were	  not	  chilled	  and	  were	  treated	  with	  5mM	  of	  the	  carrier	  DMSO	  (section	  2.1.9).	  Following	  a	  brief	  incubation	  period	  post	  drug	  treatment,	  cells	  were	  transfected	  with	  250	  ng	  of	  PV3	  full-­‐length	  clone	  RNA	  and	  left	  to	  incubate	  for	  48	  hrs.	  A	  dilution	  series	  of	  harvested	  media	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  4.16).	  Quantification	  of	  virus	  yield	  showed	  that	  the	  drug	  nocodazole	  did	  not	  significantly	  affect	  replication	  of	  PV3	  following	  transfection,	  in	  agreement	  with	  results	  from	  a	  previous	  study	  (Egger	  and	  Bienz,	  2005).	  	  
A	  similar	  experimental	  approach	  to	  the	  CRE-­‐REP	  assays	  described	  in	  section	  4.3	  involving	  the	  intertypic	  partners	  (RLucWT	  and	  SL3)	  and	  the	  intratypic	  partners	  (Rep3-­‐L	  and	  SL3)	  was	  then	  carried	  out.	  The	  experiment	  also	  incorporated	  the	  nocodazole	  and	  control	  DMSO	  treatment	  prior	  and	  post	  transfection.	  Following	  an	  incubation	  of	  48	  hrs	  post	  transfection,	  media	  supernatant	  was	  harvested	  and	  used	  diluted	  and	  undiluted	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs	  and	  stained	  with	  crystal	  violet.	  In	  both	  combinations,	  disruption	  of	  the	  MTs	  followed	  by	  nocodazole	  treatment	  significantly	  reduced	  recombination	  frequencies	  (figure	  4.17).	  Indeed,	  intratypic	  recombination	  was	  reduced	  to	  around	  30%	  compared	  to	  the	  DMSO	  treated	  control	  while	  intertypic	  recombination	  frequency	  was	  reduced	  to	  less	  than	  10%	  of	  the	  DMSO	  treated	  control.	  	  	  	   	  







Figure	  4.16:	  Nocodazole	  treatment	  does	  not	  affect	  PV3	  replication	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Figure	  4.17:	  Nocodazole	  treatment	  inhibits	  replicative	  recombination	  
(A)	  Figures	  represent	  intratypic	  recombinant	  virus	  yield	  from	  three	  independent	  samples	  using	  RNA	  generated	  in	  vitro	  from	  pT7rep3-­‐L	  and	  pT7FLC/SL3.	  Transfection	  treatments	  with	  either	  nocodazole	  or	  the	  carrier	  DMSO	  are	  indicated.	  Error	  bars	  indicate	  standard	  deviation.	  Asterisk;	  **P	  <	  0.005	  by	  Student’s	  T-­‐test	  test	  (B)	  Figures	  represent	  intertypic	  recombinant	  virus	  yield	  from	  three	  independent	  samples	  using	  RNA	  generated	  in	  vitro	  from	  pRLucWT	  and	  pT7FLC/SL3.	  Transfection	  treatments	  with	  either	  nocodazole	  or	  the	  carrier	  DMSO	  are	  indicated.	  Error	  bars	  indicate	  standard	  deviation.	  Asterisk;	  **P	  <	  0.005	  by	  Student’s	  T-­‐test	  test	  (C)	  Representative	  crystal	  violet	  stained	  HeLa	  cell	  monolayers	  infected	  with	  diluted	  transfection	  supernatant	  (dilutions	  as	  indicated)	  and	  overlayed	  with	  plaque	  assay	  overlay	  medium.	  RNA	  partners	  as	  indicated.	  Transfection	  treatment	  conditions	  as	  indicated.	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Results	  strongly	  suggested	  that	  recombination	  was	  primarily	  a	  replicative	  process	  that	  was	  reliant	  upon	  co-­‐localisation	  of	  replication	  complexes.	  In	  principle,	  MT	  disruption	  and	  subsequent	  nocodazole	  treatment	  should	  have	  had	  little	  affect	  upon	  non-­‐replicative	  recombination.	  To	  ensure	  that	  nocodazole	  treatment	  was	  solely	  affecting	  replicative	  recombination	  a	  final	  experiment	  was	  considered	  necessary.	  The	  treatments	  outlined	  in	  this	  section	  were	  incorporated	  into	  the	  NON-­‐REP	  assay	  described	  in	  section	  3.9	  using	  the	  non-­‐replicative	  intratypic	  partners	  only.	  Recombinant	  progeny	  counts	  under	  both	  conditions	  (nocodazole	  and	  DMSO)	  were	  low,	  as	  expected,	  with	  no	  significant	  difference	  between	  the	  two	  (figure	  4.18).	  	  	  
4.11 Discussion	  
The	  ‘copy-­‐choice’	  mechanism	  of	  recombination	  is	  a	  replicative	  process	  (Kirkegaard	  and	  Baltimore,	  1986b).	  The	  results	  in	  this	  study	  have	  showed	  that	  the	  recombinant	  progeny	  produced	  from	  the	  CRE-­‐REP	  assay	  was	  primarily	  due	  to	  replicative	  recombination	  that	  is	  biphasic	  in	  nature.	  The	  aim	  in	  this	  area	  of	  the	  investigation	  was	  to	  identify	  characteristics	  of	  the	  viral	  RdRp	  that	  were	  important	  in	  recombination.	  The	  results	  in	  section	  4.2	  showed	  that	  manipulation	  of	  RdRp	  fidelity	  did	  not	  affect	  recombinant	  progeny	  yield	  from	  the	  NON-­‐REP	  assay.	  This	  result	  was	  important	  because	  it	  showed	  that	  this	  recombination	  process	  is	  via	  a	  mechanism	  that	  is	  independent	  of	  the	  viral	  polymerase.	  Presumably	  the	  recombinant	  RNA	  produced	  in	  the	  NON-­‐REP	  assay	  is	  via	  an	  unknown	  cellular	  ligase	  or	  via	  a	  trans-­‐esterification	  reaction	  that	  has	  been	  postulated	  in	  previous	  studies	  (Gmyl	  et	  al.,	  1999,	  Gmyl	  et	  al.,	  2003).	  In	  contrast,	  results	  showed	  that	  RdRp	  fidelity	  influenced	  recombination	  frequency	  in	  the	  replicative	  CRE-­‐REP	  assay.	  The	  use	  of	  a	  well-­‐characterised	  high	  fidelity	  RdRp	  variant	  (Pfeiffer	  and	  Kirkegaard,	  2003,	  Vignuzzi	  et	  al.,	  2005)	  that	  carried	  a	  G64S	  mutation	  within	  the	  RdRp	  coding	  region	  (3D),	  inhibited	  intratypic	  and	  intertypic	  recombination	  frequencies	  by	  10	  and	  20-­‐fold	  respectively.	  Importantly,	  the	  luciferase	  assays	  conducted	  in	  section	  4.3	  showed	  that	  this	  mutation	  does	  not	  significantly	  affect	  the	  replication	  kinetics	  of	  the	  virus,	  a	  result	  that	  is	  supported	  by	  a	  previous	  study	  (Vignuzzi	  et	  al.,	  2006).	  This	  ensured	  that	  any	  difference	  in	  	  





Figure	  4.18:	  Nocodazole	  does	  not	  inhibit	  non-­‐replicative	  recombination	  Figures	  represent	  non-­‐replicative	  intratypic	  recombinant	  virus	  yield	  from	  three	  independent	  samples	  co-­‐transfected	  with	  RNA	  templates	  ΔRep3-­‐L	  and	  SL3Δ.	  Treatments	  with	  either	  nocodazole	  or	  the	  carrier	  DMSO	  are	  indicated.	  Error	  bars	  indicate	  standard	  deviation.	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recombination	  frequency	  was	  due	  to	  fidelity	  of	  the	  viral	  RdRp	  alone.	  In	  contrast,	  the	  use	  of	  the	  nucleoside	  analogue	  mutagen	  ribavirin,	  that	  is	  known	  to	  decrease	  RdRp	  fidelity	  (Vignuzzi	  et	  al.,	  2005),	  led	  to	  a	  significant	  increase	  in	  recombination	  frequency	  whilst	  having	  no	  impact	  upon	  transfection	  efficiency.	  The	  levels	  of	  ribavirin	  required	  to	  increase	  recombination	  were	  between	  100-­‐200	  μM	  in	  the	  intertypic	  CRE-­‐REP	  assay	  and	  50	  μM	  in	  the	  intratypic	  CRE-­‐REP	  assay.	  The	  differences	  in	  the	  dosage	  that	  led	  to	  a	  significant	  increase	  in	  recombination	  may	  indicate	  an	  underlying	  difference	  between	  the	  two	  serotypes	  at	  the	  RdRp	  level.	  Further	  experiments	  in	  this	  area	  will	  be	  required.	  Ribavirin	  treatment	  at	  the	  100-­‐200	  μM	  levels	  was	  shown	  to	  reduce	  viability	  of	  a	  full	  length	  PV3	  virus	  by	  up	  80%	  (figure	  4.19A).	  If	  the	  level	  of	  recombination	  increases	  with	  higher	  concentrations	  of	  ribavirin	  then	  why	  wasn’t	  there	  an	  increase	  at	  levels	  above	  200	  μM?	  Poliovirus	  lives	  on	  the	  edge	  of	  ‘error	  catastrophe’	  (Crotty	  and	  Andino,	  2002).	  In	  all	  probability	  the	  mutagenic	  load	  carried	  by	  the	  recombinant	  genomes	  that	  were	  produced	  at	  the	  higher	  doses	  of	  ribavirin	  made	  them	  non-­‐viable.	  As	  the	  CRE-­‐REP	  assay	  measures	  viable	  recombinant	  virus	  only	  and	  not	  the	  generation	  of	  hybrid	  RNA,	  these	  would	  not	  have	  been	  detected.	  It	  seems	  there	  is	  a	  critical	  ‘tipping-­‐point’	  between	  increased	  recombination	  frequency	  and	  general	  mutation	  rates,	  above	  which	  genomes	  become	  non-­‐viable.	  This	  hypothesis	  fits	  well	  with	  the	  ‘error-­‐catastrophe’	  theory.	  To	  further	  support	  the	  role	  of	  RdRp	  fidelity,	  a	  similar	  nucleoside	  analogue	  called	  5-­‐FU	  was	  used.	  This	  was	  considered	  an	  appropriate	  mutagen	  to	  use	  because	  it	  has	  a	  similar	  mode	  of	  action	  as	  ribavirin.	  An	  infectivity	  assay	  showed	  that	  levels	  of	  100	  μM	  and	  above	  reduced	  virus	  yield	  by	  over	  two	  log10.	  	  A	  lower	  range	  was	  subsequently	  used,	  and	  it	  was	  shown	  that	  treatment	  of	  cells	  prior	  and	  post	  infection	  with	  40	  μM	  was	  enough	  to	  lower	  virus	  viability	  by	  80%.	  At	  this	  same	  level	  recombination	  from	  the	  intertypic	  and	  intratypic	  CRE-­‐REP	  assays	  was	  significantly	  increased	  (figure	  4.19B).	  This	  result	  correlates	  with	  the	  ribavirin	  results	  and	  indicates	  that	  lowering	  fidelity	  leads	  to	  an	  increase	  in	  template	  switching.	  	  	  A	  number	  of	  biologically	  cloned	  isolates	  were	  characterised	  in	  sections	  4.3	  and	  4.8.	  The	  presence	  of	  a	  high	  fidelity	  RdRp	  had	  little	  effect	  upon	  the	  location	  of	  the	  recombination	  junctions	  characterised	  in	  figure	  4.5.	  All	  were	  at	  or	  spanned	  the	  previously	  observed	  cluster	  1	  and	  cluster	  2	  protein	  cleavage	  boundaries,	  and	  the	  majority	  were	  imprecise	  with	  additional	  





Figure	  4.19:	  Comparison	  of	  recombination	  frequency	  and	  virus	  viability	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sequence	  (Lowry	  et	  al.,	  2014).	  This	  further	  supports	  the	  hypothesis	  that	  the	  overriding	  criteria	  in	  selection	  of	  an	  early	  recombinant	  are	  based	  upon	  a	  genome	  that	  doesn’t	  encode	  chimeric	  proteins;	  this	  ensures	  correct	  protein-­‐protein	  interactions	  during	  subsequent	  replication.	  	  Unlike	  the	  Lowry	  et	  al.,	  2014	  study,	  the	  majority	  of	  intertypic	  biologically	  cloned	  recombinant	  genomes	  in	  this	  chapter	  have	  recombination	  junctions	  that	  are	  associated	  to	  U/A	  dinucleotide	  motifs,	  a	  similar	  finding	  to	  a	  previous	  study	  (King,	  1988b).	  This	  suggests	  that	  use	  of	  a	  high	  fidelity	  RdRp	  or	  mutagen	  have	  biased	  the	  location	  of	  template	  switch	  upon	  the	  donor	  template.	  Perhaps	  the	  high	  fidelity	  RdRp	  will	  leave	  a	  donor	  template	  but	  only	  at	  regions	  of	  the	  lowest	  stability.	  The	  two	  hydrogen	  bonds	  between	  A:U	  during	  RNA	  replication	  represent	  the	  most	  unstable	  interaction.	  When	  interpreting	  the	  data	  caution	  is	  required.	  The	  sequenced	  junctions	  may	  not	  represent	  the	  initial	  crossover	  event,	  even	  though	  the	  experimental	  approach	  isolates	  the	  products	  as	  early	  as	  possible.	  	  	  
As	  described	  in	  sections	  4.2	  and	  4.6,	  ribavirin	  and	  5-­‐FU	  are	  nucleoside	  analogues	  that	  have	  been	  shown	  to	  interact	  directly	  with	  the	  viral	  RdRp	  mimicking	  the	  kinetics	  of	  incorrect	  nucleotides.	  If	  the	  mutagen	  had	  been	  inserted	  into	  the	  nascent	  RNA	  and	  been	  a	  factor	  in	  template	  switching	  then	  transition	  mutations	  would	  be	  expected	  at	  the	  site	  of	  recombination.	  No	  mutations	  were	  observed	  in	  the	  recombinant	  junctions	  analysed	  following	  ribavirin	  treatment	  (figure	  4.13	  and	  4.14).	  Potentially,	  the	  interaction	  of	  the	  mutagen	  with	  the	  viral	  RdRp	  alone	  during	  replication	  could	  have	  been	  enough	  to	  de-­‐stabilise	  the	  elongation	  complex	  and	  induce	  template	  switching.	  Indeed,	  66%	  of	  recombinant	  junctions	  characterised	  in	  figures	  4.13	  and	  4.14	  are	  associated	  with	  a	  ‘UU’	  or	  ‘UA’	  dinucleotide	  motif	  upon	  the	  donor	  template.	  In	  principle,	  the	  attempt	  to	  incorporate	  ribavirin	  opposite	  the	  template	  base	  ‘U’	  could	  have	  been	  enough	  to	  de-­‐stabilise	  the	  elongation	  complex	  inducing	  a	  template	  switch.	  Alternatively,	  the	  mutagen	  could	  be	  having	  an	  indirect	  role	  within	  the	  host	  cell.	  Ribavirin	  monophosphate	  (RMP)	  has	  been	  shown	  to	  inhibit	  a	  host	  enzyme,	  Inosine	  Monophosphate	  Dehydrogenase	  (IMPDH).	  This	  causes	  a	  decrease	  in	  the	  intracellular	  concentration	  of	  GTP	  (Crotty	  et	  al.,	  2000).	  The	  subsequent	  effect	  upon	  nucleotide	  homeostasis	  may	  be	  a	  trigger	  for	  stalling	  events	  that	  increases	  the	  opportunity	  for	  template	  switching	  to	  occur.	  A	  study	  involving	  a	  larger	  data	  set	  is	  required;	  this	  may	  provide	  insights	  into	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the	  possible	  mechanisms	  of	  recombination	  that	  these	  nucleoside	  mutagens	  induce.	  At	  present,	  the	  limited	  sequences	  identified	  only	  allow	  a	  hypothesis.	  	  The	  resolution	  phenomenon,	  where	  additional	  sequence	  is	  lost	  has	  provided	  data	  to	  suggest	  that	  sequence	  identity	  may	  play	  a	  role	  in	  this	  stage	  of	  recombination	  (section	  3.10).	  The	  results	  in	  section	  4.9	  strongly	  suggest	  that	  the	  mechanisms	  of	  ‘resolution’	  are	  replicative.	  By	  using	  a	  molecular	  clone	  (JC105B)	  with	  a	  high	  fidelity	  RdRp	  it	  was	  shown	  that	  the	  process	  of	  resolution	  where	  additional	  sequence	  is	  lost	  was	  inhibited,	  or	  ‘slowed’	  down	  when	  compared	  to	  a	  wild	  type	  RdRp	  control.	  In	  contrast,	  passaging	  the	  same	  high	  fidelity	  clone	  in	  the	  presence	  of	  the	  mutagen	  ribavirin	  sped	  up	  the	  process,	  with	  loss	  of	  sequence	  occurring	  four	  passages	  earlier.	  These	  observations	  strongly	  suggest	  that	  the	  resolution	  event	  is	  RdRp	  dependent	  and	  that	  fidelity	  is	  important.	  This	  could	  be	  due	  to	  a	  copy-­‐choice	  recombination	  event	  where	  the	  RdRp	  leaves	  one	  template	  and	  associates	  to	  another,	  a	  jumping	  event	  that	  leads	  to	  loss	  of	  sequence.	  Alternatively,	  the	  resolution	  events	  that	  have	  been	  observed	  could	  be	  in	  cis.	  Potentially,	  a	  ‘looping’	  out	  event	  within	  the	  same	  RNA	  template	  has	  occurred,	  where	  additional	  sequence	  is	  eventually	  lost.	  The	  two	  models	  of	  resolution	  may	  not	  be	  mutually	  exclusive	  and	  could	  both	  be	  happening.	  Perhaps	  the	  resolution	  event	  is	  M.O.I.	  dependent?	  By	  lowering	  the	  multiplicity	  of	  infection	  a	  distinction	  between	  the	  two	  may	  be	  found.	  What	  these	  results	  do	  show	  is	  that	  by	  increasing	  and	  decreasing	  RdRp	  fidelity	  this	  process	  was	  affected	  in	  a	  similar	  fashion	  to	  that	  shown	  in	  the	  CRE-­‐REP	  assays	  under	  the	  same	  conditions.	  This	  emphasises	  the	  role	  of	  the	  viral	  RdRp	  in	  both	  stages	  of	  recombination.	  	  
Mixing	  of	  replication	  complexes	  with	  both	  parental	  RNA	  would	  seem	  to	  be	  a	  key	  prerequisite	  for	  replicative	  recombination	  to	  occur.	  Transiently	  disrupting	  the	  host	  cell	  microtubules	  using	  a	  cold-­‐shock	  approach	  and	  then	  preventing	  their	  re-­‐polymerisation	  by	  using	  nocodazole	  inhibits	  poliovirus	  RNA	  co-­‐localisation	  (Egger	  and	  Bienz,	  2005).	  Similar	  treatments	  in	  this	  study	  showed	  that	  this	  does	  not	  affect	  replication	  of	  the	  virus.	  This	  key	  control	  experiment	  allowed	  an	  interpretation	  of	  the	  results	  obtained	  from	  the	  CRE-­‐REP	  assay	  under	  the	  same	  conditions.	  Subsequent	  CRE-­‐REP	  assays	  carried	  out	  in	  the	  presence	  of	  nocodazole	  showed	  that	  this	  treatment	  did	  have	  an	  inhibitory	  affect	  upon	  recombination.	  These	  results	  support	  the	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hypothesis	  that	  co-­‐occupancy	  of	  the	  same	  replication	  complex	  is	  necessary	  for	  ‘copy-­‐choice’	  recombination	  to	  occur.	  This	  is	  further	  supported	  by	  the	  fact	  that	  similar	  nocodazole	  treatment	  had	  no	  affect	  upon	  the	  NON-­‐REP	  assay.	  	  	  
In	  summary,	  the	  observations	  in	  this	  chapter	  strongly	  suggest	  that	  fidelity	  of	  the	  viral	  RdRp	  is	  a	  key	  determinant	  of	  recombination	  in	  enteroviruses.	  The	  impact	  upon	  recombination	  frequency	  following	  treatment	  with	  a	  chemical	  that	  inhibits	  viral	  RNA	  co-­‐localisation	  also	  strongly	  supports	  the	  replicative	  ‘copy-­‐choice’	  model.	  Additionally,	  the	  influence	  of	  fidelity	  upon	  the	  resolution	  stage	  suggests	  that	  the	  RdRp	  is	  involved	  in	  additional	  template	  switching	  in	  cis	  or	  
trans,	  which	  aids	  the	  subsequent	  selection	  of	  recombinant	  progeny	  where	  additional	  sequence	  is	  lost.	  Taken	  together,	  these	  observations	  strongly	  support	  the	  replicative	  ‘copy-­‐choice’	  model	  of	  recombination.	  Poliovirus	  has	  evolved	  a	  low	  fidelity	  polymerase	  and	  exist	  as	  a	  quasi-­‐species	  (Crotty	  et	  al.,	  2001).	  This	  diversity	  allows	  the	  population	  to	  adapt	  and	  evolve	  to	  new	  and	  changing	  environments.	  The	  results	  in	  this	  study	  show	  that	  low	  fidelity	  also	  allows	  a	  basal	  level	  of	  recombination.	  This	  process	  leads	  to	  vast	  changes	  in	  the	  viral	  genome,	  leading	  to	  far	  greater	  diversity,	  an	  obvious	  advantageous	  characteristic.	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CHAPTER	  FIVE:	  RNA	  Dependent	  RNA	  Polymerase	  Variants	  
That	  Influence	  Recombination	  and	  the	  Development	  of	  an	  
Expanded	  CRE-­‐REP	  Assay	  	  	  
5.1 	  	  	  	  	  Introduction	  	  The	  results	  in	  chapter	  four	  showed	  that	  the	  yield	  of	  recombinant	  progeny	  from	  the	  CRE-­‐REP	  assay	  was	  influenced	  when	  viral	  RdRp	  fidelity	  was	  manipulated.	  Additionally,	  co-­‐localisation	  of	  viral	  RNA	  was	  shown	  to	  be	  important	  in	  the	  replicative	  assay.	  Taken	  together,	  these	  findings	  supported	  the	  ‘copy-­‐choice’	  replicative	  model	  of	  recombination.	  	  
Previous	  studies	  have	  looked	  at	  RdRp	  fidelity	  as	  a	  way	  of	  generating	  new	  attenuated	  vaccine	  strains	  (Vignuzzi	  et	  al.,	  2006,	  Weeks	  et	  al.,	  2012,	  Vignuzzi	  et	  al.,	  2008).	  These	  studies	  have	  shown	  that	  high	  fidelity	  variants,	  like	  G64S,	  produce	  populations	  of	  viruses	  that	  are	  not	  as	  diverse	  as	  wild-­‐type	  populations	  and	  this	  is	  the	  basis	  of	  their	  attenuation.	  The	  ‘quasi-­‐species’	  are	  considered	  as	  a	  cloud	  of	  viruses	  that	  contain	  potentially	  beneficial	  mutations	  that	  allow	  the	  population	  to	  evolve	  and	  adapt	  to	  new	  environments	  (Vignuzzi	  et	  al.,	  2006,	  Vignuzzi	  et	  al.,	  2008).	  The	  lack	  of	  diversity	  in	  the	  high	  fidelity	  population	  is	  thought	  to	  limit	  viral	  pathogenesis,	  as	  this	  population	  is	  unable	  to	  adapt	  to	  adverse	  growth	  conditions	  (Korboukh	  et	  al.,	  2014).	  The	  G64S	  mutation	  considered	  in	  chapter	  four	  had	  an	  additional	  benefit	  that	  may	  be	  relevant	  to	  future	  vaccine	  development.	  The	  high	  fidelity	  RdRp	  dramatically	  reduced	  recombination	  frequency,	  which	  is	  a	  problem	  with	  the	  current	  live	  attenuated	  strains	  (section	  1.3).	  	  
There	  are	  other	  well-­‐characterised	  RdRp	  variants	  that	  have	  altered	  fidelity	  phenotypes	  (Korboukh	  et	  al.,	  2014,	  Weeks	  et	  al.,	  2012).	  Due	  to	  the	  results	  with	  the	  high	  fidelity	  variant,	  G64S,	  the	  next	  step	  in	  this	  study	  was	  to	  introduce	  another	  well-­‐characterised	  RdRp	  fidelity	  variant	  into	  the	  CRE-­‐REP	  assay	  and	  observe	  its	  effect	  upon	  recombination	  frequency.	  Additionally,	  during	  the	  course	  of	  this	  study	  other	  interesting	  mutations	  to	  the	  poliovirus	  RdRp	  that	  may	  affect	  recombination	  frequency	  were	  made	  available	  and	  were	  also	  introduced	  into	  the	  assay	  (Raul	  Andino,	  personal	  communication).	  Currently,	  the	  CRE-­‐REP	  assay	  is	  limited	  to	  an	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area	  of	  1.058	  Kb,	  as	  previously	  outlined.	  Development	  of	  a	  new	  recombination	  assay	  that	  has	  a	  region	  of	  recombination	  that	  spans	  the	  entire	  non-­‐structural	  region	  of	  the	  poliovirus	  genome	  was	  undertaken.	  This	  was	  deemed	  important,	  as	  it	  would	  allow	  a	  larger	  scale	  study	  on	  recombination	  frequency	  and	  location	  of	  recombination	  junctions.	  	  
Aims	  The	  aim	  was	  to	  introduce	  additional	  RdRp	  variants	  into	  the	  RNA	  partners	  that	  are	  currently	  used	  in	  the	  CRE-­‐REP	  assay	  and	  characterise	  their	  influence	  on	  recombination	  frequency.	  Additionally,	  development	  of	  an	  altered	  CRE-­‐REP	  assay	  was	  undertaken.	  Potentially,	  recombination	  can	  occur	  outside	  of	  the	  current	  1.058	  Kb	  window	  which	  is	  a	  limitation	  of	  the	  current	  CRE-­‐REP	  assay.	  Manipulation	  of	  viral	  RNA	  elements	  was	  considered	  as	  an	  approach	  that	  would	  expand	  this	  window	  to	  the	  entire	  non-­‐structural	  region	  -­‐	  an	  area	  of	  around	  4.1	  Kb.	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5.2 RdRp	  variant	  K359R	  	  All	  positive	  stranded	  RNA	  viruses	  share	  a	  conserved	  amino	  acid	  triplet	  motif	  at	  their	  active	  site	  that	  consist	  of	  a	  glycine	  and	  two	  aspartic	  acids	  (GDD)	  (Jablonski	  and	  Morrow,	  1995).	  These	  amino	  acid	  residues	  in	  the	  active	  site	  of	  polymerases	  are	  thought	  to	  contribute	  only	  indirectly	  to	  catalysis	  by	  serving	  as	  ligands	  for	  the	  two	  divalent	  cations	  required	  for	  activity	  or	  substrate	  binding	  (Castro	  et	  al.,	  2009).	  Two	  proton	  transfer	  reactions	  are	  necessary	  for	  polymerase-­‐catalyzed	  nucleotidyl	  transfer.	  The	  first	  is	  de-­‐protonation	  of	  the	  terminal	  3′-­‐hydroxyl	  group	  of	  the	  nascent	  RNA	  (or	  primer).	  This	  leads	  to	  nucleophilic	  attack	  of	  the	  triphosphate	  moiety	  upon	  the	  incoming	  base.	  The	  subsequent	  pyrophosphate-­‐leaving	  group	  is	  protonated	  in	  the	  second	  reaction	  by	  a	  general	  acid	  found	  within	  an	  area	  known	  as	  motif	  D	  (Castro	  et	  al.,	  2007,	  Castro	  et	  al.,	  2009,	  Weeks	  et	  al.,	  2012).	  Indeed,	  studies	  that	  have	  used	  model	  enzymes	  representing	  all	  four	  classes	  of	  nucleic	  acid	  polymerases	  show	  that	  the	  proton	  donor	  to	  pyrophosphate	  is	  an	  active	  site	  amino	  acid	  residue	  (figure	  5.1).	  A	  conserved	  lysine	  at	  position	  359	  of	  the	  3D	  coding	  region	  serves	  as	  the	  general	  acid	  in	  the	  poliovirus	  RdRp	  (Castro	  et	  al.,	  2009).	  	  
	  
Functional	  studies	  that	  have	  mutated	  the	  lysine	  residue	  to	  an	  arginine	  (K359R)	  show	  that	  this	  polymerase	  is	  still	  active,	  but	  turns	  over	  nucleotides	  at	  a	  rate	  between	  10-­‐20	  fold	  slower	  than	  wild-­‐type	  RdRp	  at	  physiological	  pH	  (Castro	  et	  al.,	  2009).	  This	  study	  also	  suggested	  that	  replication	  speed	  might	  be	  directly	  linked	  to	  fidelity.	  A	  later	  study	  showed	  that	  the	  K359R	  mutation	  did	  indeed	  produce	  a	  viral	  RdRp	  that	  replicated	  slower	  and	  with	  a	  high	  fidelity	  phenotype	  when	  compared	  to	  wild	  type	  RdRp.	  A	  poliovirus	  population	  that	  carried	  the	  K359R	  variation	  was	  genetically	  stable,	  replicated	  well	  in	  cell	  culture,	  and	  was	  attenuated	  whilst	  eliciting	  a	  highly	  protective	  immune	  response	  in	  a	  murine	  model	  (Weeks	  et	  al.,	  2012).	  Due	  to	  the	  conservation	  of	  this	  residue	  in	  viral	  polymerases,	  this	  study	  suggested	  that	  a	  universal,	  mechanism-­‐based	  strategy	  might	  exist	  for	  viral	  attenuation	  and	  vaccine	  development.	  The	  results	  in	  chapter	  four	  strongly	  suggested	  that	  fidelity	  also	  influences	  recombination	  frequency.	  The	  K359R	  mutation	  was	  therefore	  considered	  an	  important	  poliovirus	  RdRp	  variant	  that	  required	  investigating	  in	  this	  study.	  




Figure	  5.1:	  The	  general	  acid	  employed	  in	  RNA	  catalysis	  Nucleoside	  triphosphate	  (yellow)	  enters	  the	  active	  site	  with	  a	  divalent	  cation	  (Mg2+,	  metal	  B).	  This	  metal	  ion	  is	  coordinated	  by	  the	  phosphates	  of	  the	  nucleotide,	  an	  Asp	  residue	  located	  in	  structural	  motif	  A	  of	  all	  polymerases.	  Metal	  B	  orientates	  the	  triphosphate	  in	  the	  active	  site.	  A	  second	  divalent	  cation	  binds	  (Mg2+,	  metal	  A)	  that	  is	  coordinated	  by	  the	  3′-­‐OH	  of	  the	  nascent	  RNA	  (blue),	  the	  nucleotide	  α-­‐phosphate,	  as	  well	  as	  Asp	  residues	  of	  structural	  motifs	  A	  and	  C.	  Metal	  A	  lowers	  the	  pKa	  of	  the	  3′-­‐OH	  facilitating	  de-­‐protonation	  and	  subsequent	  nucleophilic	  attack	  at	  physiological	  pH.	  As	  the	  transition	  state	  of	  nucleotidyl	  transfer	  is	  approached	  (indicated	  by	  dashed	  red	  lines),	  the	  nascent	  RNA	  3′-­‐OH	  proton,	  Ha,	  is	  transferred	  to	  an	  unidentified	  base	  (B).	  The	  model	  suggests	  that	  the	  pyrophosphate-­‐leaving	  group	  is	  protonated	  (Hb)	  by	  a	  basic	  amino	  acid	  on	  the	  enzyme.	  The	  positions	  of	  the	  candidate	  general	  acids	  of	  the	  model	  polymerases	  are	  shown.	  DdDp	  =	  DNA	  dependent	  DNA	  polymerases.	  RT	  =	  reverse	  transcriptases.	  DdRp	  =	  DNA	  dependent	  RNA	  polymerases.	  Adapted	  with	  permission	  from	  Castro	  et	  al.,	  2009.	  	  	  
Figure 1. Extending the two-metal-ion mechanism of nucleotidyl transfer to include general acid
catalysis
Nucleoside triphosphate (yellow) nters the active site with a divalent cation (Mg2+, metal
B). This metal ion is coordinated by the phosphates of the nucleotide, an Asp residue located
in structural motif A of all polymerases, and likely water molecules (indicated as oxygen
ligands to metal without specific designation). Metal B orients the triphosphate in the active
site and may contribute to charge neutralization during catalysis. A second divalent cation
binds (Mg2+, metal A) that is coordinated by the 3′-OH of primer terminus (blue), the
nucleotide α-phosphate, as well as Asp residues of structural motifs A and C. Metal A
lowers the pKa of the 3′-OH facilitating deprotonation and subsequent nucleophilic attack at
physiological pH. As the transition state of nucleotidyl transfer is approached (indicated by
dashed red lines), the primer 3′-OH proton, Ha, is transferred to an unidentified base (B),
and we propose that the pyrophosphate leaving group is protonated (Hb) by a basic amino
acid on the enzyme. The positions of the candidate general acids of the model polymerases
employed in this study are shown.
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The	  K359R	  mutation	  was	  introduced	  into	  the	  PV1	  and	  PV3	  replicon	  cDNA	  (pRLucWT	  and	  pT7rep3-­‐L)	  along	  with	  the	  mutated	  CRE	  acceptor	  template	  (pT7FLC/SL3)	  by	  overlap	  extension	  PCR.	  All	  constructs	  were	  sequenced	  to	  verify	  the	  presence	  of	  the	  mutation	  and	  used	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  An	  initial	  luciferase	  assay	  was	  undertaken	  to	  look	  at	  the	  replication	  kinetics	  of	  the	  K359R	  variant	  compared	  to	  its	  wild	  type	  counterpart	  using	  both	  PV1	  and	  PV3	  replicons.	  HeLa	  cells	  in	  24	  well	  plates	  were	  transfected	  in	  duplicate	  wells	  with	  250	  ng	  of	  wild	  type	  RdRp	  replicon	  or	  replicon	  carrying	  the	  K359R	  mutation.	  Additional	  controls	  were	  also	  used,	  including	  a	  mock	  transfection	  and	  transfection	  in	  the	  presence	  of	  guanidine	  hydrochloride	  (an	  inhibitor	  of	  RNA	  replication).	  Samples	  were	  harvested	  at	  the	  time	  points	  indicated	  and	  luciferase	  activity	  was	  measured	  and	  normalised	  using	  a	  mock	  transfection	  control	  (figure	  5.2AB).	  	  The	  luciferase	  signal	  of	  the	  K359R	  RdRp	  variant	  replicons	  indicated	  that	  the	  K359R	  mutation	  was	  inhibiting	  replication	  when	  compared	  to	  the	  luciferase	  signal	  from	  a	  replicon	  with	  an	  unmodified	  RdRp.	  This	  was	  not	  surprising	  given	  that	  previous	  studies	  have	  shown	  this	  RdRp	  variant	  replicates	  at	  a	  speed	  around	  10-­‐fold	  slower	  than	  wild	  type	  (Weeks	  et	  al.,	  2012,	  Castro	  et	  al.,	  2009).	  After	  14	  hrs	  in	  both	  experiments	  the	  luciferase	  signal	  is	  ~30%	  of	  the	  unmodified	  replicons,	  consistent	  with	  a	  previous	  study	  (Weeks	  et	  al.,	  2012).	  It	  has	  to	  be	  noted	  that	  there	  was	  a	  definite	  ‘stalling’	  in	  replication	  with	  both	  mutant	  replicons	  between	  2-­‐6	  hrs	  when	  compared	  to	  unmodified	  replicon.	  The	  signals	  were	  however	  higher	  than	  the	  guanidine	  hydrochloride	  control	  that	  produced	  a	  luciferase	  signal	  based	  upon	  translation	  only,	  as	  replication	  was	  inhibited.	  This	  showed	  that	  the	  modified	  replicons	  were	  replicating,	  albeit	  at	  a	  lower	  level	  than	  the	  unmodified	  replicon.	  	  	  	  Both	  intratypic	  and	  intertypic	  combinations	  were	  then	  used	  in	  a	  CRE-­‐REP	  assay	  with	  the	  yield	  of	  recombinant	  virus	  produced	  when	  the	  K359R	  mutation	  is	  present	  compared	  to	  a	  wild	  type	  RdRp	  combination	  control.	  L929	  cells	  were	  seeded	  in	  12	  well	  plates	  and	  co-­‐transfected	  in	  triplicate	  wells	  with	  0.5	  μg	  of	  total	  RNA	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant),	  RNA	  pairings	  as	  shown	  in	  figure	  5.2CD.	  Cells	  were	  incubated	  for	  48	  hrs	  and	  then	  the	  transfection	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  60	  hrs	  incubation,	  cells	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were	  stained	  with	  crystal	  violet	  and	  virus	  titre	  was	  quantified.	  In	  both	  intratypic	  and	  intertypic	  CRE-­‐REP	  assays	  no	  recombinant	  virus	  was	  produced	  when	  the	  K359R	  mutation	  was	  present	  in	  the	  replicon	  (donor	  template)	  or	  in	  both	  templates	  (donor	  and	  acceptor).	  At	  the	  same	  time	  recombinant	  progeny	  was	  produced	  when	  wild-­‐type	  RdRp	  partners	  were	  present.	  This	  positive	  control	  indicated	  that	  the	  assay	  was	  functional.	  Many	  additional	  experiments	  were	  subsequently	  carried	  out	  that	  used	  an	  alternate	  rodent	  cell	  line	  (BsrT7)	  and	  various	  donor	  to	  acceptor	  RNA	  ratios.	  In	  all	  experiments	  no	  recombinant	  virus	  was	  identified	  when	  the	  K359R	  mutation	  was	  present.	  	  	  It	  was	  considered	  that	  the	  production	  of	  recombinant	  virus	  may	  have	  occurred	  but	  was	  below	  the	  level	  of	  detection.	  If	  any	  recombinant	  were	  produced	  it	  would	  have	  carried	  the	  K359R	  mutation,	  which	  slows	  replication	  and	  may	  not	  have	  been	  detectable	  in	  a	  plaque	  assay	  (Craig	  Cameron,	  personal	  communication).	  In	  order	  to	  answer	  this,	  additional	  controls	  were	  done.	  Transfection	  supernatant	  was	  also	  used	  in	  TCID50	  assays	  (section	  2.1.5)	  as	  a	  method	  to	  quantify	  recombinant	  virus.	  The	  control	  CRE-­‐REP	  assays	  (wild	  type	  RdRp	  partners)	  produced	  plaque	  assay,	  and	  TCID50	  results	  that	  correlated	  well	  (data	  not	  shown).	  In	  contrast,	  no	  recombinant	  virus	  was	  found	  in	  any	  TCID50	  assay	  when	  the	  K359R	  mutation	  was	  present.	  	  	  The	  K359R	  mutation	  in	  a	  full	  length	  poliovirus	  construct	  produces	  a	  titre	  of	  virus	  that	  is	  normally	  around	  one	  log10	  lower	  than	  wild	  type	  (Weeks	  et	  al.,	  2012).	  Potentially,	  this	  defect	  in	  replication	  alone	  could	  have	  accounted	  for	  the	  lack	  of	  recombinant	  virus	  seen	  in	  the	  intertypic	  CRE-­‐REP	  assay,	  which	  usually	  yields	  between	  80-­‐140	  pfu/ml.	  However,	  this	  fall	  in	  replication	  does	  not	  account	  for	  the	  lack	  of	  intratypic	  recombination	  that	  was	  observed.	  Intratypic	  yields	  in	  the	  CRE-­‐REP	  assay	  are	  typically	  over	  1000	  pfu/ml,	  we	  would	  therefore	  have	  expected	  to	  see	  recombinant	  virus	  even	  if	  replication	  were	  inhibited.	  Potentially,	  the	  K359R	  mutation	  that	  has	  a	  high	  fidelity	  phenotype	  that	  is	  linked	  to	  its	  slower	  replication	  rate	  is	  non-­‐recombinogenic.	  	  	  In	  order	  to	  compensate	  for	  any	  replication	  defect	  that	  the	  K359R	  mutation	  provides,	  and	  to	  consider	  recombination	  outside	  the	  current	  1.058	  Kb	  window	  a	  new	  approach	  to	  expand	  the	  region	  within	  which	  recombination	  could	  occur	  was	  developed.	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Figure	  5.2:	  Replication	  kinetics	  and	  recombination	  frequency	  of	  the	  RdRp	  K359R	  variant	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5.3 An	  expanded	  in	  vitro	  recombination	  assay	  	  The	  CRE-­‐REP	  assay	  has	  a	  region	  of	  recombination	  of	  1.058	  Kb	  that	  is	  determined	  by	  the	  lesions	  that	  are	  present	  in	  the	  donor	  and	  acceptor	  templates	  (described	  in	  section	  3.1).	  The	  function	  of	  the	  2C	  CRE	  in	  poliovirus	  is	  not	  location	  specific.	  A	  previous	  study	  has	  shown	  that	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  hyper-­‐variable	  region	  of	  the	  5’NTR	  of	  the	  CRE	  mutated	  genome	  SL3	  rescues	  replication	  (Goodfellow	  et	  al.,	  2003a).	  Additionally,	  the	  positioning	  of	  a	  native	  CRE	  within	  the	  3’NTR	  of	  FMDV	  (normally	  found	  within	  the	  5’NTR)	  rescues	  replication	  of	  a	  CRE	  defective	  virus	  (Mason	  et	  al.,	  2002).	  	  	  
Mutation	  of	  the	  native	  CRE	  and	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  3’NTR	  of	  PV1	  
	  By	  manipulating	  the	  position	  of	  the	  CRE	  in	  the	  PV1	  replicon	  (pRLucWT)	  a	  new	  intertypic	  recombination	  assay	  was	  developed.	  Eight	  synonymous	  mutations,	  similar	  to	  the	  ones	  put	  into	  the	  pT7FLC/SL3	  template	  (Goodfellow	  et	  al.,	  2000)	  were	  incorporated	  into	  pRLucWT	  by	  a	  process	  of	  overlap	  extension	  PCR	  (figure	  5.3A).	  This	  ensured	  that	  the	  amino-­‐acid	  coding	  region	  of	  2C	  was	  maintained,	  but	  the	  secondary	  structure	  of	  the	  RNA	  in	  this	  area	  was	  affected.	  The	  presence	  of	  the	  desired	  mutations	  was	  verified	  by	  sequencing,	  with	  the	  predicted	  affect	  upon	  secondary	  RNA	  structure	  of	  the	  critical	  CRE	  stem-­‐loop	  shown	  in	  figure	  5.3B.	  This	  was	  called	  pRLucΔCRE.	  A	  unique	  restriction	  enzyme	  site,	  BssHII,	  was	  then	  introduced	  into	  the	  3’NTR	  of	  the	  pRLucΔCRE	  directly	  after	  the	  termination	  codon	  by	  overlap	  extension	  PCR.	  A	  34	  nt	  synthetic	  CRE	  shown	  to	  restore	  replication	  in	  poliovirus	  (Goodfellow	  et	  al.,	  2003a)	  was	  then	  cloned	  into	  the	  cDNA	  by	  use	  of	  the	  BssHII	  restriction	  enzyme	  site	  (figure	  5.4).	  Two	  complementary	  oligonucleotides	  carrying	  the	  required	  sequences	  with	  complementary	  ‘sticky’	  ends	  of	  a	  cleaved	  
BssHII	  restriction	  enzyme	  site	  were	  annealed	  and	  used	  as	  templates	  (see	  table	  2.4).	  The	  decision	  to	  use	  a	  synthetic	  CRE	  that	  is	  smaller	  and	  different	  in	  sequence	  to	  the	  native	  CRE	  was	  done	  to	  avoid	  duplicated	  sequences	  in	  the	  virus	  genome.	  Importantly,	  the	  design	  of	  the	  3’NTR	  CRE	  replicon	  was	  predicted	  not	  to	  alter	  the	  native	  3’NTR	  structure,	  including	  the	  important	  X	  and	  Y	  stems	  (Rohll	  et	  al.,	  1995).	  The	  cDNA	  was	  verified	  by	  sequencing	  and	  was	  called	  pRLucΔCRE_3’CRE.	  To	  ensure	  that	  this	  modification	  did	  not	  compromise	  replication,	  a	  luciferase	  time-­‐course	  assay	  was	  carried	  out	  (figure	  5.5).	  Oligonucleotides	  that	  were	  used	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Figure	  5.3:	  Sequence	  alignment	  and	  predicted	  secondary	  structure	  of	  wild	  type	  and	  
mutagenized	  PV1	  CRE	  stem	  loop	  	  
(A)	  Alignment	  of	  native	  PV1	  2C	  CRE	  and	  mutated	  PV1	  2C	  CRE	  bearing	  8	  synonymous	  mutations,	  shown	  in	  red.	  Stars	  and	  numbering	  indicate	  position	  within	  the	  PV1	  Mahoney	  genome.	  The	  CAAACA	  motive	  that	  is	  required	  for	  CRE	  dependent	  VPg	  uridylylation	  is	  shown	  underlined.	  (B)	  Wild-­‐type	  PV1	  CRE	  structure	  (left)	  and	  the	  predicted	  mutated	  PV1	  CRE	  structure	  (right)	  created	  by	  MFold	  (Zuker	  and	  Stiegler,	  1981).	  Numbering	  from	  1-­‐61	  based	  upon	  first	  and	  final	  nt	  in	  the	  stem-­‐loop	  structure.	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Figure	  5.4:	  Predicted	  secondary	  structure	  of	  the	  3’NTR	  of	  FLCΔCRE_3’CRE	  and	  
pRLucΔCRE_3’CRE	  following	  insertion	  of	  a	  synthetic	  CRE.	  MFold	  predicted	  structure	  of	  the	  CRE	  modified	  3’NTR.	  Numbering	  from	  1-­‐133,	  beginning	  from	  the	  termination	  codon	  UAG	  (boxed).	  A	  synthetic	  CRE	  known	  as	  Synth3	  (Goodfellow	  et	  al.,	  2003a)	  along	  with	  a	  unique	  BssHII	  restriction	  enzyme	  site	  are	  located	  after	  the	  termination	  codon.	  BssHII	  restriction	  sequence	  as	  indicated.	  Predicted	  structures	  of	  stem	  X	  and	  Y	  are	  also	  indicated	  (Rohll	  et	  al.,	  1995).
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in	  all	  of	  the	  constructs	  can	  be	  found	  in	  section	  2.9.	  L929	  cells	  in	  12	  well	  plates	  were	  transfected	  with	  RNA	  as	  indicated.	  Samples	  were	  harvested	  at	  various	  time-­‐points	  and	  luciferase	  activity	  was	  measured	  and	  normalised	  using	  a	  mock	  transfection	  control.	  The	  RLucΔCRE	  template	  produced	  a	  luciferase	  signal	  over	  time	  that	  was	  very	  similar	  to	  the	  controls,	  which	  had	  been	  incubated	  with	  guanidine	  hydrochloride	  indicating	  that	  this	  was	  from	  translation	  only.	  This	  chemical,	  as	  previously	  described,	  is	  a	  reversible	  inhibitor	  of	  RNA	  replication	  (Pfister	  and	  Wimmer,	  1999).	  As	  expected,	  this	  result	  indicated	  that	  the	  synonymous	  mutations	  introduced	  into	  the	  2C	  CRE	  had	  indeed	  inhibited	  RNA	  replication.	  The	  RNA	  generated	  from	  pRLucΔCRE_3’CRE	  in	  contrast,	  produced	  a	  luciferase	  signal	  over	  time	  that	  was	  slightly	  higher	  than	  the	  RLucWT,	  indicating	  that	  it	  was	  replication	  competent.	  This	  demonstrated	  that	  the	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  3’NTR	  does	  not	  significantly	  influence	  replication.	  	  	  To	  further	  validate	  the	  results	  obtained	  in	  the	  luciferase	  assay	  it	  was	  decided	  to	  introduce	  the	  same	  modifications	  into	  a	  PV1	  full-­‐length	  clone	  to	  characterise	  their	  effect.	  This	  was	  felt	  important,	  as	  the	  luciferase	  assay	  is	  an	  indirect	  way	  to	  measure	  RNA	  replication	  only.	  Potentially,	  the	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  3’NTR	  could	  have	  had	  an	  effect	  on	  packaging	  of	  the	  viral	  RNA.	  This	  was	  done	  in	  a	  similar	  process	  to	  the	  PV1	  replicon.	  Briefly,	  overlap	  extension	  PCR	  was	  used	  to	  introduce	  the	  8	  synonymous	  mutations	  into	  a	  PCR	  product.	  The	  PCR	  product	  was	  then	  sub-­‐cloned	  into	  the	  PV1	  Mahoney	  full-­‐length	  clone	  background	  using	  the	  unique	  restriction	  enzyme	  sites	  NheI	  and	  BglII.	  This	  produced	  an	  intermediate	  known	  as	  pPV1FLCΔCRE,	  analogous	  to	  pT7FLC/SL3.	  The	  3’NTR	  region	  of	  the	  pRLucΔCRE_3’CRE	  was	  then	  sub-­‐cloned	  into	  the	  intermediate	  pPV1FLCΔCRE	  by	  use	  of	  the	  unique	  restriction	  enzyme	  sites	  
ApaI	  and	  BglII.	  This	  produced	  the	  final	  pFLCΔCRE_3’CRE	  construct	  which	  was	  verified	  by	  sequencing	  and	  restriction	  enzyme	  digestion.	  An	  experiment	  was	  carried	  out	  that	  compared	  virus	  yields	  from	  a	  wild	  type	  virus	  and	  a	  CRE	  modified	  version.	  The	  PV1	  full-­‐length	  clone,	  pPV1FLCΔCRE	  and	  pFLCΔCRE_3’CRE	  were	  linearised	  with	  the	  restriction	  enzyme	  ApaI	  and	  used	  as	  templates	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  L929	  cells	  in	  a	  12	  well	  plate	  were	  transfected	  individually	  with	  250	  ng	  RNA	  in	  triplicate	  wells	  and	  left	  to	  incubate	  for	  48	  hrs.	  Dilutions	  of	  transfection	  supernatant	  were	  then	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	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Figure	  5.6:	  Synthetic	  CRE	  in	  the	  3’NTR	  of	  PV1FLCΔCRE	  restores	  replication	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plaque	  assays.	  Cells	  were	  incubated	  for	  60	  hrs,	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  5.6).	  As	  expected	  the	  PV1FLCΔCRE	  transfection	  supernatant	  produced	  no	  plaques,	  which	  indicated	  no	  virus	  was	  present	  (data	  not	  shown),	  in	  agreement	  with	  the	  same	  mutations	  that	  were	  introduced	  into	  a	  PV3	  virus	  (Goodfellow	  et	  al.,	  2000).	  This	  supported	  the	  luciferase	  assay	  produced	  from	  the	  replicon	  containing	  the	  same	  2C	  CRE	  mutations.	  Blind	  passage	  of	  the	  supernatant	  was	  subsequently	  done	  five	  times,	  and	  no	  virus	  was	  found.	  The	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  3’NTR	  of	  the	  PV1FLCΔCRE	  rescued	  replication,	  as	  indicated	  by	  the	  formation	  of	  plaques.	  The	  RNA	  generated	  from	  pFLCΔCRE	  _3’CRE	  produced	  a	  yield	  of	  virus	  that	  was	  almost	  identical	  to	  the	  yield	  from	  the	  PV1	  wild	  type	  RNA.	  In	  addition,	  there	  was	  no	  discernable	  difference	  in	  plaque	  phenotype.	  This	  result	  fully	  supported	  the	  luciferase	  time-­‐course	  assay	  and	  indicated	  that	  the	  CRE	  can	  be	  positioned	  into	  the	  3’NTR	  without	  affecting	  viability	  and	  yield	  of	  the	  virus	  from	  a	  single	  transfection.	  	  	  However,	  it	  remained	  to	  be	  determined	  if	  re-­‐positioning	  of	  the	  CRE	  had	  any	  affect	  in	  a	  mixed	  infection	  environment.	  It	  was	  therefore	  deemed	  necessary	  to	  carry	  out	  a	  competition	  assay,	  which	  included	  wild-­‐type	  virus	  and	  the	  re-­‐positioned	  CRE	  variant.	  If	  there	  were	  any	  subtle	  differences	  in	  replication	  capability	  then	  this	  type	  of	  assay	  would	  highlight	  it.	  HeLa	  cells	  in	  T20	  flasks	  were	  infected	  at	  an	  M.O.I	  of	  10	  at	  a	  ratio	  of	  1:1,	  10:1	  and	  1:10	  (PV1	  wild	  type	  virus:	  FLCΔCRE_3’CRE	  virus).	  Each	  was	  serially	  passaged	  five	  times.	  RNA	  was	  extracted	  from	  passage	  1	  and	  5	  respectively	  and	  a	  region	  that	  covered	  the	  native	  2C	  CRE	  region	  was	  amplified	  by	  RT-­‐PCR	  using	  the	  forward	  primer	  PV1/3-­‐3280F	  and	  reverse	  primer	  PV1-­‐5440R.	  An	  equal	  mass	  of	  PCR	  product	  was	  then	  run	  on	  a	  1%	  agarose	  gel	  (figure	  5.7A).	  The	  PCR	  products	  from	  each	  sample,	  as	  well	  as	  the	  controls,	  migrated	  to	  a	  similar	  position	  on	  the	  gel,	  as	  expected.	  The	  introduction	  of	  the	  8	  synonymous	  mutations	  into	  the	  native	  CRE	  also	  introduced	  a	  unique	  SwaI	  restriction	  enzyme	  site	  (Goodfellow	  et	  al.,	  2000).	  This	  site	  was	  used	  to	  screen	  the	  relative	  proportion	  of	  wild	  type	  virus	  to	  CRE	  modified	  virus	  in	  a	  mixed	  population	  infection.	  An	  equal	  mass	  of	  each	  PCR	  product	  was	  incubated	  with	  the	  SwaI	  restriction	  enzyme	  then	  run	  on	  a	  1%	  agarose	  gel	  (figure	  5.7B).	  The	  controls	  indicated	  that	  this	  restriction	  enzyme	  is	  unique	  to	  the	  FLCΔCRE_3’CRE	  virus	  as	  this	  PCR	  product	  was	  cut	  to	  produce	  two	  bands	  and	  the	  wild	  type	  virus	  PCR	  product	  did	  not.	  	  










Figure	  5.7:	  PV1FLC	  and	  FLCΔCRE_3’CRE	  competition	  assay	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Additionally,	  the	  controls	  show	  that	  sufficient	  enzyme	  was	  present	  to	  cut	  all	  available	  restriction	  sites.	  The	  1:1	  ratio	  infection	  PCR	  product	  following	  restriction	  enzyme	  screening	  produced	  banding	  with	  no	  visual	  difference	  in	  density	  from	  passage	  1	  and	  passage	  5.	  This	  indicated	  that	  the	  modified	  virus	  (FLCΔCRE_3’CRE)	  was	  present	  and	  competed	  well	  with	  the	  wild	  type	  virus.	  The	  1:10	  and	  10:1	  ratio	  infections	  also	  produced	  banding	  patterns	  that	  inferred	  that	  the	  FLCΔCRE_3’CRE	  virus	  competed	  well	  in	  a	  mixed	  infection	  environment.	  Taken	  together,	  these	  results	  show	  that	  positioning	  of	  a	  synthetic	  CRE	  into	  the	  3’NTR	  of	  poliovirus	  does	  not	  affect	  replication	  and	  the	  virus’s	  ability	  to	  compete.	  	  	  By	  positioning	  a	  synthetic	  CRE	  sequence	  within	  the	  3’NTR	  of	  the	  RLucΔCRE	  replication	  was	  rescued	  and	  this	  modification	  was	  shown	  to	  have	  no	  affect	  upon	  the	  overall	  replication	  of	  a	  full-­‐length	  clone	  carrying	  the	  same	  alterations.	  The	  new	  replicon	  RLucΔCRE_3’CRE	  could	  therefore	  be	  used	  as	  a	  donor	  template	  that	  allowed	  for	  an	  expanded	  intertypic	  CRE-­‐REP	  assay	  hereafter	  termed	  3’-­‐CRE-­‐REP.	  The	  acceptor	  template	  remained	  the	  same	  as	  in	  the	  CRE-­‐REP	  assay	  (SL3).	  The	  functional	  synthetic	  CRE	  sequence	  in	  the	  3’NTR	  of	  the	  replicon	  would	  be	  incorporated	  after	  initiation	  of	  anti-­‐sense	  RNA	  synthesis,	  any	  template	  exchange	  to	  SL3	  past	  this	  point	  would	  potentially	  produce	  a	  viable	  recombinant	  genome	  (figure	  5.8).	  This	  increased	  the	  potential	  region	  of	  recombination	  from	  1.058	  Kb	  (CRE-­‐REP)	  to	  4.1	  Kb,	  incorporating	  the	  entire	  P2	  and	  P3	  non-­‐structural	  coding	  region.	  	  	  An	  assay	  was	  carried	  out	  to	  determine	  if	  the	  3’-­‐CRE-­‐REP	  approach	  increased	  recombinant	  progeny	  yield	  when	  compared	  to	  the	  control	  CRE-­‐REP	  assay.	  Expectations	  were	  that	  the	  3’-­‐CRE-­‐REP	  assay	  would	  produce	  more	  recombinant	  progeny	  than	  the	  CRE-­‐REP,	  and	  this	  would	  correlate	  with	  the	  increased	  region	  of	  recombination.	  L929	  cells	  in	  12	  well	  plates	  were	  co-­‐transfected	  in	  triplicate	  wells	  with	  intertypic	  partners	  (CRE-­‐REP	  and	  3’-­‐CRE-­‐REP).	  An	  additional	  co-­‐transfection	  control	  involving	  the	  RNA	  partners	  RLucΔCRE	  and	  SL3	  was	  also	  done.	  Total	  RNA	  was	  0.5	  μg	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant	  genome).	  Cells	  were	  incubated	  for	  48	  hrs	  and	  the	  transfection	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  60	  hrs	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  photographed	  (figure	  5.9).	  Additional	  single	  transfection	  controls	  were	  also	  carried	  out	  (data	  not	  shown).	  







Figure	  5.8:	  Expansion	  of	  the	  original	  CRE-­‐REP	  assay	  
(A)	  Original	  CRE-­‐REP	  assay,	  see	  chapter	  3	  for	  description	  (B)	  Expanded	  CRE-­‐REP	  assay	  known	  as	  3’-­‐CRE-­‐REP.	  The	  upper	  genome	  (dark	  shading)	  bearing	  a	  defective	  CRE	  indicated	  as	  a	  broken	  line	  with	  a	  superimposed	  X	  in	  the	  2C-­‐coding	  region	  and	  a	  luciferase-­‐encoding	  replicon	  (light	  shading)	  that	  also	  bears	  a	  defective	  2C	  CRE.	  The	  sub-­‐genomic	  replicon	  has	  a	  3’NTR	  CRE	  as	  indicated	  by	  an	  intact	  stem.	  Following	  co-­‐transfection	  into	  permissive	  cells	  (indicated	  by	  an	  arrow),	  a	  replication	  competent	  recombinant	  genome	  may	  be	  recovered	  of	  the	  generic	  structure	  shown,	  consisting	  of	  the	  5’	  part	  of	  the	  genome	  derived	  from	  the	  CRE-­‐defective	  parent	  (the	  acceptor)	  and	  the	  3’	  part	  of	  the	  genome	  from	  the	  luciferase-­‐encoding	  replicon	  (the	  donor).	  This	  modification	  increases	  the	  potential	  ‘zone’	  of	  recombination	  from	  1.058Kb	  to	  4.1Kb.	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Figure	  5.9:	  3’-­‐CRE-­‐REP	  intertypic	  in	  vitro	  recombination	  assay	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As	  expected	  the	  co-­‐transfection	  with	  RLucΔCRE	  and	  SL3	  yielded	  no	  recombinant	  virus,	  showing	  that	  the	  presence	  of	  a	  functional	  CRE	  from	  one	  parental	  genome	  is	  required.	  The	  yield	  of	  recombinant	  progeny	  from	  the	  intertypic	  CRE-­‐REP	  assay	  was	  broadly	  in	  line	  with	  previous	  results	  averaging	  at	  157	  pfu/ml.	  This	  control	  showed	  that	  the	  conditions	  for	  any	  recombination	  assay	  were	  satisfactory.	  In	  contrast	  the	  intertypic	  3’-­‐CRE-­‐REP	  assay	  produced	  a	  yield	  of	  recombinant	  progeny	  that	  averaged	  at	  920	  pfu/ml,	  a	  5.85	  fold	  increase	  when	  compared	  to	  the	  CRE-­‐REP	  assay,	  larger	  than	  expected.	  Subsequent	  repeated	  experiments	  found	  the	  increase	  in	  yield	  to	  be	  reproducible	  and	  consistent	  (data	  not	  shown).	  A	  large	  in-­‐depth	  study	  upon	  the	  type	  of	  intertypic	  recombinant	  virus	  isolated	  from	  the	  3’-­‐CRE-­‐REP	  is	  being	  conducted	  in	  collaboration	  with	  a	  colleague,	  Fadi	  Alnaji.	  The	  aim	  of	  this	  work	  is	  to	  identify	  and	  characterise	  the	  recombinant	  junctions	  across	  the	  4.1	  Kb	  window.	  This	  in	  principle	  will	  identify	  any	  link	  between	  RNA	  sequence	  and	  structure	  that	  may	  determine	  the	  location	  of	  recombination.	  	  
5.4 K359R	  high	  fidelity	  RdRp	  variant	  in	  the	  3’-­‐CRE-­‐REP	  assay	  	  As	  described	  in	  section	  5.2,	  the	  K359R	  RdRp	  variant	  typically	  reduces	  replication	  rates	  by	  around	  1	  log10	  when	  compared	  to	  wild	  type	  (Weeks	  et	  al.,	  2012).	  This	  could	  have	  explained	  why	  no	  intertypic	  recombinant	  was	  isolated	  from	  the	  CRE-­‐REP	  assay	  when	  the	  mutation	  was	  present	  in	  the	  donor	  and	  acceptor	  templates.	  It	  was	  hoped	  that	  the	  near	  six-­‐fold	  increase	  in	  recombinant	  progeny	  observed	  in	  the	  3’-­‐CRE-­‐REP	  would	  overcome	  any	  replication	  defect	  that	  the	  K359R	  variant	  provides.	  The	  K359R	  mutation	  was	  therefore	  introduced	  into	  the	  pRLucΔCRE_3’CRE	  by	  overlap	  extension	  PCR	  using	  the	  unique	  restriction	  enzyme	  sites	  BglII	  and	  
ApaI.	  The	  construct	  was	  verified	  by	  sequencing	  the	  entire	  sub-­‐cloned	  region.	  The	  cDNA	  carrying	  the	  K359R	  mutation	  was	  then	  linearised	  with	  ApaI	  and	  the	  template	  was	  used	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  An	  experiment	  was	  carried	  out	  that	  measured	  the	  yield	  of	  intertypic	  recombinant	  virus	  produced	  when	  the	  K359R	  mutation	  was	  present	  compared	  to	  a	  wild	  type	  RdRp	  combination	  control.	  L929	  cells	  in	  a	  12	  well	  plate	  were	  co-­‐transfected	  in	  triplicate	  wells	  with	  3’-­‐CRE-­‐REP	  partners.	  An	  additional	  co-­‐transfection	  involving	  3’-­‐CRE-­‐REP	  partners	  carrying	  the	  K359R	  mutation	  was	  also	  done.	  Total	  RNA	  was	  0.5	  μg	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant	  genome).	  Cells	  were	  incubated	  for	  48	  hrs	  and	  then	  the	  transfection	  supernatant	  was	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used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  60	  hrs	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  recombinant	  progeny	  quantified	  (figure	  5.10).	  The	  control	  co-­‐transfection	  produced	  a	  yield	  of	  recombinant	  virus	  broadly	  in	  line	  with	  previous	  results	  and	  averaged	  1200	  pfu/ml.	  This	  indicated	  that	  the	  conditions	  for	  the	  assay	  were	  satisfactory.	  No	  recombinant	  virus	  was	  identified	  from	  the	  K359R	  variant	  co-­‐transfection	  supernatant.	  The	  supernatant	  from	  this	  experiment	  was	  further	  analysed	  by	  TCID50.	  The	  results	  of	  the	  control	  TCID50	  correlated	  well	  with	  the	  plaque	  assay	  results.	  No	  virus	  was	  identified	  with	  the	  K359R	  samples.	  This	  experiment	  was	  repeated	  and	  produced	  similar	  results	  (data	  not	  shown).	  	  	  
5.5 RdRp	  variant	  D79H-­‐Y275H	  	  During	  the	  course	  of	  this	  investigation	  additional	  RdRp	  mutations	  that	  were	  considered	  important	  in	  poliovirus	  recombination	  were	  made	  available.	  The	  Raul	  Andino	  research	  group	  at	  the	  University	  of	  California,	  San	  Francisco,	  U.S.A.	  isolated	  poliovirus	  variants	  from	  an	  assay	  that	  were	  unable	  to	  recombine.	  The	  Andino	  group	  identified	  mutations	  within	  the	  RdRp	  coding	  sequence	  that	  were	  considered	  important.	  Selection	  of	  the	  RdRp	  variants	  was	  done	  by	  a	  green	  
fluorescent	  protein	  (GFP)	  retention	  assay.	  In	  the	  assay,	  a	  poliovirus	  construct,	  which	  has	  the	  GFP	  reporter	  gene	  inserted	  between	  the	  VP1	  and	  2A	  genes,	  is	  used	  to	  infect	  HeLa	  cells.	  Normally,	  the	  GFP	  reporter	  gene	  is	  rapidly	  lost	  following	  serial	  passage	  in	  HeLa	  cells	  in	  a	  process	  that	  is	  analogous	  to	  the	  ‘resolution’	  stage	  of	  recombination	  outlined	  in	  chapter	  three.	  Using	  a	  process	  of	  fluorescence-­‐activated	  cell	  sorting	  (FACS),	  cells	  that	  retain	  expression	  of	  the	  GFP	  were	  isolated	  (infected	  with	  virus	  that	  has	  not	  lost	  the	  GFP	  coding	  gene).	  Subsequent	  isolation	  and	  characterisation	  of	  the	  poliovirus	  RNA	  identified	  two	  mutations	  that	  were	  present	  in	  the	  RdRp	  coding	  region,	  D79H	  and	  Y275H	  respectively.	  These	  mutations	  were	  considered	  important	  because	  they	  were	  the	  only	  ones	  found	  in	  the	  RdRp	  consensus	  sequence	  produced	  (Raul	  Andino,	  personal	  communication).	  The	  mutations	  were	  isolated	  from	  a	  PV1	  Mahoney	  background,	  but	  the	  residues	  identified	  are	  conserved	  in	  all	  poliovirus	  strains.	  It	  was	  therefore	  considered	  important	  to	  characterise	  these	  mutations	  in	  the	  CRE-­‐REP	  assay	  and	  also	  in	  the	  molecular	  clone	  JC105B,	  which	  was	  used	  in	  this	  study	  to	  look	  at	  the	  resolution	  stage	  of	  recombination.	  The	  mutations	  were	  introduced	  into	  the	  PV1	  replicon	  (pRLucWT)	  individually	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and	  dually	  by	  overlap	  extension	  PCR	  using	  the	  unique	  restriction	  enzymes	  BglII	  and	  ApaI.	  This	  produced	  the	  replicons	  pRLuc-­‐D79H,	  pRLuc-­‐Y275H	  and	  pRLuc-­‐D79H-­‐Y275H.	  The	  presence	  of	  all	  mutations	  was	  verified	  by	  sequencing	  of	  the	  constructs.	  All	  three	  were	  linearised	  with	  the	  restriction	  enzyme	  ApaI	  and	  templates	  were	  used	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  A	  luciferase	  assay	  was	  carried	  out	  to	  characterise	  the	  effect	  of	  the	  mutations	  on	  replication.	  L929	  cells	  in	  12	  well	  plates	  were	  transfected	  with	  250	  ng	  of	  replicon	  RNA	  in	  duplicate	  wells.	  Luciferase	  activity	  was	  measured	  and	  normalised	  using	  a	  mock	  transfection	  control	  (figure	  5.11).	  The	  D79H	  mutation	  reduced	  luciferase	  signal	  to	  56%	  of	  wild	  type	  and	  the	  Y275H	  mutation	  reduced	  luciferase	  signal	  to	  36%	  of	  wild	  type	  at	  7.5	  hrs	  post	  transfection.	  When	  both	  mutations	  are	  present,	  overall	  replication	  at	  7.5	  hrs	  was	  reduced	  to	  31%	  of	  wild	  type.	  	  	  The	  replicons	  used	  in	  the	  luciferase	  assay	  were	  then	  introduced	  into	  a	  CRE-­‐REP	  assay,	  with	  the	  wild	  type	  intertypic	  partners	  considered	  as	  the	  control.	  L929	  cells	  in	  12	  well	  plates	  were	  co-­‐transfected	  in	  triplicate	  wells	  with	  0.5	  μg	  of	  total	  RNA	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant),	  RNA	  partners	  as	  indicated	  (figure	  5.12A).	  Cells	  were	  incubated	  for	  48	  hrs	  and	  then	  the	  transfection	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  60	  hrs	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  recombinant	  yield	  was	  quantified.	  When	  the	  D79H	  mutation	  was	  present	  in	  the	  donor	  replicon	  template	  recombination	  progeny	  yield	  fell	  to	  57%	  of	  wild	  type,	  in	  line	  with	  the	  fall	  in	  replication	  that	  was	  characterised	  in	  the	  luciferase	  assay.	  When	  the	  Y275H	  mutation	  was	  present	  alone	  or	  in	  combination	  with	  the	  D79H	  mutation	  in	  the	  donor	  replicon	  template	  no	  recombinant	  progeny	  was	  recovered.	  The	  supernatant	  was	  additionally	  subjected	  to	  a	  TCID50	  assay,	  which	  produced	  results	  in	  line	  with	  the	  plaque	  assay	  (data	  not	  shown).	  This	  result	  suggested	  that	  the	  presence	  of	  the	  Y275H	  mutation	  in	  the	  donor	  template	  alone	  might	  have	  been	  enough	  to	  inhibit	  recombination.	  	  	  For	  completeness	  the	  D79H	  and	  Y275H	  mutations	  were	  also	  introduced	  into	  the	  acceptor	  template	  pT7FLC/SL3	  by	  overlap	  extension	  PCR	  using	  the	  unique	  restriction	  enzyme	  sites	  XhoI	  and	  SalI.	  The	  presence	  of	  the	  mutations	  was	  confirmed	  by	  sequencing.	  This	  template	  was	  also	  	  








Figure	  5.11:	  pRLucWT	  replicon	  bearing	  a	  D79H	  and/or	  Y275H	  RdRp	  luciferase	  time-­‐
course	  

















































Figure	  5.12:	  Intertypic	  CRE-­‐REP	  assay	  with	  D79H	  and	  Y275H	  RdRp	  variants	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introduced	  into	  the	  CRE-­‐REP	  assay	  using	  a	  similar	  protocol	  outlined	  previously	  in	  this	  section.	  As	  expected	  no	  recombinant	  virus	  was	  isolated	  from	  co-­‐transection	  supernatant	  when	  both	  mutations	  were	  in	  the	  donor	  and	  recipient	  templates	  (figure	  5.12B).	  	  	  
5.6 Y275H	  variant	  in	  the	  intratypic	  CRE-­‐REP	  assay	  	  The	  results	  from	  the	  intertypic	  CRE-­‐REP	  assay	  suggested	  that	  the	  Y275H	  mutation	  in	  the	  donor	  template	  was	  sufficient	  to	  inhibit	  recombination.	  The	  Y275H	  mutation	  was	  subsequently	  introduced	  into	  the	  PV3	  replicon	  donor	  cDNA	  (pT7rep3-­‐L)	  and	  acceptor	  cDNA	  (pT7FLC/SL3)	  by	  overlap	  extension	  PCR	  using	  the	  unique	  restriction	  enzyme	  sites	  XhoI	  and	  SalI.	  All	  constructs	  were	  verified	  by	  sequencing.	  Plasmids	  were	  linearised	  with	  the	  restriction	  enzyme	  SalI	  and	  used	  as	  templates	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  The	  replication	  kinetics	  of	  the	  Y275H	  replicon	  variant	  was	  compared	  to	  the	  wild	  type	  RdRp	  replicon	  in	  a	  luciferase	  time	  course	  assay.	  L929	  cells	  in	  12	  well	  plates	  were	  transfected	  with	  250	  ng	  of	  Rep3-­‐L	  or	  the	  Y275H	  variant	  in	  duplicate	  with	  samples	  taken	  at	  the	  times	  indicated.	  Luciferase	  activity	  was	  measured	  and	  normalised	  using	  a	  mock	  transfection	  control	  (figure	  5.13A).	  The	  Y275H	  mutation	  had	  a	  similar	  inhibitory	  effect	  upon	  replication	  as	  the	  K359R	  mutation	  characterised	  in	  section	  5.2.	  The	  luciferase	  activity	  of	  the	  Y275H	  replicon	  at	  7.5	  hrs	  was	  one	  log10	  lower	  than	  the	  wild	  type	  RdRp	  replicon,	  a	  larger	  decrease	  in	  replication	  than	  that	  observed	  in	  a	  PV1	  replicon	  background.	  However,	  the	  replication	  defect	  that	  the	  Y275H	  provides	  would	  have	  been	  overcome,	  as	  recombinant	  progeny	  yields	  from	  the	  intratypic	  CRE-­‐REP	  assay	  are	  typically	  1-­‐2	  log10	  higher	  than	  the	  intertypic	  CRE-­‐REP.	  A	  subsequent	  CRE-­‐REP	  assay	  was	  therefore	  carried	  out.	  It	  was	  reasoned	  that	  if	  replication	  were	  inhibited	  by	  one	  log10	  then	  recombination	  frequency	  would	  fall	  by	  a	  similar	  amount	  if	  the	  mutation	  had	  no	  effect	  upon	  template	  switching.	  Three	  separate	  co-­‐transfections	  were	  carried	  out	  in	  triplicate.	  The	  control	  co-­‐transfection	  consisted	  of	  RNA	  from	  the	  wild	  type	  intratypic	  CRE-­‐REP	  partners	  (Rep3-­‐L	  and	  SL3).	  The	  remaining	  two	  conditions	  had	  the	  Y275H	  mutation	  present	  in	  the	  donor	  template	  only	  or	  in	  both	  donor	  and	  acceptor	  templates.	  L929	  cells	  in	  12	  well	  plates	  were	  co-­‐transfected	  with	  0.5	  μg	  of	  total	  RNA	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant).	  Cells	  were	  incubated	  for	  48	  hrs	  and	  then	  the	  transfection	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  









Figure	  5.13:	  Luciferase	  and	  intratypic	  CRE-­‐REP	  assay	  with	  Y275H	  RdRp	  variant	  
(A)	  Replication	  kinetics	  of	  a	  PV3	  sub-­‐genomic	  replicon	  (Rep3-­‐L)	  bearing	  either	  a	  Y275H	  polymerase	  mutation.	  250ng	  of	  RNA	  as	  indicated	  were	  transfected	  into	  L929	  cells.	  Samples	  were	  taken	  at	  the	  times	  indicated	  and	  luciferase	  activity	  was	  measured	  and	  normalised	  using	  a	  mock	  transfected	  control.	  Error	  bars	  indicate	  standard	  deviation	  of	  two	  independent	  samples	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Following	  60	  hrs	  incubation,	  cells	  were	  stained	  with	  crystal	  violet	  and	  recombinant	  progeny	  was	  quantified	  (figure	  5.13B).	  The	  control	  transfection	  yielded	  an	  average	  of	  1300	  pfu/ml,	  in	  line	  with	  previous	  results.	  Recombinant	  progeny	  was	  produced	  when	  the	  Y275H	  mutation	  was	  present	  in	  the	  donor	  template	  alone.	  The	  yield	  was	  only	  4.1%	  of	  the	  control	  co-­‐transfection	  (average	  of	  53	  pfu/ml).	  No	  recombinant	  virus	  was	  identified	  when	  the	  mutation	  was	  present	  in	  both	  donor	  and	  acceptor	  templates.	  	  
5.7 D79H	  -­‐	  Y275H	  RdRp	  variant	  and	  the	  resolution	  event	  	  The	  results	  outlined	  in	  section	  4.3	  showed	  that	  a	  high	  fidelity	  variant	  (G64S)	  significantly	  reduced	  the	  yield	  of	  recombinant	  progeny	  in	  the	  CRE-­‐REP	  assay.	  The	  G64S	  RdRp	  variant	  also	  affected	  the	  rate	  of	  resolution	  of	  the	  molecular	  clone	  JC105B.	  In	  section	  5.6,	  the	  dual	  mutation	  (D79H-­‐Y275H)	  had	  been	  shown	  to	  affect	  the	  yield	  of	  recombinant	  progeny	  from	  the	  CRE-­‐REP	  assay.	  The	  discovery	  of	  the	  D79H	  and	  Y275H	  dual	  mutation	  was	  from	  a	  GFP	  retention	  assay,	  described	  previously.	  This	  approach	  was	  used	  to	  identify	  RdRp	  variants	  based	  upon	  the	  ability	  of	  the	  construct	  to	  retain	  additional	  non-­‐viral	  sequences.	  The	  JC105B	  construct	  in	  contrast	  is	  a	  natural	  recombinant	  intermediate;	  it	  was	  therefore	  considered	  that	  the	  role	  of	  D79H	  and	  Y275H	  deserved	  investigation	  in	  a	  true	  resolution	  assay.	  A	  similar	  approach	  to	  the	  one	  outlined	  in	  section	  4.9	  was	  done	  to	  validate	  whether	  these	  mutations	  did	  indeed	  affect	  the	  resolution	  stage	  of	  recombination.	  The	  RdRp	  coding	  region	  of	  pRLuc-­‐D79H-­‐Y275H	  was	  sub-­‐cloned	  into	  JC105B	  cDNA	  using	  the	  unique	  restriction	  enzyme	  sites	  XhoI	  and	  ApaI.	  The	  new	  construct	  pJC105B-­‐D79H-­‐Y275H	  was	  verified	  by	  sequencing	  the	  entire	  region	  that	  was	  sub-­‐cloned.	  The	  cDNA	  was	  then	  linearised	  with	  ApaI	  and	  used	  as	  a	  template	  to	  transcribe	  RNA	  using	  T7	  polymerase.	  L929	  cells	  in	  a	  12	  well	  plate	  were	  transfected	  with	  250	  ng	  of	  JC105B	  or	  the	  D79H-­‐Y275H	  variant.	  Cells	  were	  incubated	  for	  48	  hrs	  and	  then	  the	  transfection	  supernatant	  was	  used	  to	  inoculate	  HeLa	  cells	  in	  T20	  flasks.	  Media	  was	  isolated	  at	  24	  hr	  periods	  and	  passaged	  a	  total	  of	  10	  times.	  RNA	  was	  extracted	  from	  various	  passages	  and	  subjected	  to	  RT-­‐PCR	  analysis.	  The	  primers	  used	  to	  amplify	  the	  specific	  region	  where	  resolution	  occurred	  were	  PV1/3-­‐3280F	  and	  GEN-­‐4615R	  (figure	  5.14).	  The	  molecular	  clone	  JC105B	  that	  had	  a	  wild	  type	  RdRp	  went	  through	  the	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Figure	  5.14:	  Resolution	  of	  an	  imprecise	  molecular	  clone	  -­‐	  JC105B	  containing	  an	  RdRp	  
with	  the	  D79H	  and	  Y275H	  mutations	  
(A)	  RT-­‐PCR	  product	  of	  the	  amplified	  region	  of	  the	  JC105B	  molecular	  clone	  recombinant	  virus	  was	  run	  on	  1%	  agarose	  gel	  and	  stained	  with	  ethidium	  bromide	  following	  serial	  passaging	  in	  HeLa	  cells.	  SL3	  indicates	  wild-­‐type	  length	  without	  insert.	  Passages	  as	  indicated	  (B)	  As	  (A),	  except	  passaged	  virus	  has	  an	  RdRp	  containing	  a	  D79H	  and	  Y275H	  mutation.	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previously	  characterised	  resolution	  process	  where	  additional	  sequences	  within	  the	  zone	  of	  recombination	  were	  rapidly	  lost,	  as	  indicated	  by	  the	  PCR	  products	  migrating	  as	  far	  as	  the	  wild	  type	  control	  template	  (SL3)	  from	  passage	  6	  onwards.	  In	  contrast,	  the	  molecular	  clone	  that	  carried	  the	  D79H-­‐Y275H	  RdRp	  variation	  produced	  a	  homogenous	  PCR	  product	  at	  each	  passage	  that	  was	  larger	  than	  the	  control	  (SL3).	  No	  obvious	  changes	  in	  the	  migration	  pattern	  of	  this	  band	  were	  observed.	  This	  suggested	  that	  the	  additional	  sequence	  within	  the	  region	  of	  recombination	  was	  still	  present.	  The	  PCR	  product	  from	  passage	  10	  was	  sequenced	  and	  all	  of	  the	  additional	  sequence	  was	  present	  and	  identical	  to	  the	  original	  cDNA.	  Additionally,	  to	  confirm	  the	  sequence	  of	  the	  viral	  RdRp,	  the	  3D	  coding	  region	  was	  also	  amplified	  by	  PCR	  and	  sequenced.	  The	  D79H	  and	  Y275H	  mutations	  were	  present	  at	  passage	  10	  and	  no	  other	  secondary	  site	  mutations	  were	  observed	  in	  the	  RdRp	  coding	  region.	  	  	  
5.8 Discussion	  	  The	  results	  in	  this	  study	  have	  supported	  the	  ‘copy-­‐choice’	  replicative	  model	  of	  recombination	  and	  have	  shown	  that	  fidelity	  of	  the	  viral	  RdRp	  is	  a	  key	  determinant	  that	  affects	  recombinant	  progeny	  yield.	  The	  experiments	  outlined	  in	  this	  chapter	  have	  introduced	  another	  characterised	  high	  fidelity	  RdRp	  variant,	  K359R,	  into	  the	  CRE-­‐REP	  assay.	  In	  all	  of	  the	  CRE-­‐REP	  assays	  conducted	  no	  intratypic	  or	  intertypic	  recombinants	  could	  be	  isolated	  when	  the	  K359R	  mutation	  was	  present	  in	  either	  the	  donor	  template	  (replicon)	  alone	  or	  when	  the	  mutation	  was	  present	  in	  both	  templates	  (donor	  and	  acceptor).	  The	  K359R	  polymerase	  variant	  has	  a	  higher	  fidelity	  than	  wild	  type	  (Weeks	  et	  al.,	  2012).	  One	  interpretation	  is	  that	  the	  high	  fidelity	  of	  this	  variant	  alone	  is	  sufficient	  to	  inhibit	  recombination,	  in	  a	  similar	  fashion	  to	  the	  G64S	  mutation,	  perhaps	  by	  reduced	  template	  transfer	  due	  to	  increased	  affinity	  of	  the	  enzyme	  for	  the	  RNA	  template.	  However,	  the	  fidelity	  of	  the	  K359R	  variant	  is	  lower	  than	  the	  G64S	  RdRp	  variant	  (Weeks	  et	  al.,	  2012).	  Results	  in	  chapter	  four	  showed	  that	  recombination	  still	  occurred,	  albeit	  at	  a	  significantly	  lower	  level,	  when	  the	  G64S	  mutation	  was	  in	  both	  templates.	  Therefore	  increased	  fidelity	  alone	  cannot	  explain	  why	  no	  recombinant	  virus	  was	  observed	  when	  the	  K359R	  mutation	  was	  present.	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The	  substitution	  of	  the	  lysine	  for	  an	  arginine	  at	  position	  359	  of	  the	  RdRp	  has	  been	  well	  characterised,	  and	  this	  modification	  reduces	  RNA	  replication	  rates	  by	  around	  10	  fold	  compared	  to	  wild	  type	  (Castro	  et	  al.,	  2009).	  This	  result	  was	  supported	  by	  the	  luciferase	  assays	  carried	  out	  in	  this	  study.	  As	  previously	  stated,	  this	  approach	  allows	  RNA	  synthesis	  to	  be	  evaluated	  indirectly	  by	  monitoring	  luciferase	  activity	  (Barclay	  et	  al.,	  1998).	  The	  replication	  defect	  of	  K359R	  could	  explain	  why	  no	  intertypic	  recombinant	  progeny	  from	  the	  CRE-­‐REP	  assay	  was	  observed.	  Potentially,	  the	  fall	  in	  replication	  rates	  by	  one	  log10	  would	  have	  been	  enough	  to	  reduce	  recombination	  to	  below	  the	  levels	  of	  detection.	  The	  plaque	  and	  TCID50	  assays	  do	  not	  use	  all	  of	  the	  transfection	  supernatant	  that	  is	  isolated.	  In	  principle,	  a	  very	  low	  level	  of	  recombinant	  may	  have	  been	  missed.	  This	  however	  does	  not	  explain	  the	  lack	  of	  recombinant	  progeny	  observed	  in	  the	  intratypic	  CRE-­‐REP	  assay	  when	  the	  K359R	  mutation	  was	  present.	  Yields	  of	  recombinant	  in	  the	  wild	  type	  RdRp	  control	  were	  above	  1000	  pfu/ml.	  If	  replication	  rates	  were	  inhibited	  by	  one	  log10,	  then	  detection	  of	  recombinant	  virus	  would	  still	  be	  possible,	  if	  they	  were	  present.	  This	  result	  suggests	  that	  the	  K359R	  mutation	  not	  only	  inhibits	  replication	  rates	  but	  also	  inhibits	  recombination	  frequency.	  	  To	  overcome	  the	  replication	  rate	  deficiencies	  of	  the	  K359R	  variant	  in	  the	  intertypic	  CRE-­‐REP	  assay	  and	  to	  allow	  a	  wider	  study	  on	  recombination	  frequency	  and	  type,	  a	  new	  intertypic	  recombination	  assay	  called	  3’-­‐CRE-­‐REP	  was	  developed.	  By	  mutating	  the	  native	  CRE	  in	  the	  PV1	  replicon	  (pRLucWT)	  in	  a	  similar	  fashion	  to	  a	  previous	  study	  (Goodfellow	  et	  al.,	  2000)	  it	  was	  shown	  that	  replication	  was	  completely	  ablated.	  Insertion	  of	  a	  synthetic	  CRE	  used	  in	  a	  previous	  study	  (Goodfellow	  et	  al.,	  2003a)	  into	  the	  3’NTR	  directly	  after	  the	  termination	  codon	  had	  no	  obvious	  impact	  on	  replication.	  The	  positioning	  of	  a	  CRE	  in	  the	  3’NTR	  of	  poliovirus	  has	  never	  been	  characterised	  before	  and	  the	  result	  supports	  previous	  observations	  that	  the	  function	  of	  the	  CRE	  is	  not	  location	  specific	  (Mason	  et	  al.,	  2002,	  Goodfellow	  et	  al.,	  2003a).	  Indeed,	  this	  study	  and	  the	  study	  by	  Goodfellow	  et	  al.,	  2003,	  have	  moved	  the	  CRE	  in	  poliovirus	  by	  a	  combined	  length	  of	  6.8	  Kb.	  The	  flexibility	  in	  location	  with	  regard	  to	  the	  CRE	  begs	  the	  question	  as	  to	  why	  it	  is	  located	  within	  the	  2C	  region	  and	  not	  elsewhere?	  One	  reason	  could	  be	  that	  the	  2C	  region	  is	  predicted	  to	  be	  highly	  unstructured	  (Goodfellow	  et	  al.,	  2000).	  This	  may	  prevent	  competing	  RNA	  interactions	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that	  affect	  its	  function.	  Alternatively,	  being	  centrally	  positioned	  may	  protect	  it	  from	  host	  exoribonuclease	  digestion.	  	  	  The	  positional	  manipulation	  of	  the	  CRE	  stem	  loop	  allowed	  a	  larger	  potential	  region	  of	  recombination.	  The	  new	  assay,	  3’-­‐CRE-­‐REP,	  increased	  recombination	  yields	  by	  5.85	  fold	  compared	  to	  the	  CRE-­‐REP	  assay.	  This	  was	  higher	  than	  expected.	  The	  potential	  region	  of	  recombination	  in	  the	  3’-­‐CRE-­‐REP	  was	  four-­‐fold	  larger,	  a	  similar	  four-­‐fold	  increase	  in	  recombination	  frequency	  would	  therefore	  have	  correlated.	  The	  increased	  recombination	  frequency	  observed	  above	  what	  was	  expected	  may	  be	  linked	  to	  a	  number	  of	  factors.	  The	  3’-­‐CRE-­‐REP	  incorporates	  an	  additional	  four	  protein	  cleavage	  boundaries	  (seven	  in	  total	  compared	  to	  three	  in	  the	  CRE-­‐REP).	  Observations	  in	  this	  study	  and	  that	  by	  Lowry	  et	  al.,	  2014,	  have	  shown	  a	  clustering	  of	  recombinant	  junctions	  to	  cleavage	  sites.	  In	  principle,	  the	  availability	  of	  more	  boundaries	  could	  provide	  an	  increased	  opportunity	  to	  produce	  a	  viable	  genome	  that	  is	  determined	  by	  correct	  protein-­‐to-­‐protein	  interactions	  during	  subsequent	  replication.	  Alternatively,	  the	  increased	  yield	  could	  be	  due	  to	  the	  processivity	  of	  the	  RdRp.	  If	  the	  rate	  of	  RdRp	  disassociation	  were	  constant	  then	  the	  opportunity	  for	  recombination	  would	  be	  proportionally	  larger	  over	  a	  longer	  region	  than	  compared	  to	  a	  shorter	  one.	  Sequence	  identity	  may	  also	  be	  a	  factor	  to	  consider.	  The	  3D	  coding	  region	  as	  well	  as	  the	  3’NTR	  of	  PV1	  and	  PV3	  shares	  high	  sequence	  similarity.	  If	  recombination	  is	  in	  fact	  influenced	  by	  sequence	  identity	  then	  this	  may	  account	  for	  the	  increased	  frequency	  above	  that	  expected.	  Detailed	  analysis	  of	  a	  large	  sample	  of	  recombinant	  junctions	  from	  this	  type	  of	  assay	  will	  provide	  data	  to	  answer	  some	  of	  these	  hypotheses.	  	  In	  respect	  to	  this	  study,	  it	  was	  hoped	  that	  the	  increased	  intertypic	  recombinant	  yield	  observed	  in	  the	  intertypic	  3’-­‐CRE-­‐REP	  assay	  would	  overcome	  the	  replication	  defect	  that	  the	  K359R	  mutation	  provides.	  No	  recombinant	  virus	  was	  observed	  in	  the	  3’-­‐CRE-­‐REP	  assay	  when	  the	  K359R	  mutation	  was	  present	  in	  the	  donor	  and	  acceptor	  templates.	  This	  suggested	  that	  this	  mutation	  provided	  a	  non-­‐recombinogenic	  phenotype.	  The	  striking	  difference	  between	  the	  G64S	  mutation	  and	  the	  K359R	  variant	  is	  its	  replication	  rates.	  Potentially,	  the	  lack	  of	  recombination	  observed	  may	  be	  in	  fact	  due	  to	  the	  reduced	  nucleotide	  incorporation	  speed	  of	  the	  K359R	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polymerase	  as	  well	  as	  the	  higher	  fidelity	  phenotype.	  As	  a	  side	  note,	  the	  Sabin	  I	  vaccine	  strain	  contains	  a	  T362I	  mutation	  within	  motif	  D	  (Georgescu	  et	  al.,	  1995,	  Bouchard	  et	  al.,	  1995).	  This	  substitution	  has	  been	  shown	  to	  produce	  a	  ‘mutator’	  phenotype	  in	  cell	  culture	  by	  disrupting	  the	  function	  of	  the	  lysine	  residue	  at	  position	  359	  (Liu	  et	  al.,	  2013).	  This	  indicates	  the	  importance	  of	  this	  residue	  in	  replication.	  	  An	  additional	  observation	  with	  the	  K359R	  variant	  needs	  to	  be	  discussed.	  The	  luciferase	  assay	  results	  outlined	  in	  figure	  5.2AB	  and	  in	  a	  previous	  study	  (Weeks	  et	  al.,	  2012)	  show	  that	  replication	  ‘stalls’	  from	  around	  2-­‐6	  hrs,	  with	  luciferase	  signal	  being	  only	  slightly	  higher	  than	  the	  guanidine	  hydrochloride	  control.	  This	  showed	  that	  replication	  was	  occurring,	  but	  at	  a	  vastly	  reduced	  rate.	  Viable	  virus	  is	  produced	  when	  this	  mutation	  is	  present	  but	  at	  yield	  that	  is	  generally	  one	  log10	  lower	  than	  wild-­‐type	  (Weeks	  et	  al.,	  2012).	  During	  this	  time,	  as	  outlined	  in	  chapter	  one,	  negative	  strand	  RNA	  production	  is	  at	  its	  peak.	  If	  ‘copy-­‐choice’	  recombination	  occurs	  during	  negative	  sense	  RNA	  synthesis	  then	  perhaps	  a	  certain	  basal	  level	  of	  replication	  is	  required.	  Potentially,	  the	  stalling	  in	  replication	  is	  enough	  at	  this	  early	  stage	  to	  inhibit	  recombination.	  Alternatively,	  the	  opportunity	  for	  recombination	  may	  not	  be	  available.	  Recombination	  via	  copy-­‐choice	  would	  require	  mixing	  and	  co-­‐occupancy	  of	  replication	  complexes.	  If	  RNA	  synthesis	  is	  temporally	  affected	  then	  perhaps	  mixing	  of	  replication	  complexes	  is	  also	  affected.	  A	  previous	  study	  that	  stalled	  RNA	  replication	  within	  the	  replication	  complex	  by	  use	  of	  the	  reversible	  inhibitor	  guanidine	  hydrochloride	  showed	  that	  the	  migration	  pattern	  of	  the	  RCs	  is	  affected	  (Egger	  and	  Bienz,	  2005),	  perhaps	  something	  similar	  is	  occurring	  with	  the	  K359R	  variant?	  	  The	  mutations	  kindly	  provided	  by	  the	  Andino	  research	  group	  were	  introduced	  into	  the	  transcripts	  used	  in	  the	  intertypic	  CRE-­‐REP	  assay,	  and	  had	  an	  effect	  on	  intertypic	  recombination	  frequency.	  When	  both	  mutations	  were	  present	  in	  the	  donor	  template	  no	  viable	  recombinant	  virus	  was	  identified.	  Of	  the	  two	  mutations,	  Y275H	  was	  the	  most	  important.	  When	  D79H	  was	  present	  in	  the	  donor	  template	  (RLuc-­‐D79H)	  alone	  recombination	  occurred	  at	  a	  rate	  lower	  than	  the	  wild	  type	  RdRp	  partner	  control.	  The	  fall	  in	  recombination	  frequency	  did	  however	  correlate	  with	  the	  reduction	  in	  replication,	  as	  shown	  in	  the	  luciferase	  time-­‐course	  assay.	  The	  reduction	  in	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the	  recombination	  frequency	  observed	  with	  the	  D79H	  mutation	  may	  have	  therefore	  been	  due	  to	  an	  overall	  reduction	  in	  replication	  rates.	  In	  contrast,	  the	  Y275H	  mutation	  in	  the	  donor	  template	  (RLuc-­‐Y275H)	  alone	  was	  enough	  to	  completely	  inhibit	  recombination,	  at	  least	  that	  detectable	  in	  the	  intertypic	  CRE-­‐REP	  assay,	  which	  detects	  viable	  recombinant	  virus	  only	  and	  not	  the	  generation	  of	  hybrid	  RNA.	  The	  absence	  of	  recombination	  cannot	  be	  completely	  attributed	  to	  any	  replication	  defects	  that	  this	  mutation	  confers,	  as	  this	  variant	  was	  still	  able	  to	  replicate	  at	  a	  level	  that	  should	  have	  been	  detectable	  if	  any	  recombinants	  were	  present.	  This	  result	  was	  further	  supported	  by	  the	  intratypic	  CRE-­‐REP	  assay	  that	  concentrated	  solely	  upon	  the	  Y275H	  mutation.	  When	  the	  mutation	  was	  present	  in	  the	  donor	  template	  alone	  a	  small	  amount	  of	  recombination	  was	  observed.	  In	  principle,	  this	  may	  have	  been	  due	  to	  the	  low	  levels	  of	  wild	  type	  RdRp	  produced	  from	  translation	  of	  the	  SL3	  template.	  It	  is	  known	  that	  the	  RdRp	  forms	  higher	  order	  lattices	  in	  the	  replication	  complex	  consisting	  of	  multiple	  RdRps	  (Tellez	  et	  al.,	  2011).	  Potentially,	  a	  small	  amount	  of	  the	  wild	  type	  RdRp	  complemented	  the	  process	  of	  recombination	  in	  trans.	  When	  the	  mutations	  were	  present	  in	  both	  donor	  and	  acceptor	  templates	  no	  recombination	  was	  identified.	  In	  principle,	  this	  could	  have	  been	  due	  to	  a	  replication	  defect.	  The	  replication	  of	  a	  PV3	  sub-­‐genomic	  replicon	  bearing	  the	  Y275H	  mutation	  was	  therefore	  characterised	  in	  a	  luciferase	  time-­‐course	  assay.	  In	  a	  PV3	  background	  this	  mutation	  has	  a	  more	  profound	  effect	  upon	  replication	  than	  when	  in	  a	  PV1	  genome,	  reducing	  luciferase	  signal	  by	  around	  one	  log10	  when	  compared	  to	  wild	  type.	  This	  however	  cannot	  account	  for	  the	  lack	  of	  recombinant	  progeny,	  as	  the	  control	  intratypic	  CRE-­‐REP	  partners	  produced	  recombinant	  yields	  of	  1-­‐2	  log10	  higher	  than	  intertypic	  partners.	  If	  this	  mutation	  had	  no	  effect	  upon	  recombination,	  progeny	  should	  have	  been	  detected.	  	  	  The	  dual	  mutations	  provided	  by	  the	  Andino	  research	  group	  were	  identified	  in	  a	  GFP	  retention	  assay,	  analogous	  to	  the	  resolution	  assay	  used	  in	  this	  study.	  The	  CRE-­‐REP	  assay	  and	  the	  resolution	  assay,	  that	  used	  the	  molecular	  clone	  JC105B,	  produced	  results	  that	  in	  part	  validated	  the	  Andino	  groups	  approach.	  Resolution	  was	  completely	  inhibited	  when	  both	  mutations	  were	  present.	  The	  results	  in	  section	  4.9	  showed	  that	  fidelity	  affected	  this	  stage	  of	  recombination	  as	  well,	  indicating	  that	  secondary	  recombination	  events	  may	  be	  important.	  However,	  the	  mechanisms	  by	  which	  these	  mutants	  inhibit	  the	  loss	  of	  the	  GFP	  coding	  insert	  remain	  to	  be	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determined.	  Potentially,	  this	  event	  can	  occur	  in	  cis	  or	  in	  trans.	  By	  characterising	  the	  mutations	  in	  the	  CRE-­‐REP	  assay	  it	  was	  shown	  that	  only	  one	  of	  the	  mutations	  inhibited	  recombination	  in	  a	  fashion	  unrelated	  to	  any	  replication	  defect.	  The	  results	  indicated	  that	  the	  Y275H	  mutation	  and	  not	  the	  D79H	  mutation	  were	  likely	  to	  be	  the	  determinant	  of	  the	  non-­‐recombinogenic	  phenotype.	  	  	  The	  K359	  residue	  is	  located	  within	  the	  characterised	  motif	  D	  of	  the	  poliovirus	  RdRp,	  a	  region	  that	  plays	  a	  direct	  role	  in	  RNA	  synthesis	  (Castro	  et	  al.,	  2009).	  The	  G64S	  mutation	  is	  believed	  to	  indirectly	  induce	  conformational	  changes	  to	  the	  RdRp	  active	  site	  (Arnold	  et	  al.,	  2005).	  The	  location	  of	  the	  D79	  and	  Y275	  residues	  upon	  the	  RdRp	  was	  therefore	  of	  particular	  interest,	  and	  provided	  information	  that	  requires	  discussion.	  The	  D79	  amino	  acid	  residue	  is	  located	  in	  a	  region	  known	  as	  interface	  II,	  an	  area	  known	  to	  be	  important	  in	  the	  higher	  order	  structure	  lattices	  formed	  by	  multiple	  RdRps	  (Tellez	  et	  al.,	  2011).	  The	  D79H	  mutation	  may	  be	  sufficient	  to	  disrupt	  the	  higher	  order	  RdRp	  structures,	  thus	  affecting	  other	  protein-­‐protein	  interactions	  that	  may	  be	  important.	  Potentially,	  this	  could	  affect	  the	  secondary	  resolution	  stage	  of	  recombination	  and	  not	  the	  initial	  template	  switch.	  The	  Y275	  residue	  in	  contrast,	  is	  located	  in	  the	  RNA	  channel	  very	  near	  to	  the	  active	  site	  of	  the	  RdRp,	  and	  is	  considered	  a	  high	  processivity	  mutant	  (Raul	  Andino,	  personal	  communication).	  It	  is	  particularly	  interesting	  to	  note	  that	  all	  of	  the	  mutations	  that	  have	  affected	  recombination	  yields	  in	  the	  CRE-­‐REP	  assays	  are	  associated	  with	  regions	  that	  directly	  (or	  indirectly	  with	  G64S)	  interact	  with	  the	  RNA	  template	  and	  nucleotide.	  This	  suggests	  that	  the	  poliovirus	  RdRp	  alone	  may	  be	  responsible	  for	  template	  switching.	  Modifications	  that	  increase	  fidelity,	  processivity	  or	  reduce	  replication	  speed	  inhibit	  this	  process.	  	  	  Although,	  the	  results	  outlined	  in	  this	  chapter	  and	  in	  the	  previous	  chapter	  provide	  interesting	  observations	  in	  relation	  to	  the	  poliovirus	  RdRp,	  they	  are	  by	  no	  means	  definitive.	  The	  replication	  defects	  that	  the	  K359R	  and	  Y275H	  mutations	  provide	  may	  have	  had	  some	  unknown	  temporal	  affect	  that	  inhibits	  recombination	  (discussed	  above).	  The	  next	  step	  of	  this	  investigation	  was	  to	  develop	  an	  in	  vitro	  biochemical	  assay	  that	  measured	  the	  kinetics	  of	  recombination	  using	  the	  RdRp	  variants	  outlined	  in	  this	  study	  so	  far.
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CHAPTER	  6:	  Biochemical	  and	  Genetic	  Support	  for	  the	  Role	  of	  
the	  RNA	  Dependent	  RNA	  Polymerase	  and	  Sequence	  Identity	  
in	  Recombination	  	  
6.1 	  	  	  	  	  Introduction	  	  The	  poliovirus	  RdRp	  has	  a	  glycine	  as	  its	  first	  amino	  acid	  as	  a	  consequence	  of	  3C	  cleavage	  that	  occurs	  in	  trans	  at	  a	  Gln/Gly	  amino	  acid	  pair	  (Semler	  et	  al.,	  1981a).	  Expression	  and	  purification	  of	  	  ‘authentic’	  poliovirus	  RdRp	  that	  has	  a	  glycine	  at	  its	  N-­‐terminus	  has	  exploited	  the	  observation	  that	  proteins	  fused	  to	  the	  carboxyl	  terminus	  of	  ubiquitin	  can	  be	  processed	  in	  E.	  coli	  to	  produce	  proteins	  with	  any	  amino	  acid	  as	  the	  first	  residue	  when	  expressed	  in	  the	  presence	  of	  a	  ubiquitin-­‐specific,	  carboxy-­‐terminal	  protease	  (Gohara	  et	  al.,	  1999).	  This	  approach	  allowed	  subsequent	  studies	  that	  characterised	  the	  mechanistic	  properties	  of	  the	  native	  poliovirus	  RdRp	  (Gohara	  et	  al.,	  2000,	  Arnold	  et	  al.,	  1999,	  Freistadt	  et	  al.,	  2007).	  Indeed,	  the	  ability	  to	  purify	  the	  poliovirus	  RdRp,	  has	  also	  allowed	  two	  of	  the	  poliovirus	  RdRp	  variants	  used	  in	  this	  study,	  G64S	  and	  K359R	  to	  be	  extensively	  studied	  and	  characterised	  (Pfeiffer	  and	  Kirkegaard,	  2003,	  Arnold	  et	  al.,	  2005,	  Vignuzzi	  et	  al.,	  2006,	  Castro	  et	  al.,	  2009,	  Weeks	  et	  al.,	  2012).	  	  This	  investigation	  has	  provided	  evidence	  to	  support	  the	  ‘copy-­‐choice’	  replicative	  model	  of	  recombination	  in	  enteroviruses.	  Manipulations	  of	  the	  poliovirus	  RdRp	  by	  use	  of	  nucleoside	  analogue	  mutagens	  or	  by	  well-­‐characterised	  mutations	  have	  shown	  that	  fidelity	  and	  replication	  speed	  are	  important	  in	  recombination	  frequency.	  However,	  the	  evidence	  provided	  with	  the	  fidelity	  variants	  G64S	  and	  K359R	  (chapters	  four	  and	  five)	  was	  reliant	  upon	  observations	  gained	  from	  a	  cell-­‐based	  assay	  approach	  only	  (CRE-­‐REP	  and	  3’-­‐CRE-­‐REP).	  It	  was	  reasoned	  that	  an	  alternate	  approach	  was	  required	  to	  validate	  the	  observations	  outlined	  in	  this	  investigation	  so	  far.	  A	  previous	  study	  that	  used	  homo-­‐polymeric	  RNA	  templates	  and	  primers	  along	  with	  purified	  poliovirus	  RdRp	  showed	  that	  the	  poliovirus	  RdRp	  alone	  was	  sufficient	  for	  template	  switching	  (Arnold	  and	  Cameron,	  1999).	  This	  study	  indicated	  that	  this	  might	  be	  the	  primary	  determinant	  of	  recombination.	  Many	  of	  the	  historic	  biochemical	  studies	  on	  the	  poliovirus	  RdRp	  have	  been	  carried	  out	  in	  the	  laboratory	  of	  Professor	  Craig	  Cameron	  at	  Penn	  State	  University,	  Pennsylvania,	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U.S.A.	  The	  Cameron	  research	  group	  kindly	  agreed	  to	  collaborate	  in	  this	  study	  with	  the	  aim	  of	  developing	  a	  biochemical	  recombination	  assay.	  This	  allowed	  the	  RdRp	  fidelity	  variants,	  identified	  in	  this	  study	  to	  be	  important	  in	  recombination	  frequency,	  to	  be	  characterised	  in	  a	  cell-­‐free	  system.	  Additionally,	  the	  characterisation	  of	  the	  Y275H	  mutation	  provided	  by	  the	  Raul	  Andino	  research	  group	  was	  further	  validated	  using	  this	  biochemical	  approach.	  	  Section	  1.3	  discussed	  the	  role	  of	  RNA	  sequence	  and	  structure	  as	  being	  key	  determinants	  of	  recombination.	  However,	  the	  sequence	  analysis	  of	  over	  100	  intertypic	  recombinant	  viruses	  characterised	  in	  a	  previous	  study	  could	  find	  no	  obvious	  link	  to	  RNA	  sequence,	  and	  only	  limited	  influence	  of	  RNA	  structure	  (Lowry	  et	  al.,	  2014).	  Although,	  the	  resolution	  assay	  described	  in	  sections	  3.6	  and	  3.8	  provided	  evidence	  to	  suggest	  that	  sequence	  identity	  may	  play	  a	  role	  in	  the	  secondary	  events	  of	  recombination.	  By	  manipulating	  sequence	  identity	  in	  the	  acceptor	  templates	  used	  in	  the	  biochemical	  assay	  (described	  later),	  minimal	  regions	  of	  RNA	  identity	  were	  identified.	  Additionally,	  modification	  of	  the	  donor	  templates	  in	  the	  CRE-­‐REP	  assay	  was	  also	  considered.	  Quantitative	  biological	  data	  was	  obtained	  by	  manipulating	  sequence	  identity	  and	  RNA	  structure	  at	  a	  known	  region	  of	  recombination.	  	  
Aims	  The	  aim	  was	  to	  develop	  an	  in	  vitro	  biochemical	  assay,	  in	  collaboration	  with	  the	  Craig	  Cameron	  research	  group	  and	  characterise	  the	  role	  played	  by	  poliovirus	  RdRp	  fidelity	  variants	  in	  recombination.	  The	  importance	  of	  sequence	  homology	  and	  recombination	  frequency	  was	  also	  investigated	  using	  a	  similar	  biochemical	  approach.	  An	  additional	  aim	  was	  to	  manipulate	  RNA	  sequence	  identity	  within	  the	  donor	  template	  at	  a	  known	  recombination	  ‘hot-­‐spot’	  and	  characterise	  its	  influence	  upon	  recombination	  location	  and	  frequency	  in	  the	  CRE-­‐REP	  assay.	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6.2 Biochemical	  assay	  Sym-­‐subU	  	  Detailed	  studies	  of	  the	  kinetics	  of	  nucleotide	  incorporation	  by	  the	  poliovirus	  RdRp	  have	  been	  aided	  by	  the	  development	  of	  a	  biochemical	  assay	  known	  as	  ‘Sym-­‐subU’.	  The	  heteropolymeric	  RNA	  primer-­‐template	  substrate	  (figure	  6.1A)	  is	  a	  10-­‐nt,	  self-­‐complementary	  radiolabelled	  RNA	  that	  forms	  a	  6-­‐base	  pair	  duplex	  flanked	  by	  two,	  4-­‐nt	  5’-­‐overhangs	  (Arnold	  and	  Cameron,	  2000).	  The	  complementary	  RNA	  is	  symmetrical	  and	  the	  first	  templating	  base	  is	  a	  ‘U’,	  hence	  the	  name	  ‘Sym-­‐subU’.	  This	  design	  allowed	  the	  evaluation	  of	  single	  and	  multiple	  cycles	  of	  nucleotide	  incorporation	  following	  addition	  of	  purified	  polio	  RdRp	  along	  with	  the	  appropriate	  co-­‐factors	  and	  nucleotides	  (Arnold	  and	  Cameron,	  2000).	  The	  observations	  in	  a	  previous	  study	  that	  showed	  the	  poliovirus	  RdRp	  alone	  was	  sufficient	  for	  template	  switching	  in	  vitro	  (Arnold	  and	  Cameron,	  1999)	  inspired	  a	  modification	  of	  the	  original	  Sym-­‐subU	  assay.	  The	  introduction	  of	  a	  potential	  acceptor	  template	  into	  the	  assay	  (figure	  6.1A)	  that	  contains	  two	  regions	  of	  sequence	  identity	  to	  the	  fully	  extended	  Sym-­‐subU	  (UACG)	  would	  provide	  the	  opportunity	  for	  a	  template-­‐switching	  event	  to	  occur.	  The	  products	  of	  any	  template	  switching	  would	  be	  quantified	  by	  running	  samples	  from	  the	  Sym-­‐subU	  assay	  on	  an	  appropriate	  denaturing	  polyacrylamide	  gel.	  The	  complete	  assay	  is	  described	  in	  full	  in	  section	  2.3.	  For	  clarity,	  as	  shown	  in	  figure	  6.1BCD,	  the	  reaction	  assay	  mix	  1	  (containing	  radiolabelled	  Sym-­‐subU,	  buffers,	  co-­‐factors	  and	  ATP)	  are	  incubated	  at	  30°C	  for	  5	  mins.	  The	  addition	  of	  the	  poliovirus	  RdRp	  (3Dpol)	  allows	  the	  elongation	  complex	  to	  be	  formed	  by	  incorporation	  of	  the	  first	  templated	  base	  (figure	  6.1D).	  The	  second	  reaction	  mix	  is	  then	  added	  (containing	  the	  remaining	  nucleotides	  along	  with	  acceptor	  template).	  Samples	  are	  then	  taken	  at	  timed	  intervals	  and	  quenched	  for	  RdRp	  activity	  by	  the	  use	  of	  a	  divalent	  cation	  chelator	  (EDTA).	  
6.3 Sym-­‐subU	  optimisation	  
Initial	  experiments	  were	  carried	  out	  with	  the	  aim	  to	  optimise	  the	  original	  assay	  in	  light	  of	  its	  modification.	  Firstly,	  historical	  Sym-­‐subU	  assays	  have	  typically	  used	  ZnCl2	  in	  the	  first	  assay	  mix.	  It	  was	  believed	  that	  that	  the	  RdRp	  didn’t	  use	  the	  divalent	  cation	  as	  a	  cofactor,	  but	  it’s	  inclusion	  might	  aid	  the	  overall	  reaction,	  potentially	  by	  increasing	  RNA-­‐RNA	  interactions	  (Craig	  Cameron,	  personal	  communication).	  	  



























Figure	  6.1:	  Sym-­‐subU	  assay	  overview	  


















  32P- 
 -32P 
  32P- 
  32P- 
 -32P 
 -32P 
  32P- 
	   184	  
A	  Sym-­‐subU	  assay	  was	  carried	  out	  with	  and	  without	  60	  μM	  ZnCl2.	  Additionally,	  two	  types	  of	  RdRp	  were	  used	  in	  the	  initial	  optimisation	  assay,	  wild-­‐type	  and	  the	  Interface	  I	  mutant	  L446D-­‐R455D.	  The	  two	  mutations	  (L446D-­‐R455D)	  within	  the	  3D	  coding	  region	  are	  known	  to	  disrupt	  the	  higher	  order	  structures	  formed	  by	  RdRp	  monomers	  (section	  1.2)	  and	  are	  lethal	  in	  cell	  culture	  (Thompson	  and	  Peersen,	  2004,	  Hobson	  et	  al.,	  2001).	  However,	  the	  mutations	  have	  little	  or	  no	  impact	  on	  the	  molecular	  dynamics	  of	  the	  RdRp	  in	  biochemical	  assays	  (Moustafa	  et	  al.,	  2014).	  The	  poliovirus	  RdRp	  can	  become	  insoluble	  at	  higher	  concentrations	  due	  to	  its	  tendency	  to	  form	  higher	  order	  structures	  (Hobson	  et	  al.,	  2001).	  Using	  the	  Interface	  I	  variant	  allowed	  higher	  concentrations	  of	  RdRp	  to	  be	  purified	  following	  expression	  in	  E.	  coli,	  thus	  allowing	  increased	  flexibility	  in	  experimental	  design.	  It	  was	  reasoned	  that	  a	  comparison	  of	  wild-­‐type	  and	  Interface	  I	  mutant	  may	  also	  highlight	  the	  potential	  role	  played	  by	  higher	  order	  RdRp	  structure	  in	  the	  template	  switching	  event.	  Samples	  were	  taken	  at	  various	  time-­‐points	  and	  then	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel.	  The	  gels	  were	  then	  visualised	  by	  using	  a	  PhosphorImager	  (figure	  6.2).	  The	  controls	  in	  this	  assay	  were	  Sym-­‐subU	  without	  extension	  and	  Sym-­‐subU	  following	  addition	  of	  the	  first	  templated	  base	  only	  (n+1).	  The	  n+1	  control	  indicated	  that	  the	  first	  templated	  base	  (ATP)	  had	  been	  incorporated	  in	  the	  absence	  of	  assay	  mix	  2.	  This	  showed	  formation	  of	  the	  elongation	  complex	  was	  successful,	  which	  is	  typically	  a	  slow	  reaction	  (Arnold	  and	  Cameron,	  2000).	  The	  assay	  generated	  extended	  Sym-­‐subU	  product	  as	  indicated	  by	  the	  banding	  of	  >n+1	  shown	  in	  figure	  6.2A.	  The	  band	  of	  n+4	  in	  the	  presence	  of	  assay	  mix	  2	  indicated	  a	  fully	  extended	  Sym-­‐subU	  template.	  Banding	  above	  this	  area	  was	  likely	  due	  to	  un-­‐templated	  nucleotide	  addition	  at	  the	  blunt	  end	  of	  the	  primer-­‐template	  (Arnold	  et	  al.,	  1999).	  Initial	  analysis	  also	  indicated	  a	  product	  following	  template	  switching	  (black	  arrow).	  An	  over	  exposed	  image	  of	  the	  gel	  (figure	  6.2B)	  clearly	  showed	  (arrow)	  a	  product	  that	  had	  arisen	  from	  extension	  following	  template	  switching.	  The	  ImageQuant	  software	  (Molecular	  Dynamics)	  was	  used	  as	  a	  tool	  to	  accurately	  measure	  the	  amount	  of	  extended	  Sym-­‐subU	  and	  the	  relative	  proportion	  that	  was	  as	  a	  result	  of	  template	  switching.	  The	  calculation	  of	  the	  RNA	  transfer	  product	  as	  a	  percentage	  of	  total	  RNA	  products	  is	  described	  in	  section	  2.3.3.	  The	  quantitative	  data	  showed	  that	  the	  addition	  of	  ZnCl2	  in	  the	  assay	  mix	  was	  beneficial	  to	  the	  overall	  yield	  of	  RNA	  product	  with	  both	  RdRps	  (figure	  6.3A).	  As	  a	  consequence	  of	  the	  increased	  yield,	  the	  amount	  of	  transfer	  product	  was	  also	  proportionally	  higher	  when	  ZnCl2	  was	  included	  (figure	  6.3B).	  At	  30	  mins	  the	  transfer	  product	  in	   






Figure	  6.2:	  Sym-­‐subU	  ZnCl2	  optimisation	  assay	  -­‐	  Gel	  images	  
(A)	  Template	  transfer	  +/-­‐	  60μM	  ZnCl2.	  Two	  polymerase	  variants	  were	  used	  -­‐	  wild	  type	  and	  an	  Interface	  I	  mutant	  variant	  LR-­‐D	  =	  L446D	  -­‐	  R455D.	  10-­‐mer	  indicates	  Sym-­‐subU,	  n+1	  indicates	  the	  product	  following	  first	  nucleotide	  incorporation,	  >n+1	  indicates	  extended	  Sym-­‐subU.	  The	  arrow	  highlights	  the	  product	  from	  template	  transfer.	  Sample	  times	  as	  indicated	  (B)	  An	  over	  exposed	  image,	  highlighting	  the	  difference	  in	  template	  transfer.	  











Figure	  6.3:	  ZnCl2	  optimisation	  quantification	  of	  RNA	  product	  and	  transfer	  product	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  both	  RdRp	  conditions	  represented	  4.7	  %	  of	  overall	  product	  (wild-­‐type	  RdRp)	  and	  4.1	  %	  of	  overall	  product	  (Interface	  I	  mutant	  RdRp)	  respectively.	  Conclusions	  from	  this	  experiment	  were	  that	  the	  poliovirus	  RdRp	  alone	  is	  sufficient	  for	  template	  switching	  and	  that	  ZnCl2	  should	  be	  included	  in	  the	  assay	  mix.	  Additionally,	  the	  results	  showed	  that	  the	  Interface	  I	  mutations	  did	  not	  significantly	  inhibit	  the	  ability	  of	  the	  RdRp	  to	  switch	  to	  the	  acceptor	  template.	  This	  implied	  that	  higher-­‐order	  RdRp	  complexes	  were	  not	  an	  absolute	  requirement	  for	  the	  template	  transfer	  event.	  	  Historical	  studies	  that	  have	  used	  the	  Sym-­‐subU	  assay	  to	  measure	  the	  kinetics	  of	  nucleotide	  incorporation	  have	  used	  a	  standard	  5	  μM	  of	  poliovirus	  RdRp	  (Arnold	  and	  Cameron,	  2000,	  Arnold	  et	  al.,	  2005).	  The	  results	  in	  this	  study	  so	  far	  have	  indicated	  a	  central	  role	  for	  the	  RdRp	  in	  recombination.	  Potentially,	  the	  template-­‐switching	  event	  can	  be	  affected	  by	  the	  concentration	  of	  RdRp.	  It	  was	  therefore	  reasoned	  that	  optimisation	  of	  RdRp	  concentration	  was	  required.	  Similar	  assay	  mixes	  and	  experimental	  approaches	  were	  used	  to	  those	  indicated	  in	  figure	  6.1BC.	  The	  only	  difference	  to	  the	  experiment	  was	  the	  use	  of	  various	  concentrations	  of	  wild	  type	  RdRp	  (0.5μM	  -­‐	  20μM).	  Two	  separate	  experiments	  were	  carried	  out	  that	  overlapped	  with	  regard	  to	  the	  concentration	  of	  RdRp	  used,	  with	  the	  product	  of	  temple	  switching	  shown	  (figure	  6.4).	  The	  overall	  RNA	  product	  was	  quantitated	  (figure	  6.5),	  and	  results	  indicated	  a	  dose	  response	  relationship	  between	  RNA	  product	  and	  RdRp	  concentration.	  Although,	  the	  increase	  in	  RNA	  yield	  did	  not	  correlate	  with	  the	  increased	  concentration	  of	  RdRp	  when	  it	  was	  at	  10	  μM	  and	  above.	  This	  result	  indicated	  that	  higher	  concentrations	  were	  sub-­‐optimal.	  This	  was	  more	  evident	  when	  the	  percentage	  of	  product	  transfer	  was	  calculated.	  RdRp	  concentrations	  of	  10	  μM	  and	  above	  inhibited	  the	  template	  transfer	  event	  by	  up	  to	  30%	  when	  compared	  to	  5	  μM	  concentrations	  (figure	  6.6B).	  	  	  The	  results	  from	  figures	  6.5A	  and	  6.6A	  indicated	  some	  variability,	  which	  may	  be	  attributed	  to	  the	  low	  concentrations	  of	  RdRp	  being	  used,	  or	  experimental	  error.	  The	  results	  in	  figures	  6.5B	  and	  6.6B	  showed	  limited	  variability,	  with	  a	  5	  μM	  concentration	  of	  RdRp	  producing	  the	  highest	  percentage	  of	  transfer	  product	  as	  a	  proportion	  of	  overall	  yield.	  As	  a	  result,	  it	  was	  decided	  that	  	  








Figure	  6.4:	  Sym-­‐subU	  3Dpol	  optimisation	  assay	  -­‐	  Gel	  images	  
(A)	  Template	  transfer	  assay	  using	  various	  concentrations	  of	  RdRp	  (concentrations	  as	  indicated)	  10-­‐mer	  indicates	  Sym-­‐subU,	  n+1	  indicates	  the	  product	  following	  first	  nucleotide	  incorporation,	  >n+1	  indicates	  extended	  Sym-­‐subU.	  The	  arrow	  highlights	  the	  product	  from	  template	  transfer.	  Sample	  times	  as	  indicated	  (B)	  A	  second	  experiment	  with	  concentrations	  of	  RdRp	  as	  indicated.











Figure	  6.5:	  3Dpol	  (RdRp)	  optimisation	  -­‐	  quantification	  of	  RNA	  product	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Figure	  6.6:	  3Dpol	  (RdRp)	  optimisation	  	  -­‐	  quantification	  of	  transfer	  product	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all	  subsequent	  experiments	  would	  use	  a	  concentration	  of	  5	  μM	  RdRp,	  in	  line	  with	  previous	  studies	  involving	  Sym-­‐subU	  (Arnold	  and	  Cameron,	  2000).	  A	  final	  experiment	  that	  involved	  determining	  the	  optimal	  concentration	  of	  acceptor	  template	  was	  considered	  necessary.	  Preliminary	  experiments	  that	  were	  conducted	  prior	  to	  the	  collaborative	  studies	  described	  in	  this	  chapter	  had	  used	  an	  arbitrary	  amount	  of	  acceptor	  template	  (60	  μM).	  This	  was	  deemed	  appropriate	  during	  initial	  experimental	  development	  because	  it	  would	  be	  greatly	  in	  excess	  of	  the	  Sym-­‐subU	  template	  (1	  μM),	  and	  would	  therefore	  provide	  a	  good	  opportunity	  for	  template	  switching	  (Jamie	  Arnold,	  personal	  communication).	  However,	  no	  verification	  that	  this	  level	  was	  optimal	  was	  available.	  In	  principle,	  a	  rate-­‐limiting	  step	  in	  any	  template	  switching	  recombination	  experiment	  would	  be	  the	  availability	  of	  an	  acceptor	  RNA	  strand.	  A	  series	  of	  Sym-­‐subU	  assays	  was	  carried	  out	  that	  used	  the	  previously	  optimised	  ZnCl2	  (60	  μM)	  and	  RdRp	  (5	  μM)	  concentrations,	  along	  with	  various	  concentrations	  of	  acceptor	  templates	  (2.5	  -­‐	  60μM).	  	  The	  products	  of	  the	  Sym-­‐subU	  assays	  were	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager	  (figure	  6.7).	  The	  product	  of	  template	  switching	  is	  barely	  visible	  when	  lower	  concentrations	  of	  acceptor	  template	  were	  used	  (2.5	  and	  5	  μM),	  even	  after	  over-­‐exposure.	  As	  the	  concentration	  of	  acceptor	  template	  increases	  so	  does	  the	  product	  of	  template	  switching	  (indicated	  by	  the	  arrow).	  This	  suggested	  that	  the	  availability	  of	  acceptor	  template	  was	  a	  limiting	  factor	  in	  the	  Sym-­‐subU	  assay.	  Quantification	  of	  the	  gels	  using	  ImageQuant	  software	  indicated	  that	  the	  higher	  concentrations	  of	  acceptor	  template	  impacted	  negatively	  on	  the	  overall	  RNA	  product	  yield	  (figure	  6.8A).	  Potentially,	  the	  excess	  of	  acceptor	  template	  may	  have	  been	  enough	  to	  recruit	  free	  RdRp	  and	  therefore	  inhibit	  potential	  extension	  of	  the	  Sym-­‐subU	  template.	  The	  transfer	  product	  however,	  increased	  as	  a	  percentage	  of	  overall	  products	  when	  acceptor	  template	  concentrations	  increased	  (figure	  6.8B).	  This	  showed	  that	  the	  amount	  of	  template	  switching	  in	  the	  Sym-­‐subU	  assay	  could	  be	  affected	  by	  the	  concentration	  of	  acceptor	  template.	  	  	  There	  was	  potential	  to	  use	  an	  even	  higher	  concentration	  of	  acceptor	  template,	  but	  due	  to	  time	  restraints	  it	  was	  considered	  that	  60	  μM	  would	  be	  sufficient	  in	  all	  future	  experiments.	  The	  three	  	  	  






Figure	  6.7:	  Sym-­‐subU	  acceptor	  template	  optimisation	  assay	  -­‐	  Gel	  images	  
(A)	  Template	  transfer	  assay	  using	  various	  concentrations	  of	  acceptor	  template	  (concentrations	  as	  indicated)	  10-­‐mer	  indicates	  Sym-­‐subU,	  n+1	  indicates	  the	  product	  following	  first	  nucleotide	  incorporation,	  >n+1	  indicates	  extended	  Sym-­‐subU.	  The	  arrow	  highlights	  the	  product	  from	  template	  transfer	  (B)	  A	  second	  experiment	  with	  concentrations	  of	  acceptor	  template	  as	  indicated.	  
	   	  








Figure	  6.8:	  Acceptor	  template	  optimisation	  -­‐	  quantification	  of	  RNA	  and	  transfer	  product	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conditions	  that	  were	  optimised	  in	  this	  section	  (ZnCl2,	  RdRp	  and	  acceptor	  template)	  allowed	  for	  the	  introduction	  of	  poliovirus	  RdRp	  fidelity	  variants	  into	  the	  assay.	  
6.4 Biochemical	  analysis	  of	  poliovirus	  RdRp	  fidelity	  variants	  	  The	  high	  fidelity	  RdRp	  variants,	  G64S	  and	  K359R	  have	  been	  shown	  to	  be	  important	  in	  reducing	  recombination	  frequency	  in	  the	  CRE-­‐REP	  and	  3’-­‐CRE-­‐REP	  cell	  based	  assays	  (chapter	  four	  and	  five).	  However,	  it	  remained	  to	  be	  determined	  if	  fidelity	  really	  was	  the	  significant	  determining	  factor.	  The	  development	  of	  a	  biochemical	  recombination	  assay,	  based	  upon	  an	  already	  successful	  assay	  (Sym-­‐subU)	  provided	  a	  quantitative	  mechanism	  to	  directly	  measure	  the	  template-­‐switching	  propensity	  of	  the	  high	  fidelity	  variants	  when	  compared	  to	  a	  wild	  type	  RdRp	  control.	  	  Results	  in	  sections	  4.5	  and	  4.6	  showed	  that	  lower	  RdRp	  fidelity	  (induced	  by	  mutagen	  treatment)	  increased	  recombination	  frequency	  in	  the	  CRE-­‐REP	  assay.	  A	  recent	  study	  identified	  a	  ‘mutator’	  poliovirus	  RdRp	  that	  had	  a	  H273R	  substitution.	  Biochemical	  studies	  have	  shown	  that	  this	  mutation	  leads	  to	  a	  two	  to	  three-­‐fold	  increase	  in	  GMP	  misincorporation.	  Additionally,	  sequencing	  of	  a	  virus	  population	  carrying	  this	  mutation	  exhibit	  a	  similar	  increase	  in	  diversity	  (Korboukh	  et	  al.,	  2014).	  It	  was	  reasoned	  that	  use	  of	  this	  low	  fidelity	  RdRp	  would	  contrast	  well	  with	  the	  high	  fidelity	  variants.	  If	  fidelity	  were	  a	  key	  determinant	  in	  recombination	  frequency	  then	  perhaps	  this	  low	  fidelity	  variant	  would	  show	  an	  increase	  in	  template	  switching.	  	  Using	  the	  optimised	  conditions	  described	  in	  section	  6.3,	  three	  RdRp	  fidelity	  variants	  (G64S,	  K359R	  and	  H273R)	  were	  introduced	  into	  the	  biochemical	  recombination	  assay	  and	  were	  compared	  to	  a	  wild	  type	  RdRp	  control.	  The	  products	  of	  the	  recombination	  assay	  were	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager	  (figure	  6.9AB).	  A	  black	  arrow	  indicates	  the	  products	  of	  template	  switching.	  The	  product	  of	  template	  switching	  with	  the	  K359R	  variant	  is	  undetectable	  in	  figure	  6.9A	  and	  only	  barely	  detectable	  following	  gross	  overexposure.	  In	  contrast,	  under	  similar	  experimental	  conditions,	  the	  wild	  type	  RdRp	  control	  produced	  an	  easily	  identifiable	  band	  as	  a	  result	  of	  template	  switching	  (figure	  6.9AB).	  This	  strongly	  suggested	  that	  template	  switching	  in	  the	  biochemical	  recombination	  assay	  is	  greatly	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inhibited	  when	  the	  RdRp	  carried	  a	  K359R	  substitution.	  This	  result	  correlated	  with	  the	  CRE-­‐REP	  and	  3’-­‐CRE-­‐REP	  cell	  based	  assays	  described	  in	  chapter	  5.	  To	  verify	  these	  observations	  the	  gel	  image	  was	  quantitated	  using	  ImageQuant	  software.	  The	  product	  of	  template	  switching	  was	  calculated	  as	  a	  percentage	  of	  overall	  RNA	  products	  over	  time	  and	  was	  plotted	  (figure	  6.9C).	  	  	  The	  data	  in	  figure	  6.9C	  clearly	  shows	  that	  template	  switching	  was	  dramatically	  inhibited	  with	  the	  K359R	  variant,	  with	  a	  maximum	  of	  0.17%	  of	  total	  RNA	  product	  as	  a	  result	  of	  template	  switching	  (compared	  to	  4.27%	  with	  wild	  type).	  This	  represented	  a	  25-­‐fold	  reduction	  in	  recombination	  frequency	  between	  the	  two,	  a	  result	  that	  fully	  supported	  the	  cell-­‐based	  assays.	  The	  G64S	  variant	  also	  showed	  a	  reduction	  in	  template	  switching	  when	  compared	  to	  wild	  type,	  with	  a	  maximum	  of	  2.4%	  of	  total	  RNA	  product	  resulting	  from	  template	  switching.	  This	  represented	  a	  near	  1.8	  fold	  reduction	  when	  compared	  to	  the	  wild	  type	  control.	  Potentially,	  this	  fall	  in	  recombination	  frequency	  may	  account	  for	  the	  reduced	  yield	  from	  the	  cell-­‐based	  assays	  conducted	  with	  the	  G64S	  RdRp	  variants	  described	  in	  chapter	  four.	  Although,	  the	  enzymatic	  ability	  of	  the	  purified	  G64S	  RdRp	  looked	  to	  be	  lower	  than	  the	  wild	  type	  RdRp	  control,	  as	  indicated	  by	  the	  overall	  RNA	  yield	  which	  was	  ~	  50%	  lower	  than	  the	  control	  (data	  not	  shown).	  The	  RNA	  product	  from	  template	  switching	  with	  the	  low	  fidelity	  variant	  (H273R)	  reached	  a	  maximum	  of	  5.82%	  of	  total	  product,	  a	  1.4-­‐fold	  increase	  compared	  to	  wild	  type	  RdRp.	  This	  result	  was	  of	  particular	  interest	  because	  it	  indicated	  that	  a	  decrease	  in	  fidelity	  led	  to	  an	  increase	  in	  template	  switching,	  a	  result	  that	  contrasts	  well	  with	  the	  higher	  fidelity	  variants.	  This	  result	  also	  supports	  the	  cell-­‐based	  assays	  conducted	  in	  the	  presence	  of	  mutagen	  (sections	  4.5	  and	  4.6)	  that	  are	  known	  to	  lower	  fidelity.	  Taken	  together,	  the	  results	  in	  figure	  6.9	  show	  that	  RdRp	  fidelity	  is	  a	  key	  determinant	  of	  template	  switching.	  	  To	  further	  verify	  the	  results	  presented	  in	  figure	  6.9,	  and	  to	  incorporate	  another	  RdRp	  variant	  (Y275H)	  that	  was	  shown	  to	  reduce	  recombination	  frequency	  in	  the	  cell-­‐based	  CRE-­‐REP	  assay,	  it	  was	  decided	  to	  carry	  out	  an	  additional	  Sym-­‐subU	  biochemical	  recombination	  assay.	  Three	  RdRp	  variants	  were	  used	  (G64S,	  K359R	  and	  Y275H)	  with	  the	  control	  being	  a	  wild	  type	  RdRp.	  The	  products	  of	  the	  biochemical	  recombination	  assay	  were	  run	  on	  a	  denaturing	  20%









	   	  





Figure	  6.9:	  Sym-­‐subU	  recombination	  assay:	  RdRp	  variants	  assay	  (1)	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polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager.	  A	  black	  arrow	  indicates	  the	  product	  of	  template	  switching	  (figure	  6.10A).	  Early	  interpretations	  suggested	  that	  an	  error	  was	  made	  during	  the	  experiment.	  The	  G64S	  samples	  at	  the	  4	  and	  8-­‐minute	  time-­‐points	  looked	  as	  if	  they	  were	  incorrectly	  loaded.	  The	  gel	  image	  was	  quantitated	  using	  ImageQuant	  software.	  To	  overcome	  any	  issues	  with	  the	  G64S	  sample,	  all	  data	  points	  from	  4	  and	  8	  minutes	  were	  removed	  in	  the	  subsequent	  analysis.	  The	  product	  of	  template	  switching	  was	  calculated	  as	  a	  percentage	  of	  overall	  RNA	  products	  over	  time	  and	  was	  plotted	  (figure	  6.10B).	  	  	  Even	  after	  removal	  of	  some	  of	  the	  data	  points,	  the	  results	  in	  figure	  6.10B	  do	  provide	  interpretable	  data.	  The	  Y275H	  and	  K359R	  showed	  a	  similar	  non-­‐recombinogenic	  phenotype,	  with	  each	  exhibiting	  on	  average	  a	  16-­‐fold	  and	  22-­‐fold	  reduction	  in	  template	  switching	  respectively	  when	  compared	  to	  the	  wild	  type	  control	  at	  the	  30-­‐minute	  time	  point.	  The	  G64S	  data	  is	  more	  difficult	  to	  interpret	  given	  the	  potential	  error	  with	  the	  samples.	  Although,	  from	  ten	  minutes	  onward	  the	  G64S	  variant	  exhibited	  a	  consistent	  near	  2-­‐fold	  reduction	  in	  template	  switching	  when	  compared	  to	  the	  wild	  type	  control.	  This	  result	  correlated	  with	  the	  previous	  Sym-­‐subU	  recombination	  assay	  shown	  in	  figure	  6.9C.	  The	  repeated	  experiment	  provided	  additional	  data	  to	  support	  the	  observations	  that	  fidelity	  directly	  influences	  recombination	  frequency	  and	  also	  showed	  that	  the	  Y275H	  has	  a	  similar	  phenotype	  as	  K359R	  with	  regard	  to	  recombination.	  The	  Y275H	  data	  supports	  the	  CRE-­‐REP	  assay	  results	  in	  section	  5.5,	  and	  also	  provides	  further	  validation	  to	  the	  GFP-­‐retention	  assay	  carried	  out	  by	  the	  Andino	  research	  group.	  However,	  due	  to	  the	  time-­‐restraints	  involved	  during	  this	  area	  of	  investigation,	  caution	  must	  be	  used	  when	  considering	  these	  results.	  The	  biochemical	  recombination	  assay	  does	  show	  reproducibility.	  For	  example,	  the	  product	  of	  template	  switching	  with	  the	  wild	  type	  RdRp	  in	  all	  of	  the	  assays	  conducted	  ranged	  from	  4.17	  %	  to	  a	  maximum	  of	  4.7%.	  Similarly,	  the	  reduction	  in	  template	  switching	  with	  the	  high	  fidelity	  RdRp	  variants	  (G64S	  and	  K359R)	  in	  two	  separate	  experiments	  was	  consistent.	  However,	  to	  completely	  validate	  this	  approach	  multiple	  samples	  at	  each	  time	  point	  will	  be	  required	  i.e.	  repeat	  each	  experiment	  in	  triplicate.	  
	   	  









Figure	  6.10:	  Sym-­‐subU	  recombination	  assay:	  RdRp	  variants	  assay	  (2)	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6.5 Minimal	  sequence	  requirements	  for	  the	  biochemical	  recombination	  
assay	  	  The	  Sym-­‐subU	  recombination	  assay	  was	  designed	  to	  have	  two	  direct	  repeats	  of	  UACG	  in	  the	  acceptor	  template	  (figure	  6.11A).	  These	  regions	  were	  thought	  to	  provide	  two	  potential	  areas	  where	  the	  extended	  Sym-­‐subU	  template	  could	  anneal,	  thus	  allowing	  continued	  RNA	  synthesis.	  The	  single	  product	  seen	  in	  figure	  6.4	  and	  6.7	  suggested	  that	  only	  one	  of	  these,	  if	  used	  at	  all,	  was	  involved.	  The	  characterisation	  of	  intertypic	  recombinants	  isolated	  from	  the	  CRE-­‐REP	  assay	  previously,	  has	  found	  no	  obvious	  link	  to	  sequence	  identity	  and	  location	  of	  the	  recombination	  junction	  (Lowry	  et	  al.,	  2014).	  Although,	  the	  resolution	  assays	  described	  in	  section	  3.8	  suggested	  that	  sequence	  identity	  might	  be	  a	  factor	  during	  subsequent	  recombination	  events.	  Due	  to	  the	  ‘promiscuous’	  nature	  of	  recombination	  in	  the	  CRE-­‐REP	  assay,	  it	  was	  reasoned	  that	  a	  study	  upon	  the	  minimal	  sequence	  requirements	  of	  the	  Sym-­‐subU	  recombination	  assay	  might	  shed	  light	  on	  the	  template-­‐switching	  event.	  In	  order	  to	  investigate	  this	  phenomenon	  a	  series	  of	  acceptor	  templates	  were	  designed	  that	  would	  enable:	  -­‐	  (1)	  identification	  of	  minimal	  sequence	  required	  for	  template	  switching,	  and	  (2)	  identify	  the	  preferred	  site	  upon	  the	  acceptor	  template	  for	  this	  switch.	  Acceptor	  templates	  #1	  and	  #2	  have	  a	  single	  UACG	  motif	  (figure	  6.11B),	  at	  the	  3’	  end	  or	  internally.	  It	  was	  reasoned	  that	  use	  of	  these	  acceptor	  templates	  would	  identify	  the	  primary	  site	  upon	  the	  acceptor	  template	  where	  the	  template-­‐switching	  event	  occurs.	  It	  was	  also	  decided	  that	  modification	  of	  the	  original	  acceptor	  template	  might	  aid	  the	  identification	  of	  the	  primary	  site	  of	  template	  switching.	  To	  accomplish	  this,	  a	  4-­‐nt	  sequence	  that	  shared	  no	  identity	  to	  the	  Sym-­‐subU	  template	  was	  positioned	  between	  the	  two	  postulated	  acceptor	  sites	  (acceptor	  #3,	  figure	  6.11B).	  This	  modified	  acceptor	  template	  was	  considered	  the	  control	  template	  in	  all	  subsequent	  reduced	  complementarity	  experiments.	  To	  carry	  out	  these	  assays	  a	  series	  of	  acceptor	  templates	  were	  designed	  and	  manufactured	  by	  Dharmacon™.	  Acceptor	  templates	  #3	  to	  #6	  have	  reduced	  complementarity	  from	  the	  3’	  end	  of	  the	  Sym-­‐subU	  template	  or	  primer	  (sequences	  underlined).	  To	  contrast	  these	  templates,	  acceptors	  #7,	  #8	  and	  #11	  have	  reduced	  complementarity	  from	  the	  5’	  end	  of	  the	  Sym-­‐subU	  template	  or	  primer	  (sequences	  underlined).	  By	  reducing	  this	  complementarity,	  in	  either	  direction,	  it	  was	  expected	  that	  a	  reduction	  in	  template	  switching	  	  
	  







Figure	  6.11:	  Alternate	  acceptor	  templates	  with	  reduced	  complementarity	  
(A)	  Sym-­‐subU	  and	  the	  original	  acceptor	  RNA	  with	  two	  (UACG)	  regions	  of	  identity	  (B)	  New	  acceptor	  templates.	  #	  1	  and	  #2	  have	  a	  single	  UACG	  sequence	  at	  3’	  end	  or	  internal.	  #3	  (new	  acceptor)	  #4	  to	  #6	  have	  reduced	  complementarity	  (underlined	  sequence)	  from	  the	  3’	  end	  of	  the	  primer.	  #7,	  #8	  and	  #11	  have	  reduced	  complementarity	  (underlined	  sequence)	  from	  the	  5’	  end	  of	  the	  primer.	  Remaining	  templates	  (#10	  and	  #12)	  have	  single	  nucleotide	  complementarity	  to	  the	  Sym-­‐subU	  template.	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might	  be	  observed	  (if	  this	  was	  important	  in	  the	  template	  switching	  event)	  in	  an	  interpretable	  manner.	  Additional	  single	  nucleotide	  templates	  are	  also	  shown.	  An	  initial	  Sym-­‐subU	  assay	  was	  carried	  out	  that	  used	  the	  acceptor	  templates	  #1	  and	  #2.	  A	  similar	  optimised	  protocol	  to	  that	  used	  in	  section	  6.3	  was	  used.	  Samples	  were	  taken	  at	  2,	  4,	  8,	  10,	  20	  and	  30	  mins	  intervals,	  quenched	  for	  RdRp	  activity,	  and	  were	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager	  (figure	  6.12).	  The	  product	  of	  template	  switching	  was	  clearly	  visible	  (band	  A)	  when	  the	  #1	  template	  was	  used,	  indicating	  that	  template	  switching	  had	  occurred.	  Additional	  bands	  can	  be	  seen	  beneath	  the	  major	  A	  band,	  and	  these	  can	  be	  potentially	  attributed	  to	  template	  switching	  that	  have	  not	  fully	  extended	  on	  the	  acceptor	  template.	  The	  presence	  of	  a	  higher	  molecular	  weight	  band	  (B)	  suggested	  that	  products	  from	  template	  switching	  had	  been	  involved	  in	  secondary	  template	  switching.	  In	  contrast,	  only	  a	  barely	  detectable	  band	  with	  a	  higher	  molecular	  weight	  than	  band	  A	  was	  observed	  when	  the	  #2	  template	  was	  used.	  In	  principle,	  if	  the	  internal	  UACG	  site	  had	  been	  used	  with	  this	  template	  then	  the	  expected	  product	  of	  template	  switching	  would	  have	  been	  shorter	  so	  should	  have	  migrated	  further	  on	  the	  gel.	  This	  higher	  molecular	  weight	  band	  is	  therefore	  hard	  to	  interpret.	  Perhaps	  this	  was	  a	  product	  from	  a	  promiscuous,	  sequence	  independent	  template	  switch?	  The	  strong	  signal	  obtained	  from	  the	  #1	  template	  (band	  A)	  that	  had	  a	  UACG	  motif	  at	  its	  3’	  end	  suggested	  that	  this	  was	  the	  primary	  site	  upon	  the	  acceptor	  where	  template	  switching	  was	  occurring.	  	  	  	  By	  using	  the	  acceptor	  templates	  #4,	  5	  and	  6	  with	  reduced	  complementarity	  from	  the	  3’end	  of	  the	  Sym-­‐subU	  primer	  it	  was	  expected	  that	  products	  from	  template	  switching	  in	  the	  biochemical	  recombination	  assay	  would	  reduce	  in	  line	  with	  the	  gradual	  reduction	  in	  sequence	  identity.	  A	  Sym-­‐subU	  recombination	  assay	  was	  carried	  out	  using	  the	  aforementioned	  templates	  along	  with	  the	  #3	  template,	  which	  was	  considered	  the	  control.	  Samples	  were	  taken	  at	  timed	  intervals	  (2,	  4,	  8,	  10,	  20	  and	  30	  mins)	  and	  quenched	  for	  RdRp	  activity.	  The	  products	  of	  the	  assay	  were	  then	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager	  (figure	  6.13A).	  The	  control	  template	  (#3)	  produced	  a	  band	  that	  was	  believed	  to	  be	  the	  product	  from	  template	  switching	  (black	  arrow).	  A	  banding	  pattern	  beneath	  the	  indicated	  product	  of	  template	  switching	  was	  also	  observed	  (lowest	  molecular	  weight	  band	  indicated	  by	  red	  arrow).	  Like	  the	  result	  outlined	  in	  figure	  6.12,	  these	  can	  be	  potentially	  attributed	  to	  template	  switching	  products	  that	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Figure	  6.13:	  Sym-­‐subU	  reduced	  acceptor	  complementarity	  assay	  (1)	  
(A)	  Template	  transfer	  assay	  using	  modified	  acceptor	  templates	  #3,	  4,	  5	  and	  6	  with	  reduced	  complementarity	  (underlined)	  from	  the	  3’	  end	  of	  the	  Sym-­‐subU	  primer.	  10-­‐mer	  indicates	  Sym-­‐subU,	  n+1	  indicates	  the	  product	  following	  first	  nucleotide	  incorporation,	  >n+1	  indicates	  extended	  Sym-­‐subU.	  The	  black	  arrow	  highlights	  the	  product	  from	  template	  transfer.	  Red	  arrow	  indicates	  the	  lowest	  molecular	  weight	  product	  from	  template	  switching	  (B)	  Scatterplot	  quantification	  of	  template	  transfer	  product,	  taken	  as	  a	  %	  of	  overall	  RNA	  product.	  Acceptor	  templates	  as	  indicated.	  (C)	  Potential	  complementarity	  following	  template	  switching.	  Green	  indicates	  fully	  extended	  Sym-­‐subU.	  Acceptor	  templates	  as	  indicated.	  Black	  upon	  acceptor	  indicates	  regions	  of	  complementarity.	  Blue	  indicates	  potential	  base	  pairing.	  Red	  indicates	  incorrect	  base	  pairing.	  Length	  of	  potential	  complementarity	  as	  indicated.	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have	  not	  fully	  extended.	  The	  image	  was	  quantitated	  using	  ImageQuant	  software	  and	  the	  product	  of	  template	  switching	  was	  calculated	  as	  a	  percentage	  of	  overall	  RNA	  products	  over	  time	  and	  was	  plotted	  (figure	  6.13B).	  The	  reduction	  in	  template	  switching	  was	  confirmed,	  with	  acceptor	  #4	  exhibiting	  1.44-­‐fold	  reduction	  in	  products	  from	  template	  switching	  than	  acceptor	  #3.	  However,	  the	  assay	  carried	  out	  using	  acceptor	  #5	  produced	  more	  products	  from	  template	  switching	  than	  acceptor	  #4,	  a	  result	  that	  was	  unexpected,	  given	  that	  complementarity	  was	  reduced.	  This	  result	  might	  be	  explained	  by	  closer	  inspection	  of	  the	  potential	  regions	  of	  identity	  between	  the	  Sym-­‐subU	  template	  and	  the	  acceptor	  templates	  (figure	  6.13C).	  Acceptor	  #4	  has	  a	  maximum	  of	  5-­‐nt	  of	  sequence	  complementarity	  with	  the	  Sym-­‐subU	  template,	  whereas	  acceptor	  #5	  has	  a	  potential	  6-­‐nt	  of	  sequence	  complementarity	  with	  the	  Sym-­‐subU	  template	  due	  to	  a	  G:U	  wobble	  base	  pairing.	  The	  product	  of	  template	  switching	  with	  acceptor	  #6	  was	  reduced	  by	  around	  4-­‐fold	  when	  compared	  to	  the	  control.	  This	  template	  has	  a	  region	  of	  complementarity	  that	  was	  at	  least	  3-­‐nt	  in	  length	  and	  could	  potentially	  be	  as	  much	  as	  4-­‐nt	  given	  the	  G:U	  wobble	  base	  pairing	  that	  may	  be	  possible.	  Conclusions	  from	  this	  assay	  were	  that	  a	  region	  of	  complementarity	  that	  was	  at	  least	  3-­‐nt	  in	  length	  was	  sufficient	  for	  template	  switching	  in	  the	  Sym-­‐subU	  recombination	  assay.	  It	  remained	  to	  be	  determined	  if	  complementarity	  could	  be	  reduced	  further.	  To	  answer	  this	  question,	  acceptor	  templates	  #8,	  9	  and	  11	  were	  used	  in	  a	  Sym-­‐subU	  recombination	  assay	  using	  the	  same	  protocol.	  The	  control	  acceptor	  #3	  remained	  the	  same.	  In	  principle,	  by	  reducing	  complementarity	  from	  the	  5’	  end	  of	  the	  Sym-­‐subU	  template	  using	  these	  alternate	  acceptor	  templates	  would	  reduce	  complementarity	  to	  only	  two	  bases	  (GG).	  Alignment	  of	  potential	  primer	  -­‐	  acceptor	  interactions	  showed	  this	  to	  be	  the	  case	  (figure	  6.14B).	  The	  samples	  from	  the	  experiment	  were	  run	  on	  a	  denaturing	  20%	  polyacrylamide	  gel	  and	  visualised	  using	  a	  PhosphorImager	  (figure	  6.14A).	  As	  expected	  the	  control	  acceptor	  (#3)	  produced	  banding	  that	  indicated	  template	  switching.	  In	  contrast,	  it	  was	  clearly	  evident	  that	  reducing	  complementarity	  to	  only	  two	  bases	  had	  almost	  completely	  inhibited	  template	  switching.	  This	  experiment	  was	  not	  quantitated	  given	  the	  clear	  reduction	  in	  template	  switching.	  Conclusions	  from	  both	  experiments	  showed	  that	  a	  minimal	  3-­‐nt	  sequence	  of	  complementarity	  is	  required	  for	  detectable	  template	  switching	  in	  the	  Sym-­‐subU	  recombination	  assay.	  	  








Figure	  6.14:	  Sym-­‐subU	  reduced	  acceptor	  complementarity	  assay	  (2)	  
(A)	  Template	  transfer	  assay	  using	  modified	  acceptor	  templates	  #3,	  8,	  9	  and	  11	  with	  reduced	  complementarity	  (underlined)	  from	  the	  5’	  end	  of	  the	  Sym-­‐subU	  primer.	  10-­‐mer	  indicates	  Sym-­‐subU,	  n+1	  indicates	  the	  product	  following	  first	  nucleotide	  incorporation,	  >n+1	  indicates	  extended	  Sym-­‐subU.	  The	  arrow	  highlights	  the	  product	  from	  template	  transfer	  (B)	  Potential	  complementarity	  following	  template	  switching.	  Green	  indicates	  fully	  extended	  Sym-­‐subU.	  Acceptor	  templates	  as	  indicated.	  Black	  upon	  acceptor	  indicates	  regions	  of	  complementarity.	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6.6 Sequence	  modifications	  in	  the	  intertypic	  CRE-­‐REP	  assay	  	  The	  results	  in	  the	  Sym-­‐subU	  recombination	  assay	  suggested	  that	  minimal	  sequence	  identity	  was	  required	  for	  a	  detectable	  level	  of	  template	  switching.	  Additionally,	  the	  resolution	  assays	  described	  in	  chapter	  three	  suggested	  that	  sequence	  homology	  might	  be	  important	  for	  this	  phase	  of	  recombination.	  	  	  The	  CRE-­‐REP	  assay,	  by	  nature	  of	  the	  lesions	  carried	  by	  the	  parental	  RNA	  templates,	  has	  a	  potential	  region	  of	  recombination	  of	  1.058	  Kb.	  Sequencing	  of	  over	  100	  intertypic	  recombinants	  isolated	  from	  this	  assay	  had	  shown	  that	  recombination	  clusters	  to	  regions	  encoding	  two	  protein-­‐protein	  cleavage	  boundaries	  (section	  3.3).	  The	  analysis	  of	  the	  primary	  products	  of	  recombination	  could	  find	  no	  obvious	  link	  to	  RNA	  sequence	  at	  the	  site	  of	  template	  switching.	  This	  might	  imply	  that	  protein-­‐protein	  compatibility	  is	  the	  overriding	  requirement	  in	  the	  selection	  of	  the	  primary	  intertypic	  recombinant.	  However,	  intratypic	  recombination	  in	  the	  CRE-­‐REP	  assay	  was	  primarily	  precise	  in	  nature	  with	  no	  additional	  sequence	  (unlike	  intertypic),	  suggesting	  that	  sequence	  identity	  between	  parental	  RNA	  might	  be	  important.	  Alternatively,	  the	  primary	  product	  of	  intratypic	  recombination	  might	  have	  a	  fitness	  advantage	  (due	  to	  the	  optimal	  protein	  content	  of	  its	  genome)	  and	  therefore	  goes	  through	  the	  resolution	  stage	  at	  a	  faster	  rate	  than	  its	  intertypic	  counterpart.	  Due	  to	  the	  sequence	  identity	  of	  the	  parental	  genomes	  it	  would	  be	  impossible	  to	  identify	  the	  sites	  of	  recombination,	  other	  than	  imprecise	  junctions.	  Poliovirus	  type	  1	  has	  an	  RNA	  sequence	  that	  is	  21%	  divergent	  to	  PV3	  within	  the	  CRE-­‐REP	  recombination	  region.	  Which	  results	  in	  a	  4-­‐9%	  divergence	  at	  the	  amino	  acid	  level	  between	  type	  1	  and	  type	  3	  proteins	  2A,	  2B	  and	  2C	  (Lowry	  et	  al.,	  2014).	  The	  observation	  that	  the	  primary	  products	  of	  intertypic	  recombination	  fall	  primarily	  into	  two	  main	  cluster	  groups	  allowed	  development	  of	  a	  modified	  donor	  template.	  The	  manipulation	  of	  sequence	  identity	  at	  a	  known	  region	  of	  recombination	  allowed	  an	  investigation	  into	  sequence	  identity	  between	  donor	  and	  recipient	  template	  to	  be	  carried	  out.	  It	  was	  reasoned	  that	  the	  cluster	  one	  region	  (luciferase	  /	  2A)	  would	  be	  the	  internal	  control	  and	  would	  therefore	  remain	  unaltered.	  A	  region	  of	  450-­‐nt	  that	  precisely	  spans	  the	  2A/2B	  cleavage	  boundary	  (cluster	  2)	  within	  the	  PV1	  replicon	  (pRLucWT)	  template	  was	  targeted	  for	  modification.	  The	  objective	  of	  this	  alteration	  was	  to	  produce	  a	  donor	  template	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that	  was	  as	  similar	  to	  the	  acceptor	  template	  in	  RNA	  sequence	  as	  possible.	  The	  450-­‐nt	  sized	  region	  was	  chosen	  because	  it	  spanned	  all	  of	  the	  characterised	  imprecise	  intertypic	  recombinant	  isolated	  to	  date	  in	  this	  region.	  This	  area	  of	  PV1	  has	  a	  divergence	  of	  22.4%	  in	  RNA	  sequence	  when	  compared	  to	  the	  same	  region	  of	  the	  PV3	  acceptor	  template	  (figure	  6.15A).	  However,	  this	  only	  represents	  a	  divergence	  of	  5.3%	  at	  the	  amino-­‐acid	  level	  (figure	  6.15B).	  This	  discrepancy	  is	  due	  to	  the	  majority	  of	  nucleotide	  differences	  being	  located	  at	  the	  ‘wobble’	  base	  position	  of	  the	  amino	  acid	  codon.	  A	  modified	  sequence	  was	  designed	  (PV3-­‐LIKE)	  that	  was	  as	  similar	  to	  the	  RNA	  sequence	  of	  the	  acceptor	  template	  (SL3)	  as	  possible,	  whilst	  still	  maintaining	  the	  amino	  acid	  code	  of	  the	  native	  PV1	  sequence	  (figure	  6.16).	  It	  was	  reasoned	  that	  if	  recombination	  frequency	  or	  location	  was	  influenced	  by	  sequence	  identity	  then	  the	  modified	  donor	  (that	  was	  only	  2.2%	  divergent	  in	  RNA	  sequence	  to	  the	  acceptor)	  might	  provide	  the	  best	  opportunity	  for	  this	  to	  be	  highlighted.	  Eurofins™	  manufactured	  the	  modified	  sequence	  as	  cDNA,	  which	  was	  subsequently	  PCR	  amplified.	  The	  PCR	  product	  (carrying	  the	  modified	  sequence)	  was	  then	  used	  to	  produce	  a	  larger	  cDNA	  fragment	  by	  two	  steps	  of	  overlap	  extension	  PCR	  (oligonucleotides	  that	  were	  used	  can	  be	  found	  in	  section	  2.9).	  The	  subsequent	  2.4	  Kb	  fragment	  was	  then	  sub-­‐cloned	  into	  pRLucWT	  by	  use	  of	  the	  unique	  restriction	  enzyme	  sites	  PacI	  and	  BglII.	  The	  final	  construct	  was	  called	  pPV3-­‐LIKE	  and	  the	  entire	  modified	  region	  was	  sequence	  verified.	  The	  cDNA	  was	  linearised	  using	  the	  restriction	  enzyme	  ApaI	  and	  RNA	  was	  transcribed	  using	  T7	  polymerase.	  A	  luciferase	  time	  course	  assay	  was	  carried	  out	  to	  examine	  the	  replication	  kinetics	  of	  the	  replicon	  encoded	  by	  the	  modified	  donor	  template	  (figure	  6.17A).	  This	  was	  considered	  an	  important	  control,	  as	  any	  effect	  on	  replication	  would	  affect	  interpretation	  of	  any	  CRE-­‐REP	  assay	  results.	  The	  luciferase	  signal	  produced	  by	  the	  PV3-­‐LIKE	  donor	  template	  was	  around	  ~30%	  of	  the	  wild	  type	  PV1	  replicon	  control.	  This	  indicated	  that	  modification	  of	  the	  450-­‐nt	  region	  had	  an	  adverse	  affect	  upon	  replication.	  This	  was	  unexpected	  given	  the	  controls	  used	  in	  the	  design	  of	  the	  sequence.	  A	  subsequent	  intertypic	  CRE-­‐REP	  assay	  was	  carried	  out	  that	  would	  compare	  the	  yield	  of	  recombinant	  virus	  from	  the	  PV3/PV3-­‐LIKE	  and	  control	  PV3/1	  partners.	  L929	  cells	  in	  a	  12-­‐well	  plate	  were	  co-­‐transfected	  in	  triplicate	  wells	  with	  RLucWT	  and	  SL3	  or	  PV3-­‐LIKE	  and	  SL3.	  Total	  RNA	  was	  0.5	  μg	  in	  a	  1:1	  ratio	  (replicon:	  CRE	  mutant	  genome).	  Cells	  were	  incubated	  for	  48	  hrs	  post	  transfection	  and	  media	  supernatant	  was	  then	  harvested	  and	  used	  to	  inoculate	  HeLa	  cell	  monolayers	  for	  plaque	  assays.	  Following	  sixty	  hours	  incubation,	  cells	  were	  stained	  with	  crystal	  	  








Figure	  6.15:	  Sequence	  alignments	  of	  PV1	  and	  PV3	  across	  the	  2A/2B	  boundary	  
(A)	  RNA	  sequence	  alignment	  of	  a	  450-­‐nt	  region	  that	  precisely	  spans	  the	  2A/2B	  cleavage	  boundary	  of	  PV1	  and	  PV3.	  Glutamine	  and	  glycine	  codons	  underlined	  (cleavage	  boundary)	  (B)	  Amino	  acid	  sequence	  of	  the	  same	  region	  of	  PV3	  and	  PV1.	  Glutamine	  and	  glycine	  residues	  underlined.
PV1             TTCGTTGGCCCAACGTTCCAGTACATGGAGGCTAATAACTATTACCCAGCTAGGTACCAG 60
PV3             TTTGTGGGACCCACCTTCCAATACATGGAGGCTAATGACTACTACCCAGCTAGATACCAA 60
                ** ** **.**.** *****.***************.**** ***********.*****.
PV1             TCCCATATGCTCATTGGCCATGGATTCGCATCTCCAGGGGATTGTGGTGGCATACTCAGA 120
PV3             TCCCACATGTTAATCGGGCACGGCTTTGCCTCACCAGGTGACTGTGGTGGTATCCTTAGG 120
                ***** *** *.** ** ** **.** **.**:***** ** ******** **.** **.
PV1             TGTCACCACGGGGTGATAGGGATCATTACTGCTGGTGGCGAAGGGTTGGTTGCATTTTCA 180
PV3             TGTCAACATGGCGTCATCGGAATCGTGACAGCTGGTGGAGAGGGATTAGTCGCATTCTCT 180
                *****.** ** ** **.**.***.* **:********.**.**.**.** ***** **:
PV1             GACATTAGAGACTTGTATGCCTACGAAGAAGAAGCCATGGAACAAGGCATCACCAATTAC 240
PV3             GACATAAGGGACTTGTATGCTTACGAGGAAGAGGCCATGGAGCAGGGCATTTCAAACTAT 240
                *****:**.*********** *****.*****.********.**.***** :*.** ** 
PV1             ATAGAGTCACTTGGGGCCGCATTTGGAAGTGGATTTACTCAGCAGATTAGCGACAAAATA 300
PV3             ATTGAGTCACTCGGTGCTGCGTTCGGTAGTGGGTTCACTCAGCAAATAGGGGATAAGATA 300
                **:******** ** ** **.** **:*****.** ********.**:.* ** **.***
PV1             ACAGAGTTGACCAATATGGTGACCAGTACCATCACTGAAAAGCTACTTAAGAACTTGATC 360
PV3             TCAGAACTAACCAGCATGGTGACCAGCACGATTACAGAGAAGCTACTTAAAAACCTAATC 360
                :****. *.****. *********** ** ** **:**.***********.*** *.***
PV1             AAGATCATATCCTCACTAGTTATTATAACTAGGAACTATGAAGACACCACAACAGTGCTC 420
PV3             AAAATTATTTCATCTCTGGTGATTATCACTAGAAATTACGAAGATACCACCACAGTGCTC 420
                **.** **:**.**:**.** *****.*****.** ** ***** *****.*********
PV1             GCTACCCTGGCCCTTCTTGGGTGTGATGCT 450
PV3             GCCACTCTAGCTCTTCTTGGGTGTGATGTT 450
                ** ** **.** **************** *
PV1             FVGPTFQYMEANNYYPARYQSHMLIGHGFASPGDCGGILRCHHGVIGIITAGGEGLVAFS 60
PV3             FVGPTFQYMEANDYYPARYQSHMLIGHGFASPGDCGGILRCQHGVIGIVTAGGEGLVAFS 60
                ************:****************************:******:***********
PV1             DIRDLYAYEEEAMEQGITNYIESLGAAFGSGFTQQISDKITELTNMVTSTITEKLLKNLI 120
PV3             DIRDLYAYEEEAMEQGISNYIESLGAAFGSGFTQQIGDKISELTSMVTSTITEKLLKNLI 120
                *****************:******************.***:***.***************
PV1             KIISSLVIITRNYEDTTTVLATLALLGCDA 150
PV3             KIISSLVIITRNYEDTTTVLATLALLGCDV 150
                *****************************.




Figure	  6.16:	  Sequence	  alignments	  of	  PV3	  and	  the	  modified	  PV1	  replicon	  (PV3-­‐LIKE)	  
(A)	  RNA	  sequence	  alignment	  of	  a	  450-­‐nt	  region	  that	  precisely	  spans	  the	  2A/2B	  cleavage	  boundary	  of	  PV3	  and	  PV3-­‐LIKE.	  Glutamine	  and	  glycine	  codons	  underlined	  (cleavage	  boundary).	  
	  
	   	  
PV3             TTTGTGGGACCCACCTTCCAATACATGGAGGCTAATGACTACTACCCAGCTAGATACCAA 60
PV3-LIKE        TTTGTGGGACCCACCTTCCAATACATGGAGGCTAATAACTACTACCCAGCTAGATACCAA 60
                ************************************.***********************
PV3             TCCCACATGTTAATCGGGCACGGCTTTGCCTCACCAGGTGACTGTGGTGGTATCCTTAGG 120
PV3-LIKE        TCCCACATGTTAATCGGGCACGGCTTTGCCTCACCAGGTGACTGTGGTGGTATCCTTAGG 120
                ************************************************************
PV3             TGTCAACATGGCGTCATCGGAATCGTGACAGCTGGTGGAGAGGGATTAGTCGCATTCTCT 180
PV3-LIKE        TGTCACCATGGCGTCATCGGAATCATTACAGCTGGTGGAGAGGGATTAGTCGCATTCTCT 180
                *****.******************.* *********************************
PV3             GACATAAGGGACTTGTATGCTTACGAGGAAGAGGCCATGGAGCAGGGCATTTCAAACTAT 240
PV3-LIKE        GACATAAGGGACTTGTATGCTTACGAGGAAGAGGCCATGGAGCAGGGCATTACAAACTAT 240
                ***************************************************:********
PV3             ATTGAGTCACTCGGTGCTGCGTTCGGTAGTGGGTTCACTCAGCAAATAGGGGATAAGATA 300
PV3-LIKE        ATTGAGTCACTCGGTGCTGCGTTCGGTAGTGGGTTCACTCAGCAAATAAGCGATAAGATA 300
                ************************************************.* *********
PV3             TCAGAACTAACCAGCATGGTGACCAGCACGATTACAGAGAAGCTACTTAAAAACCTAATC 360
PV3-LIKE        ACAGAACTAACCAACATGGTGACCAGCACGATTACAGAGAAGCTACTTAAAAACCTAATC 360
                :************.**********************************************
PV3             AAAATTATTTCATCTCTGGTGATTATCACTAGAAATTACGAAGATACCACCACAGTGCTC 420
PV3-LIKE        AAAATTATTTCATCTCTGGTGATTATCACTAGAAATTACGAAGATACCACCACAGTGCTC 420
                ************************************************************
PV3             GCCACTCTAGCTCTTCTTGGGTGTGATGTT 450
PV3-LIKE        GCCACTCTAGCTCTTCTTGGGTGTGATGCT 450
                **************************** *









Figure	  6.17:	  Replication	  kinetics	  and	  recombination	  frequency	  of	  PV3-­‐LIKE	  pRLuc	  
replicon	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violet	  and	  plaques	  quantified	  (figure	  6.17B).	  Results	  indicated	  that	  the	  modified	  donor	  template	  led	  to	  an	  increase	  in	  recombination	  frequency	  (average	  of	  96	  pfu/ml)	  when	  compared	  to	  the	  wild	  type	  intertypic	  partner	  control	  (average	  of	  62	  pfu/ml).	  The	  data	  was	  analysed	  by	  Students	  T-­‐test.	  A	  two-­‐tailed	  test	  found	  no	  significant	  difference.	  A	  one-­‐tailed	  test	  did	  find	  significance	  with	  the	  P	  value	  at	  0.035.	  The	  increase	  in	  recombination	  frequency	  might	  have	  been	  due	  to	  a	  bias	  in	  recombination	  to	  the	  cluster	  two	  boundary.	  It	  was	  therefore	  decided	  to	  investigate	  the	  location	  of	  recombination	  in	  a	  pool	  of	  PV3/PV3-­‐LIKE	  intertypic	  recombinant	  isolates.	  	  In	  order	  to	  characterise	  a	  pool	  of	  intertypic	  recombinants	  it	  was	  decided	  to	  carry	  out	  six	  separate	  co-­‐transfections	  in	  L929	  cells	  using	  the	  same	  intertypic	  partners	  shown	  in	  figure	  6.17B.	  It	  was	  reasoned	  that	  pooling	  of	  the	  media	  supernatant	  would	  avoid	  any	  bias	  in	  recombinant	  that	  may	  be	  due	  to	  any	  ‘founder-­‐effect’.	  In	  principle,	  a	  recombinant	  genome	  that	  is	  produced	  at	  a	  very	  early	  stage	  may	  be	  subsequently	  used	  as	  a	  template	  for	  further	  replication	  in	  the	  same	  cell,	  which	  may	  bias	  any	  down-­‐stream	  characterisation.	  This	  phenomenon	  can	  probably	  account	  for	  the	  numerous	  similar	  sequences	  obtained	  in	  a	  previous	  study	  (Lowry	  et	  al.,	  2014).	  All	  separate	  transfections	  produced	  similar	  yields	  of	  viable	  intertypic	  recombinant	  virus	  (data	  not	  shown).	  The	  transfection	  supernatant	  (carrying	  viable	  recombinant	  virus)	  was	  used	  in	  a	  limiting	  dilution	  approach	  to	  biologically	  clone	  individual	  recombinants.	  Thirty	  biologically	  cloned	  recombinants	  from	  the	  wild	  type	  intertypic	  partners	  (RLucWT	  /	  SL3)	  and	  thirty	  recombinants	  from	  the	  modified	  partners	  (PV3-­‐LIKE	  /	  SL3)	  were	  isolated	  and	  their	  RNA	  was	  extracted	  and	  reverse	  transcribed.	  The	  region	  of	  recombination	  in	  all	  samples	  was	  then	  amplified	  by	  PCR	  using	  the	  primers	  PV3-­‐2995F	  and	  PV1-­‐4470R	  (figure	  6.18A).	  This	  produced	  a	  PCR	  product	  that	  covered	  the	  entire	  1.058	  Kb	  region	  of	  recombination.	  In	  order	  to	  screen	  a	  large	  pool	  of	  recombinants	  in	  a	  timely	  and	  cost-­‐effective	  manner,	  a	  restriction	  fragment	  length	  polymorphism	  (RFLP)	  approach	  was	  deemed	  most	  appropriate.	  The	  donor	  templates	  (RLucWT	  and	  PV3-­‐LIKE)	  have	  a	  unique	  PstI	  restriction	  enzyme	  site	  located	  immediately	  adjacent	  to	  the	  luciferase/2A	  boundary.	  It	  was	  reasoned	  that	  the	  unique	  restriction	  enzyme	  site	  would	  be	  present	  in	  the	  recombinant	  genome	  if	  the	  recombination	  junction	  were	  located	  within	  cluster	  one.	  Similarly,	  if	  the	  recombination	  junction	  were	  within	  the	  characterised	  cluster	  two-­‐region	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Figure	  6.18:	  Comparison	  of	  recombination	  junctions	  by	  restriction	  fragment	  
polymorphism	  (RFLP)	  
(A)	  Representative	  ethidium	  bromide	  stained	  1%	  agarose	  gel	  showing	  the	  products	  of	  RT-­‐PCR	  amplification	  from	  biologically	  cloned	  PV3/1	  recombinants.	  Molecular	  clone	  105B	  control	  as	  indicated.	  (B)	  Recombinant	  genome.	  Forward	  and	  reverse	  arrows	  indicate	  primers	  used	  to	  amplify	  the	  region	  of	  recombination	  from	  VP1	  to	  the	  2C	  CRE.	  Beneath	  is	  a	  black	  5’	  to	  3’	  line	  representing	  the	  PCR	  product.	  Subsequent	  digestion	  with	  the	  restriction	  enzyme	  PstI	  should	  produce	  two	  bands	  if	  the	  recombinant	  has	  a	  junction	  within	  cluster	  1,	  no	  digestion	  occurs	  in	  the	  PCR	  product	  if	  the	  recombinant	  has	  a	  junction	  within	  cluster	  2	  (C)	  Representative	  ethidium	  bromide	  stained	  1%	  agarose	  gel	  showing	  the	  products	  of	  RT-­‐PCR	  amplification	  from	  biologically	  cloned	  PV3/1	  recombinants	  following	  PstI	  restriction	  enzyme	  digestion.	  *	  Indicates	  a	  potential	  mixed	  population	  (D)	  Representative	  ethidium	  bromide	  stained	  1%	  agarose	  gel	  showing	  the	  products	  of	  RT-­‐PCR	  amplification	  from	  biologically	  cloned	  PV3/PV3-­‐Like	  recombinants	  following	  PstI	  restriction	  enzyme	  digestion.	  *	  Indicates	  a	  potential	  mixed	  population.	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the	  restriction	  enzyme	  site	  would	  not	  be	  present	  (detailed	  in	  figure	  6.18B).	  The	  control	  samples	  in	  this	  assay	  were	  the	  recombinant	  clones	  isolated	  from	  the	  co-­‐transfections	  using	  the	  intertypic	  partners	  RLucWT	  and	  SL3.	  To	  further	  validate	  the	  approach,	  a	  molecular	  clone	  carrying	  a	  cluster	  one	  junction	  (JC105B)	  was	  also	  assayed.	  All	  PCR	  products	  that	  were	  amplified	  from	  the	  viral	  cDNA	  were	  incubated	  with	  the	  restriction	  enzyme	  PstI	  and	  the	  samples	  were	  then	  run	  on	  a	  1%	  agarose	  gel	  (figure	  6.18C).	  A	  single	  band	  would	  indicate	  that	  the	  isolate	  falls	  outside	  of	  the	  cluster	  one	  region.	  A	  double	  band	  (as	  a	  result	  of	  digestion)	  would	  indicate	  the	  presence	  of	  the	  restriction	  enzyme	  site	  and	  indicate	  that	  the	  recombinant	  had	  a	  junction	  that	  falls	  within	  cluster	  one.	  The	  digestion	  of	  the	  control	  PCR	  product	  (JC105B)	  indicated	  that	  the	  approach	  was	  valid.	  A	  mixed	  banding	  pattern	  indicated	  a	  mixed	  population	  (highlighted	  with	  asterisk).	  These	  samples	  were	  removed	  from	  the	  subsequent	  statistical	  analysis,	  with	  values	  being	  normalised	  to	  the	  overall	  sample	  size.	  In	  total,	  71%	  of	  the	  control	  PV3/1	  recombinant	  isolates	  had	  a	  cluster-­‐one	  recombination	  junction,	  with	  the	  remaining	  junctions	  falling	  outside	  of	  this	  area.	  A	  similar	  approach	  was	  used	  to	  screen	  the	  products	  of	  PCR	  amplification	  from	  the	  PV3/PV3-­‐LIKE	  isolates	  (figure	  6.18D).	  The	  products	  following	  restriction	  enzyme	  incubation	  looked	  largely	  un-­‐digested.	  The	  additional	  control	  (105B)	  indicated	  that	  the	  restriction	  enzyme	  was	  working	  correctly.	  This	  result	  suggested	  that	  the	  majority	  of	  recombinants	  in	  the	  PV3-­‐LIKE	  isolates	  had	  recombination	  junctions	  that	  were	  not	  within	  cluster	  one,	  and	  presumably	  within	  cluster	  2.	  In	  total,	  only	  10%	  of	  these	  isolates	  had	  a	  cluster	  one	  junction.	  Statistical	  analysis	  of	  the	  data	  was	  carried	  using	  a	  Chi	  square	  test	  for	  association.	  The	  wild	  type	  PV3/1	  samples	  were	  considered	  the	  expected	  values	  and	  the	  PV3/PV3-­‐LIKE	  were	  considered	  the	  observed.	  The	  null	  hypothesis	  was	  that	  there	  would	  be	  no	  significant	  difference	  between	  the	  two	  samples.	  The	  results	  in	  table	  6.1	  show	  that	  there	  was	  a	  significant	  difference	  between	  the	  two	  groups,	  as	  expected.	  This	  suggested	  that	  sequence	  identity	  does	  influence	  the	  location	  of	  recombination	  in	  the	  CRE-­‐REP	  assay.	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(E)	   O-­‐E	   (O-­‐E)2	   (O-­‐E)2/E	  
Cluster	  1	   3.1	   21.25	   -­‐18.15	   329.42	   15.5	  
Non-­‐cluster	  
1	   26.9	   8.75	   18.15	   329.42	   37.65	  
	   	   	   	  
χ2	  =	   **53.15	  
	  
Table	  6.1:	  Statistical	  test	  upon	  the	  PV3/1	  and	  PV3/PV3-­‐LIKE	  recombination	  junctions	  Degrees	  of	  freedom	  =	  n-­‐1.	  One	  degree	  of	  freedom	  at	  the	  0.01	  confidence	  level	  =	  6.63.	  **	  Asterisk;	  
P	  <	  0.01	  by	  Chi	  square	  test	  for	  association.	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6.7 Discussion	  
The	  major	  aim	  in	  this	  area	  of	  the	  investigation	  was	  to	  develop	  a	  biochemical	  in	  vitro	  recombination	  assay	  that	  would	  assist	  in	  characterising	  the	  influence	  of	  RdRp	  fidelity	  upon	  recombination	  frequency.	  The	  collaboration	  with	  the	  Cameron	  research	  group	  at	  Penn	  State	  University,	  using	  their	  Sym-­‐subU	  experimental	  approach	  (Arnold	  and	  Cameron,	  2000)	  was	  successful	  in	  producing	  a	  fully	  defined	  cell	  free	  assay	  that	  would	  recapitulate	  the	  template	  switching	  event.	  The	  optimisation	  experiments	  shown	  in	  section	  6.3	  provided	  a	  standardised	  protocol	  that	  allowed	  comparison	  of	  template	  switching	  frequency	  between	  RdRp	  variants.	  In	  principle,	  the	  concentration	  of	  acceptor	  template	  in	  the	  assay	  could	  have	  been	  optimised	  further	  given	  that	  the	  results	  suggested	  that	  saturation	  point	  was	  not	  reached.	  Due	  to	  time	  limitations	  the	  conditions	  that	  were	  used	  in	  subsequent	  experiments	  was	  considered	  sufficient.	  Section	  6.4	  described	  the	  analysis	  of	  a	  range	  of	  poliovirus	  RdRps	  in	  the	  Sym-­‐subU	  recombination	  assay.	  The	  experiments	  were	  not	  repeated	  sufficiently	  to	  allow	  robust	  statistical	  analysis,	  so	  caution	  must	  be	  used	  when	  interpreting	  the	  results.	  However,	  the	  experiments	  that	  were	  carried	  out	  did	  show	  reproducibility.	  The	  G64S	  high	  fidelity	  variant	  did	  switch	  templates	  in	  the	  Sym-­‐subU	  recombination	  assays,	  but	  at	  a	  frequency	  that	  was	  nearly	  two-­‐fold	  lower	  than	  wild	  type	  RdRp	  and	  this	  was	  consistent	  in	  the	  two	  assays	  carried	  out.	  The	  reduction	  in	  template	  switching	  ability	  may	  account	  for	  the	  reduced	  recombination	  frequency	  observed	  in	  the	  CRE-­‐REP	  assays	  described	  in	  chapter	  four.	  Although,	  the	  overall	  activity	  of	  the	  enzyme	  sample	  that	  was	  used	  seemed	  to	  be	  sub-­‐optimal,	  given	  the	  reduction	  in	  extension	  of	  the	  Sym-­‐subU	  template	  when	  compared	  to	  the	  wild	  type	  RdRp.	  This	  experiment	  would	  need	  to	  be	  repeated	  with	  a	  sample	  of	  RdRp	  that	  was	  more	  enzymatically	  active	  to	  be	  assured	  of	  the	  results	  obtained	  to	  date.	  What	  was	  clearly	  evident	  is	  that	  the	  K359R	  substitution	  significantly	  inhibited	  template	  switching,	  and	  this	  was	  also	  consistent	  in	  the	  two	  assays	  carried	  out.	  This	  was	  an	  important	  finding	  that	  validated	  the	  results	  from	  the	  cell-­‐based	  CRE-­‐REP	  and	  3’-­‐CRE-­‐REP	  assays	  described	  in	  chapter	  five	  that	  used	  the	  same	  RdRp	  variant.	  The	  non-­‐recombinogenic	  phenotype	  observed	  in	  the	  biochemical	  assay	  can	  explain	  why	  no	  recombinant	  virus	  was	  obtained	  from	  any	  cell-­‐based	  assays	  conducted	  in	  this	  study.	  One	  point	  of	  discussion	  provided	  in	  section	  5.8	  suggested	  that	  a	  K359R	  substitution	  in	  the	  poliovirus	  RdRp	  led	  to	  a	  temporal	  or	  basal	  disruption	  in	  replication	  
	   219	  
that	  might	  account	  for	  the	  lack	  of	  recombinant.	  In	  principle,	  this	  theory	  can	  now	  be	  dismissed.	  The	  results	  with	  the	  K359R	  variant	  should	  also	  be	  considered	  in	  a	  wider	  context.	  All	  viral	  RNA	  dependent	  RNA	  polymerases	  have	  a	  conserved	  element	  known	  as	  motif	  D	  (Liu	  et	  al.,	  2013).	  As	  shown	  in	  figure	  5.1,	  nucleic	  acid	  polymerases	  employ	  a	  general	  acid	  for	  nucleotidyl	  transfer	  (Castro	  et	  al.,	  2009),	  and	  in	  many	  examples	  this	  is	  a	  lysine	  residue	  within	  the	  conserved	  motif	  D	  (Castro	  et	  al.,	  2007,	  Liu	  et	  al.,	  2013).	  The	  attenuation	  that	  a	  K359R	  substitution	  elicits	  has	  been	  described	  in	  section	  5.2,	  the	  additional	  benefit	  that	  this	  mutation	  provides	  is	  to	  inhibit	  template	  switching	  frequency.	  The	  live-­‐attenuated	  poliovirus	  vaccine	  strains	  have	  been	  hugely	  successful	  in	  limiting	  the	  outbreak	  of	  poliomyelitis,	  but	  they	  are	  prone	  to	  recombination	  events,	  which	  can	  lead	  to	  severe	  illness	  (Kew	  et	  al.,	  2002,	  Zhang	  et	  al.,	  2010,	  Kew	  et	  al.,	  2005).	  Perhaps	  the	  K359R	  variant	  could	  be	  considered	  as	  a	  suitable	  vaccine	  candidate	  that	  will	  aid	  poliovirus	  eradication?	  Vaccines	  are	  successful	  in	  preventing	  the	  onset	  of	  severe	  disease	  symptoms.	  Potentially,	  the	  development	  of	  this	  cell-­‐free	  biochemical	  assay	  might	  provide	  a	  suitable	  system	  that	  will	  allow	  the	  characterisation	  of	  other	  viral	  RdRps	  and	  their	  propensity	  to	  recombine.	  	  	  The	  role	  of	  high	  RdRp	  fidelity	  in	  reducing	  recombination	  frequency	  has	  now	  been	  shown	  in	  two	  distinct,	  separate	  assays	  in	  this	  study.	  In	  contrast,	  the	  use	  of	  mutagen	  (that	  decreases	  RdRp	  fidelity)	  was	  shown	  to	  increase	  recombinant	  yield	  in	  the	  CRE-­‐REP	  assay.	  The	  well	  characterised	  H273R	  low	  fidelity	  RdRp	  (Korboukh	  et	  al.,	  2014)	  was	  used	  in	  the	  Sym-­‐subU	  recombination	  assay	  in	  order	  to	  investigate	  the	  role	  of	  low	  fidelity	  and	  recombination	  frequency.	  Initial	  experimental	  design	  considered	  the	  use	  of	  ribavirin	  triphosphate	  as	  a	  potential	  analogue	  to	  investigate	  fidelity	  in	  the	  cell	  free	  biochemical	  assay.	  However,	  the	  optimisation	  steps	  that	  would	  have	  been	  required	  were	  not	  permissible	  given	  the	  timeframe	  involved.	  The	  increase	  in	  template	  switching	  observed	  with	  the	  H273R	  variant	  in	  the	  Sym-­‐subU	  recombination	  assay	  lends	  support	  to	  the	  previous	  results	  outlined	  in	  section	  4.4	  that	  used	  ribavirin	  as	  a	  mechanism	  to	  reduce	  fidelity.	  The	  sharper	  incline	  and	  higher	  amount	  in	  template	  switching	  when	  compared	  to	  the	  wild	  type	  RdRp	  control	  (figure	  6.9)	  provided	  direct	  evidence	  to	  show	  that	  low	  fidelity	  leads	  to	  an	  increase	  in	  template	  switching.	  However,	  the	  products	  from	  template	  switching	  seemed	  to	  plateau	  from	  8	  minutes	  onwards.	  This	  could	  be	  attributed	  to	  lack	  of	  acceptor	  template	  at	  this	  point.	  Although,	  the	  acceptor	  template	  was	  in	  60-­‐fold	  excess,	  so	  this	  seems	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unlikely.	  Potentially,	  the	  plateau	  observed	  could	  be	  due	  to	  the	  concentration	  of	  enzymatically	  active	  RdRp.	  Previous	  studies	  that	  have	  used	  a	  similar	  experimental	  approach	  have	  shown	  that	  only	  1%	  of	  the	  elongation	  complexes	  are	  enzymatically	  active	  (Arnold	  and	  Cameron,	  2000).	  This	  would	  limit	  any	  recycling	  of	  active	  RdRp	  following	  a	  template	  switch.	  Perhaps	  a	  repeated	  experiment	  with	  a	  higher	  concentration	  of	  RdRp	  would	  provide	  better	  conditions	  to	  characterise	  this	  RdRp	  variant	  completely.	  In	  contrast,	  the	  wild	  type	  RdRp	  didn’t	  seem	  to	  reach	  any	  saturation	  point,	  indicating	  a	  reduced	  template	  switching	  phenotype.	  The	  recombinogenic	  phenotype	  observed	  with	  the	  H273R	  variant	  may	  provide	  some	  answers	  to	  why	  a	  population	  with	  this	  variation	  can	  replicate	  successfully	  in	  cell	  culture.	  The	  increase	  in	  mutation	  rates	  (2-­‐3	  fold)	  observed	  with	  this	  variant	  (Korboukh	  et	  al.,	  2014)	  would	  suggest	  that	  this	  population	  would	  be	  lost	  rapidly	  due	  to	  ‘error-­‐catastrophe’	  (Crotty	  and	  Andino,	  2002).	  The	  higher	  template	  switching	  phenotype	  observed	  with	  this	  variant	  maybe	  a	  characteristic	  that	  aids	  the	  population	  as	  a	  whole.	  If	  a	  genome	  carried	  a	  lethal	  mutation	  due	  to	  low	  RdRp	  fidelity,	  then	  in	  principle	  this	  mutation	  could	  be	  removed	  by	  a	  recombination	  event	  to	  an	  acceptor	  template	  that	  carries	  a	  non-­‐lethal	  allele.	  As	  discussed	  in	  section	  5.8,	  there	  seems	  to	  be	  fine-­‐line	  between	  fidelity	  and	  a	  viable	  recombinant	  virus.	  As	  recombination	  rates	  increase	  due	  to	  low	  fidelity	  so	  do	  the	  potential	  lethal	  mutations	  that	  the	  genome	  carries	  as	  a	  whole.	  	  	  The	  Y275H	  variant	  provided	  by	  the	  Andino	  research	  group	  was	  further	  validated	  in	  this	  study.	  The	  high	  processivity	  RdRp	  variant	  (Raul	  Andino,	  personal	  communication)	  had	  a	  similar	  non-­‐recombinogenic	  phenotype	  as	  the	  K359R	  variant.	  Their	  individual	  mechanisms	  of	  reducing	  recombination	  frequency	  still	  remain	  to	  be	  fully	  characterised.	  The	  Y275H	  has	  a	  stronger	  affinity	  for	  the	  RNA	  template,	  and	  this	  is	  the	  basis	  of	  its	  high	  processivity	  (Jamie	  Arnold,	  personal	  communication).	  Potentially,	  the	  RdRp	  interaction	  is	  strong	  enough	  on	  its	  own	  to	  prevent	  any	  template	  switch.	  	  The	  results	  in	  the	  optimisation	  assays,	  described	  in	  section	  6.3,	  showed	  that	  the	  interface	  mutant	  I	  (L446D	  -­‐	  R455D)	  RdRp	  could	  template	  switch	  at	  a	  level	  only	  slightly	  lower	  than	  that	  of	  the	  wild	  type	  RdRp.	  This	  RdRp	  variant	  is	  lethal	  in	  a	  full-­‐length	  virus,	  but	  has	  no	  affect	  on	  the	  dynamics	  of	  the	  RdRp	  in	  biochemical	  assays	  (Moustafa	  et	  al.,	  2014,	  Hobson	  et	  al.,	  2001).	  Initial	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interpretations	  would	  therefore	  suggest	  that	  the	  interaction	  of	  RdRp	  monomers	  within	  interface	  I	  are	  not	  an	  absolute	  requirement	  for	  recombination.	  This	  is	  an	  important	  finding	  given	  the	  Andino	  research	  group	  have	  identified	  a	  pool	  of	  RdRp	  variants	  that	  have	  mutations	  within	  the	  interface	  II	  region	  from	  their	  GFP-­‐retention	  assay	  (discussed	  in	  chapter	  seven).	  Like	  the	  Y275H	  variant,	  these	  were	  isolated	  under	  conditions	  that	  assumed	  that	  the	  virus	  was	  non-­‐recombinogenic.	  Perhaps	  RdRp	  interactions	  at	  interface	  II	  and	  not	  interface	  I	  are	  important	  in	  recombination?	  However,	  caution	  must	  be	  used	  with	  this	  interpretation.	  Disruption	  of	  residues	  at	  known	  protein-­‐protein	  interaction	  sites	  may	  have	  a	  gross	  impact	  on	  interactions	  with	  other	  viral	  proteins	  that	  are	  involved	  in	  replication	  (i.e.	  P3	  precursor	  proteins).	  	  	  The	  results	  in	  section	  6.5	  suggested	  that	  the	  template-­‐switching	  event	  occurred	  at	  the	  3’	  end	  of	  the	  acceptor	  template	  and	  that	  a	  3/4-­‐nt	  identity	  was	  required	  for	  detectable	  template	  switching.	  This	  suggests	  that	  minimal	  regions	  of	  identity	  are	  required	  for	  recombination	  to	  occur.	  A	  finding	  that	  does	  not	  support	  the	  characterised	  intertypic	  recombinants	  isolated	  previously,	  which	  were	  more	  promiscuous	  in	  nature	  with	  limited	  identity	  at	  the	  recombination	  junction	  (Lowry	  et	  al.,	  2014).	  The	  identification	  of	  sequence	  identity	  at	  the	  recombination	  junction	  of	  three	  resolved	  intertypic	  recombinants	  described	  in	  section	  3.6,	  suggests	  that	  the	  Sym-­‐subU	  recombination	  assay	  recapitulates	  the	  resolution	  stage	  only.	  However,	  these	  observations	  highlight	  a	  potential	  flaw	  in	  the	  Sym-­‐subU	  recombination	  assay	  in	  its	  current	  format.	  The	  assay	  does	  not	  include	  additional	  poliovirus	  proteins	  that	  are	  known	  to	  interact	  with	  the	  RNA	  and	  RdRp	  within	  the	  replication	  complex.	  One	  example	  is	  the	  precursor	  3AB	  that	  is	  known	  to	  have	  chaperone	  activity	  that	  influence	  RNA-­‐RNA	  interactions	  (DeStefano	  and	  Titilope,	  2006,	  Gangaramani	  et	  al.,	  2010).	  Perhaps	  template	  switching	  in	  a	  more	  ‘promiscuous’	  manner	  would	  be	  observed	  if	  this	  precursor	  protein	  were	  added	  into	  the	  assay?	  A	  further	  potential	  limitation	  of	  the	  Sym-­‐subU	  recombination	  assay	  is	  the	  length	  of	  the	  templates	  involved.	  Can	  the	  results	  from	  a	  duplex	  RNA	  template	  that	  is	  only	  10-­‐nt	  in	  length	  be	  representative	  of	  what	  is	  happening	  in	  vivo?	  Perhaps	  this	  accounts	  for	  the	  need	  of	  sequence	  identity	  for	  efficient	  template	  switching	  in	  this	  assay?	  A	  further	  modification	  could	  be	  the	  inclusion	  of	  longer	  templates	  into	  the	  approach,	  then	  an	  investigation	  into	  the	  influence	  of	  size	  of	  template	  and	  recombination	  frequency	  could	  be	  undertaken.	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The	  modification	  of	  the	  donor	  template	  (RLuc)	  in	  the	  CRE-­‐REP	  assay	  provided	  some	  results	  that	  strongly	  suggested	  that	  sequence	  identity	  was	  influencing	  the	  yield	  and	  location	  of	  recombination.	  The	  sequence	  of	  a	  450-­‐nt	  stretch	  that	  precisely	  spanned	  the	  2A/2B	  boundary	  (cluster	  two)	  was	  modified	  to	  be	  as	  like	  the	  acceptor	  template	  (SL3)	  as	  possible.	  The	  change	  in	  sequence	  reduced	  the	  22.4%	  divergence	  in	  this	  region	  to	  only	  2.2%.	  Importantly,	  protein	  coding	  was	  maintained.	  The	  fall	  in	  replication	  that	  was	  observed	  in	  the	  luciferase	  assay	  when	  compared	  to	  the	  control	  was	  therefore	  unexpected.	  The	  dinucleotide	  frequency	  in	  the	  genome	  of	  enteroviruses	  has	  recently	  been	  shown	  to	  be	  a	  key	  modulator	  of	  replication	  efficiency	  (Atkinson	  et	  al.,	  2014).	  This	  cannot	  account	  for	  the	  fall	  in	  replication,	  as	  the	  dinucleotide	  frequency	  of	  the	  modified	  donor	  remained	  the	  same.	  Perhaps	  there	  is	  an	  unknown	  cis-­‐acting	  element	  within	  the	  modified	  sequence	  that	  has	  been	  disrupted?	  However,	  this	  region	  is	  highly	  unstructured	  (Goodfellow	  et	  al.,	  2000).	  This	  remains	  to	  be	  explained.	  Perhaps,	  sub-­‐cloning	  the	  modified	  region	  into	  a	  full-­‐length	  virus	  followed	  by	  transfection,	  virus	  isolation	  and	  subsequent	  sequencing	  may	  allow	  identification	  of	  the	  key	  sequences	  that	  have	  impacted	  upon	  replication	  (if	  reversions	  were	  observed).	  The	  fall	  in	  replication	  that	  was	  observed	  with	  the	  PV3-­‐LIKE	  replicon	  made	  it	  impossible	  to	  accurately	  interpret	  the	  output	  from	  the	  CRE-­‐REP	  assay.	  The	  increase	  in	  yield	  observed	  with	  the	  modified	  replicon	  when	  compared	  to	  the	  original	  might	  have	  been	  greater	  if	  they	  replicated	  in	  a	  similar	  fashion.	  However,	  the	  yield	  of	  recombinant	  virus	  was	  higher	  than	  the	  control	  when	  the	  PV3-­‐LIKE	  replicon	  was	  used.	  This	  suggested	  that	  there	  might	  have	  been	  a	  bias	  in	  where	  the	  recombination	  event	  had	  occurred.	  By	  carrying	  out	  a	  simple	  RFLP	  assay	  on	  biologically	  cloned	  recombinant	  isolates	  it	  was	  clear	  to	  see	  that	  there	  was	  a	  difference	  between	  the	  control	  group	  and	  the	  modified	  donor	  group,	  even	  when	  the	  mixed	  population	  isolates	  were	  removed.	  This	  difference	  was	  significant.	  An	  interpretation	  of	  this	  result	  would	  suggest	  that	  sequence	  identity	  is	  a	  key	  regulator	  of	  recombination	  frequency	  and	  type.	  In	  preliminary	  studies,	  modification	  of	  structure	  in	  the	  same	  region	  does	  not	  significantly	  alter	  the	  location	  of	  recombination	  (data	  not	  shown).	  This	  is	  surprising	  given	  that	  a	  recent	  study	  showed	  that	  structure	  was	  a	  key	  determinant	  in	  recombination	  junction	  location	  (Runckel	  et	  al.,	  2013).	  The	  sequences	  of	  the	  primary	  products	  of	  intertypic	  recombination	  in	  the	  CRE-­‐REP	  assay	  suggested	  that	  protein-­‐protein	  compatibility	  was	  key	  in	  selection.	  The	  sequence	  that	  was	  modified	  in	  section	  6.6	  covered	  a	  natural	  protein	  cleavage	  site	  (2A/2B).	  In	  principle,	  the	  key	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selection	  criteria	  with	  protein	  compatibility	  were	  still	  paramount.	  The	  modified	  sequences	  just	  increased	  the	  opportunity	  of	  recombination	  to	  occur	  in	  this	  region,	  presumably	  by	  potential	  base	  pairing	  during	  replication.	  If	  it	  is	  RNA	  sequence	  and	  not	  protein	  compatibility	  of	  the	  recombinant	  genome	  that	  are	  important	  in	  frequency	  and	  location,	  then	  regions	  away	  from	  the	  protein	  boundaries	  need	  to	  be	  modified	  in	  a	  similar	  fashion.	  If	  recombination	  then	  occurs	  and	  produces	  chimeric	  proteins,	  then	  sequence	  identity	  can	  be	  then	  deemed	  as	  the	  key	  factor.	  Alternatively,	  the	  availability	  of	  additional	  protein	  cleavage	  boundaries	  in	  the	  3’-­‐CRE-­‐REP	  assay	  provides	  for	  an	  expansion	  on	  this	  area	  of	  investigation.	  Similar	  sequence	  modifications	  can	  be	  introduced	  across	  the	  entire	  non-­‐structural	  region.	  This	  would	  provide	  the	  best	  opportunity	  to	  link	  sequence	  identity	  and	  location	  of	  recombination.	  	  In	  summary,	  the	  results	  outlined	  in	  this	  chapter	  shows	  that	  recombination	  frequency	  is	  affected	  by	  fidelity	  of	  the	  viral	  RdRp.	  These	  results	  support	  the	  previous	  cell	  based	  data	  that	  have	  concentrated	  on	  the	  same	  RdRp	  fidelity	  variants.	  The	  new	  Sym-­‐subU	  recombination	  assay	  also	  shows	  that	  the	  RdRp	  alone	  is	  sufficient	  for	  template	  switching.	  Modifications	  and	  further	  optimisation	  may	  be	  required.	  In	  principle,	  this	  new	  biochemical	  approach	  can	  be	  used	  with	  other	  viral	  RdRps.	  This	  will	  allow	  the	  characterisation	  of	  RdRp	  variants	  that	  may	  be	  important	  in	  recombination	  in	  other	  viral	  species.	  There	  is	  also	  potential	  to	  include	  other	  non-­‐RdRp	  viral	  proteins	  that	  are	  involved	  in	  genome	  replication.	  Sequence	  identity	  also	  seems	  to	  be	  important	  in	  recombination	  location.	  However,	  additional	  studies	  will	  be	  required	  to	  confirm	  this.
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CHAPTER	  SEVEN:	  General	  Discussion	  	  
7.1 	  	  	  	  	  Current	  understanding	  	  Members	  of	  the	  Picornaviridae	  have	  error	  prone	  polymerases,	  short	  replication	  cycles	  and	  high	  yields	  that	  together	  generate	  genetic	  diversity.	  The	  high	  mutation	  rates	  create	  virus	  populations	  that	  contain	  potentially	  beneficial	  mutations	  that	  allow	  the	  population	  to	  evolve	  and	  adapt	  to	  new	  environments.	  However,	  far	  greater	  genetic	  variation	  is	  achieved	  by	  chance	  recombination	  events	  than	  is	  possible	  in	  a	  single	  round	  of	  genome	  replication.	  The	  implications	  of	  such	  genomic	  re-­‐arrangements	  can	  be	  the	  onset	  of	  disease	  that	  is	  associated,	  for	  example	  the	  outbreak	  of	  poliomyelitis	  due	  to	  chance	  recombination	  events	  between	  the	  live	  attenuated	  poliovirus	  oral	  vaccine	  and	  unknown	  circulating	  enterovirus	  C	  members.	  	  
	  
This	  study	  has	  benefited	  from	  using	  novel	  cell	  based	  assays,	  which	  have	  provided	  insights	  into	  the	  potential	  mechanisms	  of	  recombination.	  To	  support	  the	  cell-­‐based	  data,	  a	  new	  cell-­‐free	  biochemical	  recombination	  assay	  has	  been	  developed	  (in	  collaboration	  with	  the	  Cameron	  research	  group)	  that	  provided	  additional	  insights	  into	  the	  template-­‐switching	  event.	  The	  biological	  relevance	  of	  this	  assay	  remains	  to	  be	  determined,	  but	  initial	  calculations	  can	  be	  done.	  The	  amount	  of	  donor	  template	  used	  in	  the	  cell-­‐based	  assays	  was	  250	  ng	  on	  average,	  which	  equates	  to	  1010	  templates	  of	  RNA.	  This	  would	  produce	  6	  x	  1010	  templates,	  assuming	  100%	  uptake	  of	  RNA	  and	  that	  each	  is	  replicated	  six	  times	  on	  average	  (Stern	  et	  al.,	  2014).	  The	  biochemical	  recombination	  assay	  showed	  that	  the	  products	  from	  template	  switching	  were	  ~4-­‐5%	  of	  total	  RNA	  product.	  This	  suggests	  that	  ~	  2.4	  x109	  hybrid	  templates	  from	  recombination	  might	  be	  produced	  in	  the	  CRE-­‐REP	  assay	  if	  the	  biochemical	  assay	  is	  correct.	  At	  face	  value	  this	  seems	  a	  very	  high	  amount.	  However,	  to	  produce	  a	  viable	  recombinant	  virus	  additional	  considerations	  are	  needed:	  -­‐	  the	  genome	  must	  be	  in-­‐frame,	  can	  contain	  no	  deletions,	  cannot	  contain	  large	  insertions	  that	  may	  adversely	  affect	  packaging,	  preferably	  outside	  the	  capsid	  coding	  region,	  cannot	  contain	  mutations	  that	  affect	  viability,	  must	  fall	  between	  the	  end	  of	  VP1	  and	  2C	  CRE	  on	  the	  donor	  and	  acceptor	  and	  can	  only	  be	  localised	  to	  certain	  regions	  within	  the	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1.058	  Kb	  region	  of	  recombination	  (protein	  cleavage	  boundaries).	  In	  order	  to	  fulfill	  all	  of	  the	  criteria	  set	  out	  (without	  even	  considering	  host	  responses)	  suggests	  that	  template	  switching	  is	  common	  and	  that	  the	  biochemical	  assay	  may	  indeed	  be	  biologically	  relevant.	  The	  work	  presented	  in	  this	  thesis	  has	  advanced	  the	  understanding	  of	  recombination	  in	  enteroviruses	  and	  is	  broadly	  summarised	  below:	  
• Recombination	  is	  primarily	  a	  replicative	  process.	  
• Co-­‐localisation	  of	  parental	  RNA	  within	  the	  host	  cell	  is	  a	  key	  determinant.	  
• Intertypic	  recombination	  is	  typically	  biphasic	  in	  nature;	  a	  promiscuous	  template-­‐switching	  event	  is	  then	  followed	  by	  a	  resolution	  stage	  where	  all	  additional	  sequence	  is	  removed	  from	  the	  genome.	  	  
• A	  number	  of	  single	  stranded	  positive	  sense	  RNA	  viruses	  have	  genomes	  that	  have	  ‘evolved	  by	  duplication’.	  The	  identification	  of	  duplicated	  sequences	  in	  this	  study	  suggests	  that	  imprecise	  recombination	  is	  a	  likely	  mechanism	  by	  which	  they	  could	  be	  produced.	  
• Clustering	  of	  intertypic	  recombination	  junctions	  to	  cleavage	  boundaries	  indicates	  that	  selection	  of	  the	  early	  viable	  recombinant	  is	  influenced	  by	  protein-­‐protein	  complementarity	  of	  the	  hybrid	  genome.	  
• The	  location	  of	  fully	  resolved	  intertypic	  recombination	  junctions	  are	  influenced	  by	  RNA	  sequence	  identity.	  
• The	  fidelity	  of	  the	  RdRp	  is	  a	  key	  determinant	  of	  recombination	  frequency.	  Lowering	  fidelity	  leads	  to	  an	  increase	  in	  recombination	  frequency	  whereas	  increasing	  fidelity	  lowers	  recombination	  frequency	  in	  the	  cell-­‐based	  assays.	  
• The	  function	  of	  the	  2C	  CRE	  is	  not	  location	  specific.	  Positioning	  a	  synthetic	  CRE	  into	  the	  3’NTR	  of	  poliovirus	  does	  not	  significantly	  affect	  replication.	  
• By	  manipulating	  the	  position	  of	  the	  CRE	  in	  a	  PV1	  sub-­‐genomic	  replicon	  an	  expanded	  intertypic	  cell-­‐based	  assay,	  termed	  3’-­‐CRE-­‐REP	  was	  developed.	  This	  produced	  an	  experimental	  approach	  where	  the	  opportunity	  for	  recombination	  across	  the	  whole	  non-­‐structural	  coding	  region	  was	  present.	  	  
• The	  development	  of	  a	  novel	  cell	  free	  biochemical	  recombination	  assay	  showed	  that	  the	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RdRp	  alone	  was	  sufficient	  for	  template	  switching.	  High	  fidelity	  and	  low	  fidelity	  RdRp	  variants	  reduced	  and	  increased	  recombination	  frequency	  in	  a	  manner	  that	  supported	  the	  cell-­‐based	  data.	  
• Reducing	  complementarity	  of	  the	  acceptor	  template	  in	  the	  biochemical	  recombination	  showed	  that	  a	  minimal	  3-­‐4-­‐nt	  sequence	  of	  identity	  is	  required	  for	  detectable	  template	  switching.	  
• Sequence	  manipulation	  of	  a	  known	  recombination	  region	  within	  the	  replicon	  donor	  template	  showed	  that	  the	  frequency	  and	  location	  of	  recombination	  could	  be	  manipulated.	  	  
7.2 	  	  	  	  	  Replicative	  models	  of	  recombination	  	  The	  role	  of	  the	  viral	  RdRp	  in	  enterovirus	  recombination	  has	  clearly	  been	  shown	  in	  this	  study,	  indicating	  that	  this	  process	  is	  primarily	  replicative.	  However,	  the	  precise	  mechanisms	  of	  template	  switching	  remain	  to	  be	  determined.	  At	  present,	  the	  results	  show	  that	  RdRp	  fidelity	  is	  a	  key	  characteristic	  that	  influences	  the	  recombination	  process.	  Previous	  studies	  have	  suggested	  that	  the	  low	  fidelity	  characteristics	  of	  the	  viral	  RdRp	  might	  be	  important	  in	  recombination	  frequency	  (Agol,	  1997,	  Freistadt	  et	  al.,	  2007).	  A	  nucleotide	  misincorporation	  event	  that	  is	  thermodynamically	  unfavourable	  might	  be	  sufficient	  to	  affect	  the	  stability	  of	  the	  elongation	  complex,	  leading	  to	  a	  template-­‐switching	  event.	  However,	  no	  mutations	  were	  found	  at	  the	  recombination	  junctions	  characterised	  in	  this	  study	  and	  in	  a	  previous	  study	  that	  used	  the	  same	  experimental	  approach	  (Lowry	  et	  al.,	  2014).	  These	  observations	  don’t	  necessarily	  mean	  that	  the	  hypothesis	  is	  incorrect.	  Potentially,	  the	  attempt	  to	  incorporate	  the	  incorrect	  nucleotide	  (or	  mutagen,	  if	  ribavirin	  and	  5-­‐FU	  are	  considered)	  is	  sufficient	  to	  de-­‐stabilise	  the	  elongation	  complex,	  leading	  to	  template	  switching.	  The	  lack	  of	  sequence	  identity	  at	  the	  recombination	  junctions	  observed	  with	  the	  primary	  products	  of	  intertypic	  recombination	  showed	  that	  sequence	  identity	  is	  not	  a	  key	  prerequisite.	  Taken	  together,	  this	  suggests	  a	  non-­‐processive	  ‘copy-­‐choice’	  mechanism,	  where	  the	  RdRp	  disassociates	  from	  the	  template	  RNA	  but	  retains	  the	  nascent	  RNA	  produced	  (Jarvis	  and	  Kirkegaard,	  1991).	  The	  RdRp	  then	  recruits	  an	  acceptor	  template	  (in	  a	  sequence	  independent	  manner)	  and	  replication	  can	  continue,	  forming	  a	  hybrid	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RNA	  sequence.	  If	  the	  selection	  criteria	  set	  out	  in	  section	  7.1	  are	  fulfilled	  then	  a	  viable	  recombinant	  may	  be	  produced.	  The	  lack	  of	  sequence	  identity	  between	  nascent	  RNA	  and	  acceptor	  template	  during	  template	  switching	  could	  potentially	  be	  overcome	  by	  the	  RNA	  chaperone	  activity	  of	  3AB	  (DeStefano	  and	  Titilope,	  2006,	  Gangaramani	  et	  al.,	  2010),	  a	  virus	  protein	  that	  is	  within	  the	  replication	  complex	  (Cameron	  et	  al.,	  2010,	  Pathak	  et	  al.,	  2007,	  Pathak	  et	  al.,	  2008).	  The	  role	  of	  P3	  precursor	  proteins,	  and	  chaperone	  activity,	  has	  been	  considered	  in	  pilot	  studies	  that	  have	  used	  the	  biochemical	  recombination	  assay	  (Craig	  Cameron,	  personal	  communication)	  and	  this	  model	  is	  described	  in	  figure	  7.1	  (pathway	  A).	  	  	  Alternatively,	  the	  misincorporation	  event	  could	  lead	  to	  stalling	  of	  the	  RdRp	  on	  the	  RNA	  template.	  Indeed,	  recent	  observations	  using	  an	  elegant	  approach	  that	  studied	  the	  elongation	  rate	  of	  individual	  poliovirus	  RdRps	  showed	  that	  the	  polymerase	  pauses	  or	  dwells	  at	  certain	  points	  during	  replication	  and	  may	  even	  slip	  on	  the	  RNA	  template	  (Dulin	  et	  al.,	  2015).	  The	  pausing	  events	  themselves	  had	  the	  signature	  of	  a	  misincorporation	  event	  (Dulin	  et	  al.,	  2015).	  It	  is	  well	  known	  that	  DNA	  and	  RNA	  can	  form	  triplex	  conformations	  via	  hoogstein-­‐base	  pairing,	  where	  the	  third	  strand	  occupies	  the	  major	  groove	  of	  the	  double	  stranded	  helix	  whilst	  having	  no	  impact	  on	  structural	  dimensions.	  Perhaps,	  the	  stalling	  in	  replication	  due	  to	  nucleotide	  misincorporation	  (or	  attempt	  to	  incorporate)	  would	  provide	  the	  best	  opportunity	  for	  a	  third	  RNA	  template	  that	  is	  present	  in	  the	  RNA	  channel	  and	  active	  site	  of	  the	  RdRp,	  to	  displace	  the	  original	  RNA	  template	  by	  a	  form	  of	  ‘strand	  invasion’	  (pathway	  B,	  figure	  7.1).	  This	  model	  would	  therefore	  suggest	  that	  sequence	  identity	  might	  contribute	  to	  the	  location	  of	  template	  switching.	  In	  this	  study,	  the	  precise	  intratypic	  recombinants	  isolated	  would	  indicate	  that	  sequence	  identity	  is	  important	  in	  template	  switching.	  Additionally,	  the	  modification	  of	  a	  450-­‐nt	  region	  that	  precisely	  spanned	  the	  2A/2B	  cleavage	  boundary	  of	  the	  PV1	  replicon	  had	  a	  significant	  affect	  upon	  the	  site	  of	  template	  switching	  in	  the	  intertypic	  CRE-­‐REP	  assay,	  indicating	  that	  sequence	  identity	  is	  a	  major	  factor	  to	  consider	  (section	  6.6).	  The	  location	  of	  the	  recombination	  junctions	  of	  the	  fully	  resolved	  intertypic	  isolates	  was	  also	  linked	  to	  regions	  of	  sequence	  identity.	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Although,	  the	  mechanism	  of	  template	  switch	  in	  the	  latter	  example	  could	  be	  either	  in	  cis	  or	  in	  
trans.	  In	  principle,	  the	  mechanism	  of	  ‘strand	  invasion’	  by	  a	  third	  template	  would	  be	  applicable	  to	  either	  form	  (cis	  or	  trans),	  three	  strands	  of	  RNA	  would	  be	  present	  in	  the	  active	  site	  at	  anyone	  time.	  The	  conformation	  of	  the	  acceptor	  template	  if	  it	  were	  in	  cis	  would	  be	  comparable	  to	  the	  lariat	  formation	  that	  occurs	  during	  mRNA	  splicing.	  	  The	  two	  models	  described	  in	  figure	  7.1	  are	  not	  necessarily	  mutually	  exclusive.	  The	  results	  in	  this	  study	  suggest	  both	  may	  be	  occurring.	  The	  lack	  of	  sequence	  identity	  in	  the	  intertypic	  recombinants	  suggests	  that	  these	  are	  derived	  from	  pathway	  A.	  Where	  there	  is	  sequence	  identity,	  pathway	  B	  may	  be	  more	  applicable.	  However,	  the	  results	  also	  show	  that	  the	  overriding	  criteria	  for	  selection	  of	  viable	  recombinant	  virus	  in	  the	  cell	  based	  CRE-­‐REP	  assay	  is	  dependent	  on	  the	  protein	  coding	  content	  of	  the	  hybrid	  genome.	  The	  genome	  must	  be	  able	  to	  establish	  a	  productive	  infection	  in	  HeLa	  cells.	  The	  clustering	  to	  cleavage	  boundaries	  observed	  in	  this	  and	  a	  previous	  study	  (Lowry	  et	  al.,	  2014)	  ensured	  that	  the	  intertypic	  recombinants	  isolated	  have	  either	  a	  complete	  2A	  and	  2B	  or	  a	  complete	  2B	  from	  one	  parental	  genome,	  thus	  no	  chimeric	  proteins	  are	  produced	  following	  the	  initial	  recombination	  event.	  This	  suggested	  that	  correct	  protein-­‐protein	  interactions	  are	  important	  in	  establishing	  foci	  of	  replication.	  This	  point	  can	  be	  related	  to	  the	  asymmetry	  in	  reciprocal	  recombinants	  in	  the	  P2	  region	  of	  poliovirus	  and	  related	  species	  C	  coxsackie	  A	  viruses	  which	  may	  reflect	  important	  protein-­‐protein	  interactions	  required	  for	  genome	  replication	  and	  particle	  assembly	  (Jiang	  et	  al.,	  2007).	  	  
7.3 	  	  	  	  	  Future	  experiments	  
The	  results	  in	  section	  3.3	  suggested	  that	  intratypic	  recombination	  was	  primarily	  precise	  in	  nature	  whereas	  intertypic	  recombination	  was	  primarily	  imprecise.	  There	  still	  remains	  some	  ambiguity	  in	  this	  area.	  Potentially,	  an	  imprecise	  intratypic	  recombinant	  could	  have	  a	  growth	  advantage	  over	  any	  intertypic	  counterpart,	  due	  to	  the	  optimal	  protein	  coding	  content	  of	  its	  genome.	  This	  may	  result	  in	  a	  swifter	  resolution	  stage.	  Indeed,	  this	  may	  occur	  during	  subsequent	  rounds	  of	  replication	  within	  the	  same	  cell	  following	  the	  initial	  recombination	  event.	  Construction	  of	  an	  imprecise	  intratypic	  molecular	  clone,	  similar	  to	  the	  JC105B	  molecular	  clone	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used	  in	  this	  study	  may	  allow	  a	  comparison	  of	  relative	  resolution	  rates.	  A	  similar	  serial	  passaging	  regime	  that	  was	  used	  in	  section	  3.8	  should	  be	  used	  and	  the	  JC105B	  molecular	  clone	  could	  be	  used	  for	  comparison.	  	  	  It	  remains	  to	  be	  determined	  if	  the	  resolution	  stage	  observed	  in	  this	  study	  is	  due	  to	  template	  switching	  in	  cis	  or	  in	  trans.	  In	  principle,	  it	  could	  be	  a	  combination	  of	  both.	  If	  it	  were	  primarily	  in	  
trans	  then	  the	  availability	  of	  acceptor	  template	  would	  be	  a	  limiting	  factor.	  There	  is	  potential	  to	  test	  this	  experimentally.	  Treatment	  of	  HeLa	  cells	  with	  nocodazole	  prior	  to	  passaging	  would	  limit	  the	  co-­‐localisation	  of	  RNA	  during	  replication.	  If	  resolution	  of	  the	  JC105B	  molecular	  clone	  were	  inhibited	  compared	  to	  an	  untreated	  control	  then	  it	  might	  suggest	  that	  resolution	  is	  via	  additional	  template	  switching	  in	  trans.	  	  The	  manipulation	  of	  sequence	  at	  a	  known	  recombination	  hotspot,	  described	  in	  section	  6.6,	  showed	  that	  sequence	  identity	  had	  an	  influence	  on	  the	  location	  of	  recombination	  in	  the	  CRE-­‐REP	  assay.	  The	  development	  of	  the	  3’-­‐CRE-­‐REP	  assay,	  described	  in	  section	  5.3,	  allows	  for	  this	  type	  of	  approach	  to	  be	  expanded	  to	  other	  regions	  of	  the	  replicon	  template.	  Similar	  sequence	  manipulations	  at	  all	  of	  the	  protein	  cleavage	  boundaries	  within	  the	  P2	  and	  P3	  regions	  could	  be	  employed	  to	  enable	  investigation	  of	  sequence	  identity	  on	  recombination	  frequency	  and	  location.	  This	  methodology	  can	  be	  expanded	  even	  further,	  preliminary	  studies	  have	  suggested	  that	  modification	  of	  the	  donor	  template	  that	  affect	  RNA	  structure	  have	  little	  influence	  on	  recombination	  frequency	  or	  location	  (data	  not	  shown).	  This	  approach	  was	  slightly	  flawed.	  Only	  the	  donor	  template	  was	  considered	  for	  modification.	  Lowry	  et	  al.,	  showed	  that	  the	  location	  of	  recombination	  on	  the	  acceptor	  template	  was	  primarily	  biased	  to	  unstructured	  regions.	  To	  completely	  characterise	  the	  influence	  of	  RNA	  structure	  and	  recombination	  frequency	  /	  location	  structural	  alterations	  to	  the	  donor	  and	  acceptor	  template	  would	  be	  required.	  	  	  Furthermore,	  a	  combination	  of	  modifications	  to	  RNA	  sequence	  and	  structure	  could	  be	  introduced	  into	  donor	  and	  acceptor	  templates.	  Exhaustive	  studies	  involving	  Turnip	  Crinkle	  virus	  indicated	  a	  central	  role	  for	  RNA	  structure	  and	  specific	  sequence	  motifs	  in	  the	  generation	  of	  satellite	  RNAs.	  A	  hairpin	  structure	  known	  as	  ‘motif1’	  along	  with	  regions	  of	  sequence	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homology	  specifically	  influenced	  the	  non-­‐random	  distribution	  of	  RNA	  recombination	  (Nagy	  and	  Simon,	  1998a,	  Nagy	  and	  Simon,	  1998b).	  Indeed,	  these	  studies	  supported	  a	  central	  role	  for	  the	  viral	  RdRp	  in	  replicative	  recombination.	  	  	  Replicative	  recombination	  involving	  the	  viral	  RdRp	  via	  a	  copy-­‐choice	  mechanism	  requires	  close	  proximity	  of	  the	  parental	  RNA,	  presumably	  within	  the	  same	  replication	  complex.	  In	  this	  study,	  repeated	  attempts	  were	  made	  to	  identify	  interspecies	  recombinant	  virus	  in	  the	  cell	  based	  CRE-­‐REP	  assays	  using	  enterovirus	  species	  C	  and	  species	  B	  partners	  (PV	  and	  echovirus	  pairings).	  The	  lack	  of	  viable	  recombinant	  may	  be	  due	  to	  protein	  incompatibility	  following	  translation	  that	  may	  affect	  replication	  or	  packaging.	  Alternatively,	  the	  rarity	  of	  interspecies	  recombination	  may	  reflect	  the	  lack	  of	  opportunity,	  perhaps	  due	  to	  occupancy	  of	  distinct	  replication	  complexes.	  Historical	  studies	  that	  have	  used	  serotype	  specific	  riboprobes	  have	  shown	  that	  two	  different	  serotypes	  of	  poliovirus	  co-­‐localise	  during	  replication	  following	  a	  co-­‐infection	  of	  HeLa	  cells	  at	  similar	  peri-­‐nuclear	  locations,	  thus	  providing	  the	  opportunity	  for	  recombination	  (Egger	  et	  al.,	  1999,	  Egger	  and	  Bienz,	  2002).	  During	  the	  course	  of	  this	  investigation	  a	  pilot	  study	  was	  conducted	  that	  used	  a	  fluorescent	  in	  situ	  hybridisation	  (FISH)	  approach.	  A	  series	  of	  Stellaris™	  serotype	  specific	  riboprobes	  were	  designed	  and	  ordered	  from	  Biosearch	  Technologies™.	  This	  approach	  was	  chosen	  due	  to	  the	  reported	  single	  molecule	  sensitivity	  of	  the	  probes	  in	  recent	  studies	  involving	  influenza	  virus	  (Chou	  et	  al.,	  2013)	  and	  other	  cell	  based	  mRNA	  (Shaffer	  et	  al.,	  2013).	  A	  set	  of	  riboprobes	  consisted	  of	  up	  to	  forty-­‐eight	  individual	  serotype	  specific	  20-­‐mer	  sequences,	  each	  containing	  a	  3’	  fluorophore.	  It	  was	  reasoned	  that	  antisense	  viral	  RNA	  would	  be	  targeted	  given	  that	  recombination	  reportedly	  occurs	  during	  antisense	  RNA	  synthesis	  (Kirkegaard	  and	  Baltimore,	  1986b).	  Riboprobes	  specific	  for	  poliovirus	  type	  3	  positive-­‐sense	  RNA	  and	  antisense	  RNA	  were	  ordered	  along	  with	  probes	  for	  echovirus	  7	  (E7)	  antisense	  RNA.	  The	  protocol	  that	  was	  used	  is	  described	  in	  section	  2.4.	  Optimisation	  experiments	  were	  carried	  out	  with	  initial	  results	  suggesting	  that	  species	  B	  and	  species	  C	  partners	  (E7	  and	  PV3)	  localise	  to	  similar	  regions	  during	  replication	  following	  a	  co-­‐infection	  (appendix	  i).	  Further	  quantifiable	  experiments	  will	  be	  required	  to	  confirm	  these	  observations.	  This	  approach,	  in	  principle,	  can	  be	  expanded	  to	  other	  virus	  serotypes	  and	  species	  groups	  in	  order	  to	  ascertain	  whether	  the	  opportunity	  for	  recombination	  exists	  (i.e.	  similar	  localisation	  patterns	  during	  replication).	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  The	  identification	  of	  recombinant	  virus	  in	  the	  CRE-­‐REP	  and	  3’-­‐CRE-­‐REP	  assays	  are	  based	  upon	  the	  viability	  of	  the	  hybrid	  genome	  that	  is	  produced.	  This	  could	  be	  considered	  a	  limitation.	  The	  identification	  of	  unviable	  genomes	  is	  not	  available	  in	  the	  current	  approach.	  If	  co-­‐localisation	  of	  different	  species	  group	  partners	  is	  confirmed	  by	  the	  use	  of	  species-­‐specific	  riboprobes	  then	  there	  is	  the	  potential	  for	  recombinant	  genome	  to	  be	  produced	  as	  well.	  The	  use	  of	  fluorophore	  labeled	  primers	  that	  are	  specific	  to	  recombinant	  genome	  in	  an	  emulsion	  PCR	  approach	  (Runckel	  et	  al.,	  2013)	  might	  provide	  the	  best	  chance	  to	  identify	  recombinant	  genome	  in	  a	  mixed	  population	  following	  RNA	  extraction.	  Sorting	  of	  the	  individual	  emulsions	  based	  upon	  their	  fluorescent	  intensities	  (akin	  to	  FACS)	  could	  highlight	  the	  type	  and	  amount	  of	  recombination.	  	  	  The	  recent	  investigation	  that	  showed	  the	  poliovirus	  RdRp	  pausing	  during	  replication,	  potentially	  due	  to	  a	  misincorporation	  event	  (Dulin	  et	  al.,	  2015)	  allows	  for	  further	  studies	  on	  the	  RdRp	  fidelity	  variants	  identified	  in	  this	  study	  as	  being	  important	  in	  recombination.	  Do	  the	  G64S	  and	  K359R	  variants	  pause	  in	  a	  similar	  fashion	  to	  wild	  type	  RdRp?	  Can	  templates	  carrying	  cold	  or	  hot	  spots	  of	  pausing	  be	  related	  to	  recombinant	  sequences	  obtained	  in	  this	  study	  or	  from	  field	  isolates?	  The	  Dulin	  et	  al.,	  study	  suggested	  that	  the	  type	  of	  co-­‐factor	  might	  influence	  the	  level	  of	  pausing	  during	  replication,	  with	  an	  increase	  observed	  with	  Mn2+	  when	  compared	  to	  Mg2+.	  This	  observation	  has	  been	  shown	  in	  a	  biochemical	  assay,	  where	  the	  error	  rate	  of	  the	  poliovirus	  RdRp	  increased	  when	  Mn2+	  was	  used	  as	  a	  co-­‐factor	  (Crotty	  et	  al.,	  2003).	  Manipulation	  of	  the	  co-­‐factor	  pool	  by	  use	  of	  a	  divalent	  cation	  chelator	  like	  EDTA	  followed	  by	  spiking	  of	  the	  media	  with	  various	  concentrations	  of	  co-­‐factor	  may	  add	  to	  the	  already	  strong	  data	  that	  shows	  fidelity	  as	  being	  important	  in	  the	  cell	  based	  CRE-­‐REP	  assay.	  This	  can	  be	  expanded	  further	  by	  carrying	  out	  similar	  modifications	  to	  the	  biochemical	  recombination	  assay	  described	  in	  section	  6.2.	  	  The	  biochemical	  recombination	  assay	  developed	  during	  this	  investigation	  provides	  the	  basis	  for	  further	  expansion.	  The	  RdRp	  alone	  was	  shown	  to	  be	  sufficient	  for	  template	  switching	  in	  this	  assay.	  To	  suggest	  that	  characteristics	  of	  the	  viral	  RdRp	  alone	  drive	  recombination	  would	  be	  too	  simplistic.	  Many	  other	  viral	  and	  host	  proteins	  are	  located	  in	  close	  proximity	  to	  the	  RdRp	  within	  
	   233	  
the	  replication	  complex	  (Andino	  et	  al.,	  1990,	  Cameron	  et	  al.,	  2010).	  In	  particular,	  the	  role	  of	  P3	  precursor	  proteins	  needs	  to	  be	  investigated.	  The	  chaperone	  activity	  of	  3AB	  has	  been	  previously	  characterised	  (DeStefano	  and	  Titilope,	  2006,	  Gangaramani	  et	  al.,	  2010).	  Inclusion	  of	  3AB	  and	  /or	  other	  viral	  (and	  host)	  proteins	  into	  the	  cell	  free	  assay	  may	  elucidate	  their	  role	  in	  template	  switching.	  Additionally,	  known	  mutations	  that	  ablate	  the	  chaperone	  activity	  of	  3AB	  (Gangaramani	  et	  al.,	  2010)	  can	  be	  incorporated	  into	  the	  CRE-­‐REP	  assay	  partners.	  This	  type	  of	  approach	  will	  show	  if	  chaperone	  activity	  is	  important	  in	  the	  non-­‐processive	  sequence	  independent	  copy-­‐choice	  pathway	  described	  in	  figure	  7.1.	  Modifications	  to	  the	  templates	  used	  in	  the	  biochemical	  recombination	  assay	  may	  highlight	  the	  role	  of	  triplex	  RNA	  formation	  and	  its	  contribution	  to	  the	  recombination	  process	  (described	  in	  figure	  7.1,	  pathway	  B).	  In	  principle,	  the	  use	  of	  triplex	  forming	  oligonucleotide	  RNA	  templates	  would	  increase	  the	  amount	  of	  template	  transfer	  if	  this	  were	  an	  important	  factor.	  	  The	  K359R	  RdRp	  has	  been	  well	  characterised	  (Castro	  et	  al.,	  2009).	  The	  non-­‐recombinogenic	  phenotype	  observed	  with	  this	  variant	  in	  the	  CRE-­‐REP	  and	  biochemical	  recombination	  assays	  could	  be	  due	  to	  either	  fidelity	  or	  speed	  of	  replication	  (or	  both).	  The	  K359H	  variant	  that	  has	  also	  been	  previously	  characterised	  (Castro	  et	  al.,	  2009)	  has	  a	  similar	  phenotype	  to	  the	  K359R	  variant.	  However,	  the	  serial	  passage	  of	  a	  virus	  population	  that	  has	  carries	  this	  RdRp	  variation	  has	  previously	  selected	  two	  separate	  second	  site	  RdRp	  substitutions	  (Jamie	  Arnold,	  personal	  communication).	  One	  of	  the	  second	  site	  substitutions	  returns	  the	  replication	  speed	  of	  the	  RdRp	  to	  wild	  type	  whilst	  the	  other	  lowers	  the	  fidelity	  of	  the	  K359H	  back	  to	  wild	  type	  levels.	  Introduction	  of	  the	  second	  site	  RdRp	  variations	  into	  both	  experimental	  approaches	  (cell	  based	  and	  biochemical)	  may	  tease	  out	  the	  relative	  contribution	  of	  replication	  speed	  and	  fidelity	  in	  the	  recombination	  process.	  	  The	  Y275H	  variant	  kindly	  provided	  by	  the	  Raul	  Andino	  research	  group	  was	  characterised	  in	  the	  CRE-­‐REP	  assay,	  resolution	  assay	  and	  biochemical	  assay	  during	  this	  investigation.	  The	  use	  of	  the	  interface	  I	  RdRp	  mutant	  (L446D	  -­‐	  R455D)	  suggested	  that	  the	  higher	  order	  structures	  formed	  by	  RdRp	  monomers	  at	  interface	  I	  are	  not	  important	  in	  template	  switching	  in	  the	  biochemical	  recombination	  assay.	  However,	  substitutions	  in	  amino	  acid	  residues	  found	  at	  the	  interface	  II	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region	  (Tellez	  et	  al.,	  2011)	  have	  been	  postulated	  to	  be	  important	  in	  recombination	  (Ashley	  Acevedo,	  personal	  communication).	  These	  were	  identified	  in	  the	  same	  GFP-­‐retention	  assay	  that	  identified	  the	  high	  processivity	  Y275H	  RdRp	  variant.	  Inclusion	  of	  the	  substitutions	  into	  the	  donor	  and	  acceptor	  templates	  in	  the	  CRE-­‐REP	  assay	  in	  a	  logical	  manner	  may	  elucidate	  their	  contribution	  to	  recombination	  frequency.	  Additionally,	  the	  RdRp	  variants	  can	  also	  be	  included	  into	  the	  biochemical	  recombination	  assay.	  However,	  caution	  may	  be	  required	  when	  characterising	  the	  interface	  II	  variants	  in	  any	  subsequent	  investigation.	  The	  interface	  II	  region	  is	  not	  known	  to	  interact	  directly	  with	  viral	  RNA,	  unlike	  the	  K359R	  and	  Y275H	  variants	  characterised	  in	  this	  study.	  Potentially,	  the	  substitution	  of	  residues	  within	  this	  region	  may	  de-­‐stabilise	  important	  protein-­‐protein	  interactions	  between	  the	  RdRp	  and	  other	  accessory	  proteins	  (viral	  or	  host)	  that	  might	  influence	  recombination.	  	  	  Genome-­‐wide	  screens	  representing	  ~95%	  of	  host	  genes	  have	  been	  performed	  with	  Tomato	  bushy	  stunt	  virus	  (TBSV)	  in	  a	  yeast	  model,	  in	  the	  attempt	  to	  identify	  host	  genes	  affecting	  RNA	  recombination	  (Serviene	  et	  al.,	  2005,	  Serviene	  et	  al.,	  2006).	  In	  one	  study,	  it	  was	  reported	  that	  inactivation	  of	  yeast	  host	  Pmr1p,	  an	  ion	  pump	  that	  controls	  Ca2+/Mn2+	  movement	  into	  the	  Golgi	  from	  the	  cytosol,	  led	  to	  an	  ~160-­‐fold	  increase	  in	  TBSV	  recombination	  in	  yeast	  (Jaag	  et	  al.,	  2010,	  Jaag	  and	  Nagy,	  2010).	  Potentially,	  this	  finding	  may	  relate	  the	  type	  of	  co-­‐factor	  used	  by	  the	  viral	  RdRp	  and	  recombination	  frequency.	  In	  this	  study,	  an	  attempt	  to	  knockdown	  a	  murine	  equivalent	  known	  as	  ATP2CI	  with	  shRNA	  was	  carried	  out	  with	  limited	  success	  (data	  not	  shown).	  Revisiting	  this	  area	  of	  investigation	  would	  seem	  logical	  given	  the	  observations	  with	  RdRp	  fidelity	  and	  recombination	  frequency.	  In	  another	  study,	  it	  was	  demonstrated	  that	  the	  
MET22/Xrn1	  pathway	  (5’	  exoribonuclease)	  regulated	  the	  frequency	  of	  TBSV	  RNA	  recombination	  and	  efficiency	  of	  virus	  replication	  in	  a	  yeast	  system	  (Jaag	  and	  Nagy,	  2010).	  In	  this	  investigation	  knockdown	  of	  murine	  XrnI	  expression	  by	  shRNA	  was	  successful	  (data	  not	  shown).	  Initial	  results	  show	  that	  knockdown	  of	  XrnI	  does	  not	  affect	  replication	  of	  full-­‐length	  poliovirus	  or	  recombination	  yield	  via	  the	  CRE-­‐REP	  assay.	  This	  is	  not	  surprising	  given	  that	  cytoplasmic	  XrnI	  is	  rapidly	  degraded	  during	  poliovirus	  infection	  (Dinh,	  2013).	  However,	  preliminary	  data	  suggests	  that	  XrnI	  knockdown	  does	  inhibit	  the	  yield	  from	  the	  non-­‐replicative	  (NON-­‐REP)	  assay.	  This	  indicates	  that	  the	  non-­‐replicative	  partners	  need	  to	  be	  processed	  by	  the	  host	  exo	  and	  
	   235	  
endonucleases	  in	  order	  to	  produce	  compatible	  RNA	  fragments	  for	  the	  postulated	  subsequent	  ligation	  events	  that	  are	  required.	  To	  further	  validate	  these	  findings	  an	  additional	  mechanism	  to	  minimise	  the	  processing	  ability	  of	  the	  XrnI	  exoribonuclease	  could	  be	  employed.	  A	  recent	  study	  has	  shown	  that	  a	  noncoding	  RNA	  from	  an	  arthropod-­‐borne	  flavivirus	  inhibits	  XrnI	  function	  (Moon	  et	  al.,	  2012).	  Constructs	  expressing	  the	  flavivirus	  RNA	  could	  be	  used	  in	  combination	  with	  the	  enterovirus	  RNA	  partners	  in	  a	  NON-­‐REP	  assay	  in	  a	  dose	  response	  manner.	  More	  recently,	  a	  DDX3-­‐like	  helicase	  has	  also	  been	  shown	  to	  affect	  recombination	  and	  RNA	  stability	  using	  TBSV	  as	  a	  model	  virus	  (Chuang	  et	  al.,	  2015).	  Whether	  this	  is	  a	  replicative	  or	  non-­‐replicative	  mechanism	  of	  recombination	  is	  still	  open	  to	  debate,	  but	  knockdown	  of	  the	  host	  factor	  by	  siRNA	  or	  shRNA	  may	  be	  applicable	  to	  either	  CRE-­‐REP	  or	  NON-­‐REP	  cell	  based	  approaches.	  	  
7.4 	  	  	  	  	  Final	  summary	  
Experimental	  evidence	  has	  shown	  that	  the	  error-­‐prone	  nature	  of	  the	  RdRp	  leads	  to	  a	  virus	  population	  that	  is	  mostly	  composed	  of	  lethal	  or	  deleterious	  mutations	  (Stern	  et	  al.,	  2014,	  Acevedo	  et	  al.,	  2014).	  How	  does	  the	  virus	  population	  tolerate	  this	  high	  mutational	  rate?	  Recombination	  provides	  a	  mechanism	  that	  can	  remove	  a	  deleterious	  mutation	  and	  also	  provides	  an	  opportunity	  to	  break	  the	  link	  between	  mutations	  that	  are	  lethal	  and	  those	  that	  are	  beneficial	  in	  the	  same	  genome.	  In	  this	  study,	  the	  role	  of	  RdRp	  fidelity	  in	  recombination	  frequency	  has	  been	  clearly	  shown.	  The	  error	  rate	  of	  the	  viral	  RdRp	  not	  only	  creates	  a	  diverse	  population	  that	  can	  respond	  to	  a	  changing	  environment,	  it	  also	  provides	  a	  mechanism	  (recombination)	  that	  ensures	  mutational	  robustness	  of	  the	  population	  is	  maintained.	  The	  global	  effort	  to	  eradicate	  poliovirus	  may	  fall	  short	  using	  the	  current	  vaccination	  regime,	  due	  in	  part,	  to	  recombination	  (Zhang	  et	  al.,	  2010).	  From	  a	  host’s	  perspective,	  the	  K359R	  non-­‐recombinogenic	  phenotype	  that	  was	  observed	  in	  this	  study	  provides	  an	  interesting	  opportunity.	  This	  variant	  is	  attenuated	  and	  elicits	  a	  suitable	  immune	  response	  in	  a	  murine	  model	  (Weeks	  et	  al.,	  2012).	  The	  potential	  of	  the	  K359R	  variant	  as	  a	  suitable	  mechanism-­‐based	  poliovirus	  vaccine	  shouldn’t	  be	  underestimated.	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Figure 1.1 Genome structure of enteroviruses. (A) The virus RNA genome 
contains the essential signals for viral translation, replication, virion assembly and 
release of viral progeny from the host cell and is divided into 3 regions, P1-P3 
(Source: Jiang et al., 2007). (B) Genome structure and cleavage products of 
picornavirus coding sequence. The red triangle indicates cleavage performed by 2A; 
the blue triangles are cleaved by 3C; the black triangle is cleaved by an unknown 













Red = E7 antisense 
Green = PV3 antisense 
Blue = Dapi 
Bar = 6.5µM 





Appendix	  i:	  Fluorescent	  in	  situ	  hybridisation	  (FISH)	  Stellaris	  probes	  
(A)	  Enterovirus	  genome	  layout.	  Red	  line	  indicates	  antisense	  RNA	  intermediate	  produced	  during	  replication.	  Blue	  lollipops	  represent	  48	  individual	  20mer	  oligonucleotides	  carrying	  a	  3’	  fluorescent	  modification.	  Each	  bind	  to	  separate	  unique	  sequences	  with	  the	  capsid-­‐coding	  region	  of	  the	  antisense	  RNA	  intermediate	  template	  (B)	  Example	  images	  obtained	  from	  a	  wide-­‐field	  microscope.	  Red	  indicates	  fluorescent	  signal	  obtained	  from	  the	  echovirus	  7	  specific	  probes.	  Green	  indicates	  fluorescent	  signal	  obtained	  from	  the	  Poliovirus	  type	  3	  specific	  probes.	  Blue	  indicates	  nuclear	  staining	  (Dapi).	  Individual	  fluorescent	  images	  from	  each	  wavelength	  followed	  with	  a	  final	  overlaid	  image	  with	  all	  fluorescent	  wavelengths.	  White	  bar	  =	  6.5	  μM	  (C)	  Repeated	  experiment.	  All	  images	  de-­‐convoluted	  and	  processed	  with	  ImageJ.	  	  	  	  	  	  	  
	  
	  	  	  	  	  
